---
document_datetime: 2023-10-31 11:12:26
document_pages: 149
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/tyruko-epar-public-assessment-report_en.pdf
document_name: tyruko-epar-public-assessment-report_en.pdf
version: success
processing_time: 254.9337944
conversion_datetime: 2025-12-15 20:25:13.321781
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
20 July 2023 EMA/359152/2023

Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Tyruko

International non-proprietary name: natalizumab

Procedure No. EMEA/H/C/005752/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                              | ..............................................7                                                           |
|-------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier....................................................................................      | 7                                                                                                         |
| 1.2. Legal basis, dossier content.................................................................................      | 7                                                                                                         |
| 1.3. Information on Paediatric requirements.................................................................            | 8                                                                                                         |
| 1.4. Information relating to orphan market exclusivity                                                                  | ................................................... 8                                                     |
| 1.4.1. Similarity                                                                                                       | ....................................................................................................... 8 |
| 1.5. Scientific advice................................................................................................. | 8                                                                                                         |
| 1.6. Steps taken for the assessment of the product                                                                      | ....................................................... 9                                                 |
| 2. Scientific discussion                                                                                                | ..............................................................................10                          |
| 2.1. Problem statement...........................................................................................       | 10                                                                                                        |
| 2.2. About the product                                                                                                  | ............................................................................................ 10           |
| 2.3. Type of application and aspects on development...................................................                  | 11                                                                                                        |
| 2.4. Quality aspects ................................................................................................   | 14                                                                                                        |
| 2.4.1. Introduction                                                                                                     | ................................................................................................. 14      |
| 2.4.2. Active substance ...........................................................................................     | 14                                                                                                        |
| 2.4.3. Finished Medicinal Product ..............................................................................        | 19                                                                                                        |
| 2.4.4. Discussion on chemical, pharmaceutical and biological aspects.............................                       | 29                                                                                                        |
| 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects                                               | ..................... 30                                                                                  |
| 2.4.6. Recommendation(s) for future quality development............................................                     | 30                                                                                                        |
| 2.5. Non-clinical aspects..........................................................................................     | 30                                                                                                        |
| 2.5.1. Introduction                                                                                                     | ................................................................................................. 30      |
| 2.5.2. Pharmacology...............................................................................................      | 31                                                                                                        |
| 2.5.3. Pharmacokinetics ..........................................................................................      | 31                                                                                                        |
| 2.5.4. Toxicology....................................................................................................   | 32                                                                                                        |
| 2.5.5. Ecotoxicity/environmental risk assessment........................................................                | 33                                                                                                        |
| 2.5.6. Discussion on non-clinical aspects....................................................................           | 33                                                                                                        |
| 2.5.7. Conclusion on the non-clinical aspects..............................................................             | 35                                                                                                        |
| 2.6. Clinical aspects                                                                                                   | ................................................................................................ 36       |
| 2.6.1. Introduction .................................................................................................   | 36                                                                                                        |
| 2.6.2. Clinical pharmacology                                                                                            | .................................................................................... 36                   |
| 2.6.3. Discussion on clinical pharmacology .................................................................            | 67                                                                                                        |
| 2.6.4. Conclusions on clinical pharmacology ...............................................................             | 70                                                                                                        |
| 2.6.5. Clinical efficacy                                                                                                | ............................................................................................. 70          |
| 2.6.6. Discussion on clinical efficacy                                                                                  | .........................................................................103                              |
| 2.6.7. Conclusions on the clinical efficacy..................................................................106        |                                                                                                           |
| 2.6.8. Clinical safety                                                                                                  | ..............................................................................................106         |
| 2.6.9. Discussion on clinical safety                                                                                    | ...........................................................................135                            |
| 2.6.10. Conclusions on the clinical safety                                                                              | ..................................................................140                                     |
| 2.7. Risk Management Plan.....................................................................................140       |                                                                                                           |
| 2.7.1. Safety concerns                                                                                                  | ...........................................................................................140            |
| 2.7.2. Pharmacovigilance plan.................................................................................140       |                                                                                                           |
| 2.7.3. Risk minimisation measures...........................................................................140         |                                                                                                           |

<div style=\"page-break-after: always\"></div>

2.8. Pharmacovigilance...........................................................................................  141

2.8.1. Pharmacovigilance system  .............................................................................  141

2.8.2. Periodic Safety Update Reports submission requirements ...................................  142

2.9. Product information  .........................................................................................  142

2.9.1. User consultation..........................................................................................  142

2.9.2. Additional monitoring  ....................................................................................  142

3. Biosimilarity assessment  .....................................................................  142

3.1. Comparability exercise and indications claimed  ....................................................  142

3.2. Results supporting biosimilarity  .........................................................................  144

3.3. Uncertainties and limitations about biosimilarity ..................................................  145

3.4. Discussion on biosimilarity  ................................................................................  146

3.5. Extrapolation of safety and efficacy  ....................................................................  146

3.6. Additional considerations  ..................................................................................  146

3.7. Conclusions on biosimilarity and benefit risk balance  ............................................  146

4. Recommendations ...............................................................................  146

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADA

Anti-Drug Antibodies

(TE)(S)AE

(Treatment-emergent)(Serious) Adverse Event

AESIs

Adverse Events of Special Interest

ALT

Alanine Aminotransferase

ANCOVA

Analysis of covariance

ANOVA

Analysis of variance

ARR

Annualized Relapse Rate

AST

Aspartate Aminotransferase

AUC0-last

Area under the concentration-time curve from zero to last timepoint

AUC0-inf

Area under the concentration-time curve from zero to infinity

AUC0-12w

Area under the effect time curve from time zero to 12 weeks

AUECbase\\_neg

Area below the individual baseline value minus the area above the individual baseline in case of time intervals for which the effect time curve exceeded the baseline value

AUEC0-12w

Area under the effect curve from zero to 12 weeks

AUEC4-12w

Area under the effect curve from four to 12 weeks

AUEC0-t

Area under the effect curve from zero to last timepoint

BBB

Blood-brain barrier

BMI

Body mass index

CI

Confidence interval

CL

Clearance

Cmax

Maximum Concentration

Cmin

Minimum Concentration

CNS

Central Nervous System

COVID-19

Coronavirus disease 2019

CRO

Contract Research Organization

CS-1

Connecting segment-1

CSR

Clinical Study Report

CSP

Clinical Study Protocol

CTMS

Clinical Trial Management System

CV

Arithmetic Coefficient of variation

gCV

Geometric Coefficient of variation

DSMB

Data and Safety Monitoring Board

<div style=\"page-break-after: always\"></div>

| ECG         | Electrocardiogram                                    |
|-------------|------------------------------------------------------|
| ECLIA       | Electrochemiluminescence immunoassay                 |
| EDC         | Electronic Data Capture                              |
| ELISA       | Enzyme Linked Immunosorbent Assay                    |
| EMA         | European Medicines Agency                            |
| E max       | Maximum effect                                       |
| E min       | Minimum effect                                       |
| EDSS        | Expanded Disability Status Scale                     |
| Fab         | Fragment antigen-binding                             |
| FDA         | Food and Drug Administration                         |
| FAS         | Full Analysis Set                                    |
| GdE         | Gadolinium-Enhancing                                 |
| IgG         | Immunoglobulin G                                     |
| ICF         | Inform Consent Form                                  |
| IHC         | International Council for Harmonisation              |
| IV          | Intravenous                                          |
| JCV         | John Cunningham virus                                |
| k el        | Terminal elimination rate constant                   |
| LDL         | Low Density Lipoprotein                              |
| LLOQ        | Lower Limit of Quantification                        |
| LS(M)       | Least Square (Mean)                                  |
| MedDRA      | Medical Dictionary for Regulatory Activities         |
| MRI         | Magnetic Resonance Imaging                           |
| MS          | Multiple Sclerosis                                   |
| (s)MAdCAM-1 | (soluble) Mucosal addressin cell adhesion molecule-1 |
| NNP         | Negative Predictive Value                            |
| QC          | Quality control                                      |
| PD          | Pharmacodynamics                                     |
| PK          | Pharmacokinetic                                      |
| PML         | Progressive multifocal leukoencephalopathy           |
| PP          | Per Protocol                                         |
| PPV         | Positive Predictive Value                            |
| PT          | Preferred Term                                       |

<div style=\"page-break-after: always\"></div>

| RRMS       | Relapsing Remitting MS                          |
|------------|-------------------------------------------------|
| (%)RS      | (Relative) Receptor saturation                  |
| SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 |
| SAF        | Safety Population                               |
| SD         | Standard Deviation                              |
| SE         | Standard Error                                  |
| SDTM       | Study Data Tabulation Model                     |
| SOC        | System Organ Class                              |
| SSW        | Safety-Switch Population                        |
| TFL        | Tables, Figures and Listings                    |
| T max, E   | time to E max                                   |
| t max      | Time to C max                                   |
| t min      | Time to C min                                   |
| t 1/2      | Half-life                                       |
| VCAM-1     | Vascular cell adhesion molecule-1               |
| Vz         | Volume of distribution                          |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The  applicant  Polpharma  Biologics  S.A.  submitted  on  24  June  2022  an  application  for  marketing authorisation to the European Medicines Agency (EMA) for Tyruko, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004.

During the procedure the applicant changed from Polpharma Biologics SA to Sandoz GmbH.

The applicant applied for the following indication Tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (RRMS) for the following patient groups:

- Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) (for exceptions and information about washout periods see sections 4.4 and 5.1)

or

- Patients with rapidly evolving severe RRMS defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain Magnetic Resonance Imaging (MRI) or a significant increase in T2 lesion load as compared to a previous recent MRI.

## 1.2. Legal basis, dossier content

## The legal basis for this application refers to:

Article 10(4) of Directive 2001/83/EC - relating to applications for a biosimilar medicinal product.

The application submitted is composed of administrative information, complete quality data, non-clinical and clinical data based on applicants' own  tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

The chosen reference product is:

Medicinal product which is or has been authorised in accordance with Union provisions in force for not less than 10 years in the EEA:

- Product name, strength, pharmaceutical form: Tysabri, 300 mg, concentrate for solution for infusion
- Marketing authorisation holder: Biogen Netherlands B.V.
- Date of authorisation: 27-06-2006
- Marketing authorisation granted by:
- -Union
- Marketing authorisation number: EU/1/06/346/001

Medicinal product authorised in the Union/Members State where the application is made or European reference medicinal product:

- Product name, strength, pharmaceutical form: Tysabri, 300 mg, concentrate for solution for infusion
- Marketing authorisation holder: Biogen Netherlands B.V.
- Date of authorisation: 27-06-2006
- Marketing authorisation granted by:
- -Union
- Marketing authorisation number: EU/1/06/346/001

<div style=\"page-break-after: always\"></div>

Medicinal product which is or has been authorised in accordance with Union provisions in force and to which bioequivalence has been demonstrated by appropriate bioavailability studies:

- Product name, strength, pharmaceutical form: Tysabri, 300 mg, concentrate for solution for infusion
- Marketing authorisation holder: Biogen Netherlands B.V.
- Date of authorisation: 27-06-2006
- Marketing authorisation granted by:
- -Union
- Marketing authorisation number: EU/1/06/346/001

## 1.3. Information on Paediatric requirements

Not applicable

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal  products  because  there  is  no  authorised  orphan  medicinal  product  for  a  condition related to the proposed indication.

## 1.5. Scientific advice

The applicant received the following Scientific advice on the development relevant for the indication subject to the present application:

| Date          | Reference                 | SAWP co-ordinators             |
|---------------|---------------------------|--------------------------------|
| 21 April 2017 | EMA/CHMP/SAWP/224608/2017 | Andrés Trelles, André Elferink |

The Scientific advice pertained to the following quality , non-clinical, and clinical aspects:

- Proposed  panel  of  analytical  methods  for  characterisation  and  physico-chemical  and  biological analytical similarity assessment.
- Proposed panel of bioassays for analytical similarity exercises.
- Classification of product quality attributes.
- Potency-related critical quality attributes to establish analytical similarity.
- Approach to analysis of Fab-arm exchange phenomena to demonstrate analytical similarity.
- Use of  alternative  host  cell  line  for  the  expression  of  PB006  as  compared  to  that  used  by  the manufacturer of the reference medicinal product.
- Approach to the establishment and use of the Internal Reference Standard.
- Need to perform animal studies to support the assessment of biosimilarity.
- Adequacy of parallel-group  study  design  to  support  demonstration  of  PK/PD  similarity  between PB006 and the reference product.

<div style=\"page-break-after: always\"></div>

- Design of a pivotal PK/PD study in healthy subjects to demonstrate PK and PD bioequivalence in α4 -integrin  receptor  saturation  as  a  marker  for  the  pharmacological  effect  using  PB006,  EU-sourced Tysabri, and US-sourced Tysabri: study population, selection of PD marker, dose level, choice of primary and secondary pharmacokinetic, pharmacodynamic, safety, and immunogenicity endpoints, PK and PD statistical analysis, blinded interim assessment, sample size calculation, need for confirmatory efficacy data in patients with multiple sclerosis.
- Design of an immunogenicity and safety study in patients with multiple sclerosis comparing PB006 with EU-sourced Tysabri to rule out any clinical meaningful differences in terms of the immune response.
- ELISA test for qualitative detection of human antibodies to John Cunningham virus.

The applicant received the following Scientific advice on the development relevant for the indication subject to the present application:

| Date            | Reference                 | SAWP co-ordinators                  |
|-----------------|---------------------------|-------------------------------------|
| 26 January 2023 | EMADOC-1700519818-1010854 | Ivana Haunerová, Caoimhin Concannon |

The Scientific advice pertained to the following quality aspects:

- Proposed grouping of type II variations related to analytical method transfer and manufacturing process transfer to additional manufacturing and quality testing site for the active substance; PB006 active  substance  testing  as  well  as  comparability  and  validation  plan  to  support  the  transfer; appropriateness  of  good  manufacturing  practice  (GMP)  quality  management  system  to  introduce additional identical manufacturing line for PB006 active substance.

## 1.6. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Christian Gartner

Co-Rapporteur:  Simona Badoi

| The application was received by the EMA on                                                                                                      | 24 June 2022     |
|-------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| The procedure started on                                                                                                                        | 14 July 2022     |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                    | 5 October 2022   |
| The CHMP Co-Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                 | 17 October 2023  |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                    | 18 October 2022  |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                         | 10 November 2022 |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                             | 22 February 2023 |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and | 05 April 2023    |

<div style=\"page-break-after: always\"></div>

| PRAC members on                                                                                                                                                                        |               |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                               | 14 April 2023 |
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanation to be sent to the applicant on                                                                | 26 April 2023 |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                        | 23 May 2023   |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on               | 07 June 2023  |
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanation to be sent to the applicant on                                                                | 22 June 2023  |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                        | 28 June 2023  |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on               | 06 July 2023  |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Tyruko on | 20 July 2023  |

## 2. Scientific discussion

## 2.1. Problem statement

Not applicable

## 2.2. About the product

Tyruko (development code PB006) has been developed as a biosimilar to the reference product Tysabri (INN natalizumab), a full-length monoclonal antibody of the IgG4 subclass that targets the α4 integrin component of adhesion molecules found on lymphocytes, monocytes, and eosinophils.

PB006 has been developed to have the same IV dosage form, route of administration, dosing regimen and  presentation  as  the  EU  reference  product  Tysabri  (hereafter  identified  as  EU-Tysabri).  The subcutaneous  presentation  recently  approved  for  Tysabri  is  not  in  the  scope  of  this  marketing authorization application for Tyruko.

The intended indication for Tyruko is the same as for the reference product EU-Tysabri, which is indicated for treatment of multiple sclerosis (MS).

Tysabri is indicated as single disease modifying therapy (DMT) in adults with highly active relapsing remitting multiple sclerosis (RRMS) for the following patient groups:

- Patients with highly active disease despite a full and adequate course of treatment with at least one DMT

<div style=\"page-break-after: always\"></div>

or

- Patients with rapidly evolving severe RRMS defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing (GdE) lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load as compared to a previous recent MRI.

Tyruko is intended to be administered at a fixed dose of 300 mg, infused IV over approximately one hour, every four weeks.

## Mode of action

Natalizumab is a selective adhesion-molecule inhibitor and binds to the α 4-subunit of human integrins, which is highly expressed on the surface of all leukocytes, with the exception of neutrophils. Specifically, natalizumab binds to the α 4 β 1 integrin, blocking the interaction with its cognate receptor, vascular cell adhesion  molecule-1  (VCAM-1),  and  ligands  osteopontin,  and  an  alternatively  spliced  domain  of fibronectin, connecting segment-1 (CS-1). Natalizumab also blocks the interaction of α 4 β 7 integrin with the mucosal addressin cell adhesion molecule-1 (MadCAM-1). Disruption of these molecular interactions prevents transmigration of mononuclear leukocytes across the endothelium into inflamed parenchymal tissue. A further mechanism of action of natalizumab may be to suppress ongoing inflammatory reactions in diseased tissues by inhibiting the interaction of α 4-expressing leukocytes with their ligands in the extracellular matrix and on parenchymal cells. As such, natalizumab may act to suppress inflammatory activity present at the disease site and inhibit further recruitment of immune cells into inflamed tissues.

In MS, lesions are believed to occur when activated T-lymphocytes cross the blood-brain barrier (BBB). Leukocyte migration across the BBB involves interaction between adhesion molecules on inflammatory cells and endothelial cells of the vessel wall. The interaction between α 4 β 1 and its targets is an important component of pathological inflammation in the brain and disruption of these interactions leads to reduced inflammation. Under normal conditions, VCAM-1 is not expressed in the brain parenchyma. However, in the presence of pro-inflammatory cytokines, VCAM-1 is upregulated on endothelial cells and possibly on glial cells near the sites of inflammation. In the setting of central nervous system (CNS) inflammation in MS, it is the interaction of α 4 β 1 with VCAM-1, CS-1 and osteopontin that mediates the firm adhesion and  transmigration  of  leukocytes  into  the  brain  parenchyma  and  may  perpetuate  the  inflammatory cascade  in  CNS  tissue.  Blockade  of  the  molecular  interactions  of α 4 β 1  with  its  targets  reduces inflammatory activity present in the brain in MS and inhibits further recruitment of immune cells into inflamed tissue, thus reducing the formation or enlargement of MS lesions (Tysabri SmPC, Mar 2022).

## 2.3. Type of application and aspects on development

The development program comprises 4 clinical studies: 1 pivotal Phase 1 PK/ PD study with PB006, USTysabri, and EU-Tysabri in healthy subjects, 1 pivotal Phase 3 study with PB006 versus EU-Tysabri in patients with RRMS, 1 pilot Phase 1 pharmacokinetic (PK)/pharmacodynamic (PD) study with EU-Tysabri in healthy subjects, and 1 supportive Phase 1 safety study with PB006 in healthy subjects.

The 3-arm PK/PD study in healthy subjects (PB006-01-03) was 1 of the 2 pivotal studies in the clinical program demonstrating similarity of PB006 versus US-Tysabri and EU-Tysabri. This PK/PD study aimed to demonstrate PK similarity and included sensitive PD endpoints in order to support the demonstration of similar efficacy in this MAA. In addition, the clinical pharmacology data generated for EU-Tysabri and US-Tysabri in this study established the scientific bridge between both products.

The Phase 3 study in RRMS patients (PB006-03-01) was the second pivotal study in the clinical program. The study aimed to show that there were no clinically meaningful differences with regard to efficacy, immunogenicity and safety between PB006 and EU-Tysabri in the target population.

<div style=\"page-break-after: always\"></div>

Scientific  advice  was  obtained  from  the  European  Medicines  Agency  (EMA)  in  2017,  early  in  the development of PB006. In this meeting, the design of the proposed clinical studies with PB006 was discussed, and main design aspects were aligned with the agency, including:

- PK and PD endpoints in the pivotal PK/PD study PB006-01-03 (with α 4-integrin  %  relative receptor saturation [%RS] as primary PD endpoint)
- Efficacy endpoints in the Phase 3 study PB006-03-01 (with magnetic resonance imaging (MRI) activity as primary endpoint and ARR as secondary endpoint)

The global development program of PB006 was subsequently also discussed with the United States Food and Drug Administration (FDA) in BPD Type 2 meetings in 2017, 2019 and 2020.

In the Scientific Advice meeting in 2017, EMA has confirmed that an evaluation of similar clinical efficacy based on MRI assessment is required. In contrast, the US FDA will evaluate similarity of efficacy of PB006 with the reference product by means of PD endpoints. The EMA considers PD data as supportive for evaluation of similarity of efficacy.

Subsequent to the meeting with the EMA, various design aspects of the clinical studies (e.g., including the choice of PD endpoints and their analysis in the pivotal PK/PD study) were discussed with the FDA and adjustments to the study designs were made to meet FDA requirements. In particular, the FDA requested to include sensitive PD endpoints in the pivotal PK/PD study, which would serve as basis for FDA's assessment of similar efficacy between PB006 and the reference product. In addition, a pilot study was requested to enable the selection of sensitive PD endpoints.

The most relevant adjustments that were implemented into the PB006 clinical program after the initial discussion of the program with the EMA in 2017 are outlined in the following.

## Study Tysabri Pilot-01-01:

- A pilot study was conducted, to collect PK/PD data with 3 different doses of EU-Tysabri in order to establish an appropriately sensitive PK/PD study setting, including the dose selection and primary PD endpoints, for the pivotal PK/PD study with PB006.

## Study PB006-01-03:

- The primary PD endpoint α 4-integrin RS was complemented with baseline-adjusted CD19+ Bcell counts as a co-primary PD endpoint.
- For the primary analysis of α 4-integrin RS, AUEC0-12 weeks was chosen. As additional analysis, a descriptive analysis of AUEC4-12 weeks was conducted.
- For the analysis of co-primary PD endpoints, a pooling approach for both comparators (EU- and US-Tysabri)  was  chosen,  due  to  the  high  variability  of  the  CD19+  endpoint.  The  pooling approach for the primary analysis (i.e., only one comparison biosimilar candidate vs reference) increases the number of subjects in the pooled reference group.
- To power the study for a CD19+ PD assessment, the sample size was increased from N=255 (sample size discussed with EMA in 2017) to N=453 subjects (N=151 per treatment group).
- CD34+, VCAM and MAdCAM were selected as secondary PD endpoints.

## Study PB006-03-01:

A single transition of a subset of RRMS patients (N=30) from treatment with EU-Tysabri after 24 weeks to PB006 was implemented on the request of the FDA. Safety and immunogenicity data collected after the transition were used to investigate whether the transition from the reference product to the biosimilar drug may be associated with any hypersensitivity or increased immunogenicity.

<div style=\"page-break-after: always\"></div>

The  key  elements  and  the  design  of  the  clinical  studies  are  considered  to  be  in  line  with  the recommendations received from the EMA in 2017. Additional efficacy endpoints included thereafter and an increase in sample size further facilitate the assessment of similarity inefficacy between PB006 and the reference product.

## Scientific advice on non-clinical issues

In the scientific advice procedure EMA/CHMP/SAWP/224608/2017 the applicant asked for agreement that  no  animal  studies  are  required  to  support  the  assessment  of  biosimilarity  between  PB006  and Tysabri. The CHMP accepted this strategy as far as analytical and functional comparability of PB006 and EU-Tysabri   can be demonstrated in vitro, which is in line with current guidance (guideline on Similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and  clinical  issues  (EMEA/CHMP/BMWP/42832/2005  Rev1),  and  the  guideline  on  Similar  biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues (EMA/CHMP/BMWP/403543/2010)).

National scientific advice was also provided in 2016. The minipig animal model was accepted as a relevant species  for  Natalizumab,  however,  a  pre-clinical  study  in  lieu  of  a  human  PK  study  for  formulation bridging was not accepted. It was agreed that no in vivo toxicity studies need to be performed.

The applicant performed a comparative subchronic repeat-dose toxicity study in cynomolgus monkeys, including PK analysis, with PB006 and EU-Tysabri

## Coronavirus disease 2019 (COVID-19) related considerations

The pivotal PK/PD study PB006-01-03 and the pivotal confirmatory Phase 3 study PB006-03-01 were conducted during the COVID-19 pandemic. In the PK/PD study, recruitment was temporarily held from March to August 2020 (when around one-third of the subjects had been enrolled) and safety measures were implemented to protect subjects from a COVID-19 infection after dosing (e.g., reducing maximum subject age to 54 years, including polymerase chain reaction [PCR] tests for severe acute respiratory syndrome coronavirus type 2 [SARS CoV-2], increasing in-house period from 3 to 8 days and including home-quarantine up to Day 14).

The Phase 3 study in RRMS was (after Data Safety Monitoring Board [DSMB] endorsement) still enrolling and treating patients as of March 2020, when COVID-19 was declared a pandemic by the World Health Organization; the last patient was randomized in May 2020.

For  study  PB006-03-01,  all  COVID-19  AEs  (according  to  Medical  Dictionary  for  Regulatory  Activities [MedDRA] coding) were identified and summarized. In order to assess the impact of COVID-19 on safety and efficacy of this study, the following analyses were performed:

- Study discontinuations and protocol deviations due to COVID-19 were summarized.
- Demography data for confirmed COVID-19 patients were summarized.
- Protocol deviations due to COVID-19 were summarized by country.
- A sensitivity analysis (for primary endpoint) was to be performed on the pre- COVID per protocol (PP) population.

These additional analyses are in line with the guidance from the EMA on the management of clinical trials during the COVID-19 pandemic (Guidance on the management of clinical trials during the COVID-19 pandemic, 2022).

<div style=\"page-break-after: always\"></div>

## 2.4. Quality aspects

## 2.4.1. Introduction

Natalizumab, the active substance contained in Tyruko, also referred of as PB006, is a recombinant humanised  antiα4 -integrin  antibody  produced  in  a  Chinese  Hamster  Ovary  (CHO)  cell  line  by recombinant DNA technology.

Tyruko  was  developed  as  biosimilar  to  the  reference  medicinal  product  (RMP)  Tysabri.  The  finished product is presented as sterile, colourless, and clear to slightly opalescent concentrate for solution for infusion,  containing  300  mg  of  natalizumab  as  active  substance  (each  vial  contains  15  mL  of concentrate). Other ingredients are: sodium chloride, histidine, histidine hydrochloride, monohydrate, polysorbate 80 and water for injections.

It is presented as a 300 mg/15 mL concentrate for solution for infusion in single-use Type I glass vial.

The product is available in type I borosilicate glass vials with bromobutyl stoppers and aluminium seals with a flip-top cap.

The subcutaneous route of administration, which was approved for Tysabri, was not in the scope of Tyruko development.

## 2.4.2. Active substance

## 2.4.2.1. General information

PB006 is a humanised monoclonal antibody of the IgG4 κ subclass consisting of two heavy (HC) and two light  chains  (LC),  connected by four inter-chain disulfide bonds. Antibodies of the IgG4 subclass are characterised by a shorter hinge region in comparison to antibodies of the IgG1 subclass, leading to a reduced flexibility of the hinge region. As expected for an IgG4 antibody, natalizumab demonstrates reduced binding to Fc γ receptors and lack of ability to fix complement in vitro . The molecular weight of the intact deglycosylated natalizumab molecule, as measured by mass spectrometry, is 146 kDa. Each heavy chain has one N-linked glycosylation site at Asn300.

As other complex glycoproteins, PB006 displays a natural amount of microheterogeneity in terms of a different  degree  of  glycosylation  and  post-translational  modifications  of  amino  acids.  The  C-terminal lysine residues of the heavy chains (Lys450) are mostly cleaved by cellular proteases during cell culture growth. As other antibodies of the IgG4 class, natalizumab contains 12 intra-chain disulfide bonds. The two heavy chains are connected in the hinge region by two inter-chain disulfide bonds and the light chain is linked to the heavy chain by an inter-chain disulfide bond. Further details on product variants due to common sources of post-translational and processing modifications of PB006 were presented by the applicant.

## 2.4.2.2. Manufacture, characterisation and process controls

## Manufacturing process

The active substance is manufactured at Polpharma Biologics S.A., Ul. Trzy Lipy 3, Gdańsk, Pomorskie 80-172, Poland. All sites involved in the manufacture and storage of the cell banks and manufacture, quality control testing of the active substance operate in accordance with EU GMP.

<div style=\"page-break-after: always\"></div>

PB006 active substance is produced based on a CHO cell line. To manufacture of PB006 active substance, a  fed-batch  process  with  preceding  expansion  stages,  followed  by  primary  recovery  and  a  series  of purification  steps,  typical  for  monoclonal  antibodies,  including  several  chromatography  steps,  virus inactivation,  virus-filtration  and  ultra-/diafiltration  (UDF)  steps  was  established.  Used  media,  critical process parameters (CPPs), critical in-process controls (IPCs), hold times and column lifetimes were presented. No reprocessing is foreseen for intermediates and PB006 active substance. The manufacturing process was sufficiently described.

## Control of materials

The control of raw materials section was split into an upstream process (USP) and a downstream (DSP) part. All raw materials used in USP and DSP are of non-animal and non-human origin, while cell culture media are chemically defined and free of animal-derived raw materials. All ingredients are certified as BSE/TSE-free. A complete list of all raw materials used for manufacture of PB006 was provided. Noncompendial raw materials are tested against in-house specifications, which were disclosed and found acceptable.  The  qualitative  and  quantitative  composition  of  cell  culture  media  and  feeds  was  not provided, and justified by being intellectually protected. The composition of all buffers and media and their physico-chemical properties was disclosed. Chromatography resins were listed, including respective suppliers. Provided information on compendial and non-compendial raw materials and respective control strategy used to manufacture PB006 is acceptable, except cell culture media and supplements used in the USP, and purchased from an external supplier. Information about the composition of these media was provided, and thus the compliance of respective control strategies is confirmed.

In relation to cell line development, the applied cloning strategy was explained. Cell line development was sufficiently described and is acceptable.

The procedure for the manufacture of the MCB and WCB was described. Cell line characterisation data and IPCs were presented. Genetic stability was assessed, and the nucleotide sequence of the transgene was confirmed in the MCB, working cell bank (WCB) and the post-production cell bank (PPCB). Gene copy numbers were comparable in the MCB, WCB, PPCB and the end-of -production cell bank (EOPCB), and flanking LC and HC nucleotide sequences were confirmed. A limit of in vitro cell age (LIVCA) study was performed at manufacturing scale to ensure the genetic stability of the recombinant production cell line until the end of production (EOP) with extended number of cell passages, including the demonstration of adventitious agents safety (such as viruses and mycoplasma). Taken together, characterisation of cell banks was performed by state-of-the-art technologies and found acceptable.

## Control of critical steps and intermediates

The applicant performed a quality attribute criticality assessment. A first criticality assessment evaluation was performed at the beginning of the development to identify and classify the criticality of the product quality attributes (QAs) to patient safety and drug efficacy. The assessment was later updated to reflect additional knowledge as well as health authority feedback/requirements.

The  applicant  gave  an  overview  of  process  controls  applied  for  the  active  substance  manufacturing process. Process parameters and IPCs were split into categories based on their criticality. A list of process parameters was provided for the USP and the DSP, and included each step of the manufacturing process. IPCs were also listed for the USP and the DSP. Corresponding method applied to assess respective IPC was indicated, as well as a short justification of criticality and the acceptable range. Process control and IPC lists are complete, and acceptance ranges and limits are tight enough and justified by experimental data. Hold times were validated at commercial scale during PPQ runs. Additional analytical procedures for controlling critical steps were briefly described. Taken together, safety and efficacy related quality attributes were controlled at critical process steps. Presented control strategy is complete and aligned with  guidance  documents,  thus  appropriate  for  this  class  of  biologics.  The  applicant  performed  a

<div style=\"page-break-after: always\"></div>

comprehensive  criticality  assessment  evaluation  of  PB006  quality  attributes  based  on  impact  and criticality of respective parameters. A detailed list of CQA's was presented. The overall risk of each quality attribute was adjusted, if e.g. multiple orthogonal methods were applied to assess the same quality attribute. The evaluation procedure was explained in enough details, scientifically justified and thus is acceptable for this molecule.

## Process validation

Process validation consisted of the assessment of USP and DSP process performance qualification (PPQ) runs at commercial scale, dispensing homogeneity of active substance, in-process material hold-time, process-related and product-related impurity clearance, and supportive studies including resin re-use and storage studies, extractable- and leachable assessment, transport validation and continued process verification.

All CPP and key process parameter (KPP) remained within proposed ranges for USP validation activities. In addition, all IPCs of the USP process, as well as all IPCs of media, feed and supplement solutions testing met the pre-defined limits. Deviations that occurred during the USP process were assessed to have no adverse impact on process performance or on product quality attributes.

The  results  obtained  during  the  manufacture  and  analysis  of  the  PPQ  batches  demonstrate  the consistency  of  the  downstream  process.  This  provides  confirmation  and  demonstrates  that  the  DSP process can consistently provide product of defined quality and in specifications and that the process can be considered validated.

A dispensing homogeneity study was performed in order to demonstrate the capability of the equipment and the process to perform homogeneous dispensing of the compounded active substance over the entire dispensing process. These parameters were shown to be efficient in order to obtain homogenous inprocess material. Evaluation of the results of the samples taken during dispensing demonstrated that the PB006 dispensing process has no impact on product quality and consistently delivers a homogenous active substance meeting with the specifications.

Impurity clearance was assessed at respective clearance steps during process validation. Again, all PPQ batches  were  analysed  and  confirmed  that  the  downstream  processing  is  able  to  efficiently  and reproducibly reduce levels of product-related impurities below specified acceptance limits.

Resin re-usage studies were performed for chromatography resins and demonstrated no adverse effects on process performance and product quality. The absence of protein carryover was also confirmed at manufacturing scale by performing a mock run (resin carry-over).

A leachable and  extractable assessment  was  performed  for polymeric materials used during manufacturing, processing and storage of PB006 active substance in order to identify potential risks caused by material in direct or indirect contact with media, buffers, in-process materials and the active substance. No organic compound or element could be released at toxicologically relevant concentrations from either process consumable. The applicant's approach is supported.

Transportation validation was performed for the temperature controlled shipment of active substance using qualified shipment containers. A transport simulation (mechanical stress, reduced air pressure) was carried out in an ISTA lab, using worst case simulations. All requirements as defined in the transport validation protocol for PB006 were met, and the applicant's conclusion that the transportation process is considered  validated  is  supported.  After  successful  process  qualification  process  performance  and product quality are monitored as part of the continued process verification (CPV) to ensure that the manufacturing process is maintained under control throughout the commercial phase. It is a planned lifecycle management program to ensure that the manufacturing process remains in a state of control.

<div style=\"page-break-after: always\"></div>

This is achieved through the systematic collection, analysis, and trending of product related and process related data.

## Manufacturing process development

The overview of PB006 active substance manufacturing process history is presented below.

After successful  USP  and  DSP  development,  consolidation  runs  were  performed  and  process characterisation  (PC)  studies  defined  process  parameter  criticality  and  its  ranges.  The  process  was upscaled to the commercial scale for production of pre-clinical and clinical material, after its robustness was confirmed in consolidation runs.

In the early development program of PB006, a change in cell banks (MCB and WCB) was implemented; a comprehensive comparability exercise at active substance level confirmed the comparability of both cell banks, and that the finished product manufactured from the initial cell bank is representative for the commercial product.

Early process development activities were initiated, and optimisation of the process was conducted and the  final  verification  of  the  optimised  process  was  performed.  The  final  setting  was  confirmed  by assessing several quality attributes using representative USP starting material. The final process was locked after the manufacture of consolidation runs.

Process characterisation included a pre-PC risk assessment to assess the process- and product related risks  which might impact on process performance and/or product quality, in order to define process parameters for further investigation during PC studies. Finally, the development of a control strategy including justifications for IPC classifications was achieved. The representativeness of the initial WCB for the USP PC characterisation studies has been also confirmed. Resin reuse studies were performed using a representative down-scaled model.

The  development  of  the  manufacturing  process  and  the  process  characterisation  were  well  and comprehensively described. Development activities were performed according to guidance documents, including  comparability  exercises  when  critical  changes  were  implemented  into  the  manufacturing process.  The  provenience  and  the  use  of  each  development  batch  is  clearly  indicated.  The  control strategy is considered state-of-the-art, and was based on an in depth understanding of each process step, supported by intense and well-coordinated development activities. This part of the dossier is found acceptable.

## Characterisation

## Elucidation of structure

PB006 active substance was thoroughly characterised on the physicochemical/biophysical level and at the level of in vitro functional activity using a broad panel of analytical procedures to investigate all relevant quality attributes.  The  applied  method  panel  included  orthogonal  analytical  methods  for  indepth analysis of higher order structures, size and charge variants and the assessment of functional properties of natalizumab.

Taken together, proposed methodological portfolio consists of a broad spectrum of orthogonal and state of the art methods, which enable an in-depth assessment of the active compound. All applied methods were validated, qualified or at least classified as suitable for the intended use. On top of the in-depth assessment  of  the  active  compound,  charge-variants  and  hydrophobic-variants  were  isolated,  and assessed for their specific physico-chemical properties. Taken together, PB006 active substance was sufficiently characterised and respective part of the dossier is considered acceptable.

<div style=\"page-break-after: always\"></div>

## Impurities

Clearance  of  the  most  important  product-related  impurities  was  sufficiently  addressed  in  the  PB006 active substance process validation chapter. It is agreed that no further evaluation of product related impurities is required.

Respective studies demonstrated that the downstream process is able to consistently reduce levels of process-related impurities to meet the limits of the PB006 active substance specification.

Qualitative and quantitative studies were conducted to analyse the extractable profiles and is acceptable for  the  most  important  consumables  used  to  manufacture  PB006  active  substance.  Overall,  the conclusion that it is highly unlikely that an identified or unidentified extractable or leachable chemical from the process equipment may affect the biological safety of PB006 is agreed.

An extractables study performed on the container closure system for PB006 finished product is assessed in the finished product section.

## 2.4.2.3. Specification

## Specifications

The active substance release and shelf life specifications include control of identity, purity and impurities, potency and other general tests.

The proposed battery of assays to control PB006 CQAs is composed of orthogonal and state-of-the-art methods.

Overall, the active substance release and shelf life specifications are considered acceptable.

## Analytical procedures

Analytical procedures used to control PB006 active substance were described.

Validation of non-compendial methods was carried out according to ICH Q2(R1) guideline. All predefined acceptance criteria were met, and thus proposed methods are considered valid within their respective ranges. Compendial methods were qualified for their intended use, but respective qualification protocols were  not  submitted.  Thus  the  applicant  justified  the  performance  in  sample  matrix  of  compendial methods used to assess bioburden and bacterial endotoxins.

## Batch analysis

The applicant presented batch analysis data from manufacturing scale batches. They confirm that the established  manufacturing  process  is  able  to  deliver  PB006  active  substance  with  a  consistent  and predefined  quality  profile,  and  the  proposed  control  strategy  besides  minor  adaptations  of  specified acceptance limits is acceptable.

## Reference Standard

The  development  reference  standards  were  prepared  for  characterisation,  qualification  and  routine testing until preparation of the Interim Reference Standard. The Interim Reference Standard was further qualified as Primary Reference Standard (PRS) prior to the first Working Reference Standard (WRS), which are the two reference standards currently in use. After establishing the PRS, any subsequent WRS will be calibrated against it (two-tiered approach). Based on the re-test results, storage conditions have been confirmed. WRSs will be used for the future routine testing of PB006 active substance and finished product batches and will be characterised against the PRS.

<div style=\"page-break-after: always\"></div>

Development,  primary  and  working  reference  standards  have  been  adequately  bridged  via  potency assays. The reference standard control strategy is properly described.

## Container closure system

The container closure system for PB006 active substance is composed of a PET bottle and a high-density polyethylene (HDPE) screw cap. An appropriate description of the container closure has been provided.

In  summary,  the  proposed  container  closure  system  is  justified  for  storing  PB006  active  substance regarding stability, integrity and compatibility of the medicinal product. All materials of the container closure system are described in the Ph. Eur. and their qualitative composition is determined by the supplier. Absence of interaction studies has been properly justified and a representative supplier product certificate has been provided.

## 2.4.2.4. Stability

The applicant initially claimed a 36-month shelf life (5 ± 3ºC).

The stability of PB006 active substance was performed at long term storage (5 ± 3ºC), accelerated (25 ± 2°C / 60 ± 5% R.H.) and stressed (40 ± 2°C / 75 ± 5% R.H.) conditions. Accelerated and stress stability studies were performed to confirm the PB006 active substance stability-indicating profile, and provided assurance that changes in the purity and potency are detected. Stability studies of PB006 active substance were designed in accordance with guidance documents ICH Q5C and ICH Q1A(R2), considering testing frequency, storage conditions, representativeness of batches, container closure system and the applied methodological portfolio.

The shelf-life of PB006 active substance was determined at long term conditions based on the totality of available  real-time  stability  data.  All  test  parameters  remained  within  the  pre-defined  shelf-life specifications for all available pull-points. Stability studies will be pursued, and data provided according to the post-approval stability commitment.

Data and graphical representations from accelerated and stress stability studies were presented.

Taken together, design of stability studies, choice of stability batches and proposed shelf-life specification is appropriate.

Overall, taking into account the totality of the data submitted by the applicant, the proposed shelf-life for the active substance is acceptable.

The applicant committed to finalise ongoing stability studies to confirm proposed shelf-life of PB006 active substance at long-term storage conditions, and to place on stability at least one commercial batch each calendar year, as long as production occurs during the respective calendar year. Stability-indicating parameters will be studied, while the assessment of quality attributes which have shown to be unaffected in  presented stability programs will be omitted. In case of any confirmed OOS result or unexpected stability  issue,  the  applicant  will  inform  the  agency  and  propose  appropriate  corrective  actions.  The proposed post-approval stability commitment is acceptable.

## 2.4.3. Finished Medicinal Product

## 2.4.3.1. Description of the product and pharmaceutical development

PB006 finished product is a sterile, colourless, and clear to slightly opalescent concentrate for solution for infusion, presented in Type I borosilicate glass vials not siliconised, with bromobutyl stoppers and

<div style=\"page-break-after: always\"></div>

aluminium seals with a flip-off cap. No overage is required. The nominal fill volume of PB006 finished product  is  15  mL  per  vial.  Each  vial  contains  an  appropriate  excess  volume  (overfill)  that  allows withdrawal of the labelled amount of the finished product from the vial.

The finished product is formulated with sodium chloride, histidine, histidine hydrochloride monohydrate, polysorbate 80 and water for injections. All excipients are widely used in the manufacturing of parenteral pharmaceutical preparations and, comply with the Ph. Eur. Certificate of analyses for all four excipients are provided. The finished product does not contain any novel excipients or any excipients of human or animal origin.

The procedure followed to determine the overfill volume is described and results have been provided.

Characterisation  studies  covering  physicochemical  and  biological  properties  of  natalizumab  were performed  using  PB006  active  substance  as  well  as  PB006  finished  product  (for  selected  quality attributes). An overview of the QTPP of PB006 is presented. In order to define the acceptable ranges for the quality attributes (QA) of the proposed biosimilar, the range and variability of the reference product was evaluated using multiple batches of Tysabri. CQAs were identified by the risk assessment performed in accordance with ICH Q9. The criticality of each quality attribute is defined by combining the impact and uncertainty assessments according to the concepts discussed in the dossier.

The  PB006  finished  product  manufacturing  process  employs  standard  methods  for  production  of parenteral products that cannot be terminally sterilised. PB006 is a concentrate for solution for infusion which is manufactured by sterile filtration and subsequent aseptic filling. PB006 active substance and PB006 finished product have the same qualitative composition and no compounding is performed in the PB006 finished product manufacturing process. The same process was used for manufacturing of finished product during clinical trials.

Changes in the manufacturing process have been properly described. PB006 finished product used for non-clinical  studies  was  manufactured  at  the  initial  manufacturing  site.  Afterwards,  the  clinical manufacturing process was established at the commercial manufacturing site. Differences introduced into the PB006 finished product manufacturing process are related to the change of the manufacturing site.

Comparability between pre-clinical and clinical manufacturing processes has been confirmed by available batch release data and stability data. No differences in the degradation rates and profiles were observed between the pre-clinical and clinical batches.

Based  on  the  change  of  the  manufacturing  site  and  the  additional  experience  gained  during  PB006 finished product manufacturing, adjustments for some of the manufacturing steps were introduced to optimise  the  process  for  the  commercial  manufacturing.  Based  on  the  results  gathered  during  the development studies and the increased product knowledge, a failure mode effect analysis (FMEA) risk assessment of the PB006 finished product manufacturing process was conducted prior to PPQ campaign to define a product control strategy and process action limits. Selection of the PB006 finished product primary packaging for clinical trials was based on the outcome of the reverse engineering evaluation of the RMP Tysabri. Extractable studies were not performed on the glass vials, which are non-polymeric and  widely  used  for  pharmaceutical  drugs,  and  are  considered  to  be  of  low  risk  and  not  requiring evaluation for extractable. The discussion on the toxicological evaluation and the final outcome have been provided.

The  applicant  explained  that  a  change  of  the  vial  became  necessary,  due  to  a  decision  of  the manufacturer to discontinue production of the vial chosen for clinical batches of PB006. An alternative manufacturer  was  selected,  and  implemented  prior  to  finished  product  process  validation  for  future commercial  production.  Comparability  to  the  previously  used  vial  was  assessed.  Studies  performed confirmed  the  suitability  of  the  vials  used  in  commercial  production.  Microbiological  quality  of  the

<div style=\"page-break-after: always\"></div>

container closure system selected was confirmed. The applicant performed in-use compatibility studies to  ensure  physicochemical  compatibility  of  PB006  finished  product  with  the  clinical  administration materials at various stages of product development A detailed justification for the low risk classification and the omission of shear force stress degradation studies have been provided. The in-use compatibility of PB006 finished product with clinical administration items was successfully proved.

## 2.4.3.2. Manufacture of the product and process controls

## Manufacturing process

Manufacturing of the finished product, including primary and secondary packaging and quality control and release testing facilities are listed in the dossier. All sites are compliant with EU GMP.

PB006 finished product and active substance have the same qualitative and quantitative composition.

PB006 finished product is manufactured according to a standard manufacturing process which includes pooling  of  active  substance,  bioburden  reduction  filtration,  sterile  filtration,  filling  and  stoppering, crimping, visual inspection, storage and final packaging. A flow chart of the manufacturing process which include all process steps, CPPs and critical IPCs is presented. The steps are properly described. The batch number system is described. Established hold times have been validated and described.

## Process controls

The  overall  control  strategy  presented  includes  definition  of  process  parameters  and  IPCs.  Process parameters have been classified in CPPs, KPPs and non-KPP. Any excursion outside of the established acceptable ranges during the GMP production is investigated and the possible impact on quality will be assessed according to the site internal procedures. Definition of IPCs has been done according to ICH guidelines. For the control of output parameters whose variability has the potential to affect a CQA in the final product (critical IPC), an acceptance criterion or an action limit is defined, and optionally an additional alert limit. Definition of process parameters and IPCs has been properly described. The control strategy  presented  is  appropriate  to  ensure  adequate  product  quality  and  manufacturing  process consistency.

## Process validation

To ensure that the process is consistent and robust, several activities have been conducted throughout the process design and process qualification (PQ) stages. A pre-PPQ risk assessment has been performed ahead of process validation according to FMEA. Validation of the manufacturing process has been done with  three  consecutive  batches  manufactured  according  to  the  PPQ  protocol,  from  active  substance batches fully representative. Test procedures applied to process validation samples and results from analytical method validation are discussed. Validation of PB006 finished product manufacturing process is discussed. The validation strategy is properly described and considered acceptable.

The  membrane  filters  used  for  bioburden  reduction  and  subsequent  sterilising  filtration  of  active substance  are  sterilised,  and  respective  qualification  reports  were  provided.  Filters  have  been validatedFilter validation has been performed according to EMA Guideline on 'the sterilisation of the medicinal product, active substance, excipient and primary container' (EMA/CHMP/CVMP/QWP/850374/2015). Validation of the aseptic filling process in the sterile area of the finished product manufacturing facilities was initially performed with three consecutive successful media fills and is periodically re-validated by media fills.

The suitability in terms of safety of the polymeric process contact materials that are used during the finished  product  manufacturing  process  has  been  evaluated.  Mandatory  E&amp;L  studies  for  the  primary packaging and the final filter of the finished product were performed. The summary reports for the PB006

<div style=\"page-break-after: always\"></div>

active substance and finished product elemental impurity risk assessment and for the elemental impurity clearance study have been provided. Vials are washed, depyrogenated and sterilised. The validation process for the depyrogenation step and vial washing step are reported. Rubber stoppers are pre-washed and sterilised. Validation of rubber sterilisation is reported.

Process performance and product quality will be monitored as part of the continued process verification (CPV) to ensure that the manufacturing process is maintained under control throughout the commercial phase.

## 2.4.3.3. Product specification

## Specifications

The  finished  product  release  and  shelf-life  specifications  include  test  methods  for  physical  state, coloration, clarity, subvisible particles, visible particles, osmolality, extractable volume, pH, excipient concentration, identity, purity, sterility, bacterial endotoxins, content and biological activity (potency).

The  quality  attributes  selected  for  release  and  stability  of  PB006  finished  product  are  considered adequate and in line with the guidelines ICH Q6B, EMA/CHMP/BWP/532517/2008 and EMEA/CHMP/BWP/157653/2007. Related analytical tests are acceptable. For compendial methods the respective references to Ph. Eur. and USP are included.

Acceptance criteria for PB006 finished product release and stability testing, as well as limits for PB006 in-process testing, were set based on the available data from PB006 finished product batches, and PB006 finished product stability studies.

Overall, the finished product release and shelf life specifications are considered acceptable.

## Analytical procedures

For methods identical to the active substance testing, the applicant refers to the corresponding active substance sections.

For  compendial  methods,  the  applicant  refers  to  the  corresponding  Ph.  Eur.  Monographs.  Noncompendial  tests  have  been  validated  according  to  ICH  Q2(R1)  and  a  validation  report  for  the instrumental method has been provided. Verification reports for the compendial microbiological methods are presented.

## Characterisation of impurities

A risk analysis in accordance with ICH Q3D guideline was performed to evaluate the potential presence of  elemental  impurities  in  PB006,  covering  raw  materials,  excipients,  manufacturing  equipment  and utilities as possible sources of elemental impurities. Mentioned strategy and the applicant's conclusion that no additional control measures are required is acceptable.

A nitrosamine risk assessment was performed and considered raw materials, single use materials and manufacturing process conditions used to manufacture PB006 active substance. Respective summary report was provided, and the conclusion that there is no risk of presence of nitrosamine impurities in the PB006 active substance is supported.

## Batch analysis

Results  of  all  batch  analyses  are  presented.  The  history  of  release  and  shelf-life  specifications  and procedures and changes for analyses of commercial processes are presented. Batch to batch consistency has been confirmed among all batches tested

<div style=\"page-break-after: always\"></div>

## Container closure system

The container closure system is a clear Type 1 non-siliconised glass vial, closed with a 20 mm bromobutyl rubber  stopper  coated  with  fluoropolymer,  and  crimped  with  20  mm  flip-top  aluminium  seal  caps). Technical drawings of stopper and vial, with critical dimensions, are provided. The secondary packaging system  is  described.  Specifications  for  vial  and  stopper  have  been  provided.  Compliance  to  Ph. Eur./pharmacopoeia is stated. Compliance status of the cap is not applicable since it is not in contact with the product, which is acceptable. Suitability of the container closure system for storage has been confirmed. Risk assessment has been conducted on all materials in contact with product. Extractable/leachable studies have been performed only on the rubber stopper.

## 2.4.3.4. Stability of the product

The applicant proposed a shelf-life of 36 months at 2 to 8°C for the undiluted product and an in-use storage up to 24 hours at 2 to 8°C for the diluted product.

The shelf-life claim is based on available data from stability studies performed in accordance with to the guidelines ICH Q5C and Q1A. Stability was tested at long-term condition (5 ± 3ºC for 48 months), accelerated condition (5 ± 2°C / 60 ± 5% R.H. for 6 months) and stress condition (40 ± 2°C / 75 ± 5% R.H. for 6 months).

The applicant included batches manufactured according to the commercial process, batches of different age and batches derived from different active substance batches. Samples were stored in an upright (intended storage condition only) and inverted position, protected from light.

Results show that all batches remained within the shelf-life specifications after storage at the intended condition of 5 ± 3ºC. Significant changes are observed when samples are stored at 40 ±2°C / 75±5 %RH: Since no significant differences in stability behaviour were observed between the batches tested, the applicant claimed a shelf-life of 36 months, based on a minimum of 3 batches with the longest real time stability data.

Photostability  was  assessed  in  accordance  to  the  guideline  ICH  Q1B.  Studies  confirmed  that  PB006 finished  product  is  light  sensitive  and  should  be  protected  from  light  in  the  secondary  packaging cardboard box. Exposure to stress conditions like oxidation, freeze-thaw, low pH and mechanical stress has been tested within the biosimilarity analytical assessment.

Overall, the acceptable shelf-life for the finished product in unopened vial is 3 years when stored at 2°C to 8°C protected from light.

From a microbiological point of view, after dilution with sodium chloride 9 mg/mL (0.9%) solution for injection, immediate use is recommended. If not used immediately, the diluted solution must be stored at 2°C to 8°C and infused within 24 hours of dilution. In-use storage times and conditions prior to use are the responsibility of the user.

## 2.4.3.5. Biosimilarity

The applicant has conducted an extensive comparative analytical assessment of PB006 and Tysabri, addressing more than 40 quality attributes to demonstrate that PB006 is identical to the EU approved RMP in amino acid sequence and similar in physicochemical and functional tests, using a broad panel of sensitive and orthogonal analytical methods.

Analytical similarity of PB006 was assessed in a comprehensive analytical similarity exercise using EUsourced Tysabri RMP. The clinical study (PB006-01-03) was conducted with US-Tysabri and thus, the

<div style=\"page-break-after: always\"></div>

applicant performed a three-way analytical similarity assessment between PB006, EU-Tysabri, and USTysabri. The biosimilarity exercise includes the comparison of physicochemical, biophysical and in vitro functional properties, forced degradation studies and stability studies under long-term, accelerated and stress conditions. Tables and figures summarising the individual results and data distribution for each parameter, chromatograms, spectra, dose-response curves etc. have been included. The presentation of data was well structured and of high quality.

An  in-depth  analysis  of  the  RMP  and  the  biosimilar  as  well  as  prior  knowledge  was  the  base  for establishment  of  the  QTPP.  Each  quality  attribute  identified  was  classified  according  to  the  risk  to potentially have an impact on activity/efficacy, pharmacokinetics/pharmacodynamics (PK/PD), immunogenicity and safety as well as the uncertainty of the impact. Similarity was primarily concluded from min-max ranges obtained from EU-Tysabri, pre-defined quality ranges (QRs) were considered as secondary criterion. QR is defined as QR = ( μ R - K σ R, μ R + K σ R) where μ R is the sample mean, σ R is the sample standard deviation based on reference product lots, and the multiplier K (in principle, the higher the risk category, the lower the multiplier).  Overall, the critical quality attributes assessment was well described and in the main the outcome of the risk assignment appears reasonable.

The  analytical  similarity  study  includes  PB006  (natalizumab)  data  from  finished  product  batches manufactured at full commercial scale. Biosimilarity was evaluated against an appropriate number of batches of the reference medicinal product, EU-approved Tysabri. A reduced but appropriate number of batches has been used for primary structure analysis by LC-MS as well as for ADCC, CDC, ADCP, binding to Fc γ R and C1q methods. US-sourced Tysabri products have been used in the clinical study (PB006-0103). Therefore, US-Tysabri batches have additionally been included in the analytical similarity analyses. A bridging report of EU-approved and US-licensed Tysabri has been provided by the applicant.

Ages of the PB006 and Tysabri batches at the time of analytical testing vary within the expiry date. The batches seem to reflect a range of expiration dates and product ages. Justification for the statistical approaches were provided, and these are considered acceptable as supportive evidence of biosimilarity. As presented by the applicant, all the assays used in the biosimilarity study are demonstrated to be suitable for their intended purpose and are either qualified, validated, fit for purpose or are compendial methods.  The  chosen  methods  are  considered  standard  methods  that  are  state-of-the-art  and  are suitable  to  characterise  and  compare  relevant  structural  and  functional  features  of  the  natalizumab finished product in comparison to the RMP. Analytical methods cover primary and higher order structure, potency/binding and Fab arm exchange kinetics as well as purity and product related variants. For each parameter under investigation, the methodology and performance of the analyses were well described, batches used and experimental data derived were well presented including raw data or chromatograms/spectra where applicable.

## Similarity between PB006 and Tysabri

For many quality attributes, PB006 was demonstrated to be analytically highly similar to EU-Tysabri. Observed differences are adequately addressed by the applicant and are not expected to impact clinical performance of the product. In addition, analytical comparability of US-Tysabri to EU-Tysabri has been sufficiently demonstrated as presented in a separate bridging report.

## Primary and higher order structure

Primary structure of PB006 was characterised for amino acid sequence by peptide mapping with 100% confirmation of the sequence. Intact deglycosylated protein, heavy chain deglycosylated and light chain masses of PB006 and RMP were demonstrated to be similar to that of theoretical masses. The same locations of posttranslational modifications (N-terminal pyroglutamic acid, oxidation, deamidation, Nglycosylation) have been detected in peptide mapping MS analyses of PB006 and Tysabri samples.

<div style=\"page-break-after: always\"></div>

Higher order structure was characterised for secondary and tertiary structure. The spectra of higher order structures are similar between PB006 and the RMP and, minor differences in the overall secondary structure are not considered impactful as the region impacted does not show strong straightforward correlation to the secondary structure of the protein.

## Fab-arm exchange kinetics

Fab-arm exchange kinetics, a process typical for IgG4 molecules has been characterized using FRET in reducing and physiological (serum) mimicking conditions as suggested within an EMA-SA. The exchange of half-molecules of PB006 was within min-max ranges set by the EU-RMP under both conditions and are thus regarded as similar.

## Functional characterisation

Natalizumab is binding to the α4 -subunit of α4β1 and α4β7 integrins expressed on the surface of all leukocytes  except  neutrophils  inhibiting  the α4 -mediated  adhesion  of  leukocytes  to  their  counterreceptor(s) vascular cell adhesion molecule-1 (VCAM-1), and mucosal adressin cell adhesion molecule1 (MAdCAM-1). The main mechanism of action (MoA) was evaluated by an ELISA method and SPR. Analysing binding to α4β1 and α4β7 by ELISA, relative potency values of PB006 batches were comparable to EU-Tysabri and US batches. Orthogonal SPR analyses showed similar relative potencies and measured binding  affinities  constants  between  compared  PB006,  EU-Tysabri  and  US-Tysabri  batches.  In  turn, inhibition of interaction between VCAM-1 and α4 integrin evaluating the MoA, was demonstrated by three potency  methods,  relevant  cell-based  assays  included,  and  the  results  were  comparable.  Highly comparable  results  have  been  provided  for  the  inhibition  of  interaction  between  MAdCAM-1  and α4 integrin.  As  natalizumab  does  not  exert  Fc-effector  functions,  the  absence  of  such  functions  was demonstrated for all three products.

Limited Fc γ receptor binding could be demonstrated for PB006, EU-RMP and US-Tysabri targeting various Fc γ receptor isoforms. In comparison to a positive control C1q activity by natalizumab could not be shown. Binding of natalizumab to FcRn was shown to have comparable relative potencies and binding affinity constants.

Although  individual  outliers  have  been  detected,  it  is  agreed  that  biosimilarity  regarding  biological functionality was demonstrated.

## Molecular heterogeneity

Molecular heterogeneity was characterised for size, charge heterogeneity and N-glycosylation. Results indicated similar structural, size, and charge heterogeneity between PB006 and the RMP Tysabri.

Size heterogeneity was assessed by multiple orthogonal, state-of-art methods and comparable profiles and chromatograms/electropherograms were observed indicating similarity. The size variants and their levels are similar. A larger non-glycosylated heavy chain (NG-HC) peak was observed in EU/US-Tysabri samples in comparison to PB006. However, this is a desirable effect and indicates consistent high degree glycosylation using CHO host cell (vs murine cells used for Tysabri). Antibody fragments in PB006 are low and similar to EU/US-Tysabri.

Free thiols and correct disulphide bridging were analysed with higher free amounts of SH groups detected for PB006 in comparison to EU and US-Tysabri. The same trend is detected by analyses of non-reduced peptides. The applicant argues that differences detected are small and related to the semi-quantitative method variability. As no effect on relative potency and higher order structure could be detected, the conclusion is followed that there is only low risk to be clinically meaningful. Further, neither thioether bonds nor incorrectly bound disulphide bonds were detected.

<div style=\"page-break-after: always\"></div>

Charge heterogeneity was verified. Overall PB006 and Tysabri were found to be similar in terms of charge heterogeneity with the exception of a basic peak at approximately 30 min elution time detected in Tysabri batches.  Consequently,  higher  main  charge  variants  for  PB006  and  lower  basic  variants  have  been reported in comparison to EU-Tysabri. The applicant investigated the basic fragment of the signal peptide present in Tysabri samples in detail. Acidic variant levels were found to be highly similar in PB006 batches as  compared  to  EU-approved  Tysabri.  Deamidation  occurs  at  very  low  levels  and  no  major  sites  of deamidation have been found within CDR and non-CDR regions of natalizumab. No concern is raised for slight differences shown between PB006 and the RMP.

Levels  of  isoaspartic  acid  and  glycation  were  shown  to  be  comparable.  N-terminal  sequence heterogeneity shows almost 100% conversion of N-terminal glutamine to pyroglutamate for all analysed natalizumab samples. An incompletely processed signal peptide was detected in EU/US-Tysabri which seems to be cell line specific. Absence in PB006 is considered beneficial. No differences in C-terminal lysine formation were determined between PB006 and the RMP. C-terminal leucine (L445) amidation however  is  reported  for  PB006  at  very  low  levels  whereas  this  posttranslational  modification  is  not present in Tysabri (murine host cell). Amidation is not considered unnatural, thus no clinical impact is expected.

Low oxidation levels of methionine residues analysed by multiple orthogonal methods observed in PB006 and EU/US-Tysabri were reported. Major oxidation sites are HC M255 and HC M431 both located at the constant region of the antibody. M255 showed higher oxidation levels in PB006 when compared to EUTysabri. However, as shown in the functional assessment section, potency was found to be highly similar and FcRn binding was not affected by Met oxidation in the constant domain. Slightly higher oxidation levels for PB006 were obtained by other applied analytical methods, which correlates with the presented site-specific results. The hydrophobic variants analyses showed higher results for PB006 in comparison to  the  EU/US-Tysabri  samples,  correlating  with  results  from  the  above  discussed  C-terminal  leucine amidation. It was concluded by the applicant that the hydrophobic variants did not impact protein folding (data from higher order structures assays) and had no influence on protein potency. Corresponding data have been provided.

N-glycosylation was characterized for site occupancy by panel of orthogonal methods. N-glycosylation site occupancy was identified at EEQFN(300)STYR peptide with slightly higher results in comparison to EU/US-Tysabri samples. Similar results were provided by other orthogonal analyses. Comparable glycan profiles with minor differences in N-glycans present were shown. While the following N-glycan groups could  be  detected  (main,  high  mannose,  afucosylated,  sialylated  and  galactosylated  glycans),  the immunogenic α(1,3) -galactosylation could not be identified in PB006 natalizumab samples analysed. Differences reported include higher values for galactosylated, afucosylated and high mannose N-glycans as well as lower values for main glycan and sialylated glycan species for PB006 samples in comparison to EU/US-Tysabri. However, all reported values are within min-max and/or QR ranges of EU-Tysabri.

## Finished product attributes

Protein  concentration  was  calculated  using  the  experimentally  determined  extinction  coefficient.  The applicant provided experimentally determined absorbance coefficients for PB006 and EU-RMP. Measured UV 280 concentration values were used for all PB006 batches and for the majority of EU-approved Tysabri batches during the biosimilarity studies. The limited use of nominal concentration values for Tysabri does not affect the similarity claim. A justification has been provided. Clinical doses in the Phase 1 PK/PD study  were  calculated  based  on  the  truly  measured  antibody  concentration,  instead  of  the  labelled concentration.

Overall, at the quality level similarity between PB006 and EU-sourced Tysabri could be demonstrated for most quality attributes in a comprehensive analytical similarity exercise. Comparability between EU- and US-sourced Tysabri, which was used as comparator in the clinical trial, could be demonstrated in the

<div style=\"page-break-after: always\"></div>

analytical similarity exercise. The uncertainties concerning differences observed in some parameters of PB006 in comparison to the RMP and issues regarding missing information are considered resolved.

The following table summarises the outcome of the analytical similarity exercise:

Table 1: Summary of analytical biosimilarity assessment

| Category                 | Product Attributes                                         | Evaluation method                           | Key findings 1                       |
|--------------------------|------------------------------------------------------------|---------------------------------------------|--------------------------------------|
| Identity and structure   | Primary Structure                                          | Peptide mapping-UV                          | Identical                            |
| Identity and structure   | Primary Structure                                          | LC-MS                                       | Identical                            |
| Identity and structure   | Molecular mass                                             | LC-MS                                       | Comparable                           |
| Identity and structure   | Higher order structure                                     | FTIR                                        | Comparable                           |
| Identity and structure   | Higher order structure                                     | CD                                          | Comparable                           |
| Identity and structure   | Higher order structure                                     | Fluorescence spectroscopy                   | Comparable                           |
| Identity and structure   | Fab arm exchange kinetics                                  | FRET in PBST-DTT conditions                 | Comparable                           |
| Identity and structure   | Fab arm exchange kinetics                                  | FRET in physiologically relevant conditions | Comparable                           |
| Potency and binding      | Binding to α4β1 - integrin                                 | ELISA                                       | Comparable                           |
| Potency and binding      | Binding to α4β1 - integrin                                 | SPR                                         | Comparable                           |
| Potency and binding      | Binding to α4β7 - integrin                                 | ELISA                                       | Comparable                           |
| Potency and binding      | Binding to α4β7 - integrin                                 | SPR                                         | Comparable                           |
| Potency and binding      | Inhibition of interaction between VCAM-1-and α4 integrin   | ELISA                                       | Comparable                           |
| Potency and binding      | Inhibition of interaction between VCAM-1-and α4 integrin   | Cell based assay                            | Comparable                           |
| Potency and binding      | Inhibition of interaction between VCAM-1-and α4 integrin   | Flow cytometry                              | Comparable                           |
| Potency and binding      | Inhibition of interaction between MAdCAM-1-and α4 integrin | ELISA                                       | Comparable                           |
| Potency and binding      | ADCC                                                       | Cell based assay                            | Comparable (no significant activity) |
| Potency and binding      | CDC                                                        | Cell based assay                            | Comparable (no significant activity) |
| Potency and binding      | ADCP                                                       | Cell based assay                            | Comparable (no significant activity) |
| Potency and binding      | Binding to Fc γ receptors                                  | SPR                                         | Comparable (low binding)             |
| Potency and binding      | Binding to C1q                                             | ELISA                                       | Comparable (no significant binding)  |
| Potency and binding      | Binding to FcRn                                            | SPR                                         | Comparable                           |
| Product related variants | Dimers                                                     | SEC                                         | Comparable                           |
| Product related variants | Dimers                                                     | SV-AUC                                      | Comparable                           |
| Product related variants | HMWI                                                       | SEC                                         | Comparable                           |
| Product related variants | HMWI                                                       | SV-AUC                                      | Comparable                           |
| Product related variants | Total aggregates Monomer peak                              | SEC                                         | Comparable                           |
| Product related variants | Total aggregates Monomer peak                              | SV-AUC                                      | Comparable                           |
| Product related variants | (Purity)                                                   | SEC                                         | Comparable                           |
| Product related variants | (Purity)                                                   | SV-AUC                                      | Comparable                           |
| Product related variants | (Purity)                                                   | CE-SDS non-reduced                          | Comparable                           |
| Product related variants | Antibody fragments (LMWI)                                  | CE-SDS non-reduced                          | Comparable                           |
| Product related variants | Antibody fragments (LMWI)                                  | CE-SDS reduced                              | Comparable                           |
| Product related variants | Half antibodies                                            | CE-SDS non-reduced                          | Comparable                           |

<div style=\"page-break-after: always\"></div>

| Category                 | Product Attributes                   | Evaluation method             | Key findings 1                                 |
|--------------------------|--------------------------------------|-------------------------------|------------------------------------------------|
|                          | Free thiols                          | Ellman's assay                | Higher values for PB006, differences justified |
| Product related variants | Open disulfide bonds                 | LC-MS                         | Higher values for PB006, differences justified |
|                          | Acidic variants                      | CEX                           | Comparable                                     |
|                          |                                      | cIEF                          | Comparable                                     |
|                          | Basic variants                       | CEX                           | Lower values for PB006, differences justified  |
|                          |                                      | cIEF                          |                                                |
|                          | Main charge variant                  | CEX                           | Higher values for PB006, differences justified |
|                          |                                      | cIEF                          |                                                |
|                          | Deamidation in the non-CDR           | LC-MS                         | Comparable                                     |
|                          | Deamidation in the CDR               | LC-MS                         | Comparable                                     |
|                          | C-terminal amidation                 | LC-MS                         | Higher values for PB006, differences justified |
|                          | Isoaspartic acid                     | Isoquant                      | Comparable                                     |
|                          | Glycation                            | LC-MS                         | Comparable                                     |
|                          | C-terminal lysine                    | LC-MS                         | Comparable                                     |
|                          |                                      | CEX-CpB                       | Comparable                                     |
|                          | N-terminal pyro- glutamate           | LC-MS                         | Comparable                                     |
|                          | Oxidation in the non- CDR            | LC-MS (absolute method)       | Higher values for PB006, differences justified |
|                          |                                      | RP-UPLC (Fc region oxidation) |                                                |
|                          | Oxidation in the non- CDR/CDR region | HIC                           | Comparable                                     |
|                          | Hydrophobic variant                  |                               | Higher values for PB006, differences justified |
|                          | Oxidation in the CDR                 | LC-MS                         | Comparable                                     |
|                          | N-glycosylation site                 | CE-SDS reduced                | Higher values for PB006,                       |
|                          | occupancy                            | LC-MS                         | differences justified                          |
|                          | Galactosylated N- glycans            | HILIC                         | Higher values for PB006, differences justified |
|                          | Sialylated N-glycans                 | HILIC                         | Lower values for PB006, differences justified  |
|                          | Afucosylated N- glycans              | HILIC                         | Comparable                                     |
|                          | High mannose N- glycans              | HILIC                         | Comparable                                     |
|                          | Main glycan                          | HILIC                         | Comparable                                     |
|                          | Galactose- α -1,3- galactosylation   | xCGE-LIF                      | Not detected in PB006                          |
| Strength and composition | Natalizumab concentration            | UV-Vis Spectroscopy           | Comparable                                     |
| Strength and composition | Extractable volume                   | Gravimetric                   | ≥ nominal volume (15.0 mL)                     |
| Particles                | Visible particles                    | Visual inspection             | Fulfills regulatory requirements               |
| Particles                | Subvisible particles                 | LO                            | Fulfills regulatory requirements               |
| Particles                |                                      | MFI                           | Comparable                                     |

1  Comparable means all batches are within min/max ranges and/or Quality Ranges

## Stability

<div style=\"page-break-after: always\"></div>

The applicant presented a detailed dataset from long-term (5 ± 3°C up to 6 months), accelerated (25 ± 2°C/60 ± 5% R.H. up to 6 months) and stress (40 ± 2°C/75 ± 5% R.H. up to 6 months) stability studies as  well  as  forced  degradation  studies  (multiple  stress  conditions),  in  order  to  establish  degradation profiles and to provide a direct stability comparison of PB006 and Tysabri.

No significant differences were observed under long-term and accelerated storage conditions up to and including the 6-month timepoint. Minor differences have been observed for stressed samples between PB006 and Tysabri, however no clinically meaningful impact is expected.

## Bridging data of EU-approved and US-licensed Tysabri

An analytical bridging report has been provided between EU-approved Tysabri and US-licensed Tysabri for supporting the conclusions drawn from the PB006 clinical studies. The report consists of data from establishment of QTPP ranges. Although minor differences were detected, it is agreed that the analytical bridge  is  established  with  regards  to  identity  and  structure,  potency  and  binding,  product-related variants, strength and composition as well as degradation pathways and degradation kinetics.

Overall,  taking  into  account  the  totality  of  the  data  provided,  biosimilarity  of  Tyruko  with  Tysabri  is considered demonstrated from a quality point of view.

## 2.4.3.6. Adventitious agents

Viral clearance studies were performed according to guidance documents. It is agreed that the PB006 active substance purification process provides sufficient capacity for virus clearance.

Process characterisation and validation studies were performed using scale down models, which were established for each step of the PB006 active substance manufacturing process. Enough details on each model were given, and the representativeness of each single manufacturing step was studied based on representative material. Results confirmed that down-scaled models for all manufacturing steps were suitable  and  representative  of  the  manufacturing  scale  behaviour  for  the  measured  attributes,  and therefore suitable for use in process characterisation and validation studies. Virus validation studies were performed  with  the  same  down  scaled  models  as  described  in  Section  3.2.R  Scale  Down  Model Qualification Active substance.

Viral safety in relation to starting materials as well as virus validation were sufficiently addressed and depicted in the dossier, and the applicant's strategy is considered acceptable.

The documentation provided by the applicant confirms that active substance and finished product pose negligible risk for transmission of TSE and BSE and in relation to mycoplasma.

In summary, the adventitious agents safety evaluation is considered acceptable.

## 2.4.4. Discussion on chemical, pharmaceutical and biological aspects

## Active substance

The applicant has developed PB006 as biosimilar to EU approved Tysabri (RMP), and submitted a well written quality part of the dossier. In brief, the QTPP of the biosimilar was designed based on the RMP, which formed the basis for all further development steps. Critical quality attributes were defined based on a risk assessment in combination with a comprehensive assessment of the active compound, based on  a  portfolio  of  validated  or  at  least  qualified  orthogonal,  and  state-of-the-art  methods.  The manufacturing process and respective control strategy were developed based on the QTPP and identified CQAs,  and  validated.  Active  substance  specification  in  combination  with  the  manufacturing  process control  strategy  covers  all  relevant  quality  attributes  of  PB006,  and  thus  the  manufacturing  process

<div style=\"page-break-after: always\"></div>

supplies  the  active  substance  at  consistent  and  acceptable  quality.  Batches  used  for  preclinical  and clinical development were representative for the commercial manufacturing process, and stability data support the claimed active substance shelf-life of up to 24 months at long term storage conditions (5 ± 3ºC).

## Finished product

Tyruko  is  manufactured  according  to  a  standard  manufacturing  process.  No  further  changes  to  the formulation are introduced within the manufacturing process of PB006 finished product. All process steps, CPPs and critical IPCs are discussed.

Pharmaceutical  development,  manufacture  and  control  of  the  finished  product  have  been  properly described.  The  results  presented  indicate  consistency  and  uniformity  of  important  product  quality characteristics. The control strategy is sufficient to guarantee consistent/ satisfactory quality/performance of the product.

The proposed shelf life of 36 months when stored at the intended storage condition (2-8 °C, protected from light) is supported by appropriate data.

## Biosimilarity

Overall, at the quality level biosimilarity between PB006 and EU-sourced Tysabri, which was used as clinical  comparator, could be demonstrated for most quality attributes in a comprehensive analytical similarity  exercise.  In  the  PK/PD  study  EU-and  US-sourced  Tysabri  were  applied,  and  biosimilarity between both products could be demonstrated in the analytical similarity exercise.

Overall,  taking  into  account  the  totality  of  the  data  provided,  biosimilarity  of  Tyruko  with  Tysabri  is considered demonstrated from a quality point of view.

## 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects

The overall  quality  of  Tyruko  is  considered  acceptable  when  used  in  accordance  with  the  conditions defined in the SmPC. The different aspects of the chemical, pharmaceutical and biological documentation comply with existing guidelines.

In conclusion, based on the review of the data provided, the marketing authorisation application for Tyruko is considered approvable from the quality point of view.

## 2.4.6. Recommendation(s) for future quality development

None.

## 2.5. Non-clinical aspects

## 2.5.1. Introduction

Analytical  and  functional  similarity  studies  of  PB006  to  both  US-  and  EU-Tysabri  are  described  and discussed in the Quality Assessment Report. No additional non-clinical PD studies, neither in vitro nor in vivo ,  were  performed for this  MAA. However, a comparative four-week repeated-dose toxicity study including  a  supportive  toxicokinetic  evaluation  was  conducted  to  compare  the  systemic  PK  and toxicological profile between PB006 and EU-Tysabri in Cynomolgus monkeys following IV infusion.

<div style=\"page-break-after: always\"></div>

## 2.5.2. Pharmacology

No in vivo PD animal studies investigating analytical, physiochemical and functional similarity between PB006 and its referenced medicinal product (RMP) Tysabri (sourced from EU) were conducted in addition to the analytical biosimilarity assessment (see quality assessment).

## 2.5.3. Pharmacokinetics

Neither stand-alone comparative PK studies nor separate absorption, distribution, metabolism and/or excretion studies were performed with PB006 and EU-Tysabri. A comparative four-week repeat-dose toxicity study including supportive toxicokinetic evaluation was conducted to compare the systemic PK profile  between  PB006  and  EU-Tysabri  in  Cynomolgus  monkeys  (3  animals/sex/treatment  group) following IV infusion. Natalizumab (PB006 or Tysabri) was given every other day at dose levels of 3 or 30mg/kg body weight. Blood samples for toxicokinetic analysis were obtained predose and several hours post  dose  after  the  end  of  infusion  on  test  days  1  and  30.  To  measure  the  concentrations  of  free Natalizumab (PB006 or Tysabri) in the cynomolgus monkey serum samples, a quantitative antibody sandwich  enzyme  linked  immunosorbent  assay  (ELISA)  was  validated.  All  projected  validation parameters and acceptance criteria, as calibration of a standard curve, accuracy, precision, freeze/thaw stability, long term stability and determination of a LLOQ (Lower Limit of Quantification), were met. In addition, an ELISA assay for determination of PB006 and EU-Tysabri   in application formulation samples and an ELISA method for determination of anti-drug antibodies (ADAs) against Natalizumab (PB006 or EU-Tysabri) in cynomolgus monkey serum were validated. All validation results fulfilled the necessary requirements.

Exposure ratios based on Cmax (maximum concentration) and AUC0-last (area under the concentrationtime curve from time 0 to the time of the last measured concentration) were observed to be highly similar for all treatment groups on day 1, whereas on test day 30 differences were noted between the Cmax and AUC values of PB006 and Tysabri in the high dose groups (males: 2831.3 µg/mL [SD: 604.6] of PB006 and 1708.6 µg/mL [SD: 651.9] of Tysabri; females: 1764.3 µg/mL [SD: 736.1] of PB006 or 858.7 µg/mL [SD: 868.2] of Tysabri). According to the applicant, this observation was considered to be due to ADA formation. To mention, in the high dose groups, only one animal was ADA positive on study day  30,  specifically  a  female  monkey  of  the  Tysabri   treatment  group,  which  had  already  been  ADA positive pre-dose on day 1. Therefore, this explanation might be applicable for females, whereas it cannot explain the differences observed between both Natalizumabs in male animals. Almost all animals in the low dose group of PB006 and Tysabri were found to be ADA positive on test day 30 and showed low serum levels of the drug substance, although female animals treated with Tysabri had significant lower ADA levels (one of them had no ADAs at all), with corresponding slightly higher Natalizumab levels in serum samples, compared to PB006 treated female monkeys. Hence, ADA formation seems to have neutralizing character mirrored by decreased levels of Natalizumab, especially in PB006 treated female animals. The lack of detection of ADAs that presumably also appeared in the high dose groups of PB006 and Tysabri, could be attributed to either immunotolerance due to high dose treatment or to the masking of these antibodies that reacted and were saturated with the test or reference item, respectively, and therefore, not quantifiable. Nevertheless, the low group size (3 animals/sex/group) in conjunction with individual data variability is limiting the sensitivity of the test system and therefore does not allow to reliably distinguish between identified differences of PB006 and Tysabri   treated animals.

<div style=\"page-break-after: always\"></div>

## 2.5.4. Toxicology

## 2.5.4.1. Single dose toxicity

No dedicated single-dose toxicological studies were conducted with PB006.

## 2.5.4.2. Repeat dose toxicity

The applicant conducted a 4-week repeat-dose toxicity study in cynomolgus monkeys to evaluate and compare  potential  toxicological  findings  and  the  toxicokinetic  profile  of  PB006  with  its  referenced medicinal product Tysabri, sourced from EU. The 4 week-duration of this study is consistent with the posology of PB006 which is to be administered by IV infusion once every 4 weeks. Therapy may be continued up to 2 years (after that therapy should be considered only following a reassessment of the potential  for  benefit  and  risk).  However,  up  to  6  months  repeated-dose  toxicity  studies  have  been performed  with  Tysabri  and  as  analytical  and  functional  similarity  of  PB006  to  EU-Tysabri  was demonstrated in in vitro studies, longer duration toxicity studies of PB006 were not conducted and are not considered relevant for this biosimilar development, in which reference is made to EMA's previous findings on safety and efficacy of Tysabri. The Cynomolgus monkey is considered an adequate model for the toxicity study of PB006, as Cynomolgus monkeys were consistently used in the original nonclinical studies performed for registration of the reference product Tysabri.

Animals were assigned to 5 treatment groups (control group, low and high dose groups of PB006 and Tysabri; with 3 animals/sex/group) receiving IV infusions of Natalizumab (0, 3 or 30mg/kg b.w.) every other day. No findings and noteworthy differences were observed with PB006 or Tysabri treated animals regarding local tolerance, mortality, clinical signs (systemic tolerance), body weight and body weight gain,  food  and  drinking  water  consumption,  electrocardiogram  (ECG),  circulatory  functions,  clinical biochemistry,  urinalysis,  ophthalmological  and  auditory  examinations,  macroscopic  systemic  post mortem findings, organ weights and histopathology. Observed differences between control groups and PB006 and RMP treated animals may likely be due to the limited sample size (3 animals/sex/group) and variability within individual animals.

However, some changes in haematological parameters were reported by the applicant. Both high dose groups (30mg/kg of PB006 or Tysabri) showed an increase in the absolute number of the total and differential  leucocyte  count  and  in  the  number  of  reticulocytes,  which  are  considered  common  and reproducible effects of natalizumab in Cynomolgus monkeys. Furthermore, again concerning the high dose groups, an increase in the absolute number of all lymphocyte subtypes compared to the control was noted. Overall, with some exceptions (e.g. sup./cyt. T-cells and act. sup./cyt. T-cells for PB006, 30mg/kg; act. sup./cyt. T-cells and double negative T-cells for Tysabri, 30 mg/kg), these observations were slightly more obvious in male animals. Again, differences between the treatment groups might be relativized by disparities of values from animals within the same treatment groups and limited sample size. Male and female animals treated with 3 or 30 mg/kg Natalizumab (PB006 or Tysabri) revealed to have elevated myeloid : erythroid ratios. Low and high dosage groups of PB006 treated animals seemed to be slightly more affected compared to animals treated with the RMP.

ADA formation was investigated in the course of the 4-week repeat-dose toxicity study in cynomolgus monkeys. Almost all animals in the low dose groups of PB006 and Tysabri were found to be ADA positive on test day 30 with corresponding low levels of Natalizumab in serum samples. Female animals treated with 3mg/kg Tysabri   had significantly lower ADA levels (one out of three revealed to have none at all), compared to 3mg/kg PB006 treated female monkeys, which correlates with slightly higher Natalizumab levels in serum samples in the RMP treated group. In contrast to the low dose groups, no ADAs were

<div style=\"page-break-after: always\"></div>

reported for the high dose groups of PB006 and Tysabri, with the exception of one female animal of the EU-Tysabri   group that already showed to have ADAs prior to its first Natalizumab infusion.

The applicant determined the No-Observed-Adverse-Effect-Level to be above 30 mg/kg PB006 or EUTysabri (IV, every second day for 4 weeks), with the justification that all findings were considered to be anticipated PD effects of natalizumab being a monoclonal antibody binding to α4 integrin.

## 2.5.4.3. Genotoxicity

No dedicated genotoxicity studies were conducted with PB006.

## 2.5.4.4. Carcinogenicity

No dedicated carcinogenicity studies were conducted with PB006.

## 2.5.4.5. Reproductive and developmental toxicity

No dedicated developmental and reproductive studies were conducted with PB006.

## 2.5.4.6. Toxicokinetic data

A comparative four-week repeat-dose toxicity study including a supportive toxicokinetic evaluation was conducted to compare the systemic PK profile between PB006 and EU-Tysabri in cynomolgus monkeys (3 animals/sex/treatment group) following IV infusion. For further details please refer to section 2.5.3. Pharmacokinetics.

## 2.5.4.7. Local Tolerance

No local tolerance studies were performed with PB006 given that all the excipients used in the final commercial formulation are commonly used in currently approved biologics with the same exposure levels and same intended route of administration. Moreover, even if stand-alone local tolerance studies of PB006 have not been performed, in the 4 weeks repeated dose toxicity study in cynomolgus monkey, no test item-related signs of local intolerance have been shown.

## 2.5.4.8. Other toxicity studies

No dedicated 'Other toxicity studies' were conducted with PB006.

## 2.5.5. Ecotoxicity/environmental risk assessment

In line with the Guideline on the environmental risk assessment (EMEA/CHMP/SWP/4447/00 corr 2) in case of products containing proteins, the applicant provided a justification that the use of Tyruko is unlikely to result in a significant risk to the environment.

This is acceptable.

## 2.5.6. Discussion on non-clinical aspects

## Pharmacodynamics

<div style=\"page-break-after: always\"></div>

No in  vivo PD  animal  studies  were  conducted  in  addition  to  the  analytical in  vitro biosimilarity assessment. This is accepted and in agreement with the EMA Guideline on similar biological medicinal products (CHMP/437/04 Rev 1; 2014) and the EMA Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMEA/CHMP/BMWP/42832/2005 Rev 1).

For review of the biosimilar comparability exercise, please refer to the discussion and conclusion section of the respective quality assessment.

## Pharmacokinetics

Overall, methods of analysis were adequately validated and the applicant's approach can be regarded as appropriate. The results of the validations confirmed that the methods employed were suitable for the detection of Natalizumab (PB006 and Tysabri) in application formulations and cynomolgus monkey serum samples, and for the detection of ADAs against PB006 or EU-Tysabri in cynomolgus monkey serum.

The similarity between the originator and the biosimilar product was assessed in the in  vitro quality biocomparability testing. In contrast to in vitro methods, in vivo studies in animals are not necessarily considered informative for the PK similarity / comparability exercise. Due to the high variability, these models are often too insensitive. This conclusion concerns both PK comparisons and comparisons on safety.  Based  on  these  considerations,  these  comparative  studies  in  animal  models  have  been discouraged in a previous Scientific Advice (EMA/CHMP/SAWP/224608/2017).

Additionally, ADA data from animals are not predictive for the clinical situation, and comparative data on ADA are of uncertain relevance. Potential differences in immunogenicity between PB006 and Tysabri should  be  evaluated  in  the  clinical  setup.  Therefore,  the  conducted in  vivo study  can  at  most  be considered supportive, but not as evidence of true clinical similarity.

As indicated by the applicant, the comparative 4-week repeat-dose toxicity study in cynomolgus monkeys with PB006 and EU-Tysabri, including toxicokinetic evaluations, was conducted to satisfy requirements laid out by other health authorities at that time to support entry into global clinical development. The study design, as well as provided data (e.g. results of ADA and Natalizumab concentration evaluations) are considered adequate and sufficient for this purpose. Toxicokinetic data evaluation revealed that there were no noteworthy differences between PB006 and Tysabri with respect to their toxicokinetic profiles in monkeys. As demonstrated in the Tysabri EPAR, natalizumab shows a pk typical profile of monoclonal antibodies,  with  dose-dependent  but  not  dose-proportional  increases  in  Cmax  and  AUC  values  and increases in elimination half-lives with increasing dose. This profile is probably the result of saturation of the major antibody clearance pathway (Fc-mediated phagocytosis).

In  this  sense,  it  is  acknowledged  that  the in  vivo study  was  conducted  due  to  expectations  from regulatory  bodies  competent  for  non-European  regions.  Though  not  endorsed,  these in  vivo testing studies are accepted.

## Toxicology

Generally, studies regarding toxicology, including developmental and reproductive toxicity studies, are not required for non-clinical testing of biosimilars according to the EMEA/CHMP/BMWP/42832/2005 Rev1 guideline.  Neither  are  studies  regarding  safety  pharmacology,  carcinogenicity  and  local  tolerance. Scientific advice was provided by the EMA (EMA/CHMP/SAWP/224608/2017), supporting the proposed strategy of the applicant to not conduct in vivo animal studies to assess biosimilarity between PB006 and its RMP Tysabri. Nevertheless, a comparative 4-week repeat-dose toxicity study in cynomolgus monkeys was conducted to satisfy requirements laid out by other health authorities to support entry into global clinical development.

<div style=\"page-break-after: always\"></div>

Overall,  the  study  design  is  regarded  as  appropriate  in  terms  of  species  selection,  used  dosages, frequency and route of administration. Observed findings, such as increased haematological parameters (lymphocytes, reticulocytes; myeloid: erythroid ratio), were seen in all animals treated with either PB006 or  Tysabri.  Altered  trafficking  of  lymphocytes,  seen  as  an  increase  in  white  blood  cells,  was  already reported in the EPAR of Tysabri   (EPAR Tysabri, latest updated version 8 th  of June 2022) and was described to be reversible without any adverse toxicological changes. In this comparative repeat-dose toxicology study with PB006 and EU- Tysabri,   no recovery groups were included. Although this would have been of interest, the lack of a recovery period is accepted, because reported findings of Natalizumab are already known for Tysabri   and related to its pharmacological activity. A main issue remains the limited number of  animals  per  treatment  group  (3/sex/group),  which  does  not  allow  to  reliable  distinguish  between differences in findings of PB006 and Tysabri   treated animals and individual data variability. Based on the results of the study and taking into consideration the intrinsic variability of the model, the limited sample size and the absence of adverse histopathological findings in any of the animals, there was no noteworthy difference between the animals treated with PB006 and the animals treated with Tysabri   from a toxicity and toxicokinetic point of view. All findings were considered to be anticipated PD effects of natalizumab as a monoclonal antibody binding to α4 integrin, i.e inhibition of lymphocyte migration from blood vessels into the surrounding tissues. Blocking of the α4 integrin also allows migration of the immature red blood cells  from  the  bone  marrow  and  consequently,  the  increase  in  progenitor  cell  circulation.  No  new unexpected toxicities were identified for PB006. The marginal differences observed are considered to be within the biological variability. The toxicological similarity assessment raised no concerns. Therefore, data  obtained  from  this  repeat-dose  toxicology  study  can  be  regarded  as  supportive  information  in addition to the in vitro similarity/comparability exercise, discussed in the quality part of the dossier.

Regarding the ADA assessment of this study, the applicant provided a discussion for possible reasons for ADA detection prior to first infusion on day 1 for female animal number 30 of the 30 mg/kg b.w. Tysabri treatment group. It was confirmed that according to the protocol only treatment naïve animals were used  in  the  repeat-dose  toxicology  study  in  cynomolgus  monkeys  and  that  due  to  the  consistent discrepancy at both pre- dose and on day 30, contamination of the serum samples is unlikely. The existence of pre-existing drug-reactive antibodies as well as other non-antibody interferences in the ELISA assay (e.g. matrix effects leading to the binding of the biotinylated antibody) was discussed, whereat a non-ADA mechanism seems to be more likely (as no ADAs developed in other animals in the high dose group due to interference with high Tysabri levels). Furthermore, serum natalizumab levels of this female animal were similar to the serum natalizumab concentrations in other animals of this dose group and ADA detection at pre-dose in female number 30 had no influence on data interpretation in this study.

## Environmental Risk Assessment

The  active  substance  is  a  natural  substance,  the  use  of  which  will  not  alter  the  concentration  or distribution of the substance in the environment. Therefore Tyruko is not expected to pose a risk to the environment.

## 2.5.7. Conclusion on the non-clinical aspects

The non-clinical dossier can be considered acceptable.

<div style=\"page-break-after: always\"></div>

## 2.6. Clinical aspects

## 2.6.1. Introduction

## GCP aspects

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

The development program comprises 4 clinical studies: 1 pivotal Phase 1 PK/ PD study with PB006, USTysabri, and EU-Tysabri in healthy subjects, 1 pivotal Phase 3 study with PB006 versus EU-Tysabri in patients with RRMS, 1 pilot Phase 1 PK/PD study with EU-Tysabri in healthy subjects and 1 supportive Phase 1 safety study with PB006 in healthy subjects.

## · Tabular overview of clinical studies

Table 2: Clinical development program of PB006

| Study Identifier       | Location of Study Report   | Objective of Study                    | Study design and Type of Control                                   | TestProducts;Dosage Regimen; Route of Administration                                       | Number (N) of Subjects (treated)                              | Healthy Subjects or Diagnosis of Patients   | Duration of Treatment   | Study Status; Type of Report   |
|------------------------|----------------------------|---------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------|-------------------------|--------------------------------|
| [Tysabri Pilot-01- 01] | Module 5.3.3.1             | Safety/immuno- genicity, PK, PD       | Single-center, randomized, 3-arm parallel group study              | EU-Tysabri Single-dose, at 1, 3 or 6 mg/kg IV infusion                                     | 36 subjects N=12 per dose group                               | Healthy subjects                            | 1 day                   | Completed; Full                |
| [PB006- 01-02]         | Module 5.3.3.1             | Safety/immuno- genicity               | Single-center, single. arm, open-label study                       | PB006 Single-dose, 300 mg IV infusion                                                      | 10 subjects                                                   | Healthy subjects                            | 1 day                   | Completed; Full                |
| [PB006- 01-03]         | Module 5.3.4.1             | PK, PD, safety/immuno- genicity       | Multi-center, randomized,double blind, 3-arm parallel group study  | PB006, US-Tysabri or EU-Tysabri Single-dose, 3 mg/kg IV infusion                           | 450 subjects PB006: N=149 US-Tysabri: N=150 EU-Tysabri: N=151 | Healthy subjects                            | 1 day                   | Completed; Full                |
| [PB006- 03-01]         | Module 5.3.5.1             | Efficacy, safety/immuno- genicity, PK | Multi-center, randomized, double blind, 2-arm parallel group study | PB006orEU-Tysabri 300 mg, every 4 weeks, for a total of48 weeks (12 infusions) IV infusion | 264 subjects PB006: N=131 EU-Tysabri: N=133*                  | Patients with RRMS                          | 48 weeks                | Completed; Full                |

EU=European  Union,  IV=intravenous,  N=number  of  subjects,  PD=pharmacodynamic,  PK=pharmacokinetic,  RRMS=relapsingremitting multiple sclerosis, US=United States.

* A subset of 30 patients enrolled in the EU-Tysabri group was switched after 24 weeks from treatment with EU-Tysabri to treatment with PB006 for the remaining period. Thus, a total of 161 patients were treated with PB006.

## 2.6.2. Clinical pharmacology

## 2.6.2.1. Pharmacokinetics

The PB006-01-03 . was a Phase 1 multicenter, double-blind, randomized, single-dose, 3-arm, parallelgroup PK/PD study in healthy subjects, to investigate the similarity between PB006 versus US-Tysabri and versus EU-Tysabri.

Study PB006-03-01 was a phase 3 confirmatory efficacy and safety study in RRMS patients and is presented in detail under efficacy section. Apart from efficacy evaluation based on MRI endpoints, relapse rates and disability status, this study also assessed natalizumab trough concentrations and immunogenicity.

<div style=\"page-break-after: always\"></div>

## Analytical methods

For  quantification  of  MAdCAM-1  and  VCAM-1  levels  in  human  serum,  the  applicant  has  applied  an automated ELISA system based on the Simple Plex ELLA multiplex platform together with combined MAdCAM-1 and VCAM-1 analysis kits purchased from R&amp;D Systems. In brief, diluted samples and running buffer  are  pipetted  into  the  inlet  of  a  cartridge.  Samples  are  directed  by  microfluidic  channels  into different  compartments,  where  they  interact  with  analyte  specific  capture  and  labelled  detection antibodies  pairs.  After  fully  automated,  sequential  incubation  and  washing  steps  fluorescence  is measured through glass nano reactor tubes. Each cartridge lot of the assay is already provided in a prevalidated format, including pre-validated ranges from 0.003 ng/ml to 13 ng/ml and from 0.6 ng/ml to 83 ng/ml for MAdCAM-1 and VCAM-1, respectively. Factory calibration curves are generated on a lot-tolot basis, including assessment of accuracy and precision over the acceptance range. The manufacturer also confirms robustness of the assay for the duration of the cartridge shelf life. No additional calibration samples nor calibration  curves  were  generated.  Partial  re-validation  of  the  assay  for  each  cartridge included the assessment of precision for QC (quality control) samples, the evaluation of a prozone (hook effect),  selectivity  (haemolyzed,  lipemic  samples),  drug  tolerance  (confirmed  up  to  328  µg/ml), freeze/thaw stability, bench-top stability for up to 24 hours, freeze/thaw stability and frozen sample storage stability. Activities were performed at ICON Bioanalytical Laboratories, NL and at PRA Health Sciences, NL. Samples were applied only once but measured in triplicates, and standard settings in the software were used for data evaluation, acceptance and rejection (&gt;10.0% coefficient variation of the RFU)  criteria.  QC  samples  (low,  medium  and  high  concentration)  were  prepared  by  using  reagents (controls  and  assay  diluents)  from  the  kit.  Thus  some  aspects  of  the  method  validation  such  as determination of precision and prozone effect were performed in assay buffer. Blank human serum was used as endogenous QC sample, and to monitor the longitudinal assay performance. All pre-defined validation parameters were met. Frozen storage stability at -70°C was demonstrated for at least 65 weeks for MAdCAM-1. For VCAM-1 endogenous QC samples were measured over a period of 65 weeks, confirming stability of study samples. Taken together, provided validation program covered most but not all aspects: Assay intermediate precision and repeatability were not indicated, and it is unclear if a matrix representative for the clinical samples was used by the manufacturer of the kit for the assessment of accuracy and range. The applicant has applied assay buffer for re-validation of precision and for the assessment of a potential prozone effect. The applicant provided further details on validation activities and justified the omission of the human serum matrix for the assessment of the precision and prozone effect.  Proposed  automated  ELISA  multiplex  MAdCAM-1  and  VCAM-1  assay  seems  suitable  for  the intended application.

The  applicant  has  developed  and  validated  for  assessment  of  PK  two  sandwich  ELISA  to  quantify 'unexchanged'  and  total  Natalizumab  in  human  serum  samples.  The  term  'unexchanged'  refers  to bivalent  antibodies  which  have  not  undergone  Fab-arm  exchange.  Thus  this  assay  is  detecting 'functional' Natalizumab, which fulfils the purpose of a PK assay, and total amounts of Natalizumab by two  different  ELISA.  In  brief,  Natalizumab  is  captured  in  the  functional  Natalizumab  setting  by  an immobilised anti-Natalizumab Fab (Fragment antigen-binding) and detected via an HRP-labelled antiNatalizumab-MAb  conjugate.  For  the  total  Natalizumab  setting,  a  human  monoclonal  Natalizumab specific IgG1 antibody is used as coating agent, while detection occurs via a HRP-labelled murine antihuman IgG4 antibody. Standard curves were fitted in both cases using a 4 parameter logistic model, and used for the evaluation of concentrations of unknown samples. Both methods seem scientifically justified.  They  were  fully  validated  for  their  precision,  selectivity  (in  normal  and  in  patient  serum), minimal required dilution, range (from 60-400 ng/ml in both cases), integrity of dilution and robustness by assessing the impact of haemolytic and lipemic serum, as well as freeze-thaw, bench top, and longterm stability for samples and stock solutions). Specific recognition of 'unexchanged' Natalizumab in the first ELISA setting was sufficiently demonstrated. The validation matrix was a pool of a suitable number of  patient  serum  samples,  and  thus  representative.  All  reagents,  their  provenience  and  the  most

<div style=\"page-break-after: always\"></div>

important methodological details were reported. Validation reports and respective amendments were provided. All predefined acceptance criteria of study plans were met which qualifies both PK assays for their intended use.

Administration of Natalizumab is associated with increased numbers of CD19+ B cells and increased numbers  of  immature  CD34+  progenitor  cells  released  from  the  bone  marrow.  The  applicant  has developed a battery of FACS based assays for immuno-phenotyping of whole blood cells, in order to assess bio-similarity of PB006, Tysabri EU and Tysabri US. Samples were analyzed with a flow cytometer (FACSCanto  II)  equipped  for  measuring  FITC,  PE,  PerCP-Cy5.5,  PE-Cy7,  APC  and  APC-Cy7.  BD FACSCanto  Clinical  Software  v3.1  was  used  for  data  acquisition.  For  data  processing,  De  Novo FCSExpress 6 Flow Clinical Edition was used.

Quantification of CD19+ B-cells in human whole blood was part of this comparability study. CD19 may be involved in activation and proliferation of B lymphocytes and is expressed at all stages of maturation, but gets lost on plasma cells. In brief, whole blood samples are treated with anti-coagulant K3EDTA and fixation reagent Cyto-Chex BCT. Staining is performed with BD Multitest™ 6-color TBNK Reagent, while only B-cells were reported in this study. A validation run is performed each day including the use of setup beads  with  stable  fluorescence  intensity  through  time  to  ensure  stable  performance  of  the  flow cytometer. Prior to the staining of cells, a white blood cell (WBC) count was carried out to ensure that the total WBC count was between below 33.0x10 6  WBC/mL. Two separate validation reports for the same analytical  procedure  were  provided  for  the  NL  and  the  US  site.  A  cross-validation  of  bioanalytical laboratories was performed. The assay was validated for its repeatability, intermediate precision, and reproducibility between  Assen  (NL)  and  Lenexa  (US)  Bioanalytical  Laboratories.  Inter-operator reproducibility and inter-analyst data analysis reproducibility were evaluated. Blank matrix consisted of whole blood donations from three individuals collected at 5 time-points. Inter-assay reproducibility was analysed in three runs on three separate days. Stability of whole blood and stained cells as well as carryover were also assessed. Tysabri EU, Tysabri US and PB006 had the same outcome with regards to intraassay reproducibility, whole blood stability and stained cell stability. Therefore it was concluded that the assay is measuring all 3 compounds in a comparable way. The method met the requirements of the validation plan and was considered suitable for determination of CD19+ B cells in human whole blood samples.

The same quantification protocol for CD34+ cells in human whole blood was applied in studies PLP1969619696X-O (NL) and PLP19696-19696XP (US). Two separate bioanalytical reports were provided. The single tube BD™ Stem Cell Enumeration kit was used enabling simultaneous enumeration of viable dual positive CD45+/CD34+ hematopoietic stem cell populations. The absolute number of positive cells in the sample was determined by comparing cellular events to a known number of fluorescent beads released by  BD  Trucount  reagent.  Concentration,  number  and  percentage  of  CD34+  cells  of  the  CD45+  cell population were reported. WBC counts prior to each measurement ensured that samples were in the linear  range  of  the  assay.  Validation  parameters  included  intra-assay  reproducibility,  inter-assay reproducibility,  interoperator  reproducibility,  inter-analyst-data-analysis  reproducibility,  stability  of whole  blood,  stability  of  stained  cells,  carry-over  and  cross-validation  of  NL  and  US  bioanalytical laboratories. PB006, EU-Tysabri and US-Tysabri were comparable within the assay, and the method was found to be suitable for the intended application.

Saturation  of α4 -integrin  on  leukocytes  surfaces  is  part  of  Natalizumab's  mechanism  of  action. α4 -integrin %RS in human whole blood is assessed by the same flow cytometry assay, which was validated in studies PLP19696-19696X-L (NL) and PLP19696-19696X-N (US), for analysis of samples collected at EU and US sites, respectively. Two separate bioanalytical reports were provided. In brief, Leukocytes are quantified via CD45, and α4 -integrin bound Natalizumab by addition of mouse anti-human IgG4 Fc-PE. Maximum %RS was assessed in a second aliquot of each sample where unlabelled PB006 was added. The method was validated for its intra-assay reproducibility, inter-assay reproducibility, interoperator

<div style=\"page-break-after: always\"></div>

reproducibility, inter-analyst-data-analysis reproducibility, stability of whole blood, stability of stained cells, carry-over and cross-validation of bioanalytical laboratories and found to be suitable for analysis of clinical samples. Again PB006, EU-Tysabri and US-Tysabri were comparable within the assay, and the method was found to be suitable for the intended application.

## Bioequivalence (Study PB006-01-03)

Study PB006-01-03 was a multicenter PK/PD study in healthy subjects, to support the demonstration of similarity between PB006 versus EU-Tysabri and versus US-Tysabri.

## Methods

## Study design

This was a randomized, double-blind study with 3 parallel arms in 453 healthy male and female subjects. Subjects received a single dose of 3 mg/kg PB006, EU-approved Tysabri, or US-licensed Tysabri as an IV infusion over a 60-minute period. Dosing was followed by PK and PD sampling for 85 days and a final follow-up visit 6 months (24 weeks) after dosing to assess new neurological symptoms that could be suggestive for progressive multifocal leukoencephalopathy (PML). Safety was monitored throughout the study  by  repeated  clinical  and  laboratory  evaluations.  Samples  were  collected  for  immunogenicity assessments for 85 days.

The study was performed at six clinical sites, 4 of which were in the US, 1 in the Netherlands, and 1 in Poland.

## Study participants

Healthy male and female subjects aged 18 to 65 years (18 to 54 years after implementation of protocol amendment 3), with a body mass index (BMI) of 18.5 to 30.0 kg/m 2  (body weight 50 - 92 kg), who were anti-John Cunningham virus (JCV) antibody negative and tested negative for SARS-CoV-2 before dosing were eligible for this study.

## Treatments

Subjects were randomized in a 1:1:1 ratio to PB006, US-Tysabri or EU-Tysabri and received single IV infusions of 3 mg/kg natalizumab.

The study drug was administered on day 1 with the subject in the upright position. Subjects fasted overnight for at least 10 hours following a light supper on the evening before. Breakfast was consumed after the end of the IV infusion. During fasting, no fluids were allowed except water; water was not allowed from 2 hours prior to dosing until the end of the IV infusion. A fasting period of at least 4 hours was required before obtaining clinical laboratory samples at all time points.

## Objectives

The primary objective of the study was to demonstrate PK and PD similarity of PB006 to both US-licensed Tysabri and EU-approved Tysabri.

## Outcomes/endpoints

## PK endpoints

The primary PK endpoint was AUC0-inf of total natalizumab, which was compared between PB006, EUTysabri,  and  US-Tysabri  in  a  3-way  comparison.  This  comparison  was  part  of  a  hierarchical  testing procedure. As a prerequisite for the pooling of the reference, PK similarity needed to be established (PK bridge between EU-Tysabri and US-Tysabri) and a pre-defined pooling criterion had to be fulfilled. For the 3 pairwise comparisons of AUC0-inf the 90% CI (confidence interval) for the ratio of the test and reference products should be contained within the acceptance interval of 80.00% to 125.00%.

<div style=\"page-break-after: always\"></div>

As secondary PK endpoints, AUC0-t, Cmax, and tmax (time to Cmax) of total natalizumab were selected to support the PK comparability of PB006 to EU-Tysabri and US-Tysabri. Further secondary PK endpoints were AUC0-inf, AUC0-t, Cmax, and tmax of unexchanged natalizumab. Other PK parameters were analyzed descriptively.

## PD endpoints

For PD, two co-primary endpoints were selected: AUEC0-12w (area under the effect curve from zero to 12 weeks) of baseline-adjusted CD19+, and AUEC0-12w of α4 -integrin %RS. As an additional analysis, AUEC412w  (area  under  the  effect  curve  from  4  to  12  weeks)  for α4 -integrin  %RS was specified. For these parameters the 95% CI for the ratio of the test and reference products should be contained within the acceptance interval of 80.00% to 125.00%.

Secondary  PD  endpoints  included  Emax  (maximum  effect)  and  tmax  of  baseline-adjusted  CD19+, AUECbase\\_neg, (area below the individual baseline value minus the area above the individual baseline in case of time intervals for which the effect time curve exceeded the baseline value), Emin (minimum effect), tmin (time to minimum concentration) of sVCAM and sMAdCAM and AUEC0-t (area under the effect curve from zero to last timepoint), Emax, tmax of CD34+.

Prior to each PK sampling point, each subject was to remain at least 5 minutes in a supine position. Blood samples of 6 mL each were taken for analysis of total and unexchanged natalizumab in plasma samples. Blood samples of approximately 11 mL were collected for measurement of relative a-integrin receptor saturation (a-integrin %RS) and CD19+ and CD34+ cells. Blood samples of approximately 6 mL were collected for measurement of sVCAM and sMAdCAM.

## Sample size

The sample size calculation was based on the following assumptions:

- Test/Reference ratio:
- o PK: 0.95-1/0.95 for AUC0-inf,
- o PD: 0.95-1/0.95 for AUC0-12w for baseline-adjusted CD19+ and AUC0-12w for α4 -integrin %RS
- Significance level: 5% (Two one-sided tests corresponding to 90% CIs for the Test/Reference ratio)
- Similarity margin: 0.8000-1.2500
- Randomization ratio: 1:1:1

The assumptions for the coefficients of variation for the arithmetic means (CV) and for the geometric means (gCV) were based on the data of the pilot study Tysabri Pilot-01-01.

The demonstration of PD similarity was planned to be conducted while combining the data of the US and EU-reference products for the statistical analysis of the primary PD endpoint baseline-adjusted CD19+ AUEC0-12w and α4 -integrin %RS AUEC0-12w subsequent to having established the PK bridge between the 2 reference products and meeting the predefined pooling criterion.

For the 3-way comparisons of PK a between-subject gCV of 36% was assumed for the first step of the hierarchical testing strategy. For the PD hypothesis, tested in the second step of the hierarchical model, a between-subject gCV of 56% was assumed. For the sample size consideration, the PD endpoint α4 -integrin %RS was neglected, since the variability was considered lower compared to CD19+ AUEC0-12w.

In earlier protocol versions 82 evaluable subjects per arm were seen required to ensure an overall power of at least 80% (93% power for each of the 3 pairwise comparisons resulting in 0.93x0.93x0.93=0.804) including the comparison of US-licensed Tysabri vs EU-approved Tysabri establishing the PK bridge.

<div style=\"page-break-after: always\"></div>

According to the latest protocol version, the analysis of baseline-adjusted CD19+ AUEC0-12w pooling USlicensed Tysabri and EU-approved Tysabri subsequent to having established the PK and thus the scientific bridge resulted in a 1:2 randomization ratio.

Total N=411 evaluable subjects (137 evaluable subjects per arm) was derived by updated sample size calculations, using a 90% CI for the geometric mean ratio, which resulted in a power of 93%. Using a 95% CI, which was seen required to meet global regulatory expectations, for the geometric mean ratio resulted in a power of 88%. The power above 80% seemed to be appropriate to account for the additional PD endpoint α4 -integrin %RS.

After accounting for 10% drop-outs, the total number of subjects to be randomized was calculated to be 453  subjects  (151  per  treatment  group).  The  10%  drop-out  rate  included  subjects  that  terminated prematurely  (discontinued  from  the  study  or  withdraw  consent),  as  well  as  subjects  with  protocol deviations that warranted their exclusion from the analysis of the primary endpoint.

## Randomisation

After obtaining informed consent, subjects were to be screened according to the inclusion and exclusion criteria. Subjects who met all eligibility criteria were supposed to receive a subject number upon inclusion in  the  study.  Subjects  were  planned  to  be  randomly  assigned  in  a  [1:1:1]  ratio  to  receive  study intervention. Stratification was to be performed according to body weight class in order to ensure balance across the study arms (50kg to 65kg, &gt;65kg to 80kg, &gt;80kg to 92kg). No gender stratification was deemed necessary, as gender was not found to have an effect on the PK properties of natalizumab. The study was planned to be performed at 6 sites by competitive recruitment. The clinical study protocol (CSP) defined 3 weight groups in order to ensure balance across the study arms; however, all eligible subjects were to be admitted in the study. For that reason, 18 randomization lists were created, 1 per site and weight group combination. Subjects were to receive the subject number just prior to dosing and according  to  the  randomization  code  generated.  The  subject  number  was  to  ensure  identification throughout the study. Replacement subjects were to be administered the same treatment as the subject replaced.  The  final  randomization  list  was  created,  reviewed,  and  approved  by  2  designated biostatisticians  who  were  not  members  of  the  study  team.  After  the  final  randomisation  list  was approved, it was transferred to the responsible pharmacy and kept in a restricted area.

## Blinding

Subjects  were  planned  to  be  randomly  assigned  in  a  [1:1:1]  ratio  to  receive  study  intervention. Investigators were planned to remained blinded to each subject's assigned study intervention throughout the course of the study. In order to maintain this blind, an otherwise uninvolved third party (e.g, site pharmacy staff) was planned to be responsible for the dilution and dispensing of all study intervention and delivery to site.

A sealed envelope that contained the study intervention assignment for each subject was planned to be provided  to  the  Investigator.  The  sealed  envelope  was  to  be  retained  by  the  Investigator  (or representative) in a secured area. In case of an emergency, the Investigator had the sole responsibility for determining if unblinding of a subject's treatment assignment was warranted.

If the Investigator decided that unblinding was warranted, the Investigator had to make every effort to contact  the  Sponsor  prior  to  unblinding  a  subject's  treatment  assignment,  unless  this  could  delay emergency treatment of the subject. If a subject's treatment assignment was unblinded, the Sponsor was to be notified within 24 hours after breaking the blind.

## Statistical methods

## Analysis Populations

<div style=\"page-break-after: always\"></div>

## Safety Population

All  subjects  assigned  to  study  intervention  and  who  were  dosed  with  study  intervention  were  to  be included in this population. Subjects were to be analysed according to the study drug received.

## Pharmacokinetic Population

All subjects randomized to study intervention and who were dosed with study intervention and have not experienced any major protocol deviations that might impact PK results and provide sufficient samples to allow calculation of the PK endpoint AUC0-inf were to be included in this population.

## Pharmacodynamic/Target Receptor Engagement Population

All subjects randomized to study intervention and who were dosed with study intervention and did not experience  any  major  protocol  deviations  that  might  impact  the  PD  results  and  provided  sufficient samples to allow calculation of the primary PD endpoints AUEC0-12w of baseline-adjusted CD19+ and/or α 4-integrin %RS were to be included in this population.

There were several analysis sets defined in addition to the sets originally defined in the SAP: CD19+ Set, RS/RO Set - primary analysis for AUEC0-12w, RS/RO Set - sensitivity analysis for AUEC0-12w, RS/RO Set - main analysis for AUEC4-12w, RS/RO Set - sensitivity analysis for AUEC4-12w, and PD Other Set - analysis set for VCAM, MadCAM, CD34.

## General aspects of statistical analyses

Baseline (demographic) data was planned to be summarized by treatment group, PK, PD, and safety results by treatment group and time point.

## Statistical analysis methods for primary endpoints

All PK analyses were to be performed on the PK Set.

For the analysis of the primary PK parameter AUC0-inf of total natalizumab a 3-way comparison was to be performed containing the comparison of PB006 to both US-licensed Tysabri and EU-approved Tysabri as well as the PK bridge between US-licensed Tysabri and EU-approved Tysabri. The 3-way comparison was the first step of the  2-step hierarchical testing procedure. For each comparison an analysis of variance  (ANOVA) was  to  be  performed  on  the  ln-transformed  primary  PK  parameter AUC0-inf. The ANOVA was to include calculation of least-squares means (LSM) for the treatments. The ratios of LSM were  to  be  calculated  using  the  exponentiation  of  the  LSM  differences  from  the  analyses  on  the corresponding ln-transformed PK-parameters. The 90% CIs were to be calculated and back-transformed to the original scale. PK similarity was to be concluded if the respective CIs for AUC0-inf were completely included in the similarity margin of 0.8000 to 1.2500.

All PD analyses were to be performed on the relevant PD population.

The comparison for PD similarity regarding the primary PD endpoint AUEC0-12w of baseline-adjusted

CD19+ and AUEC0-12w of α 4-integrin %RS was considered the second step of the 2-step hierarchical testing  procedure.  The  data  of  US-licensed  Tysabri  and  EU-approved  Tysabri  were  planned  to  be combined/pooled for the comparison with PB006 if:

- the analytical  and  PK  bridge  has  demonstrated  similarity  between  US-licensed  Tysabri  and  EUapproved Tysabri and
- the subsequently described predefined pooling criterion for the respective PD parameter (see further below) was fulfilled.

For the analysis of the primary PD endpoint AUEC0-12w of baseline-adjusted CD19+, an ANCOVA was to be performed on the ln-transformed PD parameter baseline-adjusted AUEC0-12w of baseline-adjusted CD19+. The ANCOVA model was to include the ln-transformed individual baseline value of CD19+ as

<div style=\"page-break-after: always\"></div>

a covariate. The ANCOVA was to include calculation of LSM for the treatments. The ratios of LSM were to be calculated using the exponentiation of the LSM difference from the analyses on the ln-transformed PD parameter. The 90% and 95% CIs were to be back-transformed to the original scale.

## Predefined pooling criterion:

The ANCOVA comparing only US-licensed Tysabri and EU-approved Tysabri was to be calculated as described above for CD19+. If the 95% CI back-transformed baseline-adjusted AUEC0-12w of baselineadjusted CD19+ did not completely fall outside of [95.00%, 105.00%], the reference data was planned to  be  pooled  for  the  primary  analysis.  If  the  data  could  not  be  pooled,  the  unpooled  analysis  was planned to be presented.

After the analytical and the PK bridge were established and the predefined pooling criterion for CD19+ was fulfilled, an ANCOVA model as described above was to be calculated comparing PB0006 and the pooled reference (US-licensed Tysabri and EU-approved Tysabri).

Similarity was to be concluded if the 90% CI (for FDA) and 95% CI (for EMA) for baseline-adjusted AUEC0-12w of baseline-adjusted CD19+ was completely included in the similarity margin of 0.8000 to 1.2500.

The analysis of the primary PD endpoint AUEC0-12w of α 4-integrin %RS was analogously performed to the analysis for AUEC0-12w of baseline-adjusted CD19+.

## Results

## Participant flow

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Recruitment

For successful recruitment, two sequential screening visits were performed. At screening 1 (between day -56 and day -2), subjects had to be tested negative for JCV. Screening 2 was then performed between day -28 and day -1 (admission). Follow-up was performed at the ambulatory visit on day 85 (end of study), and at an ambulatory visit on day 169 ±7 days (6 months).

The first screening took place on 30 Oct 2019, the last follow-up was performed on 10 Mar 2021.

## Conduct of the study

The study was performed according to the CSP dated 30 Sep 2019, and 6 CSP amendments were issued during clinical execution of the study, comprising 4 general CSP amendments and 2 CSP amendments applicable to 1 country only (Poland). These changes to the protocol included extensive modifications to both primary endpoints as well as sample size, and other variables of the study. A summary of changes to the study protocol is presented in table below.

Table 3: Summary of Changes to Protocol PB006-01-03

| Document                     | Date Issue   | of   | Summary of Changes                                                                                                                                                                                                                                                                                                                                                                 |
|------------------------------|--------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Original CSP                 | 30 Sep 2019  |      | Not applicable                                                                                                                                                                                                                                                                                                                                                                     |
| CSP Version 2.0/ Amendment 1 | 05 Dec       | 2019 | Overall Rationale for the CSP amendment: To incorporate clarifications and corrections deemed necessary from the previous version of the CSP.                                                                                                                                                                                                                                      |
| Note to file                 | 09 Dec 2019  |      | Maximum weight of study subjects reduced to 92 kg to ensure that a maximum of 1 vial is used per dose. Information included in CSP Version 3.0. No subjects were randomized before this Note to file was issued.                                                                                                                                                                   |
| CSP Version 3.0/ Amendment 2 | 12 Dec 2019  |      | Changes introduced were: • Maximum weight of study subjects reduced from 95 kg to 92 kg to ensure that a maximum of 1 vial is used per dose • Highest stratification group amended to >80 kg to 92 kg • Clarification that a JCV test can be performed again if a subject who was otherwise screening positive had his first negative JCV test longer than 56 days prior to dosing |
| CSP Version 4.0/ Amendment 3 | 20 Jun 2020  |      | Overall rationale for CSP Amendment 3: Implementing measures to be taken to protect subjects after dosing from a COVID-19 infection.                                                                                                                                                                                                                                               |
| Note to file                 | 02 Jul 2020  |      | According to CSP Version 4.0 (Table 4, Table 5 and Section 8.2.2) all vital signs assessments, except temperature, should be done in triplicate for the listed timepoints (Screening 2 and Day -1).                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| Document                     | Date Issue   | of   | Summary of Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|------------------------------|--------------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                              |              |      | This Note to file explained that the oxygen saturation was also not required in triplicate for the timepoints listed in the CSP Version 4.0. This was updated in CSP Version 4.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| CSP Version 4.1/ Amendment 4 | 14 Aug 2020  |      | Changes to the CSP requested by the IEC in Poland only. Changes introduced were: • Clarifications on controlled and home quarantine. • Clarifications on oxygen saturation procedures.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| CSP Version 5.0/ Amendment 5 | 28 Aug 2020  |      | The revision of endpoints was agreed with the FDA in a Type 2 meeting, which included to add CD19+ AUEC as scientific most relevant PD parameter. This parameter is now defined as primary endpoint and the sample size of the study was adjusted accordingly.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                              |              |      | Changes introduced were: • Increase of sample size to 453 subjects, 151 subject per arm • Correction of primary PK endpoint AUC 0-inf and related objective • Demotion of CD19+ E max to a secondary endpoint • Use of pooled EU-approved Tysabri and US-licensed Tysabri data as a comparison with PB006 in terms of AUEC 0-12w of baseline-adjusted CD19+ • Removal of t 1/2 , CL, and K e as secondary PK parameters • To align endpoints among regulatory regions and following the scientific advice discussion, the primary PD endpoint on α4­integrin %RS was adjusted to AUEC 0-12w and the partial receptor saturation AUEC 4-12w was removed* • Modification of the definition of the analysis sets • Update of PK Analysis Methods • Update of PD and Target Receptor Engagement Analysis Methods |
| CSP Version 5.1              | 28 Aug 2020  |      | Changes the same as the changes implemented for CSP Version 5.0 but based on CSP Version 4.1 (Poland only)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Note to file                 | 01 Oct 2020  |      | Information to the site in Poland that 1 of the batches of study drug had a slightly lower concentration of study drug. The site was asked to try to limit the subject weight to 90.4 kg though weights up to 92.0 kg could be feasible.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Note to file                 | 29 Apr 2021  |      | CSP deviations on site level were described                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

%RS=relative receptor saturation; ADA=antidrug antibody; AUEC=area under the effect curve; BMI=body mass index; CSP=clinical study protocol; CD19+=Cluster of Differentiation  19  activation;  COVID-19=coronavirus  disease-19;  EMA=European  Medicines  Agency;  FDA=Food  and  Drug  Administration;  IEC=independent  ethics committee; JCV=John Cunningham virus; PCR=polymerase chain reaction; PD=pharmacodynamic(s); PK=pharmacokinetic(s); SAP=statistical analysis plan; SARS-CoV2=severe acute respiratory syndrome coronavirus-2 * Despite being removed as endpoint from the protocol, AUEC4-12w was calculated and presented in line with the SAP

## Protocol deviations

Throughout  the  study  675  protocol  deviations  were  reported  for  246  subjects  from  all  6  sites.  The frequency of the most important protocol deviations are presented below.

Important protocol deviations related to COVID-19 were reported for 5 subjects, 3 in the Netherlands, all related to compliance with quarantine requirements, and 2 in the US, both related to use of medication without consulting the Investigator.

<div style=\"page-break-after: always\"></div>

Table 4: Summary of Important Protocol Deviations

|                                         | 3 mg/kg sd IV PB006 (N=149)   | 3 mg/kg sd Tysabri EU (N=151)   | IV 3 mg/kg sd IV Tysabri US (N=150)   | Overall (N=450)   |
|-----------------------------------------|-------------------------------|---------------------------------|---------------------------------------|-------------------|
| Deviation Category                      | n (%)                         | n (%)                           | n (%)                                 | n (%)             |
| Assessment Safety                       | -                             | -                               | 1 (0.7)                               | 1 (0.2)           |
| Exclusion Criteria                      | -                             | -                               | 2 (1.3)                               | 2 (0.4)           |
| Inclusion Criteria                      | -                             | 1 (0.7)                         | 1 (0.7)                               | 2 (0.4)           |
| Informed Consent                        | 11 (7.4)                      | 12 (7.9)                        | 12 (8.0)                              | 35 (7.8)          |
| Other                                   | -                             | 1 (0.7)                         | -                                     | 1 (0.2)           |
| Overdose/Misuse                         | 2 (1.3)                       | 1 (0.7)                         | 1 (0.7)                               | 4 (0.9)           |
| Prohibited Co-Medication                | 3 (2.0)                       | 2 (1.3)                         | 3 (2.0)                               | 8 (1.8)           |
| Study Drug                              | -                             | 2 (1.3)                         | -                                     | 2 (0.4)           |
| Visit Window                            | -                             | 1 (0.7)                         | -                                     | 1 (0.2)           |
| Protocol Deviations Related to COVID-19 | 2 (1.3)                       | 1 (0.7)                         | 2 (1.3)                               | 5 (1.1)           |
| US                                      | 1 (0.7)                       | -                               | 1 (0.7)                               | 2 (0.4)           |
| the Netherlands                         | 1 (0.7)                       | 1 (0.7)                         | 1 (0.7)                               | 3 (0.7)           |

IV=intravenous; n=number of subjects in this category; N=number of subjects receiving study drug; Tysabri EU=EU-approved Tysabri; Tysabri US=US-licensed Tysabri

## Baseline data

A total of 450 subjects between 18 and 61 years of age and with a BMI between 18.6 and 30.3 kg/m 2 were dosed with the study drug in the study.

Demographic and baseline characteristics were similar across groups. The majority of subjects were white. The ratio of males and females was balanced in all 3 groups. Mean age was 31 years, mean weight was approximately 72 kg and mean height was 172-173 cm across groups. Approximately half of the subjects in each group were in the weight class &gt;65 kg to ≤ 80 kg.

Table 5: Demographic and baseline characteristics in study PB006-01-03 (PK population)

|                                           | PB006 N=142   | EU-Tysabri N=147   | US-Tysabri N=148   |
|-------------------------------------------|---------------|--------------------|--------------------|
| Age (years)                               |               |                    |                    |
| Mean (SD)                                 | 31 (11)       | 31 (11)            | 31 (11)            |
| Sex, n (%)                                |               |                    |                    |
| Male                                      | 78 (54.9)     | 68 (46.3)          | 71 (48.0)          |
| Female                                    | 64 (45.1)     | 79 (53.7)          | 77 (52.0)          |
| Race, n (%)                               |               |                    |                    |
| White                                     | 118 (83.1)    | 122 (83.0)         | 132 (89.2)         |
| Black or Afirican-American                | 16 (11.3)     | 15 (10.2)          | 10 (6.8)           |
| Asian                                     | 3 (2.1)       | 5 (3.4)            | 3 (2.0)            |
| White+Black or African-American           | 2 (1.4)       | 1 (0.7)            | 0                  |
| White + Asian                             | 1 (0.7)       | 0                  | 0                  |
| White + American Indian or Alaska Native  | 0             | 2 (1.4)            | 0                  |
| American Indian or Alaska Native          | 2 (1.4)       | 1 (0.7)            | 2 (1.4)            |
| Native Hawaiian or Other Pacific Islander | 0             | 1 (0.7)            | 0                  |
| Unknown                                   | 0             | 0                  | 1 (0.7)            |
| Weight (kg)                               |               |                    |                    |
| Mean (SD)                                 | 72.5 (10.4)   | 71.4 (10.4)        | 72.4 (10.4)        |
| Height (cm)                               |               |                    |                    |
| Mean (SD)                                 | 173 (9)       | 172 (10)           | 172 (9)            |
| Body mass index (kg/m2)                   |               |                    |                    |
| Mean (SD)                                 | 24.3 (2.7)    | 24.1 (2.9)         | 24.4 (2.7)         |
| Weight class, n (%)                       |               |                    |                    |
| ≤65 kg                                    | 34 (23.9)     | 37 (25.2)          | 38 (25.7)          |
| > 65 kg to ≤ 80 kg                        | 73 (51.4)     | 77 (52.4)          | 76 (51.4)          |
| > 80 kg to ≤ 92 kg                        | 35 (24.6)     | 33 (22.4)          | 34 (23.0)          |

N=Number of subjects in treatment group, n=number of subjects in category, PK=pharmacokinetic, SD=standard deviation.

<div style=\"page-break-after: always\"></div>

The difference between the subjects enrolled before and after the study stop due to COVID-19 was limited and primarily due to the small number of subjects randomized before the study stop (n=16) when compared to the number of subjects randomized after the study restart (n=434).

In the PK Set, 437 subjects between 18 and 61 years of age and with a BMI between 18.6 and 30.3 kg/m 2  were included. There was no relevant difference between the demographics in the Safety Set and in the PK Set.

In the PD Set (Other), 438 subjects between 18 and 61 years of age and a BMI between 18.6 and 30.3 kg/m 2  were included. In the PD Set (CD19+), 437 subjects between 18 and 61 years of age and a BMI between 18.6 and 30.3 kg/m 2  were included. In the PD Set (Primary α4 -integrin %RS), 389 subjects between 18 and 61 years of age and a BMI between 18.7 and 30.3 kg/m 2  were included. There were no relevant differences between the demographics in the Safety Set and those in the PD Set (Other), the PD Set (CD19+), or the PD Set (Primary  a-integrin %RS).

Administration  of  the  study  drug  was  performed  by  the  Investigator  or  authorized  designee  as  an  IV infusion over 60 minutes. There was no indication of noncompliance based on observations during study drug administration. Compliance was further confirmed by bioanalytical assessment of natalizumab in serum samples.

## Numbers analysed

The PK Set consists of 437 subjects; 13 subjects were not included in the PK Set because they dropped out before the serum natalizumab levels approached LLOQ or they missed 2 or more consecutive visits before the serum natalizumab levels approached LLOQ.

The PD Set (CD19+) consists of 437 subjects; 13 subjects were not included in the PD Set (CD19+) because they dropped out before the CD19+ levels returned  to  baseline  or  they  missed  3  or  more consecutive visits before the CD19+ levels returned to baseline.

The PD Set (Primary α4 -integrin %RS) consists of 389 subjects; 61 subjects were not included in the PD Set (Primary α4 -integrin %RS) because they dropped out before the α4 -integrin %RS levels returned to baseline,  samples  were  analyzed  outside  the  validation  stability  window,  or  they  missed  3  or  more consecutive visits before the α4 -integrin %RS levels returned to baseline.

The PD Set (Sensitivity α4 -integrin %RS) consists of 432 subjects; 18 subjects were not included in the PD  Set  (Secondary α4 -integrin  %RS)  because  they  dropped  out  before  the α4 -integrin  %RS  levels returned to baseline or they missed 3 or more consecutive visits before the α4 -integrin  %RS levels returned to baseline.

<div style=\"page-break-after: always\"></div>

Table 6: Subject disposition and analysis sets in study PB006-01-03 (all subjects)

|                                             | PB006 N=150 n (%)   | EU-Tysabri N=152 n (%)   | US-Tysabri N=151 n (%)   |
|---------------------------------------------|---------------------|--------------------------|--------------------------|
| Randomized                                  | 150 (100)           | 152 (100)                | 151 (100                 |
| Safety population*                          | 149 (99)            | 151 (99)                 | 150 (99)                 |
| PK population                               | 142 (95)            | 147 (97)                 | 148 (98)                 |
| PD population (other)                       | 145 (97)            | 148 (97)                 | 145 (96)                 |
| PD population (CD19+)                       | 142 (95)            | 147 (97)                 | 148 (98)                 |
| PD population (Primary α4-integrin %RS)     | 126 (84)            | 137 (90)                 | 126 (83)                 |
| PD population (Sensitivity α4-integrin %RS) | 141 (94)            | 146 (96)                 | 145 (96)                 |
| Dosed                                       | 149 (99)            | 152 (100)                | 150 (99)                 |
| Completed                                   | 145 (97)            | 148 (97)                 | 145 (96)                 |
| Withdrew                                    | 5 (3)               | 4 (3)                    | 6 (4)                    |
| Reason for withdrawal:                      |                     |                          |                          |
| Lost to follow-up                           | 0                   | 2 (1)                    | 2 (1)                    |
| Withdrawal by subject                       | 3 (2)               | 1 (1)                    | 3 (2)                    |
| Other                                       | 2 (1)               | 1 (1)                    | 1(1)                     |

PD=pharmacodynamic, PK=pharmacokinetic, SAF=safety population.*Three subjects did not receive study drug after randomization.

## Outcomes and estimation

## A. Pharmacokinetic Results

## A1. Total natalizumab

Concentration-time profiles of total natalizumab were similar in the 3 treatment groups over the entire sampling period. A rapid increase in total natalizumab was observed, with concentrations reaching nearly maximum values already at the end of the 1-hour infusion period. Concentrations remained high (at values  of  around  60000  µg/L)  until  Day  3  and  subsequently  declined.  From  Day  57  onwards,  no natalizumab concentrations above the LLOQ were observed in any of the groups.

Figure 2: Arithmetic mean (SD) plasma concentration-time profiles of total natalizumab (PK population) in study PB006-01-03, linear plot (left) and semi-log plot (right)

Total Natalizumab(ug/L)

ArithmeticMean(SD)

80000

Serum Concentration (ug/L)

60000

40000

20000

PharmacokineticSet

LinearPlot

3mg/kgsdIVPB006

(N=142)

3 mg/kg sd IV Tysabri EU (N=147)

3 mg/kg sd IV Tysabri US (N=148)

28

35

42

4956

63

70

77

84

Time(DaysafterDosing)

<!-- image -->

The primary PK parameter was AUC0-inf of total natalizumab. For this parameter, a 3-way comparison was performed containing the comparison of PB006 to both US-Tysabri and EU-Tysabri, as well as the PK bridge between US-Tysabri and EU-Tysabri. The 3-way comparison was part of a hierarchical testing procedure. The hierarchical testing procedure foresees that subjects in the treatment arms receiving USTysabri and EU-Tysabri, respectively, can be pooled for the primary PD analysis. As prerequisite for the

0

7

14

21

<div style=\"page-break-after: always\"></div>

pooling of the reference, PK similarity needs to be established and the pre-defined pooling criterion has to be fulfilled. Results from the statistical analysis are presented below.

Table 7: Statistical analysis of the primary PK parameter AUC0-inf of total natalizumab (PK population) in study PB006-01-03

| Parameter         | Treatment   | n   | Geometric LS Means   | Pairwisecomparison       | Pairwisecomparison   | Pairwisecomparison   |
|-------------------|-------------|-----|----------------------|--------------------------|----------------------|----------------------|
|                   |             |     |                      | Pair                     | Ratio                | 90% CI               |
| AUCo-inf (mg.h/L) | PB006       | 141 | 22118                | PB006 vS EU-Tysabri      | 0.9864               | 0.9410, 1.0340       |
| AUCo-inf (mg.h/L) | EU-Tysabri  | 147 | 22424                | PB006 vs US-Tysabri      | 0.9491               | 0.9054, 0.9948       |
| AUCo-inf (mg.h/L) | US-Tysabri  | 148 | 23306                | EU-Tysabri vs US-Tysabri | 0.9622               | 0.9184.1.0080        |

AUC0-inf=area under the concentration time curve from time zero to infinity, CI=confidence interval, LS=least square, n=number of subjects with data available, PK=pharmacokinetic, vs=versus. The analysis was performed on natural log (ln) transformed parameters using an analysis of variance model with treatment as a fixed effect. Similarity could be concluded if the 90% CI fell completely in the margin of 0.80 to 1.25.

PK similarity was demonstrated for all comparisons (PB006 vs EU-Tysabri, PB006 vs US-Tysabri, EUTysabri  vs  US-Tysabri).  For  all  pairwise  comparisons,  the  90%  CIs  were  completely  included  in  the similarity margin of 0.80 to 1.25. Thus, the primary PK endpoint was met.

Cmax and AUC0-t of total natalizumab were secondary PK parameters and supportively evaluated in the same  manner  as  for  the  primary  analysis  using  AUC0-inf.  Results  from  this  statistical  analysis  are presented below.

Table 8: Statistical analysis of the secondary PK parameters Cmax and AUC0-t of total natalizumab (PK population) in study PB006-01-03

| Parameter       | Treatment   | n   | Geometric LS Means   | Pairwise comparison      | Pairwise comparison   | Pairwise comparison   |
|-----------------|-------------|-----|----------------------|--------------------------|-----------------------|-----------------------|
|                 |             |     |                      | Pair                     | Ratio                 | 90% CI                |
| Cmax (mg/L)     | PB006       | 142 | 68.6                 | PB006 vs EU-Tysabri      | 0.9565                | 0.9215, 0.9929        |
| Cmax (mg/L)     | EU-Tysabri  | 147 | 71.7                 | PB006 vs US-Tysabri      | 0.9621                | 0.9269, 0.9987        |
| Cmax (mg/L)     | US-Tysabri  | 148 | 71.3                 | EU-Tysabri vs US-Tysabri | 1.0059                | 0.9694, 1.0438        |
| AUCo-t (mg.h/L) | PB006       | 142 | 22014                | PB006 vs EU-Tysabri      | 0.9840                | 0.9387, 1.0316        |
| AUCo-t (mg.h/L) | EU-Tysabri  | 147 | 22371                | PB006 vs US-Tysabri      | 0.9468                | 0.9032, 0.9925        |
| AUCo-t (mg.h/L) | US-Tysabri  | 148 | 23251                | EU-Tysabri vs US-Tysabri | 0.9622                | 0.9183, 1.0081        |

AUC0-t=area  under  the  concentration  time  curve  from  time  zero  to  last  measurable  concentration,  CI=confidence  interval, Cmax=maximum concentration, LS=least square, n=number of subjects with data available, PK=pharmacokinetic, vs=versus. The analysis was performed on natural log (ln) transformed parameters using an analysis of variance model with treatment as a fixed effect. Similarity could be concluded if the 90% CI fells completely in 0.80 to 1.25.

PK similarity was further supported by results from secondary endpoints. For both parameters (Cmax and AUC0-t) and for all comparisons (PB006 vs EU-Tysabri, PB006 vs US- Tysabri, EU-Tysabri vs US-Tysabri), the 90% CIs were completely included in 0.80 to 1.25.

<div style=\"page-break-after: always\"></div>

The PK parameters tmax, t1/2 (half-life), CL (clearance), kel (terminal elimination rate constant) for total natalizumab  were  analyzed  descriptively.  A  summary  of  the  PK  parameters  for  total  natalizumab  is presented below.

Table 9: Summary of PK parameters for total natalizumab (PK population) in study PB006-01-03

|                                | PB006 N=142        | EU-Tysabri N=147   | US-Tysabri N=148   |
|--------------------------------|--------------------|--------------------|--------------------|
| AUCo-inf (mg.h/L)              | n=141              | n=147              | n=148              |
| Geometric mean (geometric CV%) | 22118 (25.2)       | 22424 (25.1)       | 23306 (23.5)       |
| Arithmetic mean (SD)           | 22766 (5240)       | 23083 (5411)       | 23894 (5058)       |
| Cmax (mg/mL)                   | n=142              | n=147              | n=148              |
| Geometric mean (geometric CV%) | 68.6 (22.4)        | 71.7 (17.5)        | 71.3 (18.1)        |
| Arithmetic mean (SD)           | 70.1 (14.2)        | 72.8 (13.0)        | 72.3 (12.2)        |
| tmax (h)                       | n=142              | n=147              | n=148              |
| Median (min - max)             | 12.00 (1.00-96.05) | 12.00 (1.00-96.00) | 9.04 (1.00-101.07) |
| AUCo-t (mg.h/L)                | n=142              | n=147              | n=148              |
| Geometric mean (geometric CV%) | 22014 (25.4)       | 22371 (25.2)       | 23251 (23.5)       |
| Arithmetic mean (SD)           | 22667 (5255)       | 23030 (5403)       | 23839 (5056)       |
| AUCextra (%)                   | n=141              | n=147              | n=148              |
| Arithmetic mean (SD)           | 0.2 (0.3)          | 0.2 (0.4)          | 0.2 (0.4)          |
| t1/2 (h)                       | n=141              | n=147              | n=148              |
| Geometric mean (geometric CV%) | 90.0 (40.3)        | 87.6 (37.4)        | 87.5 (32.6)        |
| Arithmetic mean (SD)           | 106 (165)          | 96.2 (68.2)        | 92.6 (37.3)        |
| CL (mL/h)                      | n=141              | n=147              | n=148              |
| Geometric mean (geometric CV%) | 9.72 (24.9)        | 9.48 (26.1)        | 9.22 (24.1)        |
| Arithmetic mean (SD)           | 10.0 (2.64)        | 9.82 (2.78)        | 9.49 (2.51)        |
| Vz (mL)                        | n=141              | n=147              | n=148              |
| Geometric mean (geometric CV%) | 1262 (42.6)        | 1198 (36.5)        | 1164 (33.2)        |
| Arithmetic mean (SD)           | 1469 (1943)        | 1291 (662)         | 1228 (427)         |
| ke (1/h)                       | n=141              | n=147              | n=148              |
| Geometric mean (geometric CV%) | 0.00770 (40.4)     | 0.00792 (37.4)     | 0.00792 (32.6)     |
| Arithmetic mean (SD)           | 0.00810 (0.00213)  | 0.00833 (0.00235)  | 0.00829 (0.00240)  |

AUC0-inf=area under the concentration time curve from time zero to infinity, AUC0-t=area under the concentration time curve from time zero to last measurable concentration, AUCextra=percentage of estimated part for the calculation of AUC0-inf, calculated as (AUC0-inf AUC0-t)/  AUC0-inf)*100%,  CL=clearance,  Cmax=maximum  concentration,  CV=coefficient  of  variation,  kel=terminal  elimination  rate constant, N=number of subjects, n=number of subjects with data available, PK=pharmacokinetic, SD=standard deviation, t½=halflife, tmax=time to Cmax, Vz=volume of distribution.

PK parameters were similar for all 3 treatment groups. Geometric mean Cmax ranged from 68.6 to 71.7 mg/L across groups, with CV being between 17.5% and 22.4%. Geometric mean AUC0-inf ranged from 22118 to 23306 mg.h/L, with CV being between 23.5% and 25.2%. Median tmax was 12 hours for PB006 and EU-Tysabri and 9 hours for US- Tysabri. Mean t1/2 ranged between 92.6 and 106 hours across groups. An AUCextra of 0.2% indicates that the duration of PK observation period has been sufficient.

## A2. Unexchanged natalizumab

Concentration-time profiles of unexchanged natalizumab were similar in the 3 treatment groups over the entire sampling period. A rapid increase in unexchanged natalizumab was observed, with concentrations reaching near maximum values already at the end of the 1 hour infusion period. From Day 29 onwards, no natalizumab concentrations above the LLOQ were observed in the PB006 and EU-Tysabri groups, while  for  US-Tysabri  no  natalizumab  concentrations  above  the  LLOQ  were  observed  from  Day  22 onwards.

<div style=\"page-break-after: always\"></div>

Figure 3: Arithmetic mean (SD) plasma concentration-time profiles of unexchanged natalizumab (PK population) in study PB006-01-03, linear plot (left) and semi-log plot (right)

<!-- image -->

The PK parameters Cmax, AUC0-inf and AUC0-t of unexchanged natalizumab were secondary endpoints and evaluated  as  supportive  evidence  (the  reported  CIs  were  of  exploratory  nature,  i.e.,  they  were  not assessed by pre-specified similarity margins). Results from the statistical analysis are presented below.

Table 10: Statistical analysis of PK parameter Cmax, AUC0-inf, and AUC0-t of unexchanged natalizumab (PK population) in study PB006-01-03

| Parameter         | Treatment   | n   | Geometric LS Means   | Pairwise comparison      | Pairwise comparison   | Pairwise comparison   |
|-------------------|-------------|-----|----------------------|--------------------------|-----------------------|-----------------------|
|                   |             |     |                      | Pair                     | Ratio                 | 90% CI                |
| AUCo-inf (mg.h/L) | PB006       | 141 | 1713                 | PB006 vs EU-Tysabri      | 0.9987                | 0.9231, 1.0804        |
| AUCo-inf (mg.h/L) | EU-Tysabri  | 146 | 1715                 | PB006 vs US-Tysabri      | 1.0208                | 0.9438, 1.1041        |
| AUCo-inf (mg.h/L) | US-Tysabri  | 148 | 1678                 | EU-Tysabri vs US-Tysabri | 1.0222                | 0.9457, 1.1048        |
| Cmax (mg/L)       | PB006       | 142 | 61.4                 | PB006 vs EU-Tysabri      | 0.9381                | 0.8874, 0.9916        |
| Cmax (mg/L)       | EU-Tysabri  | 147 | 65.5                 | PB006 vs US-Tysabri      | 0.9440                | 0.8931, 0.9978        |
| Cmax (mg/L)       | US-Tysabri  | 148 | 65.0                 | EU-Tysabri vs US-Tysabri | 1.0063                | 0.9525, 1.0631        |
| AUCo-t (mg.h/L)   | PB006       | 142 | 1692                 | PB006 vs EU-Tysabri      | 1.0037                | 0.9267, 1.0873        |
| AUCo-t (mg.h/L)   | EU-Tysabri  | 147 | 1686                 | PB006 vs US-Tysabri      | 1.0164                | 0.9385, 1.1008        |
| AUCo-t (mg.h/L)   | US-Tysabri  | 148 | 1665                 | EU-Tysabri vs US-Tysabri | 1.0126                | 0.9356, 1.0960        |

AUC0-inf=area under the concentration time curve from time zero to infinity, AUC0-t=area under the concentration time curve from time zero to last measurable concentration, CI=confidence interval, Cmax=maximum concentration, LS=least square, n=number of subjects with data available, PK=pharmacokinetic, vs=versus. The analysis was performed on natural log (ln) transformed parameters using an analysis of variance model with treatment as a fixed effect. Similarity could be concluded if the 90% CI fell completely in 0.80 to 1.25.

For all 3 parameters similar results were seen for PB006, EU-Tysabri and US-Tysabri.

<div style=\"page-break-after: always\"></div>

As supportive evidence, the PK parameters of unexchanged natalizumab were evaluated in the same manner  as  described  for  total  natalizumab.  A  summary  of  the  PK  parameters  for  unexchanged natalizumab is presented below.

Table 11: Summary of PK parameters for unexchanged natalizumab (PK population) in study PB006-0103

|                                | PB006 N=142       | EU-Tysabri N=147   | US-Tysabri N=148   |
|--------------------------------|-------------------|--------------------|--------------------|
| AUCo-inf (mg.h/L)              | n=141             | n=146              | n=148              |
| Geometric mean (geometric CV%) | 1713 (42.6)       | 1715 (42.9)        | 1678 (41.0)        |
| Arithmetic mean (SD)           | 1873 (899)        | 1884 (952)         | 1833 (935)         |
| Cmax (mg/mL)                   | n=142             | n=147              | n=148              |
| Geometric mean (geometric CV%) | 61.4 (37.1)       | 65.5 (17.4)        | 65.0 (30.4)        |
| Arithmetic mean (SD)           | 64.1 (13.7)       | 66.4 (11.4)        | 67.0 (13.1)        |
| tmax (h)                       | n=142             | n=147              | n=148              |
| Median (min - max)             | 1.50 (1.00-48.00) | 1.50 (1.00-6.08)   | 1.50 (1.00-48.00)  |
| AUCo-t (mg.h/L)                | n=142             | n=147              | n=148              |
| Geometric mean (geometric CV%) | 1692 (43.1)       | 1686 (44.8)        | 1665 (41.1)        |
| Arithmetic mean (SD)           | 1853 (898)        | 1861 (953)         | 1820 (935)         |
| AUCextra (%)                   | n=141             | n=146              | n=148              |
| Arithmetic mean (SD)           | 0.7 (0.6)         | 0.7 (0.5)          | 0.8 (0.7)          |
| t1/2 (h)                       | n=141             | n=146              | n=148              |
| Geometric mean (geometric CV%) | 73.0 (70.5)       | 68.9 (61.8)        | 71.9 (75.1)        |
| Arithmetic mean (SD)           | 90.1 (75.9)       | 80.3 (47.7)        | 91.7 (83.7)        |
| CL (mL/h)                      | n=141             | n=146              | n=148              |
| Geometric mean (geometric CV%) | 125 (45.3)        | 124 (43.3)         | 128 (40.1)         |
| Arithmetic mean (SD)           | 137 (56.0)        | 134 (49.5)         | 137 (49.5)         |
| Vz (mL)                        | n=141             | n=146              | n=148              |
| Geometric mean (geometric CV%) | 13198 (79.5)      | 12316 (69.9)       | 13278 (80.1)       |
| Arithmetic mean (SD)           | 17009 (15037)     | 14854 (9723)       | 17352 (16608)      |
| kel (1/h)                      | n=141             | n=146              | n=148              |
| Geometric mean (geometric CV%) | 0.00950 (70.5)    | 0.0101 (61.8)      | 0.00964 (75.1)     |
| Arithmetic mean (SD)           | 0.0117 (0.00887)  | 0.0119 (0.00800)   | 0.0120 (0.00875)   |

AUC0-inf=area under the concentration time curve from time zero to infinity, AUC0-t=area under the concentration time curve from time zero to last measurable concentration, AUCextra=percentage of estimated part for the calculation of AUC0-inf, calculated as (AUC0-inf AUC0-t)/  AUC0-inf)*100%,  CL=clearance,  Cmax=maximum  concentration,  CV=coefficient  of  variation,  kel=terminal  elimination  rate constant, N=number of subjects, n=number of subjects with data available, PK=pharmacokinetic, SD=standard deviation, t½=halflife, tmax=time to Cmax, Vz=volume of distribution.

PK parameters for unexchanged natalizumab were similar for all 3 treatment groups.

## A3. %Fab-arm exchange

Natalizumab is a full-length antibody of the IgG4 subclass. It consists of 2 heavy and 2 light chains connected by 4 inter-chain disulfide bonds. Assessment of natalizumab in serum is complicated by the ability of human IgG4 antibodies to undergo Fab-arm exchange in vivo . Such exchange generates IgG4 molecules of mixed specificity comprising a natalizumab heavy-light chain pair coupled to an endogenous IgG4 heavy-light chain pair of unknown specificity (Shapiro et al. 2011).

Since exchanged and unexchanged species cannot be quantified independently using a single ELISA, a quantitation strategy was developed employing 2 ELISAs: one measuring total natalizumab including both unexchanged (i.e., intact) and exchanged molecules, and the second measuring only unexchanged (intact) natalizumab. The presence and amount of exchanged natalizumab in serum was calculated by the  difference  in  values  obtained  in  the  2  assays.  This  approach  was  previously  developed  for quantification of Tysabri and is summarized in the article by Shapiro et al. in 2011.

<div style=\"page-break-after: always\"></div>

Mean values for %Fab-arm exchange increased to &gt;95% by Day 8 for PB006 (95.4%), EU- Tysabri (95.9%), and US-Tysabri (96.2%). Maximum values reached 100% in individual subjects at Day 8 for the 3 treatments.

Overall, Fab-arm exchange was rapid and complete, with similar results for all 3 treatment groups.

## B. Pharmacodynamic Results

## B1. α4 -integrin %RS

The α4 -integrin %RS profiles over time were similar in all treatment groups. Mean α4 -integrin %RS increased to a level close to the maximum value (&gt;90%) at the first postdose time point (6 hours) for all treatments.

Figure  4: Arithmetic  Mean  of  α4 -integrin  %RS  Whole  BloodTime  Profile  (PD  Set  [Primary  α4 -integrin %RS])

<!-- image -->

%RS=relative receptor saturation; IV=intravenous; N=number of subjects; RO=receptor occupancy; sd=single dose

After  administration  of  3 mg/kg  PB006,  a  mean  maximum  response  of  92.6%  was  reached  after 24 hours.  A  mean α4 -integrin  %RS  level  &gt;80%  was  maintained  until  Day 29.  After  Day 29  the α4 -integrin %RS value showed a decline to a value similar to the baseline value (&lt;5% α4 -integrin %RS) at Day 71.

After administration of 3 mg/kg EU-approved Tysabri, a mean maximum response of 93.2% was reached on Day 5 (96 hours). A mean α4 -integrin %RS level &gt;80% was maintained until Day 29. After Day 29 the α4 -integrin %RS value showed a decline to a value similar to the baseline value at Day 71.

After administration of 3 mg/kg US-licensed Tysabri, a mean maximum response of 93.1% was reached on Day 5 (96 hours). A mean α4 -integrin %RS level &gt;80% was maintained until Day 29. After Day 29 the α4 -integrin %RS value showed a decline to a value similar to the baseline value at Day 78.

One of the 2 co-primary PD endpoints was AUEC0-12w for α4 -integrin %RS. Similarity was concluded if the 90% CI and 95% CI for baseline-adjusted AUEC0-12w of α4 -integrin %RS was completely included in the similarity margin of 0.80 to 1.25.

The results from the primary PD analysis of α4 -integrin %RS are presented in below table.

<div style=\"page-break-after: always\"></div>

Table 12: Statistical analysis of the primary PD endpoint AUEC0-12w of α4 -integrin %RS (PD [Primary α4 -integrin %RS] population) in study PB006-01-03

| Parameter                       | Treatment      |     | Geometric LS Means   | Pairwise comparison     | Pairwise comparison   | Pairwise comparison   |
|---------------------------------|----------------|-----|----------------------|-------------------------|-----------------------|-----------------------|
|                                 |                |     |                      | Pair                    | Ratio                 | 95% CI                |
| AUEC0-12w α4-integrin %RS (%*h) | PB006          | 126 | 99003                | PB006 vs pooled Tysabri | 0.9933                | 0.9523.1.0362         |
| AUEC0-12w α4-integrin %RS (%*h) | Pooled Tysabri | 263 | 99668                |                         |                       |                       |

AUEC0-12w=area under the effect time curve from time zero to 12 weeks, CI=confidence interval, LS=least square, n=number of subjects with data available, PD=pharmacodynamic, RS=receptor saturation.

When comparing AUEC0-12w of α4 -integrin %RS between PB006 (test) and pooled Tysabri (reference) using an ANCOVA (analysis of covariance) model, the point estimates were close to 1 and the 95% CI for the geometric LS means of AUEC0-12w was narrow, between 0.9523 and 1.0362. The 95% CI was completely included in the similarity margin of 0.80 to 1.25. Thus, the primary PD endpoint α4 -integrin %RS was met.

Results for the individual comparisons (using 95% CIs), i.e., PB006 vs EU-Tysabri, PB006 vs US-Tysabri and EU-Tysabri vs US-Tysabri, are presented below.

Table 13: Statistical analysis of the PD endpoint AUEC0-12w of α4 -integrin %RS, individual comparisons (PD [Primary α4 -integrin %RS] population) in study PB006-01-03

| Parameter                       | Treatment   | n   | Geometric LS Means   | Pairwisecomparison        | Pairwisecomparison   | Pairwisecomparison   |
|---------------------------------|-------------|-----|----------------------|---------------------------|----------------------|----------------------|
|                                 |             |     |                      | Pair                      | Ratio                | 95% CI               |
| AUECo-12w α4-integrin %RS (%*h) | PB006       | 126 | 99003                | PB006vsEU-Tysabri         | 1.0142               | 0.9667, 1.0641       |
| AUECo-12w α4-integrin %RS (%*h) | EU-Tysabri  | 137 | 97616                | PB006 vs US-Tysabri       | 0.9711               | 0.9247,1.0198        |
| AUECo-12w α4-integrin %RS (%*h) | US-Tysabri  | 126 | 101949               | EU-Tysabri vs US- Tysabri | 0.9575               | 0.9126, 1.0046       |

AUEC0-12w=area under the effect time curve from time zero to 12 weeks, CI=confidence interval, LS=least square, n=number of subjects with data available, PD=pharmacodynamic, RS=receptor saturation.

For all comparisons, the point estimates were close to 1 and the 95% CIs were completely included in the similarity margin of 0.80 to 1.25.

## Additional analysis based on AUEC4-12w

Mean AUEC4-12w was an additional analysis to the primary analysis of α4 -integrin %RS to meet EMA requirements.  Mean  AUEC4-12w  was  similar  for  the  3  treatments  at  approximately  40%  of  the  mean AUEC0-12w (compare Table 14 Table 15).

## Sensitivity Analysis for Samples Analyzed Outside the Validation Stability Window

To assess the effect of the samples analyzed outside the validation stability window for α4 -integrin %RS, the  PD  parameters  AUEC0-12w  and  AUEC4-12w  for α4 -integrin  %RS  were  also  calculated  including  all samples analyzed outside the validation stability window.

Inclusion of samples analyzed outside the validation stability window for α4 -integrin %RS (sensitivity analysis)  did  result  in  changes  in  the  values  for  AUEC0-12w  and  AUEC4-12w.  The  value  for  AUEC0-12w calculated  for  PB006  and  EU-approved  Tysabri  increased  1%  and  4%  and  for  US-licensed  Tysabri decreased 2%. The value for AUEC4-12w calculated for PB006 and EU-approved Tysabri increased 1% and

<div style=\"page-break-after: always\"></div>

10% and for US-licensed Tysabri decreased less than 1% (Table 16). These changes were not expected to influence the outcome of the study.

Table  14: Summary Statistics  of  Primary  PD  Parameters  for  α4 -integrin  %RS  (PD Set  [Primary  α4 -integrin %RS])

| Parameter (unit)   | Treatment Statistic   | 3 mg/kg IV PB006 N=126   | 3 mg/kg IV Tysabri EU N=137   | 3 mg/kg IV Tysabri US N=126   |
|--------------------|-----------------------|--------------------------|-------------------------------|-------------------------------|
| AUEC0-12w (%*h)    | Mean (SD)             | 100,685 (17,724)         | 99,704 (19,447)               | 103,687 (18,656)              |
|                    | CV (%)                | 17.6                     | 19.5                          | 18.0                          |
|                    | Min-Max               | 43,341-146,484           | 54,217-135,299                | 59,516-144,957                |
|                    | Geom mean (gCV%)      | 99,003 (19.1)            | 97,616 (21.6)                 | 101,949 (18.9)                |

%RS=relative  receptor  saturation;  AUEC=area  under  the  effect  curve;  CV=coefficient  of  variation;  gCV=coefficient  of  variation  (geometric  mean); Geom=geometric; IV=intravenous; Max=maximum; Min=minimum; N=number of subjects; PD=pharmacodynamic(s); Tysabri EU=EU-approved Tysabri; Tysabri US=US-licensed Tysabri

Table 15 : Supportive Analysis of PD Parameters for α4­integrin %RS (Safety Set)

| Parameter (unit)   | Treatment Statistic   | 3 mg/kg IV PB006   | 3 mg/kg IV Tysabri EU   | 3 mg/kg IV Tysabri US   |
|--------------------|-----------------------|--------------------|-------------------------|-------------------------|
| AUEC4-12w (%*h)    | n                     | 136                | 141                     | 136                     |
|                    | Mean (SD)             | 41,336 (14,939)    | 40,498 (16,708)         | 43,054 (17,250)         |
|                    | CV (%)                | 36.1               | 41.3                    | 40.1                    |
|                    | Min-Max               | 1718-84,384        | 5058-72,943             | 3294-82,297             |
|                    | Geom mean (gCV%)      | 37,712 (53.1)      | 35,704 (62.3)           | 38,655 (56.0)           |

%RS=relative  receptor  saturation;  AUEC=area  under  the  effect  curve;  CV=coefficient  of  variation;  gCV=coefficient  of  variation  (geometric  mean); Geom=geometric; IV=intravenous; Max=maximum; Min=minimum; n=number of subjects with data available; PD=pharmacodynamic(s); Tysabri EU=EUapproved Tysabri; Tysabri US=US-licensed Tysabri

Note: This analysis is based on the safety set and including subjects with enough values to calculate an AUEC4-12w.

Table  16: Sensitivity  Analysis  of  PD  Parameters  for  α4­integrin  %RS  (PD  Set [Sensitivity  α4 -integrin %RS])

| Parameter (unit)   | Treatment Statistic   | 3 mg/kg IV PB006   | 3 mg/kg IV Tysabri EU   | 3 mg/kg IV Tysabri US   |
|--------------------|-----------------------|--------------------|-------------------------|-------------------------|
| AUEC0-12w (%*h)    | n                     | 141                | 146                     | 145                     |
|                    | Mean (SD)             | 102,102 (19,779)   | 103,474 (39,258)        | 102,123 (19,252)        |
|                    | CV (%)                | 19.4               | 37.9                    | 18.9                    |
|                    | Min-Max               | 44,447-218,019     | 54,217-482,038          | 54,381-144,957          |
|                    | Geom mean (gCV%)      | 100,255 (19.5)     | 99,479 (26.3)           | 100,220 (20.1)          |
| AUEC4-12w (%*h)    | n                     | 144                | 146                     | 145                     |
|                    | Mean (SD)             | 42,821 (17,789)    | 44,238 (37,838)         | 42,824 (17,121)         |
|                    | CV (%)                | 41.5               | 85.5                    | 40.0                    |
|                    | Min-Max               | 2825-161,038       | 5058-418,783            | 3771-82,297             |
|                    | Geom mean (gCv%)      | 38,966 (51.0)      | 36,924 (67.4)           | 38,468 (55.7)           |

%RS=relative  receptor  saturation;  AUEC=area  under  the  effect  curve;  CV=coefficient  of  variation;  gCV=coefficient  of  variation  (geometric  mean); Geom=geometric; IV=intravenous; Max=maximum; Min=minimum; n=number of subjects with data available; PD=pharmacodynamic(s); Tysabri EU=EU approved Tysabri; Tysabri US=US-licensed Tysabri. Note: Sensitivity analysis - samples outside of the controlled stability window were included. Note: The analysis of AUEC4-12w is based on the safety set and including subjects with enough values to calculate an AUEC4-12w.

<div style=\"page-break-after: always\"></div>

## B2. CD19+

The CD19+ profiles over time were similar in all treatment groups. Mean CD19+ levels increased rapidly after administration of all treatments. At the first postdose time point (6 hours) mean CD19+ levels increased for all treatments.

A time profile of mean CD19+ levels is presented below.

Figure 5: Arithmetic Mean Change from Baseline CD19+ (10 6 /L) Level - Time Profile (PD Set [CD19+])

<!-- image -->

IV=intravenous, N=number of subjects, sd=single dose, SD=standard deviation.

For subjects receiving 3 mg/kg PB006, the mean absolute CD19+ level at baseline was 251 10 6 /L. After 6 hours  the  mean  CFB  was  111 10 6 /L.  Baseline-adjusted  CD19+  levels  increased  further  to  reach  a maximum mean on Day 8 (466 10 6 /L). From Day 8 to Day 29 baseline-adjusted CD19+ levels were stable (CFB &gt;400 10 6 /L) and started to decline from Day 36 onwards to return to baseline on Day 78 (CFB 4 10 6 /L).

For subjects receiving 3 mg/kg EU-approved Tysabri, the mean absolute CD19+ level at baseline was 255 10 6 /L. After 6 hours the mean CFB was 115 10 6 /L. A maximum mean CFB was reached on Day 15 (489 10 6 /L). From Day 15 to Day 29, baseline-adjusted CD19+ levels were stable (CFB &gt;400 10 6 /L) and started to decline from Day 36 onwards to return to baseline on Day 71 (CFB 14 10 6 /L).

For subjects receiving 3 mg/kg US-licensed Tysabri, the mean absolute CD19+ level at baseline was 266 10 6 /L. After 6 hours the mean CFB was 106 10 6 /L. A maximum mean CFB was reached on Day 15 (496 10 6 /L). From Day 15 to Day 29, baseline-adjusted CD19+ levels were stable (CFB &gt;400 10 6 /L) and started to decline from Day 36 onwards to return to baseline on Day 71 (CFB 12 10 6 /L).

AUEC0-12w for baseline-adjusted CD19+ was the co-primary PD parameter. Similarity was concluded if the 90% CI and 95% CI for baseline-adjusted AUEC0-12w of baseline-adjusted CD19+ was completely included in the similarity margin of 0.80 to 1.25.

The results from the primary PD analysis of CD19+, based on 95% CIs, are presented below.

<div style=\"page-break-after: always\"></div>

Table 17: Statistical analysis of the primary PD endpoint AUEC0-12w of baseline- adjusted CD19+ (PD [CD19+] population) in study PB006-01-03

| Parameter                                    | Treatment      |     | Geometric LS Means   | Pairwisecomparison      | Pairwisecomparison   | Pairwisecomparison   |
|----------------------------------------------|----------------|-----|----------------------|-------------------------|----------------------|----------------------|
|                                              |                |     |                      | Pair                    | Ratio                | 95% CI               |
| AUEC0-12w baseline- adjusted CD19+ (10%/L*h) | PB006          | 142 | 423080               | PB006 vS pooled Tysabri | 1.0159               | 0.8955. 1.1525       |
| AUEC0-12w baseline- adjusted CD19+ (10%/L*h) | Pooled Tysabri | 295 | 416453               | PB006 vS pooled Tysabri | 1.0159               | 0.8955. 1.1525       |

AUEC0-12w=area under the effect time curve from time zero to 12 weeks, CI=confidence interval, LS=least square, n=number of subjects with data available, PD=pharmacodynamic

When  comparing  AUEC0-12w  of  baseline-adjusted  CD19+  between  PB006  (test)  and  pooled  Tysabri (reference) using an ANCOVA model, for all comparisons, the point estimates were close to 1 and the 95% CI for the geometric LS means of AUEC0-12w was narrow, between 0.8955 and 1.1525. The 95% CI was completely included in the similarity margin of 0.80 to 1.25. Thus, the primary PD endpoint CD19+ was met.

Results for the individual comparisons (using 95% CIs), i.e., PB006 vs EU-Tysabri, PB006 vs US-Tysabri and EU-Tysabri vs US-Tysabri, are presented in below table.

Table  18:  Statistical  analysis  of  the  PD  endpoint  AUEC0-12w  of  baseline-adjusted  CD19+,  individual comparisons, (PD [CD19+] population) in study PB006-01-03

| Parameter                                    | Treatment   | n   | Geometric LS Means   | Pairwisecomparison        | Pairwisecomparison   | Pairwisecomparison   |
|----------------------------------------------|-------------|-----|----------------------|---------------------------|----------------------|----------------------|
|                                              |             |     |                      | Pair                      | Ratio                | 95% CI               |
| AUEC0-12w baseline- adjusted CD19+ (10%/L*h) | PB006       | 142 | 423080               | PB006vsEU-Tysabri         | 1.0163               | 0.8787,1.1754        |
| AUEC0-12w baseline- adjusted CD19+ (10%/L*h) | EU-Tysabri  | 147 | 416312               | PB006vsUS-Tysabri         | 1.0156               | 0.8783,1.1744        |
| AUEC0-12w baseline- adjusted CD19+ (10%/L*h) | US-Tysabri  | 148 | 416593               | EU-Tysabri vs US- Tysabri | 0.9993               | 0.8653, 1.1541       |

AUEC0-12w=area under the effect time curve from time zero to 12 weeks, CI=confidence interval, LS=least square, n=number of subjects with data available, PD=pharmacodynamic

For all comparisons, the point estimates were close to 1 and the 95% CIs were completely included in the similarity margin of 0.80 to 1.25.

For  the  secondary  PD  endpoint  baseline-adjusted  Emax  of  CD19+  geometric  mean  ratios  and corresponding 90% CI and 95% CI were calculated, following the same methodology as described for the primary PD endpoints.

For the secondary PD endpoints baseline-adjusted Emax and tmax of CD19+ a descriptive evaluation was performed, and results based on 95% CIs are provided in Table 20.

Results from the statistical analysis of baseline-adjusted Emax of CD19+ are presented below.

<div style=\"page-break-after: always\"></div>

Table  19:  Statistical  analysis  of  the  secondary  PD  endpoint  baseline-adjusted  Emax  of  CD19+  (PD [CD19+] population) in study PB006-01-03

| Parameter                                | Treatment   | n   | Geometric LS Means   | Pairwisecomparison        | Pairwisecomparison   | Pairwisecomparison   |
|------------------------------------------|-------------|-----|----------------------|---------------------------|----------------------|----------------------|
|                                          |             |     |                      | Pair                      | Ratio                | 95% CI               |
| Emax baseline- adjusted of CD19+ (10%/L) | PB006       | 142 | 566                  | PB006vsEU-Tysabri         | 0.9961               | 0.9081, 1.0926       |
| Emax baseline- adjusted of CD19+ (10%/L) | EU-Tysabri  | 147 | 568                  | PB006vsUS-Tysabri         | 1.0317               | 0.9407, 1.1316       |
| Emax baseline- adjusted of CD19+ (10%/L) | US-Tysabri  | 148 | 548                  | EU-Tysabri vs US- Tysabri | 1.0358               | 0.9452,1.1350        |

AUEC0-12w=area under the effect time curve from time zero to 12 weeks, CI=confidence interval, LS=least square, n=number of subjects with data available, PD=pharmacodynamic

Table 20: Summary of PD parameters for CD19+ cells (PD [CD19+] population) in study PB006-01-03

|                                       | PB006 N=142            | EU-Tysabri N=147       | US-Tysabri N=148        |
|---------------------------------------|------------------------|------------------------|-------------------------|
| AUECo-12v baseline-adjusted (10%/L*h) | n=142                  | n=147                  | n=148                   |
| Arithmetic mean (SD)                  | 481948 (218317)        | 481715 (237973)        | 500108 (275663)         |
| CV (%)                                | 45.3                   | 49.4                   | 55.1                    |
| Geometric mean (geometric CV%)        | 422346 (64.8)          | 416278 (65.3)          | 417321 (78.7)           |
| Emax (10%/L)                          | n=142                  | n=147                  | n=148                   |
| Arithmetic mean (SD)                  | 865 (334)              | 870 (326)              | 876 (350)               |
| CV (%)                                | 38.6                   | 37.5                   | 39.9                    |
| Geometric mean (geometric CV%)        | 808 (38.1)             | 813 (38.4)             | 811 (41.9)              |
| Emax baseline-adjusted (10%/L)        | n=142                  | n=147                  | n=148                   |
| Arithmetic mean (SD)                  | 613 (265)              | 615 (254)              | 612 (273)               |
| CV (%)                                | 43.3                   | 41.2                   | 44.6                    |
| Geometric mean (geometric CV%)        | 562 (43.9)             | 568 (42.2)             | 552 (51.2)              |
| tmax, E (h)                           | n=142                  | n=147                  | n=148                   |
| Median (min-max)                      | 336.62 (6.00- 1011.82) | 336.83 (6.00- 1848.28) | 337.48 (48.00- 1680.45) |

AUEC0-12w=area under the effect time curve from time zero to 12 weeks, Emax=maximum effect, CV=coefficient of variation, N=number of subjects, n=number of subjects with data available, PD=pharmacodynamic, SD=standard deviation, tmax, E=time to Emax.

Note: AUEC0-12w and Emax of baseline-adjusted CD19+ cell counts were calculated as the area above zero following administration of 3 mg/kg natalizumab until CD19+ values returned and crossed zero for the first time after Emax and the maximal change from baseline of CD19+ measurements, respectively

Emax adjusted for baseline of CD19+ and tmax were secondary PD parameters. For Emax the changes from baseline were similar in the 3 treatment groups (mean of 612 to 615 x 10 6 /L across groups). Median tmax was approximately 337 hours in all groups.

B3. CD34+

The CD34+ profiles over time were similar in all treatment groups.

After administration of 3 mg/kg PB006, mean absolute values for CD34+ increased from a predose value of 2.92x10 6 /L to 4.43x10 6 /L after 6 hours. Mean CD34+ values further increased to reach a maximum on Day 15 (10.18x10 6 /L). After this maximum, mean CD34+ values decreased and returned to values similar to predose values by Day 78.

<div style=\"page-break-after: always\"></div>

After administration of 3 mg/kg EU-approved Tysabri, mean absolute values for CD34+ increased from a predose value of 2.93x10 6 /L to 4.57x10 6 /L after 6 hours. Mean CD34+ values further increased to reach a maximum on Day 15 (10.03x10 6 /L). After this maximum mean CD34+ values decreased and returned to values similar to predose values by Day 78.

After administration of 3 mg/kg US-licensed Tysabri, mean absolute values for CD34+ increased from a predose value of 2.65x10 6 /L to 4.17 10 6 /L after 6 hours. Mean CD34+ values further increased to reach a maximum on Day 15 (9.57x10 6 /L). After this maximum mean CD34+ values decreased and returned to values similar to predose values by Day 85.

AUEC0-t,  Emax,  and  tmax,E  for  CD34+  were  secondary  PD  endpoints,  and  a  descriptive  evaluation  was performed. A summary of these PD parameters for CD34+ is provided in below table.

Table 21: Summary Statistics of PD Parameters for CD34+ (PD Set [Other])

| Parameter(unit)   | Treatment Statistic   | 3 mg/kg IV PB006 N=145   | 3 mg/kg Iv Tysabri EU N=148    | 3 mg/kg IV Tysabri US N=145   |
|-------------------|-----------------------|--------------------------|--------------------------------|-------------------------------|
| AUEC0-t (10%/L*h) | Mean (SD)             | 12,591 (6564)            | 12,632 (7207) 57.1 3371-43,862 | 12,206 (7022) 57.5            |
|                   | CV (%)                | 52.1                     |                                |                               |
|                   | Min-Max               | 3723-44,794              |                                | 3157-50,905                   |
|                   | Geom mean (gCV%)      | 11,182 (51.3)            | 10,958 (57.1)                  | 10,604 (57.0)                 |
| tmax,E (h)        | Median                | 340.03                   | 341.94                         | 338.48                        |
|                   | Min-Max               | 48.00-1007.00            | 6.00-1345.00                   | 48.00-1874.08                 |
| Emax (10%/L)      | Mean (SD)             | 12.5 (6.59)              | 12.6 (6.84)                    | 11.8 (6.53)                   |
|                   | CV (%)                | 52.6                     | 54.3                           | 55.4                          |
|                   | Min-Max               | 3.73-37.7                | 3.09-43.4                      | 3.05-46.5                     |
|                   | Geom mean (gCV%)      | 11.1 (51.5)              | 11.0 (55.9)                    | 10.3 (55.1)                   |

AUEC=area  under  the  effect  curve  (above  threshold  effect);  CD34+=Cluster  of  Differentiation  34  activation;  CV=coefficient  of variation;  gCV=coefficient  of  variation  (geometric  mean);  Geom=geometric;  IV=intravenous;  Max=maximum;  Min=minimum; N=number of subjects; PD=pharmacodynamic(s); Tysabri EU=EU-approved Tysabri; Tysabri US=US-licensed Tysabri

The mean AUEC0-t and Emax and median tmax,E were similar for the 3 treatments.

## B4. sVCAM

The sVCAM profiles over time were similar in all treatment groups.

After administration of 3 mg/kg PB006, the mean absolute values for sVCAM decreased from a predose value of 725,662 µg/L to 592,104 µg/L after 6 hours. A minimum mean value was reached on Day 8 (344,803 µg/L). After this minimum, sVCAM returned to values similar to the predose value by Day 57 (745,579 µg/L).

After administration of 3 mg/kg EU-approved Tysabri, the mean absolute values for sVCAM decreased from  a  predose  value  of  751,493 µg/L  to  620,966 µg/L  after  6 hours.  A  minimum  mean  value  was reached on Day 8 (366,531 µg/L). After this minimum, sVCAM returned to values similar to the predose value by Day 57 (784,801 µg/L).

After administration of 3 mg/kg US-licensed Tysabri, the mean absolute values for sVCAM decreased from  a  predose  value  of  743,345 µg/L  to  610,690 µg/L  after  6 hours.  A  minimum  mean  value  was

<div style=\"page-break-after: always\"></div>

reached on Day 8 (355,386 µg/L). After this minimum, sVCAM returned to values similar to the predose value by Day 57 (769,688 µg/L).

AUECbase\\_neg, Emin and tmin of sVCAM were secondary PD endpoints, and a descriptive evaluation was performed.

Table 22: Summary Statistics of PD Parameters for sVCAM (PD Set [Other])

| Parameter (unit)      | Treatment Statistic   | 3 mg/kg IV PB006 N=145   | 3 mg/kg IV Tysabri EU N=148   | 3 mg/kg IV Tysabri US N=145   |
|-----------------------|-----------------------|--------------------------|-------------------------------|-------------------------------|
| AUECbase nea (μg/L*h) | Mean (SD)             | -331,097 (203,511)       | -293,641 (209,432)            | -308,654 (191,012)            |
|                       | CV (%)                |                          |                               |                               |
|                       | Min-Max               | -1,095,420-294,164       | -995,285-287,038              | -1,307,922-221,398            |
|                       | Geom mean (gCV%)      | NC                       | NC                            | NC                            |
| tmin (h)              | Median                | 168.00                   | 168.00                        | 168.00                        |
|                       | Min-Max               | 24.00-843.43             | 46.35-1011.82                 | 48.00-838.00                  |
| Emin (μg/L)           | Mean (SD)             | 320 (75.9)               | 343 (94.1)                    | 335 (94.1)                    |
|                       | CV (%)                | 23.7                     | 35.7                          | 28.1                          |
|                       | Min-Max               | 168-548                  | 115-1474                      | 145-882                       |
|                       | Geom mean (gCV%)      | 311 (24.0)               | 330 (27.5)                    | 323 (26.9)                    |

AUECbase\\_neg= area below the individual baseline value minus the area above the individual baseline in case of time intervals for which  the  curve  exceeded  the  baseline  value;  CV=coefficient  of  variation;  gCV=coefficient  of  variation  (geometric  mean); Geom=geometric; IV=intravenous; Max=maximum; Min=minimum; N=number of subjects; NC=not calculated; PD=pharmacodynamic(s); sVCAM=soluble vascular cell adhesion molecule; Tysabri EU=EU-approved Tysabri; Tysabri US=US-licensed Tysabri

In an exploratory manner, geometric mean ratios with 90% and 95% CIs were calculated for AUECbase\\_neg and Emin using the same methods as described for the primary PD parameters.  The results were not assessed by pre-specified similarity margins. Results are presented for the 95% CIs in the table below.

Table 23: Statistical analysis of the PD endpoint sVCAM (PD [other] population) in study PB006-01-03

| Parameter                      | Treatment   | n   | Geometric LS Means   | Pairwise comparison       | Pairwise comparison   | Pairwise comparison   |
|--------------------------------|-------------|-----|----------------------|---------------------------|-----------------------|-----------------------|
|                                |             |     |                      | Pair                      | Ratio                 | 95% CI                |
| AUECbase _neg of VCAM (μg/L*h) | PB006       | 145 | -331097              | PB006 vs EU- Tysabri      | 1.1276                | 0.9700, 1.2852        |
| AUECbase _neg of VCAM (μg/L*h) | EU-Tysabri  | 148 | -293641              | PB006 vs US- Tysabri      | 1.0727                | 0.9220, 1.2234        |
| AUECbase _neg of VCAM (μg/L*h) | US-Tysabri  | 145 | -308654              | EU-Tysabri vs US- Tysabri | 0.9514                | 0.8014, 1.1013        |
| Emin Of VCAM (μg/L)            | PB006       | 145 | 320                  | PB006 vs EU- Tysabri      | 0.9320                | 0.8654, 0.9986        |
| Emin Of VCAM (μg/L)            | EU-Tysabri  | 148 | 343                  | PB006 vs US- Tysabri      | 0.9558                | 0.8872, 1.0245        |
| Emin Of VCAM (μg/L)            | US-Tysabri  | 145 | 335                  | EU-Tysabri vs US- Tysabri | 1.0256                | 0.9573, 1.0939        |

AUECbase\\_neg=area below the individual baseline value minus the area above the individual baseline in case of time intervals for which the curve exceeded the baseline value, CI=confidence interval, Emin=minimum effect, LS=Least scare, n=number of subjects with data available, PD=pharmacodynamic.

<div style=\"page-break-after: always\"></div>

## B5. sMAdCAM

The sMAdCAM profiles over time were similar in all treatment groups.

After  administration  of  3 mg/kg  PB006,  the  mean  absolute  values  for  sMAdCAM  decreased  from  a predose value of 20,158 µg/L to 18,422 µg/L after 6 hours. A minimum mean value was reached on Day 29 (4146 µg/L). After this minimum, sMAdCAM returned to values similar to the predose value by Day 71 (20,094 µg/L).

After administration of 3 mg/kg EU-approved Tysabri, the mean absolute values for sMAdCAM decreased from a predose value of 19,778 µg/L to 18,330 µg/L after 6 hours. A minimum mean value was reached on Day 29 (4270 µg/L). After this minimum, sMAdCAM returned to values similar to the predose value by Day 71 (20,173 µg/L).

After administration of 3 mg/kg US-licensed Tysabri, the mean absolute values for sMAdCAM decreased from a predose value of 19,237 µg/L to 17,410 µg/L after 6 hours. A minimum mean value was reached on Day 29 (4023 µg/L). After this minimum, sMAdCAM returned to values similar to the predose value by Day 71 (18,813 µg/L).

AUECbase\\_neg, Emin and tmin for sMAdCAM were secondary PD endpoints, and a descriptive evaluation was performed.

Table 24: Summary Statistics of PD Parameters for sMAdCAM (PD Set [Other])

| Parameter (unit)      | Treatment Statistic   | 3 mg/kg IV PB006 N=145   | 3 mg/kg IV Tysabri EU N=148   | 3 mg/kg IV Tysabri US N=145   |
|-----------------------|-----------------------|--------------------------|-------------------------------|-------------------------------|
| AUECbase_neg (μg/L*h) | Mean (SD)             | -16,706 (6351)           | -15,746 (7552)                | -16,055 (7265)                |
| AUECbase_neg (μg/L*h) | CV (%)                |                          |                               |                               |
| AUECbase_neg (μg/L*h) | Min-Max               | -36,638- -1399           | -43,197- -2306                | -45,333- -2945                |
| AUECbase_neg (μg/L*h) | Geom mean (gCV%)      | NC                       | NC                            | NC                            |
| tmin (h)              | Median                | 839.70                   | 839.21                        | 839.00                        |
| tmin (h)              | Min-Max               | 168.02-1011.63           | 340.55-1012.40                | 501.53-1347.53                |
| Emin (μg/L)           | Mean (SD)             | 3.69 (1.16)              | 3.67 (1.32)                   | 3.53 (1.23)                   |
| Emin (μg/L)           | CV (%)                | 31.4                     | 36.0                          | 34.8                          |
| Emin (μg/L)           | Min-Max               | 1.04-9.04                | 1.06-9.31                     | 1.15-9.68                     |
| Emin (μg/L)           | Geom mean (gCV%)      | 3.51 (32.7)              | 3.46 (36.0)                   | 3.34 (34.8)                   |

AUECbase\\_neg= area below the individual baseline value minus the area above the individual baseline in case of time intervals for which the curve exceeded the baseline value; CV=coefficient of variation; gCV=coefficient of variation (geometric mean); Geom=geometric; IV=intravenous;  Max=maximum;  Min=minimum;  N=number  of  subjects;  PD=pharmacodynamic(s);  sMAdCAM=soluble  mucosal addressin cell adhesion molecule; Tysabri EU=EU-approved Tysabri; Tysabri US=US-licensed Tysabri

In  an  exploratory  manner,  geometric  mean  ratios  with  90%  and  95%  CIs  were  calculated  for AUECbase\\_neg (Area below the individual baseline value minus the area above the individual baseline in case of time intervals for which the curve exceeded the baseline value) and Emin using the same methods as described for the primary PD parameters. The results were not assessed by pre-specified similarity margins. Results are presented for the 95% CIs in the table below.

<div style=\"page-break-after: always\"></div>

Table 25: Statistical analysis of the PD endpoint sMAdCAM (PD [other] population) in study PB006-0103

| Parameter                      | Treatment   | n   | Geometric LS Means   | Pairwise comparison       | Pairwise comparison   | Pairwise comparison   |
|--------------------------------|-------------|-----|----------------------|---------------------------|-----------------------|-----------------------|
|                                |             |     |                      | Pair                      | Ratio                 | 95% CI                |
| AUECbase_neg ofMAdCAM (μg/L*h) | PB006       | 145 | -16706               | PB006 vs EU- Tysabri      | 1.0609                | 0.9577, 1.1642        |
| AUECbase_neg ofMAdCAM (μg/L*h) | EU-Tysabri  | 148 | -15746               | PB006 vs US- Tysabri      | 1.0406                | 0.9388, 1.1423        |
| AUECbase_neg ofMAdCAM (μg/L*h) | US-Tysabri  | 145 | -16055               | EU-Tysabri vs US- Tysabri | 0.9808                | 0.8795, 1.0820        |
| Emin of MAdCAM (μg/L)          | PB006       | 145 | 3.69                 | PB006 vs EU- Tysabri      | 1.0034                | 0.9260, 1.0809        |
| Emin of MAdCAM (μg/L)          | EU-Tysabri  | 148 | 3.67                 | PB006 vs US- Tysabri      | 1.0438                | 0.9628, 1.1248        |
| Emin of MAdCAM (μg/L)          | US-Tysabri  | 145 | 3.53                 | EU-Tysabri vs US- Tysabri | 1.0402                | 0.9597, 1.1208        |

AUECbase\\_neg=area below the individual baseline value minus the area above the individual baseline in case of time intervals for which the curve exceeded the baseline value, CI=confidence interval, Emin=minimum effect, LS=Least scare, n=number of subjects with data available, PD=pharmacodynamic.

Ancillary analyses

COVID-19-Impact

## Plan

Changes in conduct or analysis of the study due to COVID-19 were not considered at start of the study since the virus was not known by that time.

In Amendment 3 (20 June 2020) of the study protocol, measures were described which were taken to protect subjects after dosing from a COVID-19 infection:

- 1) Inclusion criteria:
- a. Reduction of maximum inclusion age from 65 years reduced to 54 years before dosing
- b. 2 negative SAS-CoV-2 tests prior dosing
- 2) Exclusion criteria: History or evidence of SARS-CoV-2 infection in the last month prior screening 1 or having been in confirmed contact with SARS-CoV-2 positive subjects in the last 2 weeks before dosing
- 3) Inclusion of polymerase chain reaction [PCR] SARS-CoV-2 tests, update of ambulatory visit period and ambulatory activities, and increase of the in-house period
- 4) Update of benefit/risk assessment of conduct of this study: The national multiple sclerosis society of the USA, as per the website information published on their website, classifies natalizumab as an immunomodulator rather than an immunosuppressant and states that treatment with natalizumab does not involve any greater risk for infection with e.g. SARS-CoV-2. Subjects in the trial also do not belong  to  potential  high-risk  groups.  The  risk  assessment  for  increase  of  serious  infections  is classified as both high impact and low possibility.

## Conduct &amp; Outcome

Due to the COVID-19 pandemic, the study was temporarily stopped on 16 Mar 2020. After approval of CSP Version 4.0 (dated 20 June 2020), study enrolment was resumed.

Prior to the enrolment halt, the study had been started with 3 sites. Due to COVID-19 related recruitment

<div style=\"page-break-after: always\"></div>

issues, 3 additional sites were included at the time enrolment was resumed.

In  order  to  assess  the  impact  of  COVID-19  on  the  safety  in  this  study,  study  discontinuations  and protocol deviations due to COVID-19 were listed and summarized, if possible.

To investigate whether there were differences between subjects completing the study prior to the study stop and subjects completing the study after the study stop, Tables, Figures and Listings (TFLs) for demographics and AEs were also created on 2 subsets of the Safety Set:

- Pre-stop Safety Set: Subjects randomized to study intervention and dosed with study intervention and who completed the study before the study stop due to COVID-19 on 16 Mar 2020.
- Post-stop Safety Set: Subjects randomized to study intervention and dosed with study intervention and who completed the study after the study stop due to COVID-19 on 16 Mar 2020.

Difference between the subjects in baseline characteristics enrolled before and after the study stop due to COVID-19 was limited and might be due to the small number of subjects randomized before the study stop (n=16) when compared to the number of subjects randomized after the study restart (n=434).

Important  protocol  deviations  related  to  COVID-19  were  reported  for  5  subjects,  3  are  related  to compliance with quarantine requirements, and 2 are related to use of medication without consulting the Investigator.

Before the study stop due to COVID-19, 25 TEAEs were reported for 10 subjects (63%) After the study stop due to COVID-19, 790 TEAEs were reported for 293 subjects (68%). Eleven (11) events of COVID19 were reported by 11 subjects (3%), 5 events by 5 subjects (3%) receiving 3 mg/kg PB006, 2 events by 2 subjects (1%) receiving 3 mg/kg EU-approved Tysabri, and 4 events by 4 subjects (3%) receiving 3 mg/kg US-licensed Tysabri. One (1) event of asymptomatic COVID-19 was reported by a subject receiving US-licensed Tysabri. There was no difference in the nature and severity of the reported TEAEs. No subjects were withdrawn due to COVID-19.

## Absorption

Since PB006 is developed as an IV solution, no clinical studies were conducted to evaluate bioavailability of the product.

No specific food-interaction studies were performed.

## Distribution

Volume of distribution (Vz) was assessed in the PK/PD study PB006-01-03. The PK results for study PB006-01-03 are presented in more detail in the Bioequivalence section. PB006 had a mean Vz of 1262 ml, Vz (EU-Tysabri) was 1198 ml and Vz (US-Tysabri) was 1164 ml.

## Elimination

t1/2 and CL were assessed in the PK/PD study PB006-01-03. PB006 had a geometric mean t1/2 of 90.3 h, geometric mean t1/2 of EU-Tysabri and US-Tysabri were 87.6 h and 87.5 h, respectively. The geometric mean values for CL were 9.72 ml/h for PB006, 9.48 ml/h for EU-Tysabri, and 9.22 for US-Tysabri.

## 2.6.2.2. Pharmacodynamics

The applicant conducted two pivotal studies to investigate the clinical similarity between PB006 and Tysabri, one single dose PK/PD study in healthy volunteers (PB006-01-03) and one multiple dose efficacy and safety study in patients with RRMS (PB006-03-01). The latter study included PK evaluation at steady state (Ctrough) but no assessment of PD was conducted in patients.

Additionally, the applicant conducted a pilot study with Tysabri in healthy subjects (Tysabri Pilot-01-01). The purpose of this pilot study was the collection of PK/PD data with 3 different doses of EU-Tysabri to

<div style=\"page-break-after: always\"></div>

establish  the  appropriately  sensitive  study  design  features  including  the  dose  selection  and  primary endpoints for the pivotal PK/PD study PB006-01-03.

Besides the comparative PK and efficacy &amp; safety evaluation conducted for this MAA, comparative PD assessed in study PB006-01-03 can be used to further support the clinical similarity assessment of PB006 and Tysabri.

## Mechanism of action

The Mechanism of Action of natalizumab is presented in the SmPC of the reference medicinal product EU-Tysabri (and referred to in the Dossier of Tyruko):

Natalizumab is a selective adhesion-molecule inhibitor and binds to the α4 -subunit of human integrins, which is highly expressed on the surface of all leukocytes, with the exception of neutrophils. Specifically, natalizumab binds to the α4β1 integrin, blocking the interaction with its cognate receptor, VCAM-1, and ligands osteopontin, and an alternatively spliced domain of fibronectin, CS-1. Natalizumab blocks the interaction of α4β7 integrin with the MadCAM-1. Disruption of these molecular interactions prevents transmigration of mononuclear leukocytes across the endothelium into inflamed parenchymal tissue. A further mechanism of action of natalizumab may be to suppress ongoing inflammatory reactions in diseased  tissues  by  inhibiting  the  interaction  of α4 -expressing  leukocytes  with  their  ligands  in  the extracellular matrix and on parenchymal cells. As such, natalizumab may act to suppress inflammatory activity present at the disease site, and inhibit further recruitment of immune cells into inflamed tissues.

In MS, lesions are believed to occur when activated T-lymphocytes cross the BBB. Leukocyte migration across the BBB involves interaction between adhesion molecules on inflammatory cells and endothelial cells of the vessel wall. The interaction between α4β1 and its targets is an important component of pathological  inflammation  in  the  brain  and  disruption  of  these  interactions  leads  to  reduced inflammation. Under normal conditions, VCAM-1 is not expressed in the brain parenchyma. However, in the presence of pro-inflammatory cytokines, VCAM-1 is upregulated on endothelial cells and possibly on  glial  cells  near  the  sites  of  inflammation.  In  the  setting  of  CNS  inflammation  in  MS,  it  is  the interaction  of α4β1 with  VCAM-1,  CS-1  and  osteopontin  that  mediates  the  firm  adhesion  and transmigration of leukocytes into the brain parenchyma and may perpetuate the inflammatory cascade in CNS tissue. Blockade of the molecular interactions of α4β1 with its targets reduces inflammatory activity present in the brain in MS and inhibits further recruitment of immune cells into inflamed tissue, thus reducing the formation or enlargement of MS lesions.

In the presented dossier for the Tyruko MAA, the applicant further describes the Mechanism of Action for natalizumab in the pathogenesis of MS:

VCAM-1 is upregulated on brain microvascular endothelial cells in inflammatory CNS lesions of patients with MS (Benkert et al., 2012). As VCAM-1 is expressed on inflamed cerebrovascular endothelial cells, α4β1 is believed to be the critical target of natalizumab in preventing leukocyte migration into the CNS in MS (Selewski et al., 2010, 'Natalizumab (Tysabri)').

MS is a chronic inflammatory demyelinating disease of the CNS. It may take a relapsing-remitting or a chronic  progressive  clinical  course.  The  immigration  of  activated  T-lymphocytes  into  the  CNS  is fundamental to its pathogenesis. During disease development, CD4+ T-cells encounter environmental triggers of unknown kind in the periphery. This, in a widely accepted view, leads to activation of CNS antigen specific CD4+ T-cells in genetically susceptible individuals. These autoreactive T-cells then cross the BBB as effector T helper cells and initiate a chronic autoimmune disease (Benkert et al., 2012).

Leucocyte migration across the BBB involves interaction between adhesion molecules on inflammatory cells and their counter-receptors present on endothelial cells of the vessel wall. The clinical effect of

<div style=\"page-break-after: always\"></div>

natalizumab in multiple sclerosis may be secondary to blockade of the molecular interaction of α4β1 integrin expressed by inflammatory cells with VCAM-1 on vascular endothelial cells, and with CS-1 and/or osteopontin expressed by parenchymal cells in the brain. In MS, the rationale for natalizumab therapy is the reduction of leukocyte migration into the CNS by specifically targeting α4β1, or very-late-activation antigen 4 (EMA Tysabri EPAR  -  Assessment  Report  -  Variation,  2013).  VCAM  is  induced  on  venular endothelium in inflammation, including in brain in experimental autoimmune encephalitis. Natalizumab, as an antibody to α4β1, blocks lymphocyte emigration into the brain, α4β1 dependent co-stimulation of immune responses, and EAE. Consequently, α4β1 and not α4β7 is the critical target for experimental autoimmune encephalitis (Yu et al., 2013, 'How Natalizumab Binds and Antagonizes α4 Integrins').

## Primary and Secondary pharmacology

## Study Tysabri Pilot-01-01

A  randomised,  parallel-group,  single  dose  clinical  pharmacology  pilot  study  was  performed  by  the applicant in order to characterise the PK and PD profiles of the reference medicinal product EU-Tysabri. Further, the study aimed to assess and compare the Fab-arm exchange of EU-Tysabri, and to assess the safety of EU-Tysabri. The study is briefly summarised below, with a focus on PD of natalizumab.

## Study Design

Tysabri Pilot-01-01 was a single-centre, single-dose, randomized, double-blind, 3-arm parallel-group study in 36 healthy male and female subjects. Subjects were randomized to one of 3 dose groups and treated with single doses of EU-Tysabri. The study schedule included 2 screening visits prior to drug administration, a clinic period from Day -1 to approximately 48 hours after drug administration and 11 ambulatory visits, on Day 5, 8, 15, 22, 29, 36, 43, 57, 71, 78, and 85. An additional follow-up visit was performed 6 months after drug administration, to assess potential neurological symptoms which could suggest PML. Safety was monitored throughout the study by repeated clinical and laboratory evaluations. Samples for assessments of PK, PD and immunogenicity were collected up to Day 85.

Healthy male and female subjects aged 18 to 65 years at screening, with a body weight of 50.0 to 110.0 kg, a BMI of 18.5 to 32.0 kg/m 2 , and JCV antibody negative were eligible to the study. Randomisation was stratified by body weight class (50.0 - 70.0 kg, 70.1 - 90.0 kg, 90.1 - 110.0 kg). No formal sample size calculation was performed.

Subjects were randomised to three treatment arms and received a single, 60-minute, IV dose of 1, 3, or 6 mg/kg EU-Tysabri (N=12 for each arm).

Blood samples for assessment of PD parameters were collected pre-dose and 6 hours after start of infusion on Day 1, and on Days 2, 5, 8, 15, 22, 29, 36, 43, 57, 71, 78 and 85.

The PD variables included sMAdCAM, sVCAM, α4 -integrin %RS, cell counts for CD34+, CD19+, CD3+, CD3+CD8+,  CD3+CD4+,  CD3-CD16+CD56+,  CD10+CD19+.  For α4 -integrin  %RS,  sVCAM  and sMadCAM, and for  all  lymphocyte  cell  counts  the  following  PD  parameters  were  calculated:  The  PD parameters were AUEC0-12w and AUEC4-12w, Emax and time to Emax (Tmax, E). The PD parameters were estimated on the absolute values, using a noncompartmental model. The linear trapezoidal interpolation method for AUEC calculation was used. Per an addendum to the SAP, geometric CV was added to the PD levels and parameter tables, and ANOVA was performed for relative α4 -integrin %RS and CD19+ using the SAS procedure for mixed effect models (with treatments as fixed effects).

The analysis of PD levels was based on the safety population, defined as all subjects who received study medication. The analysis of PD parameters was based on the PD population, defined as all subjects who have received the dose of study medication and provided sufficient bioanalytical assessment results to calculate reliable estimates of the PD parameters.

The demographics and baseline characteristics are described in the following table.

<div style=\"page-break-after: always\"></div>

Table 26: Demographic and baseline characteristics in study Tysabri Pilot-01-01 (PK population)

|                                           | EU-Tysabri 1 mg/kg N=12   | EU-Tysabri 3 mg/kg N=12   | EU-Tysabri 6 mg/kg N=12   |
|-------------------------------------------|---------------------------|---------------------------|---------------------------|
| Age (years)                               |                           |                           |                           |
| Mean (SD)                                 | 33 (10)                   | 36 (13)                   | 37 (11)                   |
| Sex, n (%)                                |                           |                           |                           |
| Male                                      | 3 (25)                    | 5 (42)                    | 7 (58)                    |
| Female                                    | 9 (75)                    | 7 (58)                    | 5 (42)                    |
| Race, n (%)                               |                           |                           |                           |
| White                                     | 7 (58)                    | 9 (75)                    | 4 (33)                    |
| Black or African American                 | 5 (42)                    | 3 (25)                    | 6 (50)                    |
| White + Black or African American         | 0                         | 0                         | 1 (8)                     |
| White + Black or African American + Asian | 0                         | 0                         | 1 (8)                     |
| Weight (kg)                               |                           |                           |                           |
| Mean (SD)                                 | 77.0 (11.5)               | 79.3 (12.1)               | 75.5 (12.3)               |
| Height (cm)                               |                           |                           |                           |
| Mean (SD)                                 | 169 (10)                  | 172 (9)                   | 174 (10)                  |
| Body mass index (kg/m²)                   |                           |                           |                           |
| Mean (SD)                                 | 26.8 (2.7)                | 26.8 (2.5)                | 25.0 (2.9)                |
| Weight class, n (%)                       |                           |                           |                           |
| 50.0-70.0 kg                              | 3 (25)                    | 3 (25)                    | 4 (33)                    |
| 70.1-90.0 kg                              | 8 (67)                    | 7 (58)                    | 7 (58)                    |
| 90.1-110.0 kg                             | 1 (8)                     | 2 (17)                    | 1 (8)                     |

N=number of subjects receiving study medication; n=number of subjects in this category; SD=Standard deviation, EU-Tysabri =EUapproved Tysabri. Please note that the PK population was identical to the PD and the safety population.

## PD Results

For α 4-integrin  (%)RS  a  clear  dose  response  relationship  was  observed  across  the  tested  doses, indicating good dynamic range of the PD marker. The increase in AUEC0-12w was approximately 1.7-fold for the dose increase from 1 mg/kg to 3 mg/kg, and approximately 1.3-fold for the dose increase from 3 mg/kg to 6 mg/kg (based on geometric mean values). With regard to variability, the geometric CV for AUEC0-12w ranged from 18.5% (with 1 mg/kg) to 27.7% (with 3 mg/kg). Overall, these results were the prerequisite for setting up the sensitive PD assessment in the pivotal study PB006-01-03 and based on these results, the 3 mg/kg dose was selected.

CD19+ B-cell counts increased in a sensitive and dose-dependent way upon natalizumab exposure. A clear dose response relationship was observed across the tested doses, indicating good dynamic range of the PD marker. The increase in AUEC0-12w change from baseline was approximately 1.8-fold for the dose increase from 1 to 3 mg/kg, and approximately 1.4-fold for the dose increase from 3 to 6 mg/kg (based on geometric mean values). The variability was high, with geometric CV being between 50.6% (for 6 mg/kg) and 101.4% (for 1 mg/kg). Based on these results, the 3 mg/kg dose was selected as a sensitive dose for the pivotal PK/PD study PB006-01-03.

CD34+ cell counts increased in a dose dependent way across the tested doses, indicating good dynamic range of the PD marker. The increase for AUEC0-12w was approximately 1.7-fold for the dose increase from 1 to 3 mg/kg, and approximately 1.5-fold for the dose increase from 3 to 6 mg/kg (based on geometric mean values). Variability was high, with geometric CV between 44.0% (for 1 mg/kg) and 68.7% (for 3 mg/kg).

For sVCAM, a clear dose response relationship was observed across the tested doses, indicating good dynamic range of the PD marker. The increase in AUEC0-12w below baseline effect was approximately 2.0-

<div style=\"page-break-after: always\"></div>

fold for the dose increase from 1 to 3 mg/kg, and approximately 1.3-fold for the dose increase from 3 to 6 mg/kg (based on geometric mean values). With regard to variability, geometric CVs ranged between 33.9 and 71.2%.

Also for sMAdCAM, a clear dose response relationship was observed across the tested doses, indicating good dynamic range of the PD marker. The increase in AUEC0-12w below baseline effect was approximately 1.7-fold for the dose increase from 1 to 3 mg/kg, and approximately 1.6-fold for the dose increase from 3  to  6  mg/kg  (based  on  geometric  mean  values).  With  regard  to  variability,  geometric  CVs  ranged between 38.9 and 54.8%.

The  additionally  tested  PD  parameters  CD3+,  CD3+CD4+,  CD3+CD8+,  CD3-CD16+56+,  and CD10+CD19+ cells were found to not be dose dependent and thus not sensitive to detect differences in efficacy. These parameters were hence not included in the pivotal PK/PD study PB006-01-03.

## 2.6.3. Discussion on clinical pharmacology

The clinical pharmacology programme for the natalizumab biosimilar candidate PB006 comprises data from two studies: the bulk of data for the biosimilarity exercise in PK and PD was generated in the pivotal phase 1 PK/PD study PB006-01-03, which investigated biosimilarity between PB006 and both EU- and US-sourced Tysabri in healthy subjects (N=453). Further, trough concentrations and immunogenicity were assessed in a pivotal phase 3 study ('efficacy study' PB006-03-01).

The primary objective of the pivotal PK/PD study was the demonstration of similarity in the PK and PD profiles. In this study, one primary PK endpoint as well as two co-primary PD endpoints were used. The study design and study population were appropriate. It is noted that for the scope of this MAA, the comparison of the biosimilar candidate and EU-Tysabri is considered of higher regulatory significance than the comparison with US-Tysabri.

The analytical methods have been adequately validated; all issues identified have been addressed by the applicant and are considered solved.

A  population  of  healthy  subjects  was  included  which  is  appropriate  to  detect  potential  differences between the two treatments since variability is minimised and the mode of action is the same in healthy subjects and patients. In addition, inclusion of only healthy volunteers who were shown to be negative for anti-JCV antibodies as a measure to minimise the risk for PML, is in line with the scientific advice.

Stratification was performed according to the body weight class (50 kg to 65 kg, &gt;65 kg to 80 kg, &gt;80 kg to 92 kg) to ensure balance across the study arms, because according to Tysabri EPAR, body weight was found to influence the natalizumab disposition.

The study protocol was amended at several time points, with extensive changes to its design, including the primary endpoints, sample size, study population, conduct of the study (introduction of a pooling criterion to allow pooling of results of EU- and US-Tysabri for PD evaluation), and evaluation of study results. Some changes were introduced in response to the worldwide SARS-CoV-2 outbreak (including the inclusion of three additional sites), which took place during the early stages of the study and led to a temporary study halt.

Amendments to the primary PD endpoints were made. In the original study protocol, AUEC4-12wk of α4 -integrin  RS  was specified. This endpoint was agreed during EMA scientific advice. Use of the partial AUEC4-12wk  was  reasoned  with  rapid  and  strong  induction  of  the  marker  immediately  following administration of natalizumab. Since receptor saturation was high (near max saturation levels) until around the 4 week mark, exclusion of the first 4 weeks leads to increased sensitivity of the marker. However, the endpoint was replaced by AUEC0-12wk α4 -integrin RS in the final amendment, for reasons

<div style=\"page-break-after: always\"></div>

of  harmonisation  across  regulatory  regions.  AUEC4-12wk α4 -integrin  RS  was  planned  as  an  additional supportive analysis. In the original study protocol, AUEC0-t and Emax of CD19+ B-cells were specified. However, these endpoints were downgraded to secondary endpoints with the first amendment. With the final amendment, AUEC0-12wk of CD19+ cells was reintroduced.

While the addition of a co-primary PD marker acting downstream of the receptor was advised during EMA scientific advice and is endorsed, no scientific justification of the CD19+ B-cells in terms of PD was provided with the documentation, and a discussion of the relevance of the marker was requested from the applicant. In said discussion, the applicant acknowledged that the CD19+ B-cell count does not qualify as a surrogate endpoint. Since the applicant does not aim to derive clinical relevance from the PD characterisation and the clinical efficacy assessment is informed by data generated in a dedicated efficacy study in a patient population, the omission to provide an adequate justification for the clinical relevance of the selected PD endpoint does not impede assessment of biosimilarity and the concern is therefore not further pursued.

In the initial submission, the additional pre-specified analysis of receptor saturation AUEC4-12wk of α4 -integrin %RS was missing and the descriptive results presented were apparently based on the safety set, instead of the pre-specified RS/RO main analysis AUEC4-12wk set. The applicant was asked to provide the  correct  analysis  and  no  concerns  arise  from  the  submitted  data.  Also  the  unpooled  sensitivity analyses for AUEC0-12 α4 -integrin RS were requested and the data provided raised no concerns.

One methodological concern pertains to potentially jeopardised trial integrity, as any potential datadriven planning of important design aspects (choice of PD endpoints, option for pooling of reference data, etc) may have a non-negligible impact on trial outcome interpretation. Due to the extensive character of the amendments relatively late into the study, a description/overview of the chronological sequence of relevant trial milestones was submitted by the applicant. Measures taken to reflect the late changes in the trial in the randomisation process were described by the applicant. Although many changes were made during study conduct, no severe impact on study integrity could be identified.

Biosimilarity  in  PK  of  PB006  and  EU-authorised and US-sourced Tysabri was demonstrated following single dose IV infusion of 3 mg/kg natalizumab, as the 90% CIs for the ratio of geometric LS means for the primary PK endpoint AUC0-inf of total natalizumab of PB006 and EU- (and US-) sourced Tysabri were completely  within  the  acceptance  interval  of  0.8  -  1.25.  This  result  was  supported  by  the  results presented for the secondary endpoints regarding total natalizumab (AUC0-t, Cmax), and  unexchanged natalizumab  (AUC0-inf,  AUC0-t,  Cmax,  tmax).  Tmax  of  total  natalizumab  supported  biosimilarity  between PB006 and EU-Tysabri, but a difference was noted for the US-sourced comparator. This however does not  raise  concerns,  given  the  higher  regulatory  significance  of  the  comparison  with  EU-Tysabri.  The primary and secondary PK endpoints as well as the equivalence margin (80-125%) used are in line with the 'Guideline on similar biological medicinal products containing monoclonal antibodies - non-clinical and clinical issues' (EMA/CHMP/BMWP/403543/2010).

For PB006 and EU-Tysabri, the ratio of geometric LS means for the primary PK endpoint AUC0-inf of total natalizumab was 0.9864 (90% CI: 0.9410, 1.0340), for AUC0-t of total natalizumab 0.9840 (90% CI: 0.9387, 1.0316), and for Cmax 0.9565 (90% CI: 0.9215, 0.9929). Therefore, bioequivalence can  be concluded from the results of the primary PK endpoint. The results of the PK secondary analyses support the results of the primary PK analysis.

Demographic and baseline characteristics (mean age, body weight, height, BMI) were balanced between the three treatment arms. Slightly more men than women were recruited in the PB006 group (males 53%) compared to both Tysabri groups (EU-Tysabri: 46.4% males, US-Tysabri: 47.3% males). Race of participants and body weight classes were well balanced between treatment arms.

<div style=\"page-break-after: always\"></div>

In study PB006-03-01 after repeated administration, the Ctrough concentrations were similar in the PB006 and Tysabri groups at all post-baseline timepoints for both FAS and PP populations.

Certificate of analyses for the biosimilar candidate batch No. P79303A, EU-Tysabri batch 1424913 and batch  No.  1425561,  US-Tysabri  batch  No.  SP0118  used  in  the  clinical  trial  PB006-01-03  have  been provided. As the regulatory decision regarding the biosimilarity is based on the comparability between the  biosimilar  candidate  PB006  and  EU-Tysabri,  for  which  certificates  of  analysis  contained  all  the relevant parameters, the issue is not further pursued.

For the demonstration of biosimilarity in PD, two co-primary endpoints were used: AUEC0-12wk α4 -integrin % RS and AUEC0-12wk of the baseline-adjusted CD19+ cell fraction. Both co-primary endpoints were met, as the 95% CIs for the ratio of geometric LS means for the co-primary PD endpoints AUEC0-12wk α4 -integrin %RS and AUEC0-12wk baseline-adjusted CD19+ were completely within a predefined interval of 0.8 - 1.25.

For PB006 and EU-Tysabri, the ratio of geometric LS means for AUEC0-12wk α4 -integrin % RS was 1.0142 (95% CI: 0.9667, 1.0641). The ratio for the comparison against pooled EU- and US-Tysabri was 0.9933 (95% CI: 0.9523, 1.0362).

For PB006 and EU-Tysabri, the ratio of geometric LS means of AUEC0-12wk of baseline-adjusted CD19+ was 1.0163 (95% CI: 0.8787, 1.1754). The ratio for the comparison against pooled EU- and US-Tysabri was 1.0159 (95% CI: 0.8955, 1.1525).

Although the EMA/CHMP scientific advice recommended to update the primary endpoint to the partial AUEC4-12W of the α4 -integrin receptor saturation to use the most sensitive part of the curve to detect differences  between  the  reference  product  and  the  biosimilar  candidate  as  primary  endpoint  for evaluating biosimilarity, the applicant did not follow the scientific advice.

The EMA/CHMP scientific advice recommended to include additional true PD markers (e.g., lymphocyte count measurements, lymphocyte subset analysis, sVCAM-1 concentration measurements, sMADCAM concentrations) to provide further supportive PD evidence, as α4 -integrin RS over time is not a true PD marker since it merely reflects occupancy of the receptor rather than translation into an effect. Thus, secondary  endpoints  measured  in  study  PB006-01-03,  i.e.,  Emax,  tmax  of  baseline  adjusted  CD19+, AUECbase\\_neg,  Emin,  tmin  of  sVCAM  and  of  sMAdCAM,  and  AUEC0-t,  Emax,  tmax  of  CD34+  are  considered adequate.

A mean maximum response of α4 -integrin %RS of 92.6% was observed more rapidly after administration of 3 mg/kg PB006 (24 hours) as compared to administration of 3 mg/kg Tysabri EU (93.2% on Day 5 (96 hours)) and of 3 mg/kg Tysabri US (93.1% on Day 5 (96 hours)).

The use of 95% CI for primary PD parameters is considered adequate. However, the used equivalence margins (80-125%) for assessment of PD endpoints were criticised during EMA scientific advice provided prior to study initiation as being too wide. Also, no sound scientific justification for the acceptance ranges was found in the documentation. The applicant was therefore asked to provide a justification for the equivalence  margins  of  0.8  -  1.25  used  for  all  PD  endpoints.  In  the  responses,  the  applicant acknowledged that none of the PD endpoints are sufficiently associated with a clinical endpoint and hence did  not  provide  a  clinical  justification  of  the  pre-specified  acceptance  margin.  Given  that  in  the developmental programme of Tyruko efficacy data were generated which are considered adequate to enable  assessment  of  biosimilarity,  this  lack  of  clinical  justification  does  not  impede  conclusions  on biosimilarity, and the issue is therefore not further pursued.

The secondary PD endpoints (Emax and tmax of baseline-adjusted CD19+, AUECbase\\_neg, Emin, tmin of sVCAM and sMAdCAM, AUEC0-t, Emax, tmax of CD34+) were overall supportive of biosimilarity between PB006 and EU-  (and  US-)Tysabri.  With  the  exception  of  sVCAM  AUECbase-neg  (ratio:  1.1276;  95%  CI:  0.9700,

<div style=\"page-break-after: always\"></div>

1.2852), the 95% CIs of the PB006 and EU-Tysabri ratios were contained within a 0.8 - 1.25 interval for all secondary parameters.

## 2.6.4. Conclusions on clinical pharmacology

From the presented data on PK and PD, biosimilarity between the biosimilar candidate PB006 and EUTysabri can be concluded.

## 2.6.5. Clinical efficacy

## 2.6.5.1. Dose response study

Not applicable

## 2.6.5.2. Main study(ies)

## Antelope: Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)

## Methods

This study was conducted at 48 study centers in 7 countries (Belarus, Croatia, Georgia, Moldova, Poland, Serbia, and Ukraine).

- Study Participants

In total, 531 patients were screened for enrolment into the study.

The main Inclusion Criteria were

- Male and female patients (age ≥ 18 to 60 years), with relapsing remitting MS (RRMS), defined by the 2010 revised McDonald criteria.
- At least 1 documented relapse within the previous year and either ≥ 1 GdE T1-weighted brain lesions or ≥ 9 T2-weighted brain lesions at Screening.
- Kurtzke Expanded Disability Status Scale (EDSS) score from 0 to 5 (inclusive) at Screening.

Patients who exhibited any of the following exclusion criteria were not eligible for admission into the study (list incomplete):

- Manifestation of MS other than RRMS
- Relapse within the 30 days prior Screening and until administration of the first dose of study drug.
- Prior treatment with natalizumab, alemtuzumab, ocrelizumab, daclizumab, rituximab, cladribine, or other B- and T-cell targeting therapies.
- Prior total lymphoid irradiation or bone marrow or organ transplantation.
- Any prior treatment within the following time period prior to Screening:
- o 30 days: systemic corticosteroids or interferonβ or glatiramer acetate

<div style=\"page-break-after: always\"></div>

- o 2  months:  fingolimod,  any  other  sphingosine-1-phosphate  receptor  modulator  (e.g., siponimod). any tumour necrosis factor-alpha (TNFα) inhibitors
- o 2 months: dimethyl fumarate
- o 3.5 months: Tysabri
- o 12 months: immunosuppressive therapy for indications other than MS (e.g., cytarabine, azathioprine, methotrexate, cyclophosphamide, cyclosporine, cladribine)
- Any prior treatment with mitoxantrone.
- Active  infections  requiring  oral  or  parenteral  antibiotic  treatment  within  2  weeks  prior  to Screening.
- Increased risk of opportunistic infections; exclusion determination to be made after consultation with the Medical Monitor.
- Patients with JCV index &gt;1.5 at Screening.
- Past or current PML diagnosis.
- Presence of malignancies or neoplastic diseases; past history of malignancies within 5 years prior to Screening (except basal cell and in situ squamous cell carcinomas of the skin that have been excised and resolved).
- History or known presence of recurrent or chronic infection other than recurring urinary tract infections (i.e., hepatitis A, B, or C, human immunodeficiency virus, tuberculosis).
- Clinically relevant, severe cardiac or pulmonary diseases, uncontrolled hypertension, or poorly controlled diabetes.
- Severe renal function impairment as defined by serum creatinine values &gt;120 μ mol/L.
- Elevated liver markers
- Decreased WBCs at Screening
- Any investigational drug within 3 months prior to enrollment or within 5 times of its half-life, whichever was longer.
- Unable to undergo MRI scans due to claustrophobia or metallic implants incompatible with MRI.
- Unable  to  receive  gadolinium-enhancing  (GdE)-based  MRI-contrast  agents  due  to  history  of hypersensitivity to Gd-based contrast agents or severe renal insufficiency.
- Has a known contraindication and (or) hypersensitivity to any of the constituents of the study drug or comparator drugs, including their excipients.

The  onset  of  the  following  diseases  or  conditions  presented  a  valid  reason  for  interrupting  or discontinuing  treatment:  PML,  JCV  granule  cell  neuronopathy,  opportunistic  infections,  liver  injury, hypersensitivity (not including infusion-related reactions), encephalitis, meningitis,  acute  retinal necrosis, low lymphocyte count or suicidal ideation/suicidal behaviors

## · Treatments

## Treatments Administered

The test drug, PB006, biosimilar natalizumab, is a concentrate for solution for IV infusion. PB006 is provided in an alternative formulation to Tysabri, based on well-established excipients and containing the same concentration of natalizumab as the reference (comparator) product.

<div style=\"page-break-after: always\"></div>

The comparator product, Tysabri (natalizumab), is a concentrate for solution for IV infusion.

Each 15 mL vial of concentrate contained 300 mg natalizumab (20 mg/mL). Both study drugs were to be diluted with 100 mL sodium chloride solution (0.9%), resulting in a natalizumab concentration of approximately 2.6 mg/mL for administration. The diluted solution was to be infused intravenously over 1 hour at a rate of approximately 2 mL/minute (115 mL total infusion volume).

Eligible patients were randomly assigned to 1 of 2 treatment groups in a 1:1 ratio to receive intravenous infusions every 4 weeks of either PB006 or Tysabri at a dose of 300 mg starting at Visit 1 (Week 0) through Visit 12 (Week 44), for a total of 12 infusions. Patients re-randomized and switched from Tysabri to PB006 at Week 24 still received a total of 12 infusions (6 infusions of Tysabri and 6 infusions of PB006).

Table 27: Identity of Investigational Products

| StudyDrug   | Formulation                                | Strength/Dose                                   |
|-------------|--------------------------------------------|-------------------------------------------------|
| PB006       | 20mg/mLconcentrateforsolutionforIVinfusion | 2.6mg/mLIVsolutioninfusedover1hour at2mL/minute |
| Tysabri     | 20mg/mLconcentrateforsolutionforIVinfusion | 2.6mg/mLIVsolutioninfusedover1hourat2mL/minute  |

## · Objectives and endpoints

The goal of the study was to support the demonstration of similarity between PB006 and Tysabri in RRMS patients. Efficacy, safety, immunogenicity, and PK of PB006 versus Tysabri were assessed.

Similarity between PB006 and Tysabri was to be assessed in the primary endpoint.

Table 28: objectives and endpoints

| Objectives                                                                                                                     | Endpoints                                                                                        |
|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Primary                                                                                                                        |                                                                                                  |
| Evaluate and compare the cumulative number of new active lesions over 24 weeks                                                 | Cumulative number of new active lesions over 24 weeks                                            |
| Secondary                                                                                                                      |                                                                                                  |
| Evaluate and compare the cumulative number of new active lesions over 48 weeks                                                 | Cumulative number of new active lesions over 48 weeks                                            |
| Evaluate and compare the cumulative number of new gadolinium-enhancing (GdE) T1-weighted lesions over 24 and 48 weeks          | Cumulative number of new GdE T1-weighted lesions over 24 and 48 weeks                            |
| Evaluate and compare the number of patients without new GdE T1-weighted lesions over 24 and 48 weeks                           | Number of patients without new GdE T1-weighted lesions over 24 and 48 weeks                      |
| Evaluate and compare the cumulative number of new/enlarging T2-weighted lesions over 24 and 48 weeks                           | Cumulative number of new/enlarging T2-weighted lesions over 24 and 48 weeks                      |
| Evaluate and compare the number of patients without new/enlarging T2-weighted lesions over 24 and 48 weeks                     | Number of patients without new/enlarging T2- weighted lesions over 24 and 48 weeks               |
| Evaluate and compare the number of persistent lesions after 24 and 48 weeks treatment with PB006 or Tysabri                    | Number of persistent lesions after 24 and 48 weeks                                               |
| Evaluate and compare the annualized relapse rates and changes in Expanded Disability Status Scale (EDSS) after 24 and 48 weeks | Annualized relapse rate after 24 and 48 weeks Change from baseline in EDSS after 24 and 48 weeks |
| Evaluate and compare local and systemic adverse events (AEs) and serious adverse events (SAEs) after 24 and 48 weeks           | Number of local and systemic AEs and SAEs after 24 and 48 weeks                                  |

<div style=\"page-break-after: always\"></div>

| Evaluate and compare the immunogenic profile (incidence rate of ADA [anti-natalizumab] and persistent antibodies) after 24 and 48 weeks and after switching   | Incidence rate of ADA and persistent antibodies after 24 and 48 weeks and after switching                                                    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Evaluate and compare the immunogenic profile (incidence rate of neutralizing antibodies) after 24 and 48 weeks and after switching                            | Incidence rate of neutralizing antibodies after 24 and 48 weeks and after switching                                                          |
| Evaluate and compare natalizumab trough concentration (Ctrough) over time                                                                                     | Natalizumab Ctrough over time                                                                                                                |
| Evaluate and compare the safety profile (physical examination, vital sign measurements, and clinical laboratory tests) over 24 and 48 weeks                   | Safety profile (physical examination, and change from baseline in vital sign measurements and clinical laboratory tests) over 24and 48 weeks |

Efficacy assessments included evaluation of lesions (assessed by MRI), and relapse rate and disability status (assessed by the Kurtzke EDSS).

For the primary endpoint, the applicant selected an equivalence margin for the mean difference of 2.1 lesions to ensure that 50% of the treatment effect based on the lower bound of the 95% CI of the pooled effect size estimated in a controlled trial of natalizumab for RMS (Miller et al., 2003) would be preserved.

Assessment  of  lesions  was  performed  using  MRI  with  contrast  agents.  Brain  MRI  scans  to  provide radiologic response data for assessing lesions were to be performed at each site. All MRI scans were to be assessed by the MRI central reading center, with the exception of the brain MRI scans for the PML Follow-up Visits, which were to be assessed locally, only.

A  macrocyclic  Gd-based  contrast  agent  (gadobutrol,  gadoteric  acid,  or  gadoteridol)  was  to  be administered as an IV infusion of 0.1 mmol/kg.

If PML was clinically suspected from Visit 1 through the End-of-Study Visit or Early Discontinuation Visit, the local radiologist was to alert the Investigator, who was to schedule an Unscheduled Suspected PML Visit with the patient within 3 days. MRI scans were to be reviewed immediately by the central reading center. The results of the review were to be communicated to the site, Sponsor, and CRO immediately.

If PML was suspected after the End-of-Study Visit or Early Discontinuation Visit, a PML Follow-up Visit was to be scheduled.

A relapse was defined as the appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality had to be present for at least 24 hours and have occurred in the absence of fever (&lt;37.5 °C) or infection.

In the event of a relapse, the study-related MRI scans were to be obtained before corticosteroid therapy was initiated. If this could not be done, the MRI scan was to be taken 14 days or more after the last corticosteroid dose. MRI scans were to be reviewed by the MRI central reading center.

The Kurtzke EDSS, commonly used to evaluate the degree of neurologic impairment in MS, is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death due to MS) in halfpoint increments. Based on a standard neurological examination, the 7 functional systems (plus 'other') are rated. These ratings are then used in conjunction with observations and information concerning gait and use of assistive  devices  to  rate  the  EDSS.  EDSS  ratings  were  to  be  performed  by  independent examining neurologists.

<div style=\"page-break-after: always\"></div>

Safety assessments included AEs (adverse events), physical examinations, ECG, vital signs, laboratory evaluations, Columbia-Suicide  Severity Rating Scale, anti-natalizumab antibodies, and  anti-JCV antibodies.

## · Sample size

A total of 230 evaluable patients (115 in each group), i.e., patients who complete the 24-week treatment period without relevant major protocol deviations and for whom sufficient postbaseline MRI data are available, were seen required to achieve 90% power for the equivalence assessment with respect to the cumulative  number  of  new  active  lesions  over  24  weeks  treatment,  assuming  a  common  standard deviation of 4.0 lesions and no difference between both groups. To account for potential dropouts and non-evaluable patients of up to 10%, approximately 260 patients were planned to be randomized to either Tysabri or PB006. The sample size calculation was based on data published by Miller et al., 2003, which showed a mean number of cumulative new active lesions of 1.0 (±2.6) in the pooled natalizumab groups (3 mg/kg and 6 mg/kg) versus 9.7 (±27.4) in the placebo group in patients with either RRMs or secondary progressive MS. An equivalence margin of 2.1 lesions was chosen to ensure that 50% of the treatment effect, based on the lower bound of the 95% CI of the pooled effect size estimated in Miller et al., 2003, was preserved.

## · Randomisation and Blinding (masking)

Investigators were required to register all patients who sign the inform consent form (ICF) in the eCRF with the date the ICF was signed. The Investigator/designee was planned to obtain a patient number using an electronic data capture (EDC) system. Patients who did not meet eligibility criteria were to be registered as screen failures in the eCRF along with the date and reason for screen failure. Patients who meet all eligibility requirements and who have signed an ICF were planned to be randomly assigned (using the eCRF Randomization Form) to one of the two treatment groups in a 1:1 ratio. Randomization was planned to be stratified by the following factors at Screening:

- Absence/presence of GdE lesions (0, &gt;0)
- Presence of T2 lesions ( ≤ 15, &gt;15)
- JCV status for safety (negative, positive)

The randomization of eligible patients was to be done dynamically using Medidata Randomization and Trial  Supply  Management  integrated  with  the  EDC  (Rave).  Some  further  details  of  the  dynamic randomization were provided in a separate Randomisation Plan, which refers to the 'Rave RTSM and EDC Integration Specification' (which is not accessible via the submitted dossier).

At Week 24, the 130 patients in the Tysabri group were planned to be re-randomized. Approximately 34 patients were to be randomized (switched) to PB006.

For a subset of patients (n=62), stratification data used for randomization was incorrectly entered at the study sites and was corrected after finalization of the CSR Version 1.0. 25 sites across all participating countries were affected. The errors were distributed across all three stratification factors: absence/presence of GdE lesions (20 errors), presence of T2 lesions (16 errors), and JCV status (38 errors). The applicant provided a separate memo describing all relevant details regarding these errors, including a root cause analysis. As a corrective measure, additional sensitivity analysis of the primary analysis using corrected strata was planned to be performed.

This study was planned to run double-blinded with regard to the study drug. An unblinded pharmacist/ designee was planned to be responsible for maintaining accountability, blinding, and dispensing the study drugs according to the handling instructions. Study center personnel, with the exception of the unblinded

<div style=\"page-break-after: always\"></div>

pharmacist/designee, were planned to remain blinded to the identity of the study drug until the database was locked and the study was unblinded.

To maintain investigator blinding, the treatment code was not be broken except in medical emergencies when the appropriate management of the patient required knowledge of the treatment randomization. In these cases, the patient was supposed to receive all appropriate medical care. Prior to any unblinding, the  Investigator  was  supposed  to  contact  the  Medical  Monitor  to  discuss  options.  The  unblinding procedure was to be done through the interactive Web response system. As soon as possible and without revealing the patient's study drug assignment (unless important to the safety of patients remaining in the study), the Investigator was to notify the Sponsor if the blind was broken for any reason and the Investigator was unable to contact the Sponsor prior to unblinding.

The Sponsor was allowed to break the code for Serious AEs (SAE) that were unexpected and believed to be  causally  related  to  study  drug,  and  that  potentially  required  expedited  reporting  to  regulatory authorities. In such cases, the minimum number of Sponsor personnel were to be unblinded. Treatment codes were not to be broken for the planned analyses of data until all decisions on the evaluability of the data from each individual patient had been made and documented and databases had been locked.

## · Statistical methods

## Analysis sets

## Safety population

Patients who received at least 1 (complete or partial) infusion of the study drug were to be included in the Safety Population (SAF). Patients in this group were to be analyzed as treated.

## Safety-switch population

Patients who were included in the SAF Population and received at least 1 infusion of the study drug after the timepoint of re-randomization, independent of whether they switched or not, were to be included in the Safety-Switch Population (SSW). Patients in this group were to be analyzed as treated after rerandomization, also considering treatment before re-randomization.

## Full analysis set

The Full Analysis Set (FAS) Population was to include all patients who were randomized and received at least 1 (complete or partial) infusion of the study drug. Patients were to be analyzed according to the treatment group to which they were randomized.

## Per-Protocol population

Only patients participating in this study who completed the 24-week treatment period without major protocol deviations that may have influenced the analysis of the primary endpoint and for whom sufficient post-baseline MRI data were available (including baseline, Week 24 and at least 1 out of the 3 other scheduled MRI visits) were to be included in the PP Population. The final decision on the PP-Population was to be made in the blinded data review meeting before database lock for the final analysis of the primary endpoint.

In addition, a pre-COVID PP Population defined as all PP patients, including those who were excluded from PP only due to major deviations related to COVID-19, was planned.

## General statistical considerations

Data collected in this study were to be presented in subject data listings and summary tables.

Descriptive statistics (number of patients with non-missing values, mean, standard deviation, median, minimum, and maximum) were to be presented for continuous variables.

<div style=\"page-break-after: always\"></div>

Frequency distributions (counts and percentages) were to be presented for categorical variables.

Demographics  (age,  sex,  race,  ethnicity,  and  child-bearing  potential)  and  baseline  characteristics (weight, height, and BMI) were to be summarized by treatment group.

Medical history  (conditions  that  ended  before  the  date  of  screening)  and  current  medical  conditions (those that started before and were ongoing at screening) were to be coded using the MedDRA v23.0 and tabulated by System Organ Class and Preferred Term and by treatment group. MS disease history data were to be summarized.

Use of prior medications (stopped before treatment started) and concomitant medications (ongoing at treatment start or started after first study treatment) were coded and tabulated by treatment group on the Anatomical Therapeutic Chemical 2, ATC 4, and preferred name levels.

MS-related treatment history was planned to be tabulated. Study drug exposure data was also planned to  be  summarised  descriptively.  Natalizumab  trough  concentration  in  serum  were  planned  to  be summarized descriptively per time point in the FAS and PP population.

## Primary efficacy analysis

The primary analysis was to be based on the PP Population. The primary endpoint was the cumulative number of new active lesions over 24 weeks. Similarity between PB006 and Tysabri was to be assessed based on the following set of hypotheses:

## H0: | μ PB006 μ Tysabri| &gt; 2.1 vs. H1: | μ PB006 μ Tysabri | ≤ 2.1

The term μ x denotes  the  cumulative  number  of  new  active  lesions  over  24  weeks  in  the  respective treatment group. Data were to be analyzed using a negative binomial generalized linear model with fixed effects for the treatment group and stratification factors with log link on the PP Population. Parameters were to be estimated using a maximum likelihood approach and back-transformed to the original scale. Similarity was to be tested based on the corresponding 95% CI. An equivalence margin for the mean difference of 2.1 lesions was chosen and prespecified to ensure that 50% of the treatment effect based on the lower bound of the 95% CI of the assumed effect size (estimate derived from literature data) would be preserved.

## Sensitivity analyses for primary efficacy comparisons

## Analysis in the Full Analysis Set

As one sensitivity analysis, the primary analysis was to be repeated for the FAS Population. For this purpose, data from early discontinuation MRIs (i.e., End-of-Study Visits that occurred before or after the protocol-scheduled timepoint) were to be incorporated into the derived cumulative endpoint (i.e., all MRI results at all previous visits until the specific timepoint were to be summed and used for analysis). The cumulative sum of measurements from prior timepoints was to be used for analysis at other timepoints with missing MRI results. For intermittent missing MRI results (i.e., missed MRI visits but with MRI data collected at subsequent visits), no imputation was to be done. This process was to ensure that lesions from missed MRI screening visits were identified at later MRI screenings.

To assess the effect of missing values in this study, one further sensitivity analysis based on the FAS Population was to be carried out using a multiple imputation method. One hundred data sets were to be created using a linear regression model with predictive variables including treatment, all stratification variables,  sex,  age,  height,  and  weight  at  baseline,  and  the  number  of  relapses  the  year  prior  to Screening. All available data, including early discontinuation data, were to be used for analysis. Only post-baseline timepoints with completely missing MRI data and no subsequent MRI screening (monotone missing) were to be imputed. No imputation was to be done for baseline measurements. Imputation was

<div style=\"page-break-after: always\"></div>

to be done only for patients with baseline and at least 1 post-baseline MRI result. Sensitivity analyses were to be performed for the primary endpoint using the negative binomial model described in the SAP.

Analysis with corrected stratification information

As  a  corrective  measure  of  the  stratification  error  (described  and  assessed  above)  an  additional sensitivity analysis of the primary analysis was to be performed using corrected data for the stratification variables.  For  this  purpose,  a  separate  negative  binomial  regression  model  was  fitted  based  on  an updated data set for the PP patient set. For the multiple imputation sensitivity analysis described above corrected stratification data was used.

## Analysis excluding patient data from Site 7002

The primary efficacy analysis was planned to be re-run as a sensitivity analysis by excluding all patient data from site 7002. Separate model fitting was carried out in the PP and the FAS sets.

## Results

## · Participant flow

A total of 531 patients were screened for enrollment into the study. Of these, 266 (50.1%) patients were considered screening failures, primarily due to failure to meet inclusion or exclusion criteria (242 [45.6%] patients). A total of 265 patients were randomized. One patient in the PB006 group withdrew consent prior to receiving study drug. Thus, 264 patients overall were treated with study drug (131 and 133 patients in the PB006 and Tysabri groups, respectively).

<div style=\"page-break-after: always\"></div>

Figure 6: Participant flow chart over Antilope Study

<!-- image -->

A total of 247 (93.6%) patients completed the 24-week Primary Treatment Period: 122 (93.1%) in the PB006 group and 125 (94.0%) in the Tysabri group. Study drug was prematurely discontinued in the 24-week Primary Treatment Period in 17 (6.4%) patients overall, with 9 (6.9%) patients in the PB006 group  and  8  (6.0%)  in  the  Tysabri  group.  Six  (4.6%)  patients  in  the  PB006  group  prematurely discontinued study drug due to an AE, compared with 3 (2.3%) patients in the Tysabri group. One patient in  the  Tysabri  group  experienced  an  AE  leading  to  study  drug  withdrawal  at  the  Week  24  visit,  but completed the 24-week Primary Treatment Period. The patient is therefore not included in the 3 patients who discontinued due to an AE. In the AE summary prior to Week 24, this patient was included in the 4 patients  who  discontinued  due  to  an  AE  because  the  event  occurred  during  the  24-week  Primary Treatment Period.

Premature  discontinuation  of  study  drug  due  to  withdrawal  of  consent  during  the  24-week  Primary Treatment Period was reported for 6 (2.3%) patients (2 [1.5%] patients in the PB006 group and 4

<div style=\"page-break-after: always\"></div>

[3.0%] patients in the Tysabri group). Two (0.8%) patients discontinued the study due to other reasons (1 [0.8%] patient in each treatment group).

At Week 24, all 125 patients in the Tysabri group who had completed the 24-week primary treatment period were re-randomized. Of those in the Tysabri group who were re-randomized, 95 patients remained on Tysabri and 30 patients were switched to PB006. Thus, the total number treated with PB006 at any time during the study was 161 patients.

Table 29: Patient Disposition - Completion by Primary Randomization (FAS Population)

|                                                            | PB006 (N=131 ) n (%)   | Tysabri (N=133 ) n (%)   | Total (N=264) n (%)   |
|------------------------------------------------------------|------------------------|--------------------------|-----------------------|
| Completed primary period (24 weeks)                        | 122 (93.1)             | 125 (94.0)               | 247 (93.6)            |
| Study drug discontinued in primary period - Reason:        | 9 (6.9)                | 8 (6.0)                  | 17 (6.4)              |
| Adverse Event                                              | 6 (4.6)                | 3 (2.3)                  | 9 (3.4)               |
| Other                                                      | 3 (2.3)                | 5 (3.8)                  | 8 (3.0)               |
| Withdrawn from study in primary period (24 week) - Reason: | 9 (6.9)                | 8 (6.0)                  | 17 (6.4)              |
| Patient withdrawal of consent                              | 2 (1.5)                | 4 (3.0)                  | 6 (2.3)               |
| Investigator / Sponsor decision                            | 0                      | 0                        | 0                     |
| Adverse Events                                             | 6 (4.6)                | 3 (2.3)                  | 9 (3.4)               |
| COVID-19 Related                                           | 0                      | 0                        | 0                     |
| Pregnancy                                                  | 0                      | 0                        | 0                     |
| Non-Compliance                                             | 0                      | 0                        | 0                     |
| Lost to Follow-up                                          | 0                      | 0                        | 0                     |
| Lack of Efficacy                                           | 0                      | 0                        | 0                     |
| Other, Specify                                             | 1 (0.8)                | 1 (0.8)                  | 2 (0.8)               |
| Re-randomized at Week 24                                   |                        | 125 (94.0)               | 125 (47.3)            |
| -to remain on Tysabri                                      |                        | 95 (71.4)                | 95 (36.0)             |
| -to switch to PB006                                        |                        | 30 (22.6)                | 30 (11.4)             |
| Completed study (48 weeks)                                 | 117 (89.3)             | 122 (91.7)               | 239 (90.5)            |
| Study drug discontinued - Reason:                          | 14 (10.7)              | 11 (8.3)                 | 25 (9.5)              |
| Adverse Event                                              | 8 (6.1)                | 4 (3.0)                  | 12 (4.5)              |
| Other                                                      | 6 (4.6)                | 7 (5.3)                  | 13 (4.9)              |
| Withdrawn from study - Reason:                             | 14 (10.7)              | 11 (8.3)                 | 25 (9.5)              |
| Patient withdrawal of consent                              | 3 (2.3)                | 6 (4.5)                  | 9 (3.4)               |
| Investigator / Sponsor decision                            | 2 (1.5)                | 0                        | 2 (0.8)               |
| Adverse Events                                             | 8 (6.1)                | 4 (3.0)                  | 12 (4.5)              |
| COVID-19 Related                                           | 0                      | 0                        | 0                     |
| Pregnancy                                                  | 0                      | 0                        | 0                     |
| Non-Compliance                                             | 0                      | 0                        | 0                     |
| Lost to Follow-up                                          | 0                      | 0                        | 0                     |
| Lack of efficacy                                           | 0                      | 0                        | 0                     |
| Other, Specify                                             | 1 (0.8)                | 1 (0.8)                  | 2 (0.8)               |

n = Number of patients with the specified event/reason; N = Number of patients in FAS; FAS = Full Analysis Set.

The 48-week summary comprises the full study period, including the first 24 weeks. Note: End of Study eCRF page was only filled-in during the treatment period.

A total of 239 patients completed the 48-week study: 117 patients in the PB006 group, 29 patients in the Tysabri switched to PB006 group, and 93 patients in the Tysabri (continued at Week 24) group.  Of the 122 patients in the PB006 group who had completed the primary treatment period, 117 (95.9%) patients  completed  the  study;  2  (1.6%)  patients  discontinued  due  to  an  AE,  2  (1.6%)  patients discontinued due to Investigator/Sponsor decision, and 1 (0.8%) patient withdrew consent. Of the 30 patients in the Tysabri switched to PB006 group, 29 (96.7%) patients completed the study, and 1 (3.3%) patient discontinued due to an AE. Of the 95 patients who remained in the Tysabri group after Week 24,

<div style=\"page-break-after: always\"></div>

93 (97.9%) patients completed the study and 2 (2.1%) patients discontinued (both due to withdrawal of consent).

## · Recruitment

Study initiation date was 30 OCT 2019 (First Patient First Visit).

Study completion date was 10 MAR 2021 (Last Patient Last Visit).

The date of the last patient completing the PML Follow-up Visit (24 weeks after last dosing) was on 23 AUG 2021.

## · Conduct of the study

The Clinical Study Report (CSR) for this study was issued on 10-DEC-2021 and later on two CSR addenda were issued (dated 07 FEB 2022 and 12 MAY 2022). Later, the identification of incorrect stratification at baseline led to preparation of a new version of the CSR (Amendment 1; Version 2.0) issued on 30-JUL2022, which is considered the final CSR for this MAA.

The most important amendments to the initial CSR were the following:

Amendment 1 (04 SEP 2019) introduced the following changes: two additional sampling times (4 weeks and 28 weeks) were added for anti-natalizumab antibody testing.

Amendment 2 (05 FEB 2020) introduced the following changes:

- The study design and other relevant section were updated to include switching a group of patients  from  Tysabri  to  PB006  at  Week  24  to  evaluate  and  compare  the  immunogenic profiles of those on Tysabri only with those who switched - including re-randomization at Week 24
- The numbers of study sites and countries was updated.
- Magnetic Resonance Imaging: Addition of requirements for MRIs performed at Baseline, at an Early Discontinuation Visit, and for unscheduled visits if PML is suspected.
- Primary Endpoint: Data analysis details were added.

Amendment 3 (15 JUL 2020) introduced the following changes:

- Sub-Section 4.1 Overall Study Design: Removal of text reflecting that secondary endpoints are evaluated only once at the end of the study, due to the shift of the primary analysis timepoint.
- Sub-Section  9.7  Primary  and  Final  Analysis  was  revised  to  reflect  a  shift  in  the  primary analysis timepoint.
- Sub-Section 10.4.2 Database Management and Quality Control: Removal of statement that database was to be locked for the primary and then for the final analysis, together with all other endpoints (at Visit 13, Week 48).

Changes in conduct or analysis of the study due to COVID-19 are discussed in a separate section.

Changes Following Study Unblinding/Database Lock and Post-hoc Analyses:

The PB006-03-01 database interim lock occurred on 30 APR 2021. Errors were discovered in the study source data after the database lock, and are described below.

- Minor protocol deviations about incorrect stratification factor use during randomization were not registered in the clinical trial management system (CTMS) for 8 patients due to oversight.

<div style=\"page-break-after: always\"></div>

The missing minor protocol deviations were recorded, Study Data Tabulation Model (SDTM) was re-run, and an updated protocol deviation listing was provided after the final database lock on 21 OCT 2021.

- After interim database lock, it was discovered that a protocol deviation for one patient was incorrectly recorded in CTMS. The minor protocol deviation was declassified, SDTM was rerun, and an updated protocol deviation listing was provided after the final database lock on 21 OCT 2021.
- Sponsor review of TFLs identified an inconsistency in the recording of the action taken with the study drug for AEs that caused patients to end treatment (9 patients). The database was unlocked and the appropriate fields were corrected.
- It was discovered after database lock that some of the reasons for end of treatment phase were not consistent with the AEs that were recorded as causing treatment to be stopped for 3 patients. The database was unlocked and the primary reason for withdrawal was corrected.

For errors 1 and 2 above, no database unlock was required and there was no impact on the statistical analysis of the interim lock. Corrected and missing protocol deviations were included in the final database lock on 21 OCT 2021.

For errors 3 and 4 above, there was no relevant impact on the statistical analyses. The database was unlocked to make corrections. Summary table for discontinuation reasons were updated for the final database lock on 21 OCT 2021.

A second database unlock occurred on 11 JUL 2022 to register additional minor protocol deviations related to incorrect stratification factors (see below).

## Summary of Changes Between Clinical Study Report Version 1 and Version 2

After finalization of the initial CSR (Version 1.0, dated 10 DEC 2021), 2 CSR addenda were prepared (dated 07 FEB 2022 and 12 MAY 2022). On 07 JUN 2022, the identification of incorrect stratification at baseline affecting 62 patients resulted in the performance of an additional sensitivity analysis of the primary  analysis  using  correct  strata.  The  Sponsor  and  Contract  Research  Organisation  (CRO) determined  that  a  CSR  amendment  should  be  prepared  to  present  the  results  from  the  additional sensitivity analysis, as well as all information from the CSR addenda 1 and 2. Additional changes resulting from Quality Control and Sponsor reviews prior to finalization are included in this CSR Amendment 1 (Version 2.0).

A history of the main changes from CSR Version 1.0 (10 DEC 2021) to this CSR Amendment 1 (Version 2.0) is presented below.

## CSR Addendum 1 (07 FEB 2022):

Results  from  the  initial  analysis  of  immunogenicity  included  in  the  CSR  Version  1.0  were  limited  to timepoints considered most relevant for immunogenicity assessment (baseline [Week 0], Week 8, Week 24,  Week  32,  and  the  End-of-Study/Week  48  or  Early  Discontinuation  Visit).  The  CSR  addendum  1 presented the analysis of the immunogenicity results for all timepoints, including Week 4, Week 16, and Week 28, as well as any changes resulting from the analysis of the data from the additional timepoints.

## CSR Addendum 2 (11 MAY 2022):

A data integrity issue at a clinical site (7002) was discovered after finalization of the initial CSR. In order to assess the impact of this issue on the validity of the primary endpoint results, a sensitivity analysis of the primary analysis was conducted, excluding patients from site 7002. Additionally, on request by the Rapporteurs, the analyses for EDSS endpoints was re-run excluding all patients from site 7002.

<div style=\"page-break-after: always\"></div>

## CSR 2.0 (30 JUL 2022)

This CSR Version 2.0 integrates all changes from the CSR addenda 1 and 2 presented above, as well as additional changes described below.

1. After  the  initial  database  lock  on  30  APR  2021,  it  was  discovered  that  for  26  patients, stratification  data  was  incorrectly  entered  into  the  eCRF  at  randomization.  This  was  corrected  postrandomization. While the primary analysis of the primary endpoint was based on the stratification data used  for  randomization,  an  additional  sensitivity  analysis  was  performed  based  on  the  corrected stratification factors for the 26 patients, in order to assess the impact of the erroneous stratification, as described in the SAP. The corresponding results were reported in CSR Version 1.0.

After finalization of CSR Version 1.0 (on 10 DEC 2021), 36 further cases of incorrect stratification (total of  62  patients)  were  discovered.  Thus,  the  sensitivity  analysis  was  re-  run  based  on  the  corrected stratification factors for the 62 patients. The eCRFs were not corrected for all patients because eCRF data had been locked and sites were closed before the discrepancy was first identified  on  07  JUN  2022. Therefore, eCRF data are not consistent with NeuroRX and/or Q2 Solutions data for 38 patients (eCRFs were corrected for 24 patients). The CSR Version 2.0 includes the results from the sensitivity analysis of all 62 patients with corrected stratification factors.

2. At the request of the applicant, a statement was added to clarify the definition of 'negative' and 'positive' for anti-JCV antibodies according to the final result provided on the Q2 Solutions laboratory report.

3. At  the  request  of  the  applicant,  text  was  revised  to  describe  the  number  of  patients  with confirmed positive ADAs at baseline rather than patients who were negative for ADAs at baseline. The change is due to the number of false positive screening assay results (which are then reported as ADA negative  upon  confirmatory  assay),  leading  to  a  lower  than  expected  number  of  patients  who  are negative for ADAs at baseline.

After database lock (on 30 APR 2021), it was determined that for 26 out of 265 randomized patients (approximately 10% of the patient population), at least 1 of the 3 stratification factors (absence/presence of  GdE  lesions,  presence  of  T2  lesions,  JCV  status)  was  entered  incorrectly  into  the  eCRF  by investigational sites at Randomization. A root cause analysis and impact assessment was performed and revealed that the immediate risk for imbalanced strata was considered low. Moreover, since the issue was only identified in its totality at the end of the study after database lock, no corrective and preventive action could be implemented within the study itself, other than verifying the correctness of the final status. Since the study was blinded and the randomization was performed according to the entered strata,  there  was  no  impact  on  the  data  integrity  of  the  study.  The  pre-specified  primary  analysis according to the SAP with the IWRS strata was following the intention to treat principle.

On  07  JUN  2022,  after  finalization  of  the  CSR  Version  1.0,  it  was  discovered  that  the  incorrect stratification was not limited to the 26 cases identified in the original MTF (19 MAY 2021). A total of 62 cases (at 25 sites across all participating countries) were affected. A discrepancy was identified in the percentage  of  patients  who  were  negative  for  JCV  at  baseline  (67.0%  of  patients  versus  59.8%  of patients).  The  outcome  of  additional  investigations  by  the  Sponsor  and  the    CRO  study  statistician revealed that at least 1 stratification factor was provided incorrectly during randomization for the 62 affected patients. The errors were distributed across 3 stratification factors: absence/presence of GDE lesions (20 errors), presence of T2 lesions (16 errors), and JCV status (38 errors), with 7 cases where 2 stratification factors were entered incorrectly and 3 cases where all 3 factors were incorrectly provided. With approximately 23% of the patient population affected by the stratification errors and a potential risk of imbalanced strata across treatments, a thorough root-cause analysis and impact assessment was performed.

<div style=\"page-break-after: always\"></div>

As corrective measures, minor protocol deviations were registered for all cases, and further training in randomization procedures was performed. The eCRFs were not corrected for all patients because eCRF data had been locked for more than a year when the issue was identified on 07 JUN 2022. Therefore, eCRF  data  are  not  consistent  with  NeuroRX  and/or  Q2  Solutions  data  for  38  patients  (eCRFs  were corrected for 24 patients). Also, an additional sensitivity analysis of the primary analysis using correct strata, as per Q2 Solutions and NeuroRX data, was performed.

Since the study was double-blinded and the randomization was performed according to the entered strata,  there  was  no  impact  on  the  data  integrity  of  the  study.  The  pre-specified  primary  analysis according to the SAP with the IWRS strata was following the ITT principle. The root cause analysis and impact assessment revealed that even with 23% of patients mis-stratified, the imbalance of strata was low and there was no significant impact on the primary analysis. The sensitivity analysis of the primary analysis using the corrected strata confirmed the primary analysis.

Major protocol deviations were reported for 72 patients overall, with 36 (27.5%) patients in the PB006 group and 36 (27.1%) patients in the Tysabri group. The majority of deviations were: study procedure or assessment (18 [13.7%] patients in the PB006 group and 15 [11.3%] patients in the Tysabri group), patient visit completion or timing (10 [7.6%] patients in the PB006 group and 7 [5.3%] patients in the Tysabri group), and inclusion/exclusion criteria (5 [3.8%] patients in the PB006 group and 8 [6.0%] patients in the Tysabri group). One (4.0%) major protocol deviation of SAE reporting in the PB006 group was reported in Poland and 1 (2.1%) major protocol deviation of randomization procedure in the Tysabri group was reported in Ukraine.

Major protocol deviations related to COVID-19 were reported for 8 (6.1%) patients in the PB006 group and 5 (3.8%) patients in the Tysabri group. The majority of deviations in all countries were related to patient visit completion or timing (7 [5.3%] patients in the PB006 group and 5 [3.8%] patients in the Tysabri group). One (0.8%) patient in Ukraine had a major protocol deviation of study procedure or assessment.

## · Baseline data

The  demographic  and  baseline  characteristics  were  similar  between  treatment  groups  for  the  FAS Population. The FAS Population was comprised of 162 (61.4%) female patients and 102 (38.6%) male patients, similarly distributed between treatment groups. Most (143 [88.3%]) female patients were of childbearing potential. The mean (SD) age of patients was 36.8 (9.05) years in the PB006 group and 36.6 (9.73) years in the Tysabri group. Race was White (100.0% for both groups), and mean (SD) BMI was 24.1 (4.88) kg/m2 in the PB006 group and 24.2 (4.54) kg/m2 in the Tysabri group. At baseline, about half (140 [53.0%]) of patients had no GdE lesions; the remaining 124 (47.0%) patients had &gt;0 GdE lesions. The majority of patients had &gt;15 T2 lesions (255 [96.6%] patients) and a negative JCV status (158 [59.8%] patients) (for details on corrected stratification factors, please see below).

<div style=\"page-break-after: always\"></div>

Table 30: Baseline and Demographic Characteristics by Primary Randomization (FAS Population)

|                                           | PB006      | Tysabri    | Total      |
|-------------------------------------------|------------|------------|------------|
|                                           | (N=131)    | (N=133)    | (N=264)    |
| Absence/presence of GdE lesions, n (%)    |            |            |            |
| 0                                         | 68 (51.9)  | 72 (54.1)  | 140 (53.0) |
| >0                                        | 63 (48.1)  | 61 (45.9)  | 124 (47.0) |
| Presence of T2 lesions, n (%)             |            |            |            |
| ≤15                                       | 4 (3.1)    | 5 (3.8)    | 9 (3.4)    |
| >15                                       | 127 (96.9) | 128 (96.2) | 255 (96.6) |
| JCV status for safety, n (%)              |            |            |            |
| Negative                                  | 80 (61.1)  | 78 (58.6)  | 158 (59.8) |
| Positive                                  | 51 (38.9)  | 55 (41.4)  | 106 (40.2) |
| Age (years)                               |            |            |            |
| n                                         | 131        | 133        | 264        |
| Mean                                      | 36.8       | 36.6       | 36.7       |
| SD                                        | 9.05       | 9.73       | 9.38       |
| Median                                    | 35.0       | 37.0       | 36.0       |
| Min/Max                                   | 18/57      | 20/ 59     | 18/59      |
| Sex, n (%)                                |            |            |            |
| Female                                    | 84 (64.1)  | 78 (58.6)  | 162 (61.4) |
| Male                                      | 47 (35.9)  | 55 (41.4)  | 102 (38.6) |
| Race, n (%)                               |            |            |            |
| American Indian or Alaska Native          | 0          | 0          | 0          |
| Black or African American                 | 0          | 0          | 0          |
| Asian                                     | 0          | 0          | 0          |
| White                                     | 131 (100)  | 133 (100)  | 264 (100)  |
| Native Hawaiian or Other Pacific Islander | 0          | 0          | 0          |
| Not Reported                              | 0          | 0          | 0          |
| Other                                     | 0          | 0          | 0          |
| Ethnicity, n (%)                          |            |            |            |
| Hispanic or Latino                        | 0          | 0          | 0          |
| Not Hispanic or Latino                    | 131 (100)  | 133 (100)  | 264 (100)  |
| Not Reported                              | 0          | 0          | 0          |
| Unknown                                   | 0          | 0          | 0          |
| Childbearing potential, n (%)             |            |            |            |
| Yes                                       | 73 (86.9)  | 70 (89.7)  | 143 (88.3) |
| No                                        | 11 (13.1)  | 8 (10.3)   | 19 (11.7)  |
| Weight (kg)                               |            |            |            |
| n                                         | 131        | 133        | 264        |
| Mean                                      | 70.0       | 70.6       | 70.3       |
| SD                                        | 16.14      | 15.65      | 15.87      |
| Median                                    | 67.7       | 70.0       | 68.9       |
| Min/Max                                   | 45/138     | 43/121     | 43/138     |
| Height (cm)                               |            |            |            |
| n                                         | 131        | 133        | 264        |
| Mean                                      | 170.0      | 170.4      | 170.2      |
| SD                                        | 8.41       | 8.61       | 8.50       |
| Median                                    | 168.0      | 168.0      | 168.0      |
| Min/Max                                   | 154/195    | 154/194    | 154/195    |
| Body Mass Index (kg/m 2 )                 |            |            |            |
| n                                         | 131        | 133        | 264        |
| Mean                                      | 24.1       | 24.2       | 24.2       |
| SD                                        | 4.88       | 4.54       | 4.70       |
| Median Min/Max                            | 23.0 17/43 | 23.5 16/41 | 23.3 16/43 |

Abbreviations: N = Number of patients in population/treatment group; FAS = Full Analysis Set; GdE = GadoliniumEnhancing; JCV = John Cunningham Virus; SD = Standard Deviation.

Note: Percentages of childbearing potential are based on number of female patients.

Note: Corrected levels of stratification factors are summarized in this table.

The frequency of patients per strata after correction of stratification factors is shown below.

<div style=\"page-break-after: always\"></div>

Table 31: Frequency of stratification factor (FAS)

|                                   | PB006 N=131   | Tysabri N=133   | Total N=264   |
|-----------------------------------|---------------|-----------------|---------------|
| Absence/presenceofGdElesions,n(%) |               |                 |               |
| 0                                 | 68 (51.9%)    | 72 (54.1%)      | 140 (53.0)    |
| >0                                | 63 (48.1%)    | 61 (45.9%)      | 124 (47.0)    |
| Presence of T2 lesions,n (%)      |               |                 |               |
| ≤15                               | 4 (3.1%)      | 5 (3.8%)        | 9 (3.4)       |
| >15                               | 127 (96.9%)   | 128 (96.2%)     | 255 (96.6)    |
| JCVstatusforsafety,n(%)           |               |                 |               |
| Negative                          | 80 (61.1%)    | 78 (58.6%)      | 158 (59.8)    |
| Positive                          | 51 (38.9%)    | 55 (41.4%)      | 106 (40.2)    |

For the COVID-19-confirmed patients (n=22) in the SAF Population, all parameters were similar to the FAS, SAF, PP, and SSW Populations.

Similar  demographic  and  baseline  characteristics  were  reported  for  the  PP  Population  and  the  SSW Population. Demographic and baseline characteristics for the SAF Population were identical to the FAS Population.

## Medical History

Similar proportions of patients in both treatment groups had any medical history other than MS (93 [71.0%] patients in the PB006 group and 94 [70.7%] patients in the Tysabri group). The medical history reported for at least 5% of patients in either treatment group were myopia, retinal vascular disorder, depression, hypertension, osteochondrosis, and astigmatism, reported by 18 (13.7%) 14 (10.7%), 9 (6.9%),  7  (5.3%),  7  (5.3%),  and  4  (3.1%)  patients,  respectively,  in    the  PB006  group,  and  in  17 (12.8%), 11 (8.3%), 5 (3.8%), 6 (4.5%), 6 (4.5%), and 7 (5.3%) patients, respectively, in the Tysabri group. Distribution of all other conditions was low and generally similar across treatment groups.

Similar results were reported for the PP Population and the SSW Population.

Similar proportions of patients in each treatment group had any current conditions (131 [100%] patients in the PB006 group and 133 [100%] patients in the Tysabri group). Current medical conditions (≥5% of patients in either treatment group) that occurred in similar proportions of patients in both treatment groups included MS, myopia, retinal vascular disorder, depression, and osteochondrosis (occurring in 131 [100%], 17 [13.0%], 14 [10.7%], 8 [6.1%],  and 7 [5.3%]  patients, respectively, in the PB006 group, and 133 [100%], 17 [12.8%], 11 [8.3%], 5 [3.8%], and 6 [4.5%] patients, respectively, in the Tysabri group). Distribution of all other conditions was low and generally similar across the treatment groups.

Similar current medical conditions were reported for the PP Population, and the SSW Population.

## Multiple Sclerosis Disease History

The mean (SD) time since diagnosis for patients in the PB006 group (5.34 [4.655] years) was similar to patients in the Tysabri group (5.32 [4.800] years). The mean (SD) time since most recent relapse for patients in the PB006 group (5.08 [2.860] months) was slightly shorter than for patients in the Tysabri group (5.88 [3.038] months).

The number of relapses in the 1 year prior to Screening was similar between treatment groups. Most patients  had  1  relapse  (86  [65.6%]  and  91  [68.4%]  patients  in  the  PB006  and  Tysabri  groups, respectively) or 2 relapses (37 [28.2%] and 38 [28.6%] patients in the PB006 and Tysabri groups, respectively) in the year prior to Screening. The mean (SD) number of relapses in the year prior to Screening (1.4 [0.68] for the PB006 group and 1.4 [0.57] for the Tysabri group) and the mean (SD) baseline EDSS (3.4 [1.07] for the PB006 group and 3.2 [1.21] for the Tysabri group) were similar for both groups.

<div style=\"page-break-after: always\"></div>

## Multiple Sclerosis-Related Treatment History

Similar numbers of patients in both treatment groups previously received any medication for MS (46 [35.1%] patients in the PB006 group and 44 [33.1%] patients in the Tysabri group). The most frequently administered  prior  medications  were  interferon  beta-1a  (17  [13.0%]  and  10  [7.5%]  patients  in  the PB006 and Tysabri groups, respectively), interferon beta-1b (11 [8.4%] and 12 [9.0%] patients in the PB006 and Tysabri groups, respectively), dimethyl fumarate (13 [9.9%] and 9 [6.8%] patients in the PB006 and Tysabri groups, respectively), glatiramer acetate (10 [7.6%] and 9 [6.8%] patients in the PB006 and Tysabri groups, respectively), and laquinimod (3 [2.3%] and 6 [4.5%] patients in the PB006 and Tysabri groups, respectively). All other MS medications were received by ≤ 1.5% of patients in either treatment group.

## · Numbers analysed

See participant flow in the prior subsection

## · Outcomes and estimation

## Primary Efficacy Analysis

The primary efficacy endpoint was the cumulative number of new active lesions over 24 weeks. The primary analysis was based on the PP Population, while the FAS Population was analyzed as sensitivity analysis. Results are presented for the PP Population in Table 32.

The difference in new active lesions between Tysabri and PB006 was derived using a negative binomial model  with  log  link.  The  point  estimate  was  back-transformed  to  the  original  scale  for  similarity assessment. The point estimate (standard error [SE]) for the exponentiated difference between Tysabri and PB006 was 0.17 (0.397). The null hypothesis was rejected, as the 90% and 95% CI for the difference Tysabri-PB006 were within the specified margins (-2.1; 2.1). Thus, the primary endpoint was met.

Table 32: Cumulative Number of New Active Lesions Over 24 Weeks - Primary Analysis (PP Population)

| Cumulative number of new active lesions over 24 weeks   | Estimate (SE)   | 90% Confidence Interval   | 95% Confidence Interval   |
|---------------------------------------------------------|-----------------|---------------------------|---------------------------|
| Least square means                                      |                 |                           |                           |
| Exponentiated Difference Tysabri-PB006                  | 0.17 (0.397)    | [-0.488; 0.819]           | [-0.613; 0.944]           |

N = Number of patients in population/treatment group; PP = Per-Protocol; SE = Standard Error.

Note: Stratification factors as registered in IWRS were used for the analysis.

## Sensitivity Analyses of the Primary Efficacy Endpoint

## Analysis Based on the Full Analysis Set

The sensitivity analysis of the primary analysis based on the FAS Population is presented in Table 33. As for the primary analysis, the difference in new active lesions between Tysabri and PB006 was derived using a negative binomial model with log link. The point estimate was back-transformed to the original scale for similarity assessment. The point estimate (SE) for the exponentiated difference between Tysabri and  PB006  was  0.23  (0.430).  The  null  hypothesis  was  rejected,  as  the  90%  and  95%  CIs  for  the difference Tysabri-PB006 were within the specified margins (-2.1; 2.1). Thus, the primary endpoint was confirmed.

The  stratification  factor  absence/presence  of  GdE  lesions  was  found  to  have  an  influence  on  the cumulative number of new active lesions (with the p-value being &lt;0.0001) and in contrast, treatment, presence of T2 lesions, and JCV status did not have an influence on the number of new active lesions (with corresponding p-values being &gt;0.05).

<div style=\"page-break-after: always\"></div>

Table 33: Cumulative number of New Active Lesions Over 24 Weeks - Sensitivity Analysis (FAS Population)

| Cumulative number of new active lesions over 24 weeks   | Estimate (SE)   | 90% Confidence Interval   | 95% Confidence Interval   |
|---------------------------------------------------------|-----------------|---------------------------|---------------------------|
| Least square means                                      |                 |                           |                           |
| Exponentiated Difference Tysabri-PB006                  | 0.23 (0.430)    | [-0.474; 0.940]           | [-0.609; 1.075]           |

Abbreviations: N = Number of patients in population/treatment group; FAS = Full Analysis Set; IWRS = Interactive Web Response System; SE = Standard Error.

Note: Stratification factors as registered in IWRS were used for the analysis.

## Corrected Stratification Variables

For a subset of patients (n=26), stratification data used for randomization was incorrectly entered at the study  sites  and  was  corrected  post-randomization.  These  cases  were  reported  as  minor  protocol deviations. While the primary analysis of the primary endpoint was based on the stratification data used for randomization, an additional sensitivity analysis was performed based on the corrected stratification factors in order to assess the impact of the erroneous stratification, as described in the SAP. This initial sensitivity analysis (n=26) was reported in CSR V1.0 (10 DEC 2021).

On  07  JUN  2022,  after  finalization  of  the  CSR  Version  1.0,  it  was  discovered  that  the  incorrect stratification was not limited to the 26 cases identified in the original CSR V1.0. A total of 62 cases (at 25  sites  across  all  participating  countries)  were  affected.  The  errors  were  distributed  across  3 stratification factors: absence/presence of GdE lesions (20 errors), presence of T2 lesions (16 errors), and JCV status (38 errors). The eCRFs were not corrected for all patients because eCRF data had been locked for more than a year when the issue was identified on 07 JUN 2022. Therefore, eCRF data are not consistent with NeuroRX and/or Q2 Solutions data for 38 patients (eCRFs were corrected for 24 patients).  For  all  newly  identified  cases,  minor  protocol  deviations  were  registered.  As  a  corrective measure,  additional  sensitivity  analysis  of  the  primary  analysis  using  corrected  strata,  as  per  Q2 Solutions and NeuroRX data, was performed.

The sensitivity analysis of the primary analysis using corrected stratification variables for all 62 patients is presented in Table 34 for the PP Population. The point estimate (SE) for the exponentiated difference between Tysabri and PB006 was 0.06 (0.083). The null hypothesis was rejected, as the 90% and 95% CIs for the difference Tysabri-PB006 were within the specified margins (-2.1; 2.1). Thus, the primary endpoint was confirmed to be met using corrected stratification variables.

The  stratification  factor  absence/presence  of  GdE  lesions  was  found  to  have  an  influence  on  the cumulative number of new active lesions (p-value &lt;0.0001). In contrast, treatment, presence of T2 lesions, and JCV status did not have an influence on the number of new active lesions (with corresponding p-values being &gt;0.05).

Table 34: Cumulative Number of New Active Lesions Over 24 Weeks by Corrected Stratification Variables - Sensitivity Analysis (PP Population)

| Cumulative number of new active lesions over 24 weeks   | Estimate (SE)   | 90% Confidence Interval   | 95% Confidence Interval   |
|---------------------------------------------------------|-----------------|---------------------------|---------------------------|
| Least square means                                      |                 |                           |                           |
| Exponentiated Difference Tysabri-PB006                  | 0.06 (0.083)    | [-0.073; 0.199]           | [-0.099; 0.225]           |

N = Number of patients in population/treatment group; PP = Per-Protocol; SE = Standard Error.

## Multiple Imputation

Sensitivity analysis of the primary efficacy endpoint using multiple imputation is presented for the FAS Population in Table 35. All available data, including early discontinuation data, was used. The difference in new active lesions between Tysabri and PB006 was derived using a negative binomial model with log link. The point estimate was back-transformed to the original scale for similarity assessment. The point

<div style=\"page-break-after: always\"></div>

estimate (SE) for the exponentiated difference between Tysabri and PB006 was -0.22 (0.300). The null hypothesis was rejected, as the 90% and 95% CIs for the difference Tysabri-PB006 were within the specified  margins  (-2.1;  2.1).  Thus,  the  sensitivity  analysis  showed  that  the  results  obtained  in  the primary analysis are robust.

The  stratification  factor  of  absence/presence  of  GdE  lesions  was  found  to  have  an  influence  on  the cumulative number of new active lesions (p-value &lt;0.0001). In contrast, treatment, presence of T2 lesions, and JCV status were found to not have an influence on the number of new active lesions (with corresponding p-values being &gt;0.05).

A sensitivity analysis of the primary analysis using multiple imputation for the pre-COVID PP Population was not performed, as there was no missing data to impute for the population.

Table  35:  Cumulative  Number  of  New  Active  Lesions  Over  24  Weeks  With  Multiple  Imputation  Sensitivity Analysis (FAS Population)

| Cumulative number of new active lesions over 24 weeks   | Estimate (SE) 90%   | Confidence Interval   | 95% Confidence Interval   |
|---------------------------------------------------------|---------------------|-----------------------|---------------------------|
| Least square means                                      |                     |                       |                           |
| Exponentiated Difference Tysabri-PB006                  | -0.22 (0.300)       | [-0.717; 0.269]       | [-0.812; 0.363]           |

N = Number of patients in population/treatment group; FAS = Full Analysis Set; MI = Multiple Imputation; SE = Standard Error.

Note: The analysis is based on 100 imputed datasets. The imputation is done using linear regression model with predictive variables including treatment, all stratification variables, sex, age, height, and weight at baseline, and number of relapses the year prior to Screening.

Note: Corrected stratification factors were used for the multiple imputation sensitivity analysis.

## Data Integrity Impact Assessment on the Primary Efficacy Analysis

The primary efficacy analysis was re-run as a sensitivity analysis by excluding all patient data from site 7002. In the following, the results of the primary efficacy analyses are compared with the corresponding results of the impact assessment sensitivity analyses.

A comparison of the primary efficacy analysis (Table 32) and the corresponding impact assessment sensitivity analysis are shown in Table 36. The impact assessment results were similar to the original primary analysis results. With site 7002 patient data excluded, the CIs were larger due to the lower sample size, but still well within the pre-specified margins (-2.1; 2.1).

Table 36: Cumulative Number of New Active Lesions Over 24 Weeks - Primary Analysis (PP Population) Versus Impact Assessment Sensitivity Analysis

| Cumulative number of new active lesions over 24 weeks                          | Estimate (SE)                                                                  | 90% Confidence Interval                                                        | 95% Confidence Interval                                                        |
|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Primary analysis (Table 32)                                                    |                                                                                |                                                                                |                                                                                |
| Least square means Exponentiated Difference Tysabri-PB006                      | 0.17 (0.397)                                                                   | [-0.488; 0.819]                                                                | [-0.613; 0.944]                                                                |
| Impact assessment sensitivity analysis (excluding all patients from site 7002) | Impact assessment sensitivity analysis (excluding all patients from site 7002) | Impact assessment sensitivity analysis (excluding all patients from site 7002) | Impact assessment sensitivity analysis (excluding all patients from site 7002) |
| Least square means Exponentiated Difference Tysabri-PB006                      | 0.13 (0.447)                                                                   | [-0.607; 0.862]                                                                | [-0.748; 1.003]                                                                |

PP = Per-Protocol; SE = Standard Error.

A comparison of the sensitivity analysis based on the FAS and the corresponding impact assessment sensitivity analysis was conducted. The impact assessment results were similar to the original results for

<div style=\"page-break-after: always\"></div>

the analysis based on the FAS. With site 7002 patient data excluded, CIs were larger due to the lower sample size, but still well within the pre-specified margins (-2.1; 2.1) (Table 37).

Table 37: Cumulative Number Of New Active Lesions Over 24 Weeks (FAS) Versus Impact Assessment Sensitivity Analysis

| Cumulative number of new active lesions over 24 weeks                          | Estimate (SE)                                                                  | 90% Confidence Interval                                                        | 95% Confidence Interval                                                        |
|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Sensitivity analysis (Table 34)                                                | Sensitivity analysis (Table 34)                                                | Sensitivity analysis (Table 34)                                                | Sensitivity analysis (Table 34)                                                |
| Least square means Exponentiated Difference Tysabri-PB006                      | 0.23 (0.430)                                                                   | [-0.474; 0.940]                                                                | [-0.609; 1.075]                                                                |
| Impact assessment sensitivity analysis (excluding all patients from site 7002) | Impact assessment sensitivity analysis (excluding all patients from site 7002) | Impact assessment sensitivity analysis (excluding all patients from site 7002) | Impact assessment sensitivity analysis (excluding all patients from site 7002) |
| Least square means Exponentiated Difference Tysabri-PB006                      | 0.20 (0.475)                                                                   | [-0.581; 0.981]                                                                | [-0.731; 1.131]                                                                |

FAS = Full Analysis Set; SE = Standard Error.

A comparison of the sensitivity analysis based on corrected stratification factors (Table  34) and the corresponding impact assessment sensitivity analysis are shown in Table 38. The impact assessment results were similar to the original results for the corrected stratification variables. With site 7002 patient data excluded, CIs were larger due to the lower sample size, but still well within the pre-specified margins (-2.1; 2.1).

Table 38: Cumulative Number of New Active Lesions Over 24 Weeks by Corrected Stratification Variables (PP population) Versus Impact Assessment Sensitivity Analysis

| Cumulative number of new active lesions over 24 weeks                          | Estimate (SE)                                                                  | 90% Confidence Interval                                                        | 95% Confidence Interval                                                        |
|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Corrected stratification variables (Table 34)                                  |                                                                                |                                                                                |                                                                                |
| Least square means Exponentiated Difference Tysabri-PB006                      | 0.06 (0.083)                                                                   | [-0.073; 0.199]                                                                | [-0.099; 0.225]                                                                |
| Impact assessment sensitivity analysis (excluding all patients from site 7002) | Impact assessment sensitivity analysis (excluding all patients from site 7002) | Impact assessment sensitivity analysis (excluding all patients from site 7002) | Impact assessment sensitivity analysis (excluding all patients from site 7002) |
| Least square means Exponentiated Difference Tysabri-PB006                      | 0.07 (0.088)                                                                   | [-0.079; 0.212]                                                                | [-0.107; 0.239]                                                                |

PP = Per-Protocol; SE = Standard Error.

a  Based on corrected stratification for the 62 patients identified with incorrect stratification at baseline.

## Summary of the Impact Assessment Analyses

An  internal  quality  assessment  at  site  7002  revealed  serious  deviations  from  the  GCP  source  data handling requirements. However, there were no indications of fraud or a deliberate falsification of data. Study patients were genuine, and the trial execution was supported by available source data. Original source data were on file for several essential data points, e.g., MRIs, lab data reports.

The exclusion of data for all 17 patients from site 7002 did not change the outcome of the primary endpoint analysis. The predefined equivalence criteria were met, and similarity of clinical efficacy was demonstrated. In total, 7 quality audits and 8 quality assessment visits were conducted at 8 investigator sites across countries. No other data integrity observations were identified at other participating study sites. As such, this data integrity issue was considered to be limited to site 7002.

<div style=\"page-break-after: always\"></div>

According to the applicant, the validity of the study results and the conclusions on the overall study outcome remain unchanged.

## Secondary Efficacy Analysis

## Cumulative Number of New Active Lesions Over 48 Weeks

The mean cumulative number of new active lesions was slightly lower in the PB006 group than in the Tysabri group at all timepoints up to Week 48. The mean (SD) cumulative number up to Week 48 was 1.5 (3.72) in the PB006 group, compared to 2.3 (5.68) in the Tysabri group. The results from the PP analysis were similar, with mean cumulative numbers being identical to the FAS for all timepoints.

The average number of new active lesions per MRI scan was lower in the PB006 group than in the Tysabri group at all timepoints up to Week 48. The average number up to Week 48 was 0.31 in the PB006 group compared to 0.48 in the Tysabri group. The results from the PP analysis were similar.

Compared to Week 8, a greater percentage of patients in the PB006 and Tysabri groups had no new active lesions at Week 48, with similar percentages in both treatment groups (116 [98.3%] patients in the PB006 group and 88 [94.6%] patients in the Tysabri group). The percentage of patients with 1 to 3 new active lesions similarly decreased in both treatment groups by Week 48 (2 [1.7%] patients in the PB006 group and 2 [2.2%] patients in the Tysabri group). No patients in the PB006 group had 4 or more new active lesions. In the Tysabri group, 4 to 6 new active lesions, 10 to 12 new active lesions, and &gt;12 new active lesions each occurred in 1 (1.1%) patient; no patients had 7 to 9 new active lesions. The results from the PP analysis were similar.

## Cumulative Number of New GdE T1-weighted Lesions Over 24 and 48 Weeks

The mean cumulative number of new GdE T1-weighted lesions was slightly lower in the PB006 group than in the Tysabri group at all timepoints up to Week 48. The mean (SD) cumulative number up to Week 24 was 0.3 (1.01) in the PB006 group compared to 0.4 (1.25) in the Tysabri group, and up to Week 48 was 0.3 (1.02) in the PB006 group compared to 0.4 (1.39) in the Tysabri group. The results from the PP analysis were similar.

The average number of new GdE T1-weighted lesions per MRI scan was lower in the PB006 group than in the Tysabri group at all timepoints up to Week 48. The average number up to Week 48 was 0.06 in the PB006 group compared to 0.09 in the Tysabri group. The results from the PP analysis were similar.

## Number of Patients Without New GdE T1-weighted Lesions Over 24 and 48 Weeks

The percentage of patients without new GdE T1-weighted lesions was similar in the PB006 and Tysabri groups  at  24  weeks  (109  [83.2%]  and  105  [78.9%]  patients  in  the  PB006  and  Tysabri  groups, respectively) and at 48 weeks (105 [80.2%]) and (80 [77.7%] patients in the PB006 and Tysabri groups, respectively). The percentage of patients with at least 1 new GdE T1-weighted lesion was similar in both treatment groups over 24 weeks (17 [13.0%] and 22 [16.5%] patients in the PB006 and Tysabri groups, respectively) and over 48 weeks (17 [13.0%] and 16 [15.5%] patients in the PB006 and Tysabri groups, respectively). The results from the PP analysis were similar.

## Cumulative Number of New/Enlarging T2-weighted Lesions Over 24 and 48 Weeks

The mean cumulative number of new/enlarging T2-weighted lesions was slightly lower in the PB006 group than in the Tysabri group at all timepoints up to Week 48. The mean (SD) cumulative number up to Week 24 was 1.5 (3.79) in the PB006 group compared to 2.0 (4.12) in the Tysabri group, and up to Week 48 was 1.6 (3.90) in the PB006 group compared to 2.4 (5.79) in the Tysabri group. The results from the PP analysis were similar, with mean cumulative numbers being nearly identical to the FAS for all timepoints.

<div style=\"page-break-after: always\"></div>

## Number of Patients Without New/Enlarging T2-weighted Lesions Over 24 and 48 Weeks

The percentage of patients without new/enlarging T2-weighted lesions was similar in the PB006 and Tysabri groups at 24 weeks (75 [57.3%] and 72 [54.1%] patients in the PB006 and Tysabri groups, respectively). At 48 weeks, a slightly greater percentage of patients in the PB006 group were without new/enlarging T2-weighted lesions (71 [54.2%] patients) compared with the Tysabri group (52 [50.5%] patients). The percentage of patients with at least 1 new/enlarging T2-weighted lesion was similar in both treatment groups over 24 weeks (51 [38.9%] patients in the PB006 group and 55 [41.4%] patients in the Tysabri group) and over 48 weeks (51 [38.9%] patients in the PB006 group and 44 [42.7%] patients in the Tysabri group).

The results from the PP analysis were similar over 24 and 48 weeks.

## Number of Persistent Lesions After 24 and 48 Weeks

The mean cumulative number of persistent lesions was similar in the PB006 and Tysabri groups at all timepoints up to Week 48. The mean (SD) number of persistent lesions up to Week 24 was 0.5 (2.46) and 0.4 (2.92) in the PB006 and Tysabri groups, respectively, and up to Week 48 was 0.5 (2.55) and 0.6 (3.35) in the PB006 and Tysabri groups, respectively.

For the PP Population, a slightly higher mean cumulative number of persistent lesions was reported in the PB006 group than in the Tysabri group at all timepoints up to Week 48.  The mean (SD) number of persistent  lesions  up  to  Week  24  was  0.5  (2.60)  and  0.2  (0.78)  in  the  PB006  and  Tysabri  groups, respectively,  and  up  to  Week  48  was  0.6  (2.69)  and  0.2  (0.87)  in  the  PB006  and  Tysabri  groups, respectively.

## Annualized Relapse Rate After 24 and 48 Weeks

Over 24 weeks, a similar percentage of patients in the PB006 group and Tysabri group had 1 relapse (12 [9.2%] and 9 [6.8%] patients in the PB006 and Tysabri groups, respectively), with a similar mean (SD) follow-up time for both groups (0.445 [0.0772] and 0.447 [0.0717] years in the PB006 and Tysabri groups, respectively). No patients in either group had 2 or more relapses at 24 weeks. The ARR was similar over 24 weeks for the PB006 group (0.206) compared with the Tysabri group (0.152).

Over 48 weeks, a similar percentage of patients in the PB006 group and Tysabri group had 1 relapse (18 [13.7%] and 12 [11.7%] patients in the PB006 and Tysabri groups, respectively), with a similar mean (SD) follow-up time for both groups (0.877 [0.1865] and 0.878 [0.1902] years in the PB006 and Tysabri groups, respectively). One (0.8%) patient in the PB006 group had 2 relapses; no patients in either group had 3 or more relapses at 48 weeks. The ARR was similar over 48 weeks for the PB006 group (0.174) compared with the Tysabri group (0.133). The results from the PP analysis were similar.

Table 39: Annualized Relapse Rate by Primary Randomization (FAS Population)

| Annualized Relapse Rate               | PB006 (N=131)   | Tysabri (N=133)   |
|---------------------------------------|-----------------|-------------------|
| ...Over 24 weeks                      |                 |                   |
| Number of patients, n (%)             | 131 (100)       | 133 (100)         |
| Number of relapses per patient, n (%) |                 |                   |
| 1                                     | 12 (9.2)        | 9 (6.8)           |
| 2                                     | 0               | 0                 |
| ≥3                                    | 0               | 0                 |
| Total number of relapses              | 12              | 9                 |
| Follow-up time (years)                |                 |                   |
| n                                     | 131             | 133               |
| Mean                                  | 0.445           | 0.447             |
| SD                                    | 0.0772          | 0.0717            |

<div style=\"page-break-after: always\"></div>

| Median                                  | 0.460     | 0.460     |
|-----------------------------------------|-----------|-----------|
| Min/Max                                 | 0.00/0.50 | 0.00/0.49 |
| Total follow-up time (years)            | 58.29     | 59.39     |
| Annualized relapse rate (relapses/year) | 0.206     | 0.152     |
| ...Over 48 weeks                        |           |           |
| Number of patients, n (%)               | 131 (100) | 103 (100) |
| Number of relapses per patient, n (%)   |           |           |
| 1                                       | 18 (13.7) | 12 (11.7) |
| 2                                       | 1 (0.8)   | 0         |
| ≥3                                      | 0         | 0         |
| Total number of relapses                | 20        | 12        |
| Follow-up time (years)                  |           |           |
| n                                       | 131       | 103       |
| Mean                                    | 0.877     | 0.878     |
| SD                                      | 0.1865    | 0.1902    |
| Median                                  | 0.920     | 0.920     |
| Min/Max                                 | 0.06/1.07 | 0.08/1.09 |
| Total follow-up time (years)            | 114.91    | 90.42     |
| Annualized relapse rate (relapses/year) | 0.174     | 0.133     |

n = Number of patients with the specified event/reason; N = Number of patients in population/treatment group; FAS = Full Analysis Set; SD = Standard Deviation.

Note: For time points after Week 24, patients who switch from Tysabri to PB006 are excluded from this table.

Note: For timepoint over 48 weeks, patients who switch from Tysabri to PB006 at Week 24 are excluded from this table.

## Change from Baseline in Expanded Disability Status Scale After 24 and 48 Weeks

At baseline, mean (SD) EDSS scores were similar between treatment groups (3.36 [1.065] in the PB006 group and 3.20 [1.206] in the Tysabri group). The mean (SD) change from baseline was minimal and similar in both treatment groups at 24 weeks (-0.03 [0.211] in the PB006 group and 0.00 [0.354] in the Tysabri group) and at 48 weeks (-0.14 [0.536] in the PB006 group and -0.05 [0.443] in the Tysabri group). The results from the PP analysis were similar.

Table 40: EDSS Scores by primary randomization (FAS population)

|          |                | PB006 (N=131)        | Tysabri (N=133)   | Tysabri (N=133)      | Total (N=264)   | Total (N=264)        |
|----------|----------------|----------------------|-------------------|----------------------|-----------------|----------------------|
|          | Observed Value | Change from Baseline | Observed Value    | Change from Baseline | Observed Value  | Change from Baseline |
| Baseline |                |                      |                   |                      |                 |                      |
| n        | 131            |                      | 133               |                      | 264             |                      |
| Mean     | 3.36           |                      | 3.20              |                      | 3.28            |                      |
| SD       | 1.065          |                      | 1.206             |                      | 1.139           |                      |
| Median   | 3.50           |                      | 3.50              |                      | 3.50            |                      |
| Min/Max  | 1.5/5.0        |                      | 1.0/5.0           |                      | 1.0/5.0         |                      |
| Week 24  |                |                      |                   |                      |                 |                      |
| n        | 122            | 122                  | 125               | 125                  | 247             | 247                  |
| Mean     | 3.37           | -0.03                | 3.18              | 0.00                 | 3.28            | -0.02                |
| SD       | 1.126          | 0.211                | 1.258             | 0.354                | 1.196           | 0.292                |
| Median   | 3.50           | 0.00                 | 3.50              | 0.00                 | 3.50            | 0.00                 |
| Min/Max  | 1.0/5.5        | -1.0/1.0             | 1.0/6.5           | -1.0/2.0             | 1.0/6.5         | -1.0/2.0             |
| Week 48  |                |                      |                   |                      |                 |                      |
| n        | 117            | 117                  | 93                | 93                   | 210             | 210                  |
| Mean     | 3.24           | -0.14                | 3.12              | -0.05                | 3.19            | -0.10                |
| SD       | 1.203          | 0.536                | 1.322             | 0.443                | 1.255           | 0.498                |
| Median   | 3.50           | 0.00                 | 3.50              | 0.00                 | 3.50            | 0.00                 |
| Min/Max  | 1.0/6.0        | -2.5/1.0             | 0.0/6.5           | -1.5/1.5             | 0.0/6.5         | -2.5/1.5             |

<div style=\"page-break-after: always\"></div>

N = Number of patients in population/treatment group; FAS = Full Analysis Set; SD = Standard Deviation.

Note: For timepoints after Week 24, patients who switch from Tysabri to PB006 are excluded from this table.

The  data  integrity  impact  evaluation  for  site  7002  showed  that  EDSS  subscores  were  subject  to backdating in the source data for some patients. Therefore, a conservative approach was chosen and the EDSS data were re-analyzed excluding the data from site 7002. The results excluding the 17 patients from site 7002 are shown below.

Table 41: Change from baseline in EDSS after 24 and 48 weeks, excluding patients from site 7002, by primary randomization (FAS population)

|          | PB006 N=122    | PB006 N=122          | EU-Tysabri N=125   | EU-Tysabri N=125     |
|----------|----------------|----------------------|--------------------|----------------------|
|          | Observed value | Change from baseline | Observed value     | Change from baseline |
| Baseline |                |                      |                    |                      |
| n        | 122            |                      | 125                |                      |
| Mean     | 3.39           |                      | 3.26               |                      |
| SD       | 1.034          |                      | 1.175              |                      |
| Median   | 3.50           |                      | 3.50               |                      |
| Min/Max  | 1.5/5.0        |                      | 1.0/5.0            |                      |
| Week 24  |                |                      |                    |                      |
| n        | 114            | 114                  | 118                | 118                  |
| Mean     | 3.38           | -0.04                | 3.24               | 0.00                 |
| SD       | 1.102          | 0.218                | 1.236              | 0.364                |
| Median   | 3.50           | 0.00                 | 3.50               | 0.00                 |
| Min/Max  | 1.0/5.5        | -1.0/1.0             | 1.0/6.5            | -1.0/2.0             |
| Week 48  |                |                      |                    |                      |
| n        | 110            | 110                  | 86                 | 86                   |
| Mean     | 3.25           | -0.15                | 3.19               | -0.05                |
| SD       | 1.182          | 0.552                | 1.302              | 0.460                |
| Median   | 3.50           | 0.00                 | 3.50               | 0.00                 |
| Min/Max  | 1.0/6.0        | -2.5/1.0             | 0.0/6.5            | -1.5/1.5             |

FAS=full analysis set, Max=maximum, Min=minimum, N=Number of patients in treatment group, n=number of patients with data available, SD=standard deviation.

Note: For time points after Week 24, patients who switched from EU-Tysabri to PB006 were excluded from this table.

By this analysis, very similar results as in the overall analysis were obtained.

## Pharmacokinetic Results

Natalizumab Ctrough was similar in the PB006 and Tysabri groups at all post-baseline timepoints. Mean (SD) natalizumab Ctrough was 26804.75 ng/mL (12949.541) and 25010.49 ng/mL (12557.895) at Week 8  in  the  PB006  and  Tysabri  groups,  respectively,  and  gradually  increased  in  both  groups  at  each timepoint,  with  natalizumab  C  Ctrough  trough  of  39097.58  ng/mL  (16801.710)  and  38432.86  ng/mL (16495.407) in the PB006 and Tysabri groups at Week 48, respectively. The results from the PP analysis were similar.

| Table 42: Natalizumab Concentration (ng/mL)   | Concentration (ng/mL) by Primary PB006 (N=131)   | Randomization (FAS Population) Tysabri (N=13 3)   |
|-----------------------------------------------|--------------------------------------------------|---------------------------------------------------|
| Week 8                                        |                                                  |                                                   |
| n                                             | 118                                              | 125                                               |
| Mean                                          | 26804.75                                         | 25010.49                                          |
| SD                                            | 12949.541                                        | 12557.895                                         |
| CV (%)                                        | 48.311                                           | 50.211                                            |
| Geometric Mean                                | 22270.65                                         | 18784.89                                          |
| Median                                        | 26150.00                                         | 25400.00                                          |

<div style=\"page-break-after: always\"></div>

| Min/Max        | 90.2/72500.0   | 61.5/61700.0   |
|----------------|----------------|----------------|
| n BLQ          | 8              | 2              |
| Week 16        |                |                |
| n              | 117            | 122            |
| Mean           | 33872.92       | 32543.28       |
| SD             | 18151.190      | 14636.925      |
| CV (%)         | 53.586         | 44.977         |
| Geometric Mean | 29159.08       | 27939.96       |
| Median         | 32300.00       | 30500.00       |
| Min/Max        | 522.0/143000.0 | 930.0/74100.0  |
| n BLQ          | 6              | 4              |
| Week 24        |                |                |
| n              | 117            | 121            |
| Mean           | 36853.93       | 35617.65       |
| SD             | 15292.389      | 16049.669      |
| CV (%)         | 41.495         | 45.061         |
| Geometric Mean | 32973.78       | 30553.77       |
| Median         | 35300.00       | 34200.00       |
| Min/Max        | 3530.0/90500.0 | 156.0/99800.0  |
| n BLQ          | 5              | 4              |
| Week 32        |                |                |
| n              | 115            | 94             |
| Mean           | 37450.04       | 36865.81       |
| SD             | 16877.010      | 19756.050      |
| CV (%)         | 45.065         | 53.589         |
| Geometric Mean | 31836.24       | 27586.41       |
| Median         | 36600.00       | 34750.00       |
| Min/Max        | 95.0/82600.0   | 78.8/109000.0  |
| n BLQ          | 4              | 1              |
| Week 48        |                |                |
| n              | 110            | 91             |
| Mean           | 39097.58       | 38432.86       |
| SD             | 16801.710      | 16495.407      |
| CV (%)         | 42.974         | 42.920         |
| Geometric Mean | 33716.63       | 34706.02       |
| Median         | 36850.00       | 37200.00       |
| Min/Max        | 64.2/98200.0   | 5490.0/100000. |
| n BLQ          | 5              | 2              |

N = Number of patients in population/treatment group; BLQ = below lower limit of quantification; FAS = Full Analysis Set; SD = Standard Deviation; CV = Coefficient of Variation.

Note: For timepoints after Week 24, patients who switch from Tysabri to PB006 are excluded from this table.

## · Ancillary analyses

## COVID-19 Impact

## Plan

Changes in conduct or analysis of the study due to Covid-19 could not be considered at start of the study since  the  virus  was  not  known  by  that  time.  In  the  documentation  of  statistical  methods  (Appendix 6.1.9), a pre-COVID PP Population was described, defined as all PP patients, including those who were excluded from PP only due to major deviations related to COVID-19.

In order to assess the impact of COVID-19 on safety and efficacy of the study the following was done:

- Study discontinuations and protocol deviations due to COVID-19 were summarized

<div style=\"page-break-after: always\"></div>

- Demography data for confirmed COVID-19 patients were summarized
- Protocol deviations due to COVID-19 were summarized by country

·  A  sensitivity  analysis  was  considered  to  be  performed  on  the  pre-COVID  PP  population.  Multiple imputation should be performed for this population. Sensitivity analysis should be done for the primary endpoint using imputed data for this population.

## Conduct &amp; Outcome

At the time COVID-19 was identified in 2019 and declared a pandemic by the World Health Organization on 11 March 2020, the PB006-03-01 study was still enrolling and treating patients, with the last patient randomized on 4 May 2020.

The frequency of reviews for data quality assurance was increased after the declaration of the pandemic in March 2022 to be able to identify and respond to the potential problems.

Major protocol deviations related to COVID-19 for the FAS were reported for 8 (6.1%) patients in the PB006 group and 5 (3.8%) patients in the Tysabri group. The majority of deviations in all countries were related to patient visit completion or timing.

COVID-19 was one of the most commonly reported treatment-emergent adverse events (in total 24 events  due  to  COVID-19).  One  patient  discontinued  due  to  a  treatment-emergent  adverse  event  of COVID-19.

For COVID-19-confirmed patients (n=22) in the SAF Population, all parameters were similar to the FAS, SAF, PP, and SSW Populations. A sensitivity analysis of the primary analysis using multiple imputation for the pre-COVID PP Population was not performed, as there was no missing data to impute for the population.

## · Summary of main efficacy results

The  following  tables  summarise  the  efficacy  results  from  the  main  studies  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the biosimilarity assessment (see later sections).

Table 43: Summary of efficacy for trial PB006-03-01

| Title: Antelope: Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)   | Title: Antelope: Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Title: Antelope: Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                   | PB006-03-01 EudraCT Number: 2018-004751-20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | PB006-03-01 EudraCT Number: 2018-004751-20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Design                                                                                                                                                             | This was a Phase 3 multicenter, double-blind, active-controlled, randomized, parallel-group study to assess the similarity in efficacy, safety, and immunogenicity of biosimilar natalizumab PB006 compared to European Union-approved Tysabri in patients with RRMS. Eligible patients were randomly assigned to 1 of the 2 treatment groups in a 1:1 ratio to receive intravenous infusions every 4 weeks of either PB006 or Tysabri at a dose of 300 mg starting at Visit 1 (Week 0) through Visit 12 (Week 44), for a total of 12 infusions. The primary efficacy endpoint, cumulative number of new active lesions over 24 weeks, was evaluated after 24 weeks. Based on requirements by the FDA a subset of 30 patients was switched after 24 weeks of treatment with Tysabri to treatment with PB006 for the remaining treatment period, to rule out any major safety risks in terms of hypersensitivity, immunogenicity or other reactions, | This was a Phase 3 multicenter, double-blind, active-controlled, randomized, parallel-group study to assess the similarity in efficacy, safety, and immunogenicity of biosimilar natalizumab PB006 compared to European Union-approved Tysabri in patients with RRMS. Eligible patients were randomly assigned to 1 of the 2 treatment groups in a 1:1 ratio to receive intravenous infusions every 4 weeks of either PB006 or Tysabri at a dose of 300 mg starting at Visit 1 (Week 0) through Visit 12 (Week 44), for a total of 12 infusions. The primary efficacy endpoint, cumulative number of new active lesions over 24 weeks, was evaluated after 24 weeks. Based on requirements by the FDA a subset of 30 patients was switched after 24 weeks of treatment with Tysabri to treatment with PB006 for the remaining treatment period, to rule out any major safety risks in terms of hypersensitivity, immunogenicity or other reactions, |
|                                                                                                                                                                    | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 48 weeks of treatment not applicable not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Hypothesis                                                                                                                                                         | Equivalence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Equivalence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| Treatments groups                               | PB006                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Treatment: PB006 Duration: 48 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Treatment: PB006 Duration: 48 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatments groups                               | Tysabri                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Tysabri                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Number randomized: 132 Treatment: Tysabri Duration: 48 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Endpoints and definitions                       | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Cumulative number of new active lesions over weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Endpoints and definitions                       | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Cumulative number of new active lesions over weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 48                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Endpoints and definitions                       | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Cumulative number of new GdE T1-weighted over 24 and 48 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | lesions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Endpoints and definitions                       | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Number of patients without new GdE lesions over 24 and 48 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | T1-weighted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Endpoints and definitions                       | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Cumulative number of new/enlarging lesions over 24 and 48 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | T2-weighted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Endpoints and definitions                       | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Number of patients without weighted lesions over 24 and 48 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | new/enlarging T2-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Endpoints and definitions                       | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Number of persistent lesions after 24 and 48 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Endpoints and definitions                       | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | ARR after 24 and 48 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Endpoints and definitions                       | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Change from baseline in EDSS after                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 24 and 48 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Database lock                                   | 21 OCT 2021                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Results and Analysis                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Analysis description                            | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Analysis population and time point description  | Per-Protocol Population : Only patients participating in this study who completed the 24-week treatment period without major protocol deviations that may have influenced the analysis of the primary endpoint and for whom sufficient post-baseline MRI data were available (including baseline, Week 24 and at least 1 out of the 3 other scheduled MRI visits) were to be included in the Per-Protocol (PP) Population. The final decision on the PP Population was to be made in the blinded data review meeting before database lock for the final analysis of the primary endpoint. Analysis Set Population: The Full Analysis Set (FAS) Population was to include all | Per-Protocol Population : Only patients participating in this study who completed the 24-week treatment period without major protocol deviations that may have influenced the analysis of the primary endpoint and for whom sufficient post-baseline MRI data were available (including baseline, Week 24 and at least 1 out of the 3 other scheduled MRI visits) were to be included in the Per-Protocol (PP) Population. The final decision on the PP Population was to be made in the blinded data review meeting before database lock for the final analysis of the primary endpoint. Analysis Set Population: The Full Analysis Set (FAS) Population was to include all | Per-Protocol Population : Only patients participating in this study who completed the 24-week treatment period without major protocol deviations that may have influenced the analysis of the primary endpoint and for whom sufficient post-baseline MRI data were available (including baseline, Week 24 and at least 1 out of the 3 other scheduled MRI visits) were to be included in the Per-Protocol (PP) Population. The final decision on the PP Population was to be made in the blinded data review meeting before database lock for the final analysis of the primary endpoint. Analysis Set Population: The Full Analysis Set (FAS) Population was to include all | Per-Protocol Population : Only patients participating in this study who completed the 24-week treatment period without major protocol deviations that may have influenced the analysis of the primary endpoint and for whom sufficient post-baseline MRI data were available (including baseline, Week 24 and at least 1 out of the 3 other scheduled MRI visits) were to be included in the Per-Protocol (PP) Population. The final decision on the PP Population was to be made in the blinded data review meeting before database lock for the final analysis of the primary endpoint. Analysis Set Population: The Full Analysis Set (FAS) Population was to include all |
| Analysis population and time point description  | Full patients who were randomized and received at least 1 (complete or partial) infusion of the study drug. Patients were to be analyzed according to the treatment group to which they were randomized.                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Full patients who were randomized and received at least 1 (complete or partial) infusion of the study drug. Patients were to be analyzed according to the treatment group to which they were randomized.                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Full patients who were randomized and received at least 1 (complete or partial) infusion of the study drug. Patients were to be analyzed according to the treatment group to which they were randomized.                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Full patients who were randomized and received at least 1 (complete or partial) infusion of the study drug. Patients were to be analyzed according to the treatment group to which they were randomized.                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | PB006                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Tysabri                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 111                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 118                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability | Cumulative number of new active lesions over 24 weeks (PP population) mean                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 1.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 1.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability | SD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 3.73                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 3.97                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Effect estimate per comparison                  | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Tysabri - PB006                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Effect estimate per comparison                  | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Exponentiated difference                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0.17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Effect estimate per comparison                  | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | -0.613; 0.944                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Effect estimate per comparison                  | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| Descriptive statistics and estimate variability   | Treatment group                                                                                                                                                                                                                                                                                                   | PB006                                                                                                                                                                                                                                                                                                             | Tysabri                                                                                                                                                                                                                                                                                                           |
|---------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive statistics and estimate variability   | Number of subjects                                                                                                                                                                                                                                                                                                | 126                                                                                                                                                                                                                                                                                                               | 127                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability   | Cumulative number of new active lesions over 24 weeks (FAS population) mean                                                                                                                                                                                                                                       | 1.4                                                                                                                                                                                                                                                                                                               | 1.9                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability   | SD                                                                                                                                                                                                                                                                                                                | 3.62                                                                                                                                                                                                                                                                                                              | 3.98                                                                                                                                                                                                                                                                                                              |
| Effect estimate per comparison                    | Primary endpoint                                                                                                                                                                                                                                                                                                  | Comparison groups                                                                                                                                                                                                                                                                                                 | Tysabri - PB006                                                                                                                                                                                                                                                                                                   |
| Effect estimate per comparison                    |                                                                                                                                                                                                                                                                                                                   | Exponentiated difference                                                                                                                                                                                                                                                                                          | 0.23                                                                                                                                                                                                                                                                                                              |
| Effect estimate per comparison                    |                                                                                                                                                                                                                                                                                                                   | 95% CI                                                                                                                                                                                                                                                                                                            | -0.609; 1.075                                                                                                                                                                                                                                                                                                     |
| Effect estimate per comparison                    |                                                                                                                                                                                                                                                                                                                   | P-value                                                                                                                                                                                                                                                                                                           | Not applicable                                                                                                                                                                                                                                                                                                    |
| Notes                                             | Summary of reasons for drop-outs in primary period (24 week): • Study drug discontinued in primary period - Reasons: - Adverse Event - Other                                                                                                                                                                      | Summary of reasons for drop-outs in primary period (24 week): • Study drug discontinued in primary period - Reasons: - Adverse Event - Other                                                                                                                                                                      | Summary of reasons for drop-outs in primary period (24 week): • Study drug discontinued in primary period - Reasons: - Adverse Event - Other                                                                                                                                                                      |
| Analysis description                              | Secondary analysis                                                                                                                                                                                                                                                                                                | Secondary analysis                                                                                                                                                                                                                                                                                                | Secondary analysis                                                                                                                                                                                                                                                                                                |
| Analysis population and time point description    | Full Analysis Set Population : The Full Analysis Set (FAS) Population was to include all patients who were randomized and received at least 1 (complete or partial) infusion of the study drug. Patients were to be analyzed according to the treatment group to which they were randomized. Time point: 48 weeks | Full Analysis Set Population : The Full Analysis Set (FAS) Population was to include all patients who were randomized and received at least 1 (complete or partial) infusion of the study drug. Patients were to be analyzed according to the treatment group to which they were randomized. Time point: 48 weeks | Full Analysis Set Population : The Full Analysis Set (FAS) Population was to include all patients who were randomized and received at least 1 (complete or partial) infusion of the study drug. Patients were to be analyzed according to the treatment group to which they were randomized. Time point: 48 weeks |
| Descriptive statistics and estimate variability   | Treatment group                                                                                                                                                                                                                                                                                                   | PB006                                                                                                                                                                                                                                                                                                             | Tysabri                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability   | Number of subjects                                                                                                                                                                                                                                                                                                | 131                                                                                                                                                                                                                                                                                                               | 133                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability   | Cumulative number of new active lesions over 48 weeks, by visit and by primary randomization (FAS population)                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability   | ... up to Week 8                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability   | n                                                                                                                                                                                                                                                                                                                 | 125                                                                                                                                                                                                                                                                                                               | 128                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability   | Mean                                                                                                                                                                                                                                                                                                              | 1.3                                                                                                                                                                                                                                                                                                               | 1.7                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability   | SD                                                                                                                                                                                                                                                                                                                | 3.14                                                                                                                                                                                                                                                                                                              | 3.09                                                                                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability   | Median                                                                                                                                                                                                                                                                                                            | 0.0                                                                                                                                                                                                                                                                                                               | 0.0                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability   | Min/Max                                                                                                                                                                                                                                                                                                           | 0/25                                                                                                                                                                                                                                                                                                              | 0/16                                                                                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability   | ... up to Week 16                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability   | n                                                                                                                                                                                                                                                                                                                 | 124                                                                                                                                                                                                                                                                                                               | 128                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability   | Mean                                                                                                                                                                                                                                                                                                              | 1.4                                                                                                                                                                                                                                                                                                               | 1.8                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability   | SD                                                                                                                                                                                                                                                                                                                | 3.54                                                                                                                                                                                                                                                                                                              | 3.42                                                                                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability   | Median                                                                                                                                                                                                                                                                                                            | 0.0                                                                                                                                                                                                                                                                                                               | 0.0                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability   | Min/Max                                                                                                                                                                                                                                                                                                           | 0/30                                                                                                                                                                                                                                                                                                              | 0/17                                                                                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability   | ... up to Week 20                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability   | n                                                                                                                                                                                                                                                                                                                 | 126                                                                                                                                                                                                                                                                                                               | 128                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability   | Mean                                                                                                                                                                                                                                                                                                              | 1.4                                                                                                                                                                                                                                                                                                               | 1.8                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability   | SD                                                                                                                                                                                                                                                                                                                | 3.57                                                                                                                                                                                                                                                                                                              | 3.42                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                                                 | Median                                                                                                                        | 0.0                                                                                            | 0.0     |
|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|---------|
|                                                 | Min/Max                                                                                                                       | 0/30                                                                                           | 0/17    |
|                                                 | ... up to Week 24                                                                                                             |                                                                                                |         |
|                                                 | n                                                                                                                             | 126                                                                                            | 127     |
|                                                 | Mean                                                                                                                          | 1.4                                                                                            | 1.9     |
|                                                 | SD                                                                                                                            | 3.62                                                                                           | 3.98    |
|                                                 | Median                                                                                                                        | 0.0                                                                                            | 0.0     |
|                                                 | Min/Max                                                                                                                       | 0/30                                                                                           | 0/29    |
|                                                 | ... up to Week 48                                                                                                             |                                                                                                |         |
|                                                 | n                                                                                                                             | 122                                                                                            | 96      |
|                                                 | Mean                                                                                                                          | 1.5                                                                                            | 2.3     |
|                                                 | SD                                                                                                                            | 3.72                                                                                           | 5.68    |
|                                                 | Median                                                                                                                        | 0.0                                                                                            | 0.0     |
|                                                 | Min/Max                                                                                                                       | 0/30                                                                                           | 0/39    |
| Notes                                           | Summary of reasons for drop-outs (48                                                                                          | week):                                                                                         |         |
|                                                 | • Study drug - Adverse - Other • Withdrawn from - Subject - Investigator - Adverse                                            | discontinued - Reasons: Event study - Reasons: withdrawal of consent / sponsor decision Events |         |
| Descriptive statistics and estimate variability | Treatment group                                                                                                               | PB006                                                                                          | Tysabri |
|                                                 | Number of subjects                                                                                                            | 131                                                                                            | 133     |
|                                                 | Cumulative number of new GdE T1-weighted lesions over 24 and 48 weeks, by visit and by primary randomization (FAS population) |                                                                                                |         |
|                                                 | ... up to Week 8                                                                                                              |                                                                                                |         |
|                                                 | n                                                                                                                             | 125                                                                                            | 128     |
|                                                 | Mean                                                                                                                          | 0.2                                                                                            | 0.3     |
|                                                 | SD                                                                                                                            | 0.78                                                                                           | 1.19    |
|                                                 | Median                                                                                                                        | 0.0                                                                                            | 0.0     |
|                                                 | Min/Max                                                                                                                       | 0/6                                                                                            | 0/11    |
|                                                 | ... up to Week 16                                                                                                             |                                                                                                |         |
|                                                 | n                                                                                                                             | 124                                                                                            | 128     |
|                                                 | Mean                                                                                                                          | 0.3                                                                                            | 0.4     |
|                                                 | SD                                                                                                                            | 0.97                                                                                           | 1.22    |
|                                                 | Median                                                                                                                        | 0.0                                                                                            | 0.0     |
|                                                 | Min/Max                                                                                                                       | 0/8                                                                                            | 0/11    |
|                                                 | ... up to Week 20                                                                                                             |                                                                                                |         |
|                                                 | n                                                                                                                             | 126                                                                                            | 128     |
|                                                 | Mean                                                                                                                          | 0.3                                                                                            | 0.4     |
|                                                 | SD                                                                                                                            | 1.01                                                                                           | 1.22    |

<div style=\"page-break-after: always\"></div>

|                            | Median                                                                                                                              | 0.0        | 0.0        |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------|------------|------------|
|                            | Min/Max                                                                                                                             | 0/8        | 0/11       |
|                            | ... up to Week 24                                                                                                                   |            |            |
|                            | n                                                                                                                                   | 126        | 127        |
|                            | Mean                                                                                                                                | 0.3        | 0.4        |
|                            | SD                                                                                                                                  | 1.01       | 1.25       |
|                            | Median                                                                                                                              | 0.0        | 0.0        |
|                            | Min/Max                                                                                                                             | 0/8        | 0/11       |
|                            | ... up to Week 48                                                                                                                   |            |            |
|                            | n                                                                                                                                   | 122        | 96         |
|                            | Mean                                                                                                                                | 0.3        | 0.4        |
|                            | SD                                                                                                                                  | 1.02       | 1.39       |
|                            | Median                                                                                                                              | 0.0        | 0.0        |
|                            | Min/Max                                                                                                                             | 0/8        | 0/11       |
| Descriptive statistics and | Treatment group                                                                                                                     | PB006      | Tysabri    |
| estimate variability       | Number of subjects                                                                                                                  | 131        | 133        |
| estimate variability       | Number (%) of patients without new GdE T1- weighted lesions over 24 and 48 weeks (FAS population)                                   |            |            |
| estimate variability       | Over 24 weeks                                                                                                                       | n=131      | n=133      |
| estimate variability       | Number (%) of patients without new GdE T1- weighted lesions                                                                         | 109 (83.2) | 105 (78.9) |
| estimate variability       | Number (%) of patients with at least one new GdE T1- weighted lesion                                                                | 17 (13.0)  | 22 (16.5)  |
| estimate variability       | Number (%) of patients without sufficient MRI data                                                                                  | 5 (3.8)    | 6 (4.5)    |
| estimate variability       | Over 48 weeks                                                                                                                       | n=131      | n=103      |
| estimate variability       | Number (%) of patients without new GdE T1- weighted lesions                                                                         | 105 (80.2) | 80 (77.7)  |
| estimate variability       | Number (%) of patients with at least one new GdE T1- weighted lesion                                                                | 17 (13.0)  | 16 (15.5)  |
| estimate variability       | Number (%) of patients without sufficient MRI data                                                                                  | 9 (6.9)    | 7 (6.8)    |
| Descriptive statistics and | Treatment group                                                                                                                     | PB006      | Tysabri    |
| estimate variability       | Number of subjects                                                                                                                  | 131        | 133        |
| estimate variability       | Cumulative number of new/enlarging T2-weighted lesions over 24 and 48 weeks, by visit and by primary randomization (FAS population) |            |            |
| estimate variability       | ... up to Week 8                                                                                                                    |            |            |
| estimate variability       | n                                                                                                                                   | 125        | 128        |
| estimate variability       | Mean                                                                                                                                | 1.3        | 1.8        |
| estimate variability       | SD                                                                                                                                  | 3.34       | 3.28       |

<div style=\"page-break-after: always\"></div>

|                      | Median                                                                                                  | 0.0       | 0.0       |
|----------------------|---------------------------------------------------------------------------------------------------------|-----------|-----------|
|                      | Min/Max                                                                                                 | 0/26      | 0/16      |
|                      | ... up to Week 16                                                                                       |           |           |
|                      | n                                                                                                       | 124       | 128       |
|                      | Mean                                                                                                    | 1.4       | 1.9       |
|                      | SD                                                                                                      | 3.72      | 3.59      |
|                      | Median                                                                                                  | 0.0       | 0.0       |
|                      | Min/Max                                                                                                 | 0/31      | 0/17      |
|                      | ... up to Week 20                                                                                       |           |           |
|                      | n                                                                                                       | 126       | 128       |
|                      | Mean                                                                                                    | 1.5       | 1.9       |
|                      | SD                                                                                                      | 3.75      | 3.59      |
|                      | Median                                                                                                  | 0.0       | 0.0       |
|                      | Min/Max                                                                                                 | 0/31      | 0/17      |
|                      | ... up to Week 24                                                                                       |           |           |
|                      | n                                                                                                       | 126       | 127       |
|                      | Mean                                                                                                    | 1.5       | 2.0       |
|                      | SD                                                                                                      | 3.79      | 4.12      |
|                      | Median                                                                                                  | 0.0       | 0.0       |
|                      | Min/Max                                                                                                 | 0/31      | 0/29      |
|                      | ... up to Week 48                                                                                       |           |           |
|                      | n                                                                                                       | 122       | 96        |
|                      | Mean                                                                                                    | 1.6       | 2.4       |
|                      | SD                                                                                                      | 3.90      | 5.79      |
|                      | Median                                                                                                  | 0.0       | 0.0       |
|                      | Min/Max                                                                                                 | 0/31      | 0/39      |
| estimate variability | and Treatment group                                                                                     | PB006     | Tysabri   |
| estimate variability | Number of subjects                                                                                      | 131       | 133       |
| estimate variability | Number (%) of patients without new/enlarging T2- weighted lesions over 24 and 48 weeks (FAS population) |           |           |
| estimate variability | Over 24 weeks                                                                                           | n=131     | n=133     |
| estimate variability | Number (%) of patients without new/enlarging T2- weighted lesions                                       | 75 (57.3) | 72 (54.1) |
| estimate variability | Number (%) of patients with at least one new/enlarging T2-weighted lesion                               | 51 (38.9) | 55 (41.4) |
| estimate variability | Number (%) of patients without sufficient MRI data                                                      | 5 (3.8)   | 6 (4.5)   |
| estimate variability | Over 48 weeks                                                                                           | n=131     | n=103     |
| estimate variability | Number (%) of patients without new/enlarging T2- weighted lesions                                       | 71 (54.2) | 52 (50.5) |

<div style=\"page-break-after: always\"></div>

|                                                 | Number (%) of patients with at least one new/enlarging T2-weighted lesion                                 | 51 (38.9)   | 44 (42.7)   |
|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-------------|-------------|
|                                                 | Number (%) of patients without sufficient MRI data                                                        | 9 (6.9)     | 7 (6.8)     |
| Descriptive statistics and estimate variability | Treatment group                                                                                           | PB006       | Tysabri     |
|                                                 | Number of subjects                                                                                        | 131         | 133         |
|                                                 | Number of persistent lesions over 24 and 48 weeks, by visit and by primary randomization (FAS population) |             |             |
|                                                 | ... up to Week 8                                                                                          |             |             |
|                                                 | n                                                                                                         | 125         | 128         |
|                                                 | Mean                                                                                                      | 0.3         | 0.3         |
|                                                 | SD                                                                                                        | 1.59        | 1.34        |
|                                                 | Median                                                                                                    | 0.0         | 0.0         |
|                                                 | Min/Max                                                                                                   | 0/16        | 0/14        |
|                                                 | ... up to Week 16                                                                                         |             |             |
|                                                 | n                                                                                                         | 124         | 128         |
|                                                 | Mean                                                                                                      | 0.4         | 0.4         |
|                                                 | SD                                                                                                        | 1.97        | 2.38        |
|                                                 | Median                                                                                                    | 0.0         | 0.0         |
|                                                 | Min/Max                                                                                                   | 0/19        | 0/26        |
|                                                 | ... up to Week 20                                                                                         |             |             |
|                                                 | n                                                                                                         | 126         | 128         |
|                                                 | Mean                                                                                                      | 0.4         | 0.4         |
|                                                 | SD                                                                                                        | 2.28        | 2.90        |
|                                                 | Median                                                                                                    | 0.0         | 0.0         |
|                                                 | Min/Max                                                                                                   | 0/22        | 0/32        |
|                                                 | ... up to Week 24                                                                                         |             |             |
|                                                 | n                                                                                                         | 126         | 127         |
|                                                 | Mean                                                                                                      | 0.5         | 0.4         |
|                                                 | SD                                                                                                        | 2.46        | 2.92        |
|                                                 | Median                                                                                                    | 0.0         | 0.0         |
|                                                 | Min/Max                                                                                                   | 0/23        | 0/32        |
|                                                 | ... up to Week 48                                                                                         |             |             |
|                                                 | n                                                                                                         | 122         | 96          |
|                                                 | Mean                                                                                                      | 0.5         | 0.6         |
|                                                 | SD                                                                                                        | 2.55        | 3.35        |
|                                                 | Median                                                                                                    | 0.0         | 0.0         |
|                                                 | Min/Max                                                                                                   | 0/23        | 0/32        |
| Descriptive statistics and Treatment group      | Descriptive statistics and Treatment group                                                                | PB006       | Tysabri     |
| estimate variability                            | Number of subjects                                                                                        | 131         | 133         |
|                                                 | ARR after 24 and 48 weeks (FAS population)                                                                |             |             |

<div style=\"page-break-after: always\"></div>

| Descriptive statistics estimate variability   | Over 24 weeks                                                                                 |                |                      |                |                      |
|-----------------------------------------------|-----------------------------------------------------------------------------------------------|----------------|----------------------|----------------|----------------------|
|                                               | Number of patients                                                                            | 131            | 131                  | 133            | 133                  |
|                                               | Number of relapses per patient, n (%)                                                         |                |                      |                |                      |
|                                               | 1                                                                                             | 12 (9.2%)      | 12 (9.2%)            | 9 (6.8%)       | 9 (6.8%)             |
|                                               | 2                                                                                             | 0              | 0                    | 0              | 0                    |
|                                               | ≥3                                                                                            | 0              | 0                    | 0              | 0                    |
|                                               | Total number of relapses                                                                      | 12             | 12                   | 9              | 9                    |
|                                               | Follow-up time (years)                                                                        |                |                      |                |                      |
|                                               | N                                                                                             | 131            | 131                  | 133            | 133                  |
|                                               | Mean                                                                                          | 0.445          | 0.445                | 0.447          | 0.447                |
|                                               | SD                                                                                            | 0.0772         | 0.0772               | 0.0717         | 0.0717               |
|                                               | Median                                                                                        | 0.460          | 0.460                | 0.460          | 0.460                |
|                                               | Min/Max                                                                                       | 0.00/0.50      | 0.00/0.50            | 0.00/0.49      | 0.00/0.49            |
|                                               | Total follow-up time (years)                                                                  | 58.29          | 58.29                | 59.39          | 59.39                |
|                                               | ARR (relapses/year)                                                                           | 0.206          | 0.206                | 0.152          | 0.152                |
|                                               | Over 48 weeks                                                                                 |                |                      |                |                      |
|                                               | Number of patients                                                                            | 131            | 131                  | 103            | 103                  |
|                                               | Number of relapses per patient, n (%)                                                         |                |                      |                |                      |
|                                               | 1                                                                                             | 18 (13.7%)     | 18 (13.7%)           | 12 (11.7%)     | 12 (11.7%)           |
|                                               | 2                                                                                             | 1 (0.8%)       | 1 (0.8%)             | 0              | 0                    |
|                                               | ≥3                                                                                            | 0              | 0                    | 0              | 0                    |
|                                               | Total number of relapses                                                                      | 20             | 20                   | 12             | 12                   |
|                                               | Follow-up time (years)                                                                        |                |                      |                |                      |
|                                               | n                                                                                             | 131            | 131                  | 103            | 103                  |
|                                               | Mean                                                                                          | 0.877          | 0.877                | 0.878          | 0.878                |
|                                               | SD                                                                                            | 0.1865         | 0.1865               | 0.1902         | 0.1902               |
|                                               | Median                                                                                        | 0.920          | 0.920                | 0.920          | 0.920                |
|                                               | Min/Max                                                                                       | 0.06/1.07      | 0.06/1.07            | 0.08/1.09      | 0.08/1.09            |
|                                               | Total follow-up time (years)                                                                  | 114.91         | 114.91               | 90.42          | 90.42                |
|                                               | ARR (relapses/year)                                                                           | 0.174          | 0.174                | 0.133          | 0.133                |
| and                                           | Treatment group                                                                               | PB006          | PB006                | Tysabri        | Tysabri              |
|                                               | Number of subjects                                                                            | 131            | 131                  | 133            | 133                  |
|                                               | Change from baseline in EDSS after 24 and 48 weeks, by primary randomization (FAS population) | Observed value | Change from baseline | Observed value | Change from baseline |
|                                               | Baseline                                                                                      |                |                      |                |                      |
|                                               | n                                                                                             | 131            | 131                  | 133            | 133                  |
|                                               | Mean                                                                                          | 3.36           | 3.36                 | 3.20           | 3.20                 |
|                                               | SD                                                                                            | 1.065          | 1.065                | 1.206          | 1.206                |

<div style=\"page-break-after: always\"></div>

| Median   | 3.50    |          | 3.50    |          |
|----------|---------|----------|---------|----------|
| Min/Max  | 1.5/5.0 |          | 1.0/5.0 |          |
| Week 24  |         |          |         |          |
| n        | 122     | 122      | 125     | 125      |
| Mean     | 3.37    | -0.03    | 3.18    | 0.00     |
| SD       | 1.126   | 0.211    | 1.258   | 0.354    |
| Median   | 3.50    | 0.00     | 3.50    | 0.00     |
| Min/Max  | 1.0/5.5 | -1.0/1.0 | 1.0/6.5 | -1.0/2.0 |
| Week 48  |         |          |         |          |
| n        | 117     | 117      | 93      | 93       |
| Mean     | 3.24    | -0.14    | 3.12    | -0.05    |
| SD       | 1.203   | 0.536    | 1.322   | 0.443    |
| Median   | 3.50    | 0.00     | 3.50    | 0.00     |
| Min/Max  | 1.0/6.0 | -2.5/1.0 | 0.0/6.5 | -1.5/1.5 |

## 2.6.6. Discussion on clinical efficacy

## Design and conduct of clinical studies

The applicant conducted a pivotal efficacy and safety study, PB006-03-01, to compare PB006 to the EU reference product Tysabri.

This was a randomized, double-blind, active-controlled, parallel-group study to compare the efficacy, safety and immunogenicity of PB006 versus EU-Tysabri, and to demonstrate similarity between PB006 and EU-Tysabri in patients with RRMS.

In general, the study design followed the Scientific Advice received from CHMP in 2017.

The inclusion criteria define patients with RRMS. The criteria in this study are less stringent than in the SmPC of the originator (e.g., only one third of patients had 2 or more relapses in the year prior to screening).  However,  the  eligibility  criteria  do  resemble  those  of  the  pivotal  phase  3  studies  of  the originator and thus, the selected study population is regarded sufficiently sensitive for the comparative efficacy assessment. The exclusion criteria are found in line with the contraindications, special warnings, and precautions for use of the reference product, Tysabri EU, and with the scientific advice received.

The dose of 300 mg, dosing frequency (once every 4 weeks), route and method of administration are in line with the SmPC of the reference product and are thus, appropriate. The number of doses (12) over a study period of 44 weeks is also considered adequate.

The primary endpoint, cumulative number of new active lesions over 24 weeks, and secondary endpoints, i.e.,  cumulative  number  of  new  active  lesions  over  48  weeks,  cumulative  number  of  new  GdE  T1weighted lesions over 24 and 48 weeks, number of patients without new GdE T1-weighted lesions over 24 and 48 weeks, cumulative number of new/enlarging T2-weighted lesions over 24 and 48 weeks, number  of  patients  without  new/enlarging  T2-weighted  lesions  over  24  and  48  weeks,  number  of persistent lesions after 24 and 48 weeks, ARR after 24 and 48 weeks and change from baseline in EDSS after 24 and 48 weeks are considered adequate to assess the clinical similarity between the biosimilar candidate  and  the  reference  product  because  they  examine  the  effect  on  brain  lesion  activity  and measure the delay of the disability, respectively. Moreover, the efficacy endpoints are in line with the 'Guideline  on  clinical  investigation  of  medicinal  products  for  the  treatment  of  Multiple  Sclerosis' (EMA/CHMP/771815/2011, Rev. 2), the efficacy endpoints studied in the clinical trials which supported

<div style=\"page-break-after: always\"></div>

the MA of the reference product, Tysabri EU and the 'Guideline on similar biological medicinal products containing interferon beta' (EMA/CHMP/BMWP/652000/2010).

The primary endpoint was also endorsed during the Scientific Advice in 2017. For this endpoint, the applicant defined an equivalence margin of 2.1 lesions based on the lower bound of the 95% CI of the pooled  effect  size  estimated  in  a  controlled  trial  of  natalizumab  for  RMS  published  in  2003.  This  is problematic in two ways.

First, the methodological considerations for the derivation of the margin are based on a single study, because  only  one  appropriate  reference  for  the  derivation  of  the  equivalence  margin  in  the  agreed primary endpoint could be sourced. The relatively small sample size in that study (approximately 70 patients per treatment arm) and the fact that in the lack of further data no meta-analysis was possible, introduce uncertainty about the actual effect size of natalizumab over placebo in the selected endpoint. Thus, a more conservative planning of the equivalence margin would have been desirable. Secondly, the mean number of new active lesions over 6 months with natalizumab was only approximately 1 in the cited publication by Miller et al. In light of this low number in new lesions observed with the comparator, the equivalence margin of 2.1 is considered rather wide for the efficacy similarity assessment from a therapeutic perspective, which was derived solely based on methodological considerations on the large effect size of natalizumab with 8.7 lesions (95% CI: 4.14 to 13.35) in the publication of Miller et al. Further, the reference article is dated in 2003. During the last years, the therapeutic management of RMS  has  evolved  towards  a  more  intensive  management  of  inflammatory  activity  so  it  is  highly questionable that 2.1 lesions within 24 weeks could be considered as no relevant from a therapeutic RMS management perspective. However, the actual difference that was observed for the primary endpoint in study PB006-03-01 was close to zero and the 95% CI was narrow and accounted for a difference of less than one lesion (point estimate: 0.17 lesions; 95% CI: -0.613; 0.944). Thus, the primary endpoint would have been met even with a tighter equivalence margin.

It is noted that no biomarker of PD was included in the study. This is striking, since a lot of emphasis has been put on the evaluation of PD markers in the phase 1 study in healthy volunteers. The inclusion of PD markers in the phase 3 study would have allowed to draw conclusions on the robustness and validity of the respective markers by comparison of the response in healthy subjects and patients.

From the methodological view, several issues concerning the randomisation procedure were identified. One of those issues pertains to the applied method of dynamic allocation per se and its potential for type-1-error inflation. The applicant provided details on the methodology, but uncertainty still persists as  regards  a  potential  inflation  due  to  the  specific  situation  resulting  from  complex  randomisation methodology and erroneous stratification. However, from an assessment perspective it is considered very unlikely that the impact is of a magnitude that altered general study conclusions, and is therefore not considered finally relevant for the conclusion on biosimilarity. Another area for further assessment is about potential implications arising from misinterpretation of stratification data which lead to erroneous stratification  during  randomisation.  However,  additional  sensitivity  analyses  corroborated  that  the influence of stratification errors was negligible and did not change study conclusions.

The definition of the analysis sets is considered adequate. In general, the statistical methods chosen for descriptive  as  well  as  inferential  analyses  are  considered  suitable.  The  use  of  negative  binomial regression analysis for the comparative primary efficacy evaluation of lesion count data is endorsed.

## Efficacy data and additional analyses

A total of 265 patients were randomized. Of those, 264 patients were treated with study drug (131 and 133 patients in the PB006 and Tysabri groups, respectively). 93.6% of the enrolled patients completed the primary study period of 24 weeks and 90.5% completed the entire study. Discontinuation due to adverse events accounted for 4.5% overall and was twice as abundant in the PB006 group compared to

<div style=\"page-break-after: always\"></div>

the Tysabri group. Baseline characteristics as well as medical history (including MS disease history) were well balanced between groups.

Misclassification of the three stratification factors was discovered on two occasions; first, after database lock but still during the study (26 cases) and later after finalization of the CSR for a total of 62 cases. The errors were distributed across all 3 stratification factors (absence/presence of GdE lesions, presence of T2 lesions, and JCV status). A root cause analysis and impact assessment were conducted. According to the applicant, this analysis revealed that even with 23% of patients mis-stratified, the imbalance of strata was low and there was no significant impact on the primary analysis. In some strata, however, the relationship between the two groups flipped and the impact on the analysis is not entirely clear. This issue  is  discussed  further  below  for  the  primary  efficacy  analysis.  Given  the  late  discovery  of  the misclassification of the three stratification factors, the applicant was asked to discuss any impact on the study results. It was affirmed that there was no significant impact of the misclassification of the three stratification  factors on the study results. The treatment arms ended up being well-balanced for the corrected strata and the sensitivity analysis performed using the corrected strata confirms the primary analysis.  Most  importantly,  it  was  affirmed  that  no  inclusion  of  subjects  with  JCV  index  &gt;1.5  had occurred.

The analysis of the primary endpoint was the cumulative number of new active lesions over 24 weeks. The primary analysis was based on the PP Population and demonstrated similarity between the test and reference product based on the pre-specified equivalence margin.

Subsequently, sensitivity analyses were conducted to account for the errors in stratification and the GCP related findings.

The first sensitivity analysis was conducted using corrected stratification variables for all 62 patients, who had been misclassified. From this model, a 95%-CI is obtained showing a width being 20% of the width of the CI resulting from the original model using faulty stratification data. The potential prognostic impact of the stratification variables was not substantially altered by using the corrected stratification factors, and the stratification factor absence/presence of GdE lesions was found to have an influence on the cumulative number of new active lesion in both models. The change in the point estimate and CI was shown to be caused by few influential outlying values. When re-conducting the primary efficacy analysis as a sensitivity analysis by excluding all patient data from site 7002, where the routine quality assessment revealed questionable data integrity, similar results to the original primary analysis were obtained. The CI was larger due to the lower sample size, but still within the pre-specified margins. Finally, after correction for stratification and excluding site 7002, the primary outcome also demonstrated a small 95% CI well within the pre-specified margin. The primary outcome measure was distinctly lower than 1 and positive in all analyses, meaning that the number of new lesions was slightly lower for PB006 than the reference product.

While sensitivity analyses were conducted on the primary efficacy endpoint to account for the impact of stratification correction and exclusion of one study centre, no such data were presented for the secondary endpoints.  Upon  request,  the  applicant  affirmed  that  the  primary  efficacy  endpoint  as  well  as  the secondary efficacy endpoints based on MRI readings were not affected by the GCP issue encountered at site 7002. EDSS was pointed out as the only efficacy or safety parameter that may have been affected by  the  inconsistencies  encountered  at  site  7002.  The  applicant  has  re-run  the  analyses  for  EDSS endpoints excluding all 17 patients from site 7002 demonstrating very similar results as in the overall analysis.

Generally, the result of the primary analysis is supported by the results of the secondary analyses.

Most  of  the  secondary  efficacy  parameters  displayed  similar  results  between  treatments.  In  some parameters,  numerically  lower  numbers  were  observed  for  PB006.  This  was  the  case  for  the  mean

<div style=\"page-break-after: always\"></div>

cumulative number of new active lesions, the number of new active lesions per MRI scan, and new active lesions at Week 48, and the mean cumulative number of new/enlarging T2-weighted lesions.

The number of disease relapse, on the other hand, was larger in the PB006 group compared to the reference product. Over 24 weeks there were 12 relapses in the PB006 group compared to 9 cases in the Tysabri group, corresponding to an ARR of 0.206 and 0.152, respectively. Over 48 weeks the number of relapses was 20 and 12 for PB006 and Tysabri, respectively, and the ARR was 0.174 as compared to 0.133.

Overall, less new active lesions and less T2-weighted lesions were observed after treatment with PB006 as compared to Tysabri. However, this trend was not reflected in the relapse rate, which was higher in the PB006 group as compared to Tysabri, although it is acknowledged that the overall number of relapses over 48 weeks was low in both treatment arms in study PB006-03-01, with 18 (13.7%) of patients having one relapse and 1 patient (0.8%) having two relapses in the PB006 and 12 (11.7%) of patients in the EU-Tysabri group having one relapse. Interpretation is slightly hampered by the fact the 131 and 133 patients began treatment in the PB006 and Tysabri arm, respectively, whereas 131 and 103 patients continued treatment through week 48 due to the fact that 30 patients were switched from Tysabri to PB006  after  24  weeks.  For  better  comparison,  the  applicant  provided  ARR  data  obtained  with  the originator. According to the Tysabri product information, ARR was 0.281 versus 0.805 for Tysabri and placebo, respectively, after one year. This shows that the relapse rate observed in study PB006-03-01 (0.174 and 0.133 for PB006 and Tysabri, respectively) is in line with the published data on Tysabri.

Further,  the  proportion  of  patients  who  received  methylprednisolone  as  rescue  therapy  was  similar between treatment groups.

EDSS scores were similar between treatment groups. The mean change from baseline was minimal and similar in both treatment groups at 24 weeks and at 48 weeks.

In order to assess the impact of COVID-19 on safety and efficacy of the study the following was done:

- Study discontinuations and protocol deviations due to COVID-19 were summarized
- Demography data for confirmed COVID-19 patients were summarized
- Protocol deviations due to COVID-19 were summarized by country

·  A  sensitivity  analysis  was  considered  to  be  performed  on  the  pre-COVID  PP  population.  Multiple imputation should be performed for this population. Sensitivity analysis should be done for the primary endpoint using imputed data for this population.

The  applicant  explained  that  this  sensitivity  analysis  was  not  conducted  because  the  pre-COVID  PP population and the PP population were identical.

## 2.6.7. Conclusions on the clinical efficacy

From the presented data on efficacy, biosimilarity between the PB006 and EU-Tysabri can be concluded.

## 2.6.8. Clinical safety

The assessment of safety in the PB006 clinical program was focused on the comparison of PB006 to Tysabri. Safety data with PB006 were collected in studies PB006-01-02, PB006-01-03 and PB006-03-01. These safety data are presented by study, i.e., no integrated analysis was performed, due to the different study designs, populations and doses administered.

<div style=\"page-break-after: always\"></div>

The principal safety data for PB006 and comparative safety data with Tysabri is derived from the pivotal, Phase 1, single-dose study in 450 healthy subjects (PB006-01-03) and the pivotal Phase 3, multipledose study in 264 RRMS patients (PB006-03-01) treated for up to 48 weeks. In both studies, safety analyses were based on the SAF, defined as all subjects who received at least one dose of study drug. Subjects were analysed as treated. In the Phase 3 study PB006-03-01, additional safety analyses were performed for the SSW population, defined as patients who received at least one infusion of study drug after the time point of re-randomization.

Similar procedures for assessing safety were followed in the Phase 1 study PB006-01-03 and the Phase 3 study PB006-03-01. In addition to evaluation of AEs, SAEs and AEs leading to discontinuation, adverse events  of  special  interest  (AESIs)  were  defined  for  study  PB006-03-01.  Both  studies  included  an assessment of ECG, vital signs and physical examination.

In study PB006-01-03, AEs were reported from start of intervention until the end of study Visit (Day 85). In  study  PB006-03-01,  AEs  were  reported  from  screening  until  Week  48/  end  of  study  or  Early Discontinuation visit.

In both studies, safety monitoring included an assessment of neurological symptoms which could be suggestive of PML, and both studies included a PML follow-up visit 6 months after the last dose of study drug to monitor for AEs suggestive of PML.

For  study  PB006-03-01,  PML,  JCV  granule  cell  neuronopathy,  opportunistic  infections,  liver  injury, hypersensitivity, encephalitis, meningitis, and acute retinal necrosis were defined as AESIs, based on the known safety profile of Tysabri.

## 2.6.8.1. Patient exposure

Overall, PB006 was administered to 159 healthy subjects as single dose (for 149 of these subjects at 3 mg/kg, and for 10 of these subjects at 300 mg), and to 161 patients with RRMS as multiple doses of 300 mg in 4-weekly intervals.

Tysabri (US-Tysabri or EU-Tysabri) was administered to 337 healthy subjects as single dose (1 to 6 mg/kg), and EU-Tysabri was administered to 133 patients with RRMS as multiple doses of 300 mg in 4weekly intervals.

## Study PB006-01-02

This was a single-dose study with PB006 in healthy male and female subjects. A total of 68 subjects were  screened,  and  10  of  these  were  enrolled  and  received  a  single  IV  dose  of  300  mg  PB006 (administered over 60 minutes). All 10 subjects completed the study as per protocol, and comprised the SAF population.

## Study PB006-01-03

This was a single dose study with PB006, EU-Tysabri and US-Tysabri in healthy male and female subjects. A total of 453 subjects were randomized (150, 152 and 151 in the PB006, EU-Tysabri and US-Tysabri groups, respectively). Three of the randomized subjects were not dosed with study drug. One subject did not receive study drug due to an error in the pharmacy (only diluent was infused); one subject was not dosed due to a vasovagal reaction prior to dosing; one subject was not dosed due to problems with venous access. Thus, 149, 151 and 150 subjects received a single IV dose of 3 mg/kg PB006, EU-Tysabri and US-Tysabri, respectively, and comprised the SAF population.

On 16 Mar 2020, study enrolment was temporarily held due to COVID-19. At this time 16 subjects completed the study (3 received 3 mg/kg PB006, 5 received 3 mg/kg EU-Tysabri, and 8 received 3

<div style=\"page-break-after: always\"></div>

mg/kg US-Tysabri), and were included in the Pre-stop Safety Set. The other 434 subjects completed the study after the study halt or were enrolled after restart of the study and were included in the Post-stop Safety Set.

A total of 438 subjects completed the study, 145, 148 and 145 in the PB006, EU-Tysabri and US-Tysabri groups, respectively. No subject discontinued the study due to an AE).

All subjects in the SAF population received the full dose of study drug. In 4 subjects, the infusion was temporarily interrupted (e.g., due to problems with the flow of infusion; not due to AEs.

For PB006, the lowest dose administered was 156 mg natalizumab and the highest dose administered was 274 mg natalizumab. For EU-Tysabri, the lowest dose administered was 150.3 mg natalizumab and the highest dose administered was 276.1 mg natalizumab. For US- Tysabri, the lowest dose administered was 151.3 mg natalizumab and the highest dose administered was 275.6 mg natalizumab.

## Study PB006-03-01

This was a multiple-dose study in RRMS patients. Study drug (PB006 or EU-Tysabri) was administered as 300 mg IV infusion, in 4-week intervals, for a total of 12 infusions.

A total of 265 patients were randomized, 132 patients to treatment with PB006 and 133 patients to treatment  with  EU-Tysabri.  One  patient  randomized  to  the  PB006  group  withdrew  consent  prior  to receiving study drug. Thus, 264 patients overall were treated with study drug, i.e., 131 and 133 patients in the PB006 and EU-Tysabri groups, respectively. After 24 weeks of treatment, 30 patients from the EU-Tysabri group were switched to treatment with PB006 for the remaining treatment period. Thus, the total number of patients treated with PB006 at any time during the study was 161.

Patient disposition by primary randomization was similar for the 2 treatment groups, as summarized for the full analysis set (FAS; identical to the SAF population with regard to patient numbers) in

<div style=\"page-break-after: always\"></div>

Table 44: Patient disposition, by primary randomization in study PB006-03-01 (FAS population)

|                                                    | PB006 N=131 n (%)   | EU-Tysabri N=133 n (%)   | Total N=264 n (%)   |
|----------------------------------------------------|---------------------|--------------------------|---------------------|
| Completed primary period (24 weeks)                | 122 (93.1)          | 125 (94.0)               | 247 (93.6)          |
| Study drug discon�nued in primary period - Reason: | 9 (6.9)             | 8 (6.0)                  | 17 (6.4)            |
| Subject withdrawal of consent                      | 2 (1.5)             | 4 (3.0)                  | 6 (2.3)             |
| Inves�gator / sponsor decision                     | 0                   | 0                        | 0                   |
| Adverse events                                     | 6 (4.6)             | 3 (2.3)                  | 9 (3.4)             |
| COVID-19 related                                   | 0                   | 0                        | 0                   |
| Pregnancy                                          | 0                   | 0                        | 0                   |
| Non-compliance                                     | 0                   | 0                        | 0                   |
| Lost to follow-up                                  | 0                   | 0                        | 0                   |
| Lack of efficacy                                   | 0                   | 0                        | 0                   |
| Other                                              | 1 (0.8)             | 1 (0.8)                  | 2 (0.8)             |
| Re-randomized at week 24                           |                     | (94.0)                   | 125 (47.3)          |
|                                                    |                     | 125                      |                     |
| -to remain on EU-Tysabri                           |                     | 95 (71.4)                | 95 (36.0)           |
| -to switch to PB006                                |                     | 30 (22.6)                | 30 (11.4)           |
| Completed study (48 weeks)                         |                     |                          |                     |
|                                                    | 117 (89.3)          | 122 (91.7)               | 239 (90.5)          |
| Study drug discon�nued - Reason:                   | 14 (10.7)           | 11 (8.3)                 | 25 (9.5)            |
| Subject withdrawal of consent                      | 3 (2.3)             | 6 (4.5)                  | 9 (3.4)             |
| Inves�gator / sponsor decision                     | 2 (1.5)             | 0                        | 2 (0.8)             |
| Adverse events*                                    | 8 (6.1)             | 4 (3.0)                  | 12 (4.5)            |
| COVID-19 related                                   | 0                   | 0                        | 0                   |
| Pregnancy                                          | 0                   | 0                        | 0                   |
| Non-compliance                                     | 0                   | 0                        | 0                   |
| Lost to follow-up                                  | 0                   | 0                        | 0                   |
| Lack of efficacy                                   | 0                   | 0                        | 0                   |
| Other                                              | 1 (0.8)             | 1 (0.8)                  | 2 (0.8)             |

AE=adverse event, COVID-19=coronavirus disease 2019, eCRF=electronic case report form, FAS=full analysis set, N=Number of patients in treatment group, n=number of patients with specified event/reason.

Note: The 48-week summary comprises the full study period, including the first 24 weeks.

Note: End of Study eCRF page was only filled-in during the treatment period.

*Except for one patient discontinuing due to COVID-19 (unrelated), all AEs leading to discontinuation were assessed as at least possibly related to study drug

A total of 247 patients (93.6%) completed the 24-week primary treatment period, 122 (93.1%) in the PB006 group and 125 (94.0%) in the EU-Tysabri group. The percentage of patients who prematurely discontinued study drug in the 24-week period was similar in the PB006 and EU-Tysabri groups (6.9% versus 6.0%). Six patients (4.6%) in the PB006 group prematurely discontinued due to an AE, compared with 3 patients (2.3%) in the EU-Tysabri group.

At Week 24, all 125 patients in the EU-Tysabri group who had completed the primary treatment period were re-randomized. Of these, 30 patients were switched to treatment with PB006 for the remaining treatment period, and 95 patients remained on EU-Tysabri and were thus treated with EU-Tysabri for the entire study.

Of the 30 patients in the switch group, 29 patients (96.7%) completed the study, and 1 patient (3.3%) discontinued due to AE. Of the 95 patients who remained in the EU-Tysabri group, 93 patients (97.9%) completed the study and 2 patients (2.1%) discontinued (both due to withdrawal of consent).

## 2.6.8.2. Adverse events

## Study PB006-01-02

Treatment-emergent  adverse  events  were  reported  in  8  subjects  (80%),  and  study  drug  related treatment emergent AEs (TEAEs) were reported in 6 subjects (60%). In all subjects, TEAEs were mild or

<div style=\"page-break-after: always\"></div>

moderate, and no severe TEAEs were reported. No SAEs, fatal AEs or AEs leading to discontinuation occurred in the study.

Most  commonly  reported  TEAEs  were  in  the  system  organ  class  (SOCs)  general  disorders  and administration site conditions (80%) and nervous system disorders (50%). On the preferred term (PT) level, most common were headache (5 subjects, 50%), and catheter site pain, fatigue and injection site haematoma (2 subjects each, 20%). All other TEAEs were reported in 1 subject each.

Of  the  6  subjects  (60%)  who  experienced  at  least  1  study  drug-related  TEAE,  the  most  commonly reported was headache (5 subjects, 50%). The remaining event was fatigue (1 subject, 10%).

## Study PB006-01-03

In  this  single-dose,  healthy  subject  study,  AE  frequencies  were  similar  across  the  3  groups. Approximately two-thirds of subjects in each group reported any TEAE, while in 34-37% of subjects across groups, study drug-related TEAEs occurred. No fatal TEAEs occurred. SAEs were reported for 2 subjects (1.3%; 6 SAEs overall) treated with US-Tysabri, while no SAEs occurred in the other 2 groups. No subject reported TEAEs leading to study drug discontinuation.

Table 45: Overall summary of AEs in study PB006-01-03 (SAF population)

|                                                  | Number of subjects (%)                           | Number of subjects (%)   | Number of subjects (%)   | Number of subjects (%)   |
|--------------------------------------------------|--------------------------------------------------|--------------------------|--------------------------|--------------------------|
|                                                  | PB006 3 mg/kg N=149                              | EU-Tysabri 3 mg/kg N=151 | US-Tysabri 3 mg/kg N=150 | Total N=450              |
| Any TEAE                                         | 103 (69.1)                                       | 102 (67.5)               | 98 (65.3)                | 303 (67.3)               |
| Any related TEAE                                 | 55 (36.9)                                        | 52 (34.4)                | 52 (34.4)                | 159 (35.3)               |
| Any treatment-emergent SAE                       | 0                                                | 0                        | 2 (1.3)                  | 2 (0.4)                  |
| Any severe TEAE                                  | 0                                                | 0                        | 1 (0.7)                  | 1 (0.2)                  |
| Any TEAE leading to study drug discontinuation 0 | Any TEAE leading to study drug discontinuation 0 | 0                        | 0                        | 0                        |
| Fatal TEAE                                       | 0                                                | 0                        | 0                        | 0                        |

SAE=serious adverse event, SAF=safety population, TEAE=treatment-emergent adverse event.

TEAEs occurring in &gt;1% of subjects in any treatment group are presented by SOC and PT in table below.

Table 46: TEAEs by SOC and PT in &gt;1% of subjects in any treatment group in study PB006-01-03 (SAF population)

|                                                      | Number of subjects (%)   | Number of subjects (%)   | Number of subjects (%)   | Number of subjects (%)   |
|------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| System organ class Preferred term                    | PB006 N=149              | EU-Tysabri N=151         | US-Tysabri N=150         | Total N=450              |
| Any event                                            | 103 (69.1)               | 102 (67.5)               | 98 (65.3)                | 303 (67.3)               |
| Nervous system disorders                             | 48 (32.2)                | 50 (33.1)                | 45 (30.0)                | 143 (31.8)               |
| Headache                                             | 44 (29.5)                | 44 (29.1)                | 39 (26.0)                | 127 (28.2)               |
| Dizziness                                            | 4 (2.7)                  | 4 (2.6)                  | 3 (2.0)                  | 11 (2.4)                 |
| Paraesthesia                                         | 1 (0.7)                  | 3 (2.0)                  | 1 (0.7)                  | 5 (1.1)                  |
| Somnolence                                           | 0                        | 1 (0.7)                  | 2 (1.3)                  | 3 (0.7)                  |
| Migraine                                             | 2 (1.3)                  | 0                        | 0                        | 2 (0.4)                  |
| General disorders and administration site conditions | 50 (33.6)                | 47 (31.1)                | 44 (29.3)                | 141 (31.3)               |
| Injection site reaction                              | 32 (21.5)                | 30 (19.9)                | 27 (18.0)                | 89 (19.8)                |
| Fatigue                                              | 9 (6.0)                  | 7 (4.6)                  | 3 (2.0)                  | 19 (4.2)                 |
| Vessel puncture site reaction                        | 2 (1.3)                  | 4 (2.6)                  | 7 (4.7)                  | 13 (2.9)                 |
| Catheter site related reaction                       | 3 (2.0)                  | 5 (3.3)                  | 3 (2.0)                  | 11 (2.4)                 |
| Infusion site reaction                               | 6 (4.0)                  | 2 (1.3)                  | 1 (0.7)                  | 9 (2.0)                  |
| Pyrexia                                              | 3 (2.0)                  | 1 (0.7)                  | 0                        | 4 (0.9)                  |

<div style=\"page-break-after: always\"></div>

| System organ class                              | Number of subjects (%)   | Number of subjects (%)   | Number of subjects (%)   | Number of subjects (%)   |
|-------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Preferred term                                  | PB006 N=149              | EU-Tysabri N=151         | US-Tysabri N=150         | Total N=450              |
| Gastrointestinal disorders                      | 23 (15.4)                | 26 (17.2)                | 28 (18.7)                | 77 (17.1)                |
| Nausea                                          | 6 (4.0)                  | 12 (7.9)                 | 9 (6.0)                  | 27 (6.0)                 |
| Diarrhoea                                       | 5 (3.4)                  | 4 (2.6)                  | 4 (2.7)                  | 13 (2.9)                 |
| Abdominal pain                                  | 3 (2.0)                  | 2 (1.3)                  | 7 (4.7)                  | 12 (2.7)                 |
| Toothache                                       | 3 (2.0)                  | 2 (1.3)                  | 2 (1.3)                  | 7 (1.6)                  |
| Infections and infestations                     | 26 (17.4)                | 25 (16.6)                | 21 (14.0)                | 72 (16.0)                |
| Nasopharyngitis                                 | 8 (5.4)                  | 9 (6.0)                  | 7 (4.7)                  | 24 (5.3)                 |
| Upper respiratory tract infection               | 6 (4.0)                  | 4 (2.6)                  | 2 (1.3)                  | 12 (2.7)                 |
| COVID-19                                        | 5 (3.4)                  | 2 (1.3)                  | 4 (2.7)                  | 11 (2.4)                 |
| Cystitis                                        | 0                        | 3 (2.0)                  | 1 (0.7)                  | 4 (0.9)                  |
| Ear infection                                   | 0                        | 3 (2.0)                  | 0                        | 3 (0.7)                  |
| Musculoskeletal and connective tissue disorders | 10 (6.7)                 | 21 (13.9)                | 12 (8.0)                 | 43 (9.6)                 |
| Back pain                                       | 4 (2.7)                  | 5 (3.3)                  | 5 (3.3)                  | 14 (3.1)                 |
| Myalgia                                         | 4 (2.7)                  | 5 (3.3)                  | 1 (0.7)                  | 10 (2.2)                 |
| Arthralgia                                      | 0                        | 4 (2.6)                  | 3 (2.0)                  | 7 (1.6)                  |
| Respiratory, thoracic and mediastinal disorders | 13 (8.7)                 | 10 (6.6)                 | 12 (8.0)                 | 35 (7.8)                 |
| Oropharyngeal pain                              | 9 (6.0)                  | 5 (3.3)                  | 3 (2.0)                  | 17 (3.8)                 |
| Epistaxis                                       | 2 (1.3)                  | 0                        | 4 (2.7)                  | 6 (1.3)                  |
| Cough                                           | 1 (0.7)                  | 3 (2.0)                  | 1 (0.7)                  | 5 (1.1)                  |
| Injury, poisoning and procedural complications  | 9 (6.0)                  | 6 (4.0)                  | 13 (8.7)                 | 28 (6.2)                 |
| Arthropod bite                                  | 4 (2.7)                  | 3 (2.0)                  | 0                        | 7 (1.6)                  |
| Skin and subcutaneous tissue disorders          | 5 (3.4)                  | 7 (4.6)                  | 9 (6.0)                  | 21 (4.7)                 |
| Metabolism and nutrition disorders              | 3 (2.0)                  | 5 (3.3)                  | 3 (2.0)                  | 11 (2.4)                 |
| Decreased appetite                              | 3 (2.0)                  | 4 (2.6)                  | 3 (2.0)                  | 10 (2.2)                 |
| Reproductive system and breast disorders        | 4 (2.7)                  | 1 (0.7)                  | 6 (4.0)                  | 11 (2.4)                 |
| Dysmenorrhoea                                   | 3 (2.0)                  | 1 (0.7)                  | 2 (1.3)                  | 6 (1.3)                  |
| Renal and urinary disorders                     | 2 (1.3)                  | 4 (2.6)                  | 4 (2.7)                  | 10 (2.2)                 |
| Dysuria                                         | 2 (1.3)                  | 3 (2.0)                  | 2 (1.3)                  | 7 (1.6)                  |
| Psychiatric disorders                           | 4 (2.7)                  | 3 (2.0)                  | 2 (1.3)                  | 9 (2.0)                  |
| Vascular disorders                              | 3 (2.0)                  | 2 (1.3)                  | 4 (2.7)                  | 9 (2.0)                  |
| Eye disorders                                   | 3 (2.0)                  | 2 (1.3)                  | 3 (2.0)                  | 8 (1.8)                  |
| Ear and labyrinth disorders                     | 1 (0.7)                  | 4 (2.6)                  | 2 (1.3)                  | 7 (1.6)                  |

N=number of subjects in group, n=number of subjects with event, PT=preferred term, SAF=safety population, SOC=system organ class, TEAE=treatment-emergent adverse event.

Sorted by descending frequency in the 'total' column.

Most frequently reported were TEAEs in the SOCs nervous system disorders (30-33% across groups) and general disorders and administration site conditions (29-34% across groups).

On the PT level, most frequently reported was headache (26-30% across groups), followed by AEs related to the injection/infusion, with PTs of injection site reaction (18-21% across groups), infusion site reaction (1-4% across groups), vessel puncture site reaction (1-5% across groups), and catheter site related reaction (2-3% across groups).

<div style=\"page-break-after: always\"></div>

While on the level of individual PTs the frequencies may have slightly differed between the PB006, the EU-Tysabri and US-Tysabri groups, the overall AE profile was considered to be similar between the 3 groups.

## COVID-19 analyses

Eleven AEs of COVID-19 and 1 AE of asymptomatic COVID-19 were reported. All cases were mild with the outcome being recovered. No subjects were withdrawn due to COVID-19. None of the subjects had received a COVID-19 vaccination.

The overall frequency of AEs was similar in the Pre-stop and the Post-stop Safety Set (62.5% versus 67.5% of subjects overall). Generally, the limited number of subjects in the Pre-stop Set (N=16) does not allow a meaningful comparison to the Post-stop Set.

## Adverse events related to study drug

TEAEs related to study drug are presented by SOC and PT in table below. The percentage of subjects with related TEAEs was similar in all 3 treatment groups.

Table 47: Study drug-related TEAEs by SOC and PT in study PB006-01-03 (SAF population)

| System organ class                                   | Number of subjects (%)   | Number of subjects (%)   | Number of subjects (%)   | Number of subjects (%)   |
|------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Preferred term                                       | PB006 N=149              | EU-Tysabri N=151         | US-Tysabri N=150         | Total N=450              |
| Any event                                            | 55 (36.9)                | 52 (34.4)                | 52 (34.7)                | 159 (35.3)               |
| General disorders and administration site conditions | 32 (21.5)                | 32 (21.2)                | 29 (19.3)                | 93 (20.7)                |
| Injection site reaction                              | 27 (18.1)                | 28 (18.5)                | 24 (16.0)                | 79 (17.6)                |
| Infusion site reaction                               | 4 (2.7)                  | 1 (0.7)                  | 1 (0.7)                  | 6 (1.3)                  |
| Chills                                               | 1 (0.7)                  | 2 (1.3)                  | 0                        | 3 (0.7)                  |
| Chest discomfort                                     | 1 (0.7)                  | 0                        | 1 (0.7)                  | 2 (0.4)                  |
| Injection site induration                            | 0                        | 1 (0.7)                  | 1 (0.7)                  | 2 (0.4)                  |
| Asthenia                                             | 0                        | 0                        | 1 (0.7)                  | 1 (0.2)                  |
| Fatigue                                              | 0                        | 1 (0.7)                  | 0                        | 1 (0.2)                  |
| Malaise                                              | 0                        | 0                        | 1 (0.7)                  | 1 (0.2)                  |
| Pyrexia                                              | 0                        | 1 (0.7)                  | 0                        | 1 (0.2)                  |
| Nervous system disorders                             | 20 (13.4)                | 23 (15.2)                | 18 (12.0)                | 61 (13.6)                |
| Headache                                             | 19 (12.8)                | 20 (13.2)                | 16 (10.7)                | 55 (12.2)                |
| Dizziness                                            | 1 (0.7)                  | 2 (1.3)                  | 2 (1.3)                  | 5 (1.1)                  |
| Paraesthesia                                         | 0                        | 1 (0.7)                  | 1 (0.7)                  | 2 (0.4)                  |
| Somnolence                                           | 0                        | 1 (0.7)                  | 1 (0.7)                  | 2 (0.4)                  |
| Migraine                                             | 1 (0.7)                  | 0                        | 0                        | 1 (0.2)                  |
| Gastrointestinal disorders                           | 5 (3.4)                  | 10 (6.6)                 | 9 (6.0)                  | 24 (5.3)                 |
| Nausea                                               | 4 (2.7)                  | 8 (5.3)                  | 6 (4.0)                  | 18 (4.0)                 |
| Diarrhoea                                            | 0                        | 2 (1.3)                  | 1 (0.7)                  | 3 (0.7)                  |
| Abdominal pain upper                                 | 0                        | 0                        | 1 (0.7)                  | 1 (0.2)                  |
| Aphthous ulcer                                       | 1 (0.7)                  | 0                        | 0                        | 1 (0.2)                  |
| Dry mouth                                            | 0                        | 0                        | 1 (0.7)                  | 1 (0.2)                  |
| Dyspepsia                                            | 0                        | 0                        | 1 (0.7)                  | 1 (0.2)                  |
| Gastrointestinal sounds abnormal                     | 0                        | 0                        | 1 (0.7)                  | 1 (0.2)                  |
| Mouth ulceration                                     | 0                        | 1 (0.7)                  | 0                        | 1 (0.2)                  |
| Retching                                             | 0                        | 1 (0.7)                  | 0                        | 1 (0.2)                  |
| Stomatitis                                           | 0                        | 0                        | 1 (0.7)                  | 1 (0.2)                  |

<div style=\"page-break-after: always\"></div>

|                                                        | Number of subjects (%)                                 | Number of subjects (%)   | Number of subjects (%)   | Number of subjects (%)   |
|--------------------------------------------------------|--------------------------------------------------------|--------------------------|--------------------------|--------------------------|
| System organ class Preferred term                      | PB006 N=149                                            | EU-Tysabri N=151         | US-Tysabri N=150         | Total N=450              |
| Infections and infestations                            | 4 (2.7)                                                | 5 (3.3)                  | 4 (2.7)                  | 13 (2.9)                 |
| Upper respiratory tract infection                      | 1 (0.7)                                                | 3 (2.0)                  | 1 (0.7)                  | 5 (1.1)                  |
| Oral herpes                                            | 1 (0.7)                                                | 0                        | 1 (0.7)                  | 2 (0.4)                  |
| Bronchitis                                             | 1 (0.7)                                                | 0                        | 0                        | 1 (0.2)                  |
| Fungal infection                                       | 0                                                      | 0                        | 1 (0.7)                  | 1 (0.2)                  |
| Gastroenteritis                                        | 1 (0.7)                                                | 0                        | 0                        | 1 (0.2)                  |
| Influenza                                              | 1 (0.7)                                                | 0                        | 0                        | 1 (0.2)                  |
| Nasal herpes                                           | 0                                                      | 0                        | 1 (0.7)                  | 1 (0.2)                  |
| Nasopharyngitis                                        | 0                                                      | 1 (0.7)                  | 0                        | 1 (0.2)                  |
| Urinary tract infection                                | 0                                                      | 1 (0.7)                  | 0                        | 1 (0.2)                  |
| Metabolism and nutrition disorders                     | 1 (0.7)                                                | 2 (1.3)                  | 2 (1.3)                  | 5 (1.1)                  |
| Decreased appetite                                     | 1 (0.7)                                                | 2 (1.3)                  | 2 (1.3)                  | 5 (1.1)                  |
| Musculoskeletal and connective tissue disorders 0      | Musculoskeletal and connective tissue disorders 0      | 4 (2.6)                  | 0                        | 4 (0.9)                  |
| Muscle spasms                                          | 0                                                      | 1 (0.7)                  | 0                        | 1 (0.2)                  |
| Muscle tightness                                       | 0                                                      | 1 (0.7)                  | 0                        | 1 (0.2)                  |
| Musculoskeletal stiffness                              | 0                                                      | 1 (0.7)                  | 0                        | 1 (0.2)                  |
| Myalgia                                                | 0                                                      | 1 (0.7)                  | 0                        | 1 (0.2)                  |
| Respiratory, thoracic and mediastinal 2 (1.3)          | Respiratory, thoracic and mediastinal 2 (1.3)          | 1 (0.7)                  | 1 (0.7)                  | 4 (0.9)                  |
| disorders Oropharyngeal pain                           | 2 (1.3)                                                | 1 (0.7)                  | 0                        | 3 (0.7)                  |
| Nasal congestion                                       | 0                                                      | 0                        | 1 (0.7)                  | 1 (0.2)                  |
| Rhinorrhoea                                            | 0                                                      | 0                        | 1 (0.7)                  | 1 (0.2)                  |
| Skin and subcutaneous disorders                        | tissue 0                                               | 1 (0.7)                  | 3 (2.0)                  | 4 (0.9)                  |
| Pruritus                                               | 0                                                      | 0                        | 2 (1.3)                  | 2 (0.4)                  |
| Erythema                                               | 0                                                      | 0                        | 1 (0.7)                  | 1 (0.2)                  |
| Rash macular                                           | 0                                                      | 0                        | 1 (0.7)                  | 1 (0.2)                  |
| Rash maculo-papular                                    | 0                                                      | 0                        | 1 (0.7)                  | 1 (0.2)                  |
| Rash morbilliform                                      | 0                                                      | 1 (0.7)                  | 0                        | 1 (0.2)                  |
| Injury, poisoning and procedural complications 1 (0.7) | Injury, poisoning and procedural complications 1 (0.7) | 1 (0.7)                  | 0                        | 2 (0.4)                  |
| Contusion                                              | 0                                                      | 1 (0.7)                  | 0                        | 1 (0.2)                  |
| Infusion related reaction                              | 1 (0.7)                                                | 0                        | 0                        | 1 (0.2)                  |
| Reproductive system and disorders                      | breast 1 (0.7)                                         | 0                        | 0                        | 1 (0.2)                  |
| Dysmenorrhoea                                          | 1 (0.7)                                                | 0                        | 0                        | 1 (0.2)                  |
| Vascular disorders                                     | 1 (0.7)                                                | 0                        | 0                        | 1 (0.2)                  |
| Hot flush                                              | 1 (0.7)                                                | 0                        | 0                        | 1 (0.2)                  |

N=number of subjects in group, n=number of subjects with event, PT=preferred term, SAF=safety population, SOC=system organ class, TEAE=treatment-emergent adverse event.

Sorted by descending frequency in the 'total' column.

Most frequently reported were TEAEs in the SOCs general disorders and administration site conditions (19-21% across groups), and nervous system disorders (12-15% across groups).

On the PT level, most frequently reported were AEs related to the injection/infusion, with PTs of injection site  reaction  (16-19% across groups), infusion site reaction (1-3% across groups) and injection site induration  (0-0.7%  across  groups).  Other  frequently  reported  AEs  were  headache  (11-13%  across groups) and nausea (3-5% across groups). All other events were reported in no more than 3 subjects per treatment group.

<div style=\"page-break-after: always\"></div>

While on the level of individual PTs the frequencies may have slightly differed between the PB006, the EU-Tysabri and US-Tysabri groups, the AE profile of study drug-related TEAEs was overall considered to be similar between the 3 groups.

In the majority of subjects, TEAEs were mild. Mild TEAEs were reported in 65.6% of subjects, with similar frequencies across groups. Moderate TEAEs were reported in 6.0% of subjects, with similar frequencies across groups. Only 1 subject, treated with US-Tysabri, reported severe TEAEs, acute kidney injury and ureterolithiasis. Both were unlikely related to study drug, and the outcome was reported as recovered.

## Study PB006-03-01

In  this  multiple-dose  study  in  RRMS  patients,  AE  frequencies  were  generally  balanced  across  the  3 groups.

Table 48: Overall summary of AEs, by treatment sequence in study PB006-03-01 (SAF population)

|                                                          | Number of patients (%)   | Number of patients (%)                         | Number of patients (%)   |
|----------------------------------------------------------|--------------------------|------------------------------------------------|--------------------------|
|                                                          | PB006 300 mg N=131       | PB006 after switch from EU-Tysabri 300 mg N=30 | EU-Tysabri 300 mg N=103  |
| Any TEAE                                                 | 85 (64.9)                | 22 (73.3)                                      | 71 (68.9)                |
| Any related TEAE                                         | 31 (23.7)                | 8 (26.7)                                       | 22 (21.4)                |
| Any TEAE of grade 3 or higher*                           | 4 (3.1)                  | 0                                              | 1 (1.0)                  |
| Any treatment-emergent SAE                               | 3 (2.3)                  | 0                                              | 2 (1.9)                  |
| Any treatment-emergent related SAE                       | 0                        | 0                                              | 0                        |
| Any TEAE of special interest                             | 6 (4.6)                  | 2 (6.7)                                        | 6 (5.8)                  |
| Any TEAE leading to temporary study drug interruption    | 4 (3.1)                  | 2 (6.7)                                        | 1 (1.0)                  |
| Any TEAE leading to permanent study drug discontinuation | 8 (6.1)                  | 1 (3.3)                                        | 3 (2.9)                  |
| Any TEAE leading to withdrawal from study**              | 0                        | 0                                              | 0                        |
| Fatal TEAE                                               | 0                        | 0                                              | 0                        |

SAE=serious adverse event, SAF=safety population, PML= progressive multifocal leukoencephalopathy, TEAE=treatment-emergent adverse event.

*No grade 4 or 5 AEs were reported.

**A TEAE was considered to be leading to withdrawal from study only if the patient did not proceed to PML follow-up because of this event.

Overall, the percentages of patients with TEAEs and with TEAEs related to study drug were similar across groups. Approximately two-thirds of patients in each group reported any TEAE, while in approximately 25% of patients in each group, study drug-related TEAEs occurred. Few patients experienced TEAEs of Grade 3, AESIs, SAEs, or AEs leading to study drug discontinuation or withdrawal. The frequencies of TEAEs of Grade 3 and of TEAEs leading to discontinuations were numerically higher in the PB006 group than in the other groups. However, these differences were not considered to be clinically meaningful.

<div style=\"page-break-after: always\"></div>

Table 49: Overall summary of AEs from Week 24 to 48 in study PB006-03-01 (SSW population)

|                                                          | Number of patients (%)        | Number of patients (%)                         | Number of patients (%)             |
|----------------------------------------------------------|-------------------------------|------------------------------------------------|------------------------------------|
|                                                          | PB006 continuing 300 mg N=131 | PB006 after switch from EU-Tysabri 300 mg N=30 | EU-Tysabri continuing 300 mg N=103 |
| Any TEAE                                                 | 55 (45.1)                     | 15 (50.0)                                      | 42 (44.2)                          |
| Any related TEAE                                         | 6 (4.9)                       | 3 (10.0)                                       | 7 (7.4)                            |
| Any TEAE of Grade 3 or higher*                           | 2 (1.6)                       | 0                                              | 1 (1.1)                            |
| Any treatment-emergent SAE                               | 2 (1.6)                       | 0                                              | 2 (2.1)                            |
| Any treatment-emergent related SAE                       | 1 (0.8)                       | 0                                              | 0                                  |
| Any TEAE of special interest                             | 1 (0.8)                       | 1 (3.3)                                        | 2 (2.1)                            |
| Any TEAE leading to temporary study drug interruption    | 3 (2.5)                       | 2 (6.7)                                        | 1 (1.1)                            |
| Any TEAE leading to permanent study drug discontinuation | 2 (1.6)                       | 0                                              | 0                                  |
| Any TEAE leading to withdrawal from study**              | 0                             | 0                                              | 0                                  |
| Fatal TEAE                                               | 0                             | 0                                              | 0                                  |

SAE=serious adverse event, SAF=safety population, PML= progressive multifocal leukoencephalopathy, TEAE=treatment-emergent adverse event.

*No Grade 4 or 5 AEs were reported.

**A TEAE was considered to be leading to withdrawal from study only if the patient did not proceed to PML follow-up because of this event.

TEAEs are presented for the overall treatment period of 48 weeks in 2 formats in the clinical study report, 1) by preceding treatment and 2) by treatment sequence.

In the tables by preceding treatment, the PB006 group includes AE data from the 131 patients who were initially randomized to PB006 plus data from the 30 patients who switched from the EU-Tysabri group to PB006 after 24 weeks (for the remaining 24-week treatment period); thus, the number of patients for this group is 161. In addition, AE data are presented for the 133 patients who were randomized to and treated with EU-Tysabri. In this presentation AEs occurring in patients after switching from EU-Tysabri to PB006 were counted for both treatment arms. In order to account for the varying exposure in the 2 groups, event rates per 100 patient years (PY) are included.

In the tables by treatment sequence, AE data are presented for the 131 patients who received only PB006 for the full treatment period, the 30 patients who switched from EU-Tysabri to PB006, and the 103 patients who received only EU-Tysabri for the full treatment period (i.e., not including the patients who switched to PB006 after 24 weeks).

In order to account for the varying exposure in the 3 treatment groups, event rates per 100 PY are included.

In the present report, the focus lies on the evaluation of events by treatment sequence.

Table 50: TEAEs by SOC and PT, by treatment sequence, in &gt;1% of patients in any group in study PB006-03-01 (SAF population)

/

|                                        | PB006 300 mg N=131        | from 300 N=30                      | PB006 after EU-Tysabri mg   | switch                          | EU-Tysabri 300 mg N=103      |                                 |       |
|----------------------------------------|---------------------------|------------------------------------|-----------------------------|---------------------------------|------------------------------|---------------------------------|-------|
| System organ class Preferred term      | Patients with event n (%) | Number of events /rate per 100 PY* | Patients with event n (%)   | Number events /rate per 100 PY* | of Patients with event n (%) | Number events /rate per 100 PY* | of    |
| Any event                              | 85 (64.9)                 | 221 192.34                         | / 22 (73.3)                 | 60 219.62                       | / 71 (68.9)                  | 176 194.65                      | /     |
| Blood and lymphatic system disorders 5 | (3.8)                     | 5 / 4.35                           | 0                           | 0 / 0                           | 4 (3.9)                      | 4 / 4.42                        |       |
| Anaemia                                | 4 (3.1)                   | 4 / 3.48                           | 0                           | 0 / 0                           | 0                            | 0 / 0                           |       |
| Ear and labyrinth disorders            | 2 (1.5)                   | 2 / 1.74                           | 0                           | 0 / 0                           | 0                            | 0 / 0                           |       |
| Gastrointestinal disorders             | 13 (9.9)                  | 17 / 14.80                         | 0                           | 0 / 0                           | 12 (11.7)                    | 18 /                            | 19.91 |

<div style=\"page-break-after: always\"></div>

| System organ class                                                                                           | PB006 300 mg N=131                                                                                           | PB006 300 mg N=131                                                                                           | PB006 after switch from EU-Tysabri                                                                           | PB006 after switch from EU-Tysabri                                                                           | EU-Tysabri 300 mg                                                                                            | EU-Tysabri 300 mg                                                                                            |
|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|
| Preferred term                                                                                               | Patients with event n (%)                                                                                    | Number events /rate per                                                                                      | N=30 of Patients with event n (%)                                                                            | Number events /rate per 100 PY*                                                                              | N=103 of Patients with event n (%)                                                                           | Number of events /rate per 100 PY*                                                                           |
| Diarrhoea                                                                                                    | 3 (2.3)                                                                                                      | 100 PY* 3 / 2.61                                                                                             | 0                                                                                                            | 0 / 0                                                                                                        | 5 (4.9)                                                                                                      | 5 / 5.53                                                                                                     |
| Nausea                                                                                                       |                                                                                                              |                                                                                                              |                                                                                                              |                                                                                                              |                                                                                                              |                                                                                                              |
|                                                                                                              | 4 (3.1)                                                                                                      | 4 / 3.48                                                                                                     | 0                                                                                                            | 0 / 0                                                                                                        | 3 (2.9)                                                                                                      | 3 / 3.32                                                                                                     |
| Constipation                                                                                                 | 2 (1.5)                                                                                                      | 2 / 1.74                                                                                                     | 0                                                                                                            | 0 / 0                                                                                                        | 3 (2.9)                                                                                                      | 4 / 4.42                                                                                                     |
| Vomiting                                                                                                     | 0                                                                                                            | 0 / 0                                                                                                        | 0                                                                                                            | 0 / 0                                                                                                        | 2 (1.9)                                                                                                      | 2 / 2.21                                                                                                     |
| General disorders and administration site conditions 13 (9.9) 14 / 12.18 7 (23.3) 8 / 29.28 5 (4.9) 5 / 5.53 | General disorders and administration site conditions 13 (9.9) 14 / 12.18 7 (23.3) 8 / 29.28 5 (4.9) 5 / 5.53 | General disorders and administration site conditions 13 (9.9) 14 / 12.18 7 (23.3) 8 / 29.28 5 (4.9) 5 / 5.53 | General disorders and administration site conditions 13 (9.9) 14 / 12.18 7 (23.3) 8 / 29.28 5 (4.9) 5 / 5.53 | General disorders and administration site conditions 13 (9.9) 14 / 12.18 7 (23.3) 8 / 29.28 5 (4.9) 5 / 5.53 | General disorders and administration site conditions 13 (9.9) 14 / 12.18 7 (23.3) 8 / 29.28 5 (4.9) 5 / 5.53 | General disorders and administration site conditions 13 (9.9) 14 / 12.18 7 (23.3) 8 / 29.28 5 (4.9) 5 / 5.53 |
| Asthenia                                                                                                     | 5 (3.8)                                                                                                      | 5 / 4.35                                                                                                     | 1 (3.3)                                                                                                      | 1 / 3.66                                                                                                     | 1 (1.0)                                                                                                      | 1 / 1.11                                                                                                     |
| Fatigue                                                                                                      | 5 (3.8)                                                                                                      | 5 / 4.35                                                                                                     | 0                                                                                                            | 0 / 0                                                                                                        | 1 (1.0)                                                                                                      | 1 / 1.11                                                                                                     |
| Pyrexia                                                                                                      | 1 (0.8)                                                                                                      | 1 / 0.87                                                                                                     | 1 (3.3)                                                                                                      | 1 / 3.66                                                                                                     | 3 (2.9)                                                                                                      | 3 / 3.32                                                                                                     |
| Hyperthermia                                                                                                 | 2 (1.5)                                                                                                      | 2 / 1.74                                                                                                     | 1 (3.3)                                                                                                      | 1 / 3.66                                                                                                     | 0                                                                                                            | 0 / 0                                                                                                        |
| Feeling hot                                                                                                  | 0                                                                                                            | 0 / 0                                                                                                        | 2 (6.7)                                                                                                      | 2 / 7.32                                                                                                     | 0                                                                                                            | 0 / 0                                                                                                        |
| Oedema peripheral                                                                                            | 1 (0.8)                                                                                                      | 1 / 0.87                                                                                                     | 1 (3.3)                                                                                                      | 1 / 3.66                                                                                                     | 0                                                                                                            | 0 / 0                                                                                                        |
| Discomfort Infusion site                                                                                     | 0                                                                                                            | 0 / 0                                                                                                        | 1 (3.3)                                                                                                      | 1 / 3.66                                                                                                     | 0 0                                                                                                          | 0 / 0 0 / 0                                                                                                  |
| pain Hepatobiliary disorders                                                                                 | 0 2 (1.5)                                                                                                    | 0 / 0 2 / 1.74                                                                                               | 1 (3.3) 1 (3.3)                                                                                              | 1 / 3.66 1 / 3.66                                                                                            | 1 (1.0)                                                                                                      | 1 / 1.11                                                                                                     |
| Hyperbilirubinaemia                                                                                          | 1 (0.8)                                                                                                      | 1 / 0.87                                                                                                     | 1 (3.3)                                                                                                      | 1 / 3.66                                                                                                     | 0                                                                                                            | 0 / 0                                                                                                        |
| Immune system disorders                                                                                      | 0                                                                                                            | 0 / 0                                                                                                        | 1 (3.3)                                                                                                      | 1 / 3.66                                                                                                     | 0                                                                                                            | 0 / 0                                                                                                        |
| Hypersensitivity                                                                                             | 0                                                                                                            |                                                                                                              |                                                                                                              |                                                                                                              |                                                                                                              |                                                                                                              |
|                                                                                                              |                                                                                                              | 0 / 0                                                                                                        | 1 (3.3)                                                                                                      | 1 / 3.66                                                                                                     | 0                                                                                                            | 0 / 0                                                                                                        |
| Infections and infestations                                                                                  | 39 (29.8)                                                                                                    | 54 / 47.00                                                                                                   | 15 (50.0)                                                                                                    | 19 / 69.55                                                                                                   | 34 (33.0)                                                                                                    | 44 / 48.66                                                                                                   |
| Nasopharyngitis                                                                                              | 11 (8.4)                                                                                                     | 16 / 13.93                                                                                                   | 5 (16.7)                                                                                                     | 5 / 18.30                                                                                                    | 8 (7.8)                                                                                                      | 9 / 9.95                                                                                                     |
| COVID-19                                                                                                     | 11 (8.4)                                                                                                     | 11 / 9.57                                                                                                    | 4 (13.3)                                                                                                     | 4 / 14.64                                                                                                    | 6 (5.8)                                                                                                      | 6 / 6.64                                                                                                     |
| Upper respiratory tract infection                                                                            | 2 (1.5) 1 (0.8)                                                                                              | 2 / 1.74                                                                                                     | 1 (3.3)                                                                                                      | 1 / 3.66 1 / 3.66                                                                                            | 3 (2.9) 3 (2.9)                                                                                              | 3 / 3.32 4 / 4.42                                                                                            |
| Pharyngitis Pneumonia                                                                                        | 3 (2.3)                                                                                                      | 2 / 1.74 3 / 2.61                                                                                            | 1 (3.3) 0                                                                                                    | 0 / 0                                                                                                        | 1 (1.0)                                                                                                      | 1 / 1.11                                                                                                     |
| Respiratory tract                                                                                            | 2 (1.5)                                                                                                      |                                                                                                              |                                                                                                              | 1 / 3.66                                                                                                     | 1 (1.0)                                                                                                      | 1 / 1.11                                                                                                     |
| infection Urinary tract infection                                                                            | 2 (1.5)                                                                                                      | 2 / 1.74                                                                                                     | 1 (3.3) 0                                                                                                    | 0 / 0                                                                                                        | 2 (1.9)                                                                                                      | 3 / 3.32                                                                                                     |
|                                                                                                              | 0                                                                                                            | 2 / 1.74 0 / 0                                                                                               | 1 (3.3)                                                                                                      | 1 / 3.66                                                                                                     | 2 (1.9)                                                                                                      | 3 / 3.32                                                                                                     |
| Bronchitis Cystitis                                                                                          | 2 (1.5)                                                                                                      |                                                                                                              |                                                                                                              | 0 / 0                                                                                                        | 1 (1.0)                                                                                                      | 1 / 1.11                                                                                                     |
| Oral herpes                                                                                                  | 1 (0.8)                                                                                                      | 2 / 1.74                                                                                                     | 0 1 (3.3)                                                                                                    | 1 / 3.66                                                                                                     | 1 (1.0)                                                                                                      | 1 / 1.11                                                                                                     |
|                                                                                                              |                                                                                                              | 1 / 0.87                                                                                                     |                                                                                                              | 1 / 3.66                                                                                                     | 1 (1.0)                                                                                                      |                                                                                                              |
| Rhinitis                                                                                                     | 1 (0.8)                                                                                                      | 1 / 0.87                                                                                                     | 1 (3.3)                                                                                                      | 1 / 3.66                                                                                                     | 0                                                                                                            | 1 / 1.11                                                                                                     |
| Respiratory tract infection viral                                                                            | 1 (0.8)                                                                                                      | 1 / 0.87                                                                                                     | 1 (3.3)                                                                                                      |                                                                                                              |                                                                                                              | 0 / 0                                                                                                        |
| COVID-19 pneumonia Laryngitis                                                                                | 0                                                                                                            | 0 / 0                                                                                                        | 1 (3.3)                                                                                                      | 1 / 3.66                                                                                                     | 0                                                                                                            | 0 / 0                                                                                                        |
| Pyoderma streptococcal                                                                                       | 0                                                                                                            | 0 / 0                                                                                                        | 1 (3.3)                                                                                                      | 1 / 3.66 1 / 3.66                                                                                            | 0 0                                                                                                          | 0 / 0 0 / 0                                                                                                  |
|                                                                                                              | 0                                                                                                            | 0 / 0                                                                                                        | 1 (3.3)                                                                                                      | 1 / 3.66                                                                                                     |                                                                                                              |                                                                                                              |
| Injury, poisoning and                                                                                        | 2 (1.5)                                                                                                      | 4 / 3.48                                                                                                     | 1 (3.3)                                                                                                      |                                                                                                              | 3 (2.9)                                                                                                      | 3 / 3.32                                                                                                     |
| procedural complications Contusion                                                                           | 0                                                                                                            | 0 / 0                                                                                                        | 1 (3.3)                                                                                                      | 1 / 3.66                                                                                                     | 1 (1.0)                                                                                                      | 1 / 1.11                                                                                                     |
| Investigations                                                                                               | 8 (6.1)                                                                                                      | 11 / 9.57                                                                                                    | 2 (6.7)                                                                                                      | 3 / 10.98                                                                                                    | 9 (8.7)                                                                                                      | 11 / 12.17                                                                                                   |
| Weight decreased Alanine                                                                                     | 2 (1.5) 2 (1.5)                                                                                              | 2 / 1.74 2 / 1.74                                                                                            | 1 (3.3) 0                                                                                                    | 1 / 3.66 0 / 0                                                                                               | 3 (2.9) 1 (1.0)                                                                                              | 3 / 3.32 2 / 2.21                                                                                            |
| aminotransferase increased                                                                                   |                                                                                                              | 1 / 0.87                                                                                                     |                                                                                                              | 0 / 0                                                                                                        | 2 (1.9)                                                                                                      | 2.21                                                                                                         |
| Blood pressure increased                                                                                     | 1 (0.8) 2 (1.5)                                                                                              |                                                                                                              | 0                                                                                                            |                                                                                                              | 1 (1.0)                                                                                                      | 2 /                                                                                                          |
| C-reactive protein increased                                                                                 | 1 (0.8)                                                                                                      | 2 / 1.74 1 / 0.87                                                                                            | 0 1 (3.3)                                                                                                    | 0 / 0 2 / 7.32                                                                                               | 0                                                                                                            | 1 / 1.11 0 / 0                                                                                               |
| Gamma-glutamyltransferase increased                                                                          | 1 (0.8)                                                                                                      | 1 / 0.87                                                                                                     | 1 (3.3)                                                                                                      | 1 / 3.66                                                                                                     | 2 (1.9)                                                                                                      | 3 / 3.32                                                                                                     |
| Metabolism and nutrition disorders                                                                           | 0                                                                                                            | 0 / 0                                                                                                        | 1 (3.3)                                                                                                      | 1 / 3.66                                                                                                     | 0 9 (8.7)                                                                                                    | 0 / 0                                                                                                        |
| Hyperlipidaemia Musculoskeletal                                                                              | 17                                                                                                           | 21 /                                                                                                         | 1 (3.3)                                                                                                      | 1 / 3.66                                                                                                     |                                                                                                              | 13 /                                                                                                         |
| and connective tissue disorders                                                                              | (13.0)                                                                                                       | 18.28                                                                                                        |                                                                                                              |                                                                                                              |                                                                                                              | 14.38                                                                                                        |
| Back pain                                                                                                    |                                                                                                              | 7 / 6.09                                                                                                     | 1 (3.3)                                                                                                      | 1 / 3.66                                                                                                     | 3 (2.9)                                                                                                      | 3 / 3.32                                                                                                     |
| Pain in extremity                                                                                            | 7 (5.3) 2 (1.5) 2 (1.5)                                                                                      | 2 / 1.74                                                                                                     | 0                                                                                                            | 0 / 0 0 / 0                                                                                                  | 4 (3.9) 1 (1.0)                                                                                              | 4 / 4.42                                                                                                     |
| Muscle spasms Myalgia                                                                                        | 2 (1.5)                                                                                                      | 2 / 1.74 2 / 1.74                                                                                            | 0 0                                                                                                          | 0 / 0                                                                                                        | 1 (1.0)                                                                                                      | 1 / 1.11 1 / 1.11                                                                                            |
| Neck pain                                                                                                    | 1 (0.8)                                                                                                      | 2 / 1.74                                                                                                     | 0                                                                                                            | 0 / 0                                                                                                        | 2 (1.9)                                                                                                      |                                                                                                              |
| Arthralgia                                                                                                   | 2 (1.5)                                                                                                      | 2 / 1.74                                                                                                     |                                                                                                              | 0 / 0                                                                                                        | 0                                                                                                            | 2 / 2.21 0 / 0                                                                                               |
|                                                                                                              |                                                                                                              |                                                                                                              | 0                                                                                                            | 0 / 0                                                                                                        | 2 (1.9)                                                                                                      | 2 / 2.21                                                                                                     |
| Musculoskeletal stiffness Neoplasms benign,                                                                  | 0                                                                                                            | 0 / 0                                                                                                        | 0                                                                                                            |                                                                                                              |                                                                                                              |                                                                                                              |
| and unspecified (incl                                                                                        | 2 (1.5)                                                                                                      | 2 / 1.74                                                                                                     | 0                                                                                                            | 0 / 0                                                                                                        | 0                                                                                                            | 0 / 0                                                                                                        |
| malignant cysts                                                                                              |                                                                                                              |                                                                                                              |                                                                                                              |                                                                                                              |                                                                                                              |                                                                                                              |
| and polyps) Nervous system disorders 33 (25.2) 48 / 41.78 8 (26.7) 13 / 47.58 24 (23.3) 56 / 61.93           | and polyps) Nervous system disorders 33 (25.2) 48 / 41.78 8 (26.7) 13 / 47.58 24 (23.3) 56 / 61.93           | and polyps) Nervous system disorders 33 (25.2) 48 / 41.78 8 (26.7) 13 / 47.58 24 (23.3) 56 / 61.93           | and polyps) Nervous system disorders 33 (25.2) 48 / 41.78 8 (26.7) 13 / 47.58 24 (23.3) 56 / 61.93           | and polyps) Nervous system disorders 33 (25.2) 48 / 41.78 8 (26.7) 13 / 47.58 24 (23.3) 56 / 61.93           | and polyps) Nervous system disorders 33 (25.2) 48 / 41.78 8 (26.7) 13 / 47.58 24 (23.3) 56 / 61.93           | and polyps) Nervous system disorders 33 (25.2) 48 / 41.78 8 (26.7) 13 / 47.58 24 (23.3) 56 / 61.93           |

<div style=\"page-break-after: always\"></div>

|                                             | PB006 300 mg N=131        |                                    | PB006 after switch from EU-Tysabri 300 mg N=30   | PB006 after switch from EU-Tysabri 300 mg N=30   | EU-Tysabri 300 mg N=103   | EU-Tysabri 300 mg N=103            |
|---------------------------------------------|---------------------------|------------------------------------|--------------------------------------------------|--------------------------------------------------|---------------------------|------------------------------------|
| System organ class Preferred term           | Patients with event n (%) | Number of events /rate per 100 PY* | Patients with event n (%)                        | Number of events /rate per 100 PY*               | Patients with event n (%) | Number of events /rate per 100 PY* |
| Headache                                    | 25 (19.1)                 | 36 / 31.33                         | 4 (13.3)                                         | 5 / 18.30                                        | 19 (18.4)                 | 47 / 51.98                         |
| Dizziness                                   | 3 (2.3)                   | 3 / 2.61                           | 2 (6.7)                                          | 2 / 7.32                                         | 1 (1.0)                   | 2 / 2.21                           |
| Hypoaesthesia                               | 2 (1.5)                   | 2 / 1.74                           | 1 (3.3)                                          | 1 / 3.66                                         | 1 (1.0)                   | 1 / 1.11                           |
| Paraesthesia                                | 1 (0.8)                   | 1 / 0.87                           | 1 (3.3)                                          | 1 / 3.66                                         | 0                         | 0 / 0                              |
| Presyncope                                  | 1 (0.8)                   | 1 / 0.87                           | 1 (3.3)                                          | 1 / 3.66                                         | 0                         | 0 / 0                              |
| Tension headache                            | 1 (0.8)                   | 2 / 1.74                           | 1 (3.3)                                          | 3 / 10.98                                        | 0                         | 0 / 0                              |
| Psychiatric disorders                       | 7 (5.3)                   | 10 / 8.70                          | 4 (13.3)                                         | 4 / 14.64                                        | 2 (1.9)                   | 2 / 2.21                           |
| Depression                                  | 3 (2.3)                   | 3 / 2.61                           | 3 (10.0)                                         | 3 / 10.98                                        | 1 (1.0)                   | 1 / 1.11                           |
| Insomnia                                    | 4 (3.1)                   | 6 / 5.22                           | 0                                                | 0 / 0                                            | 1 (1.0)                   | 1 / 1.11                           |
| Sleep disorder                              | 0                         | 0 / 0                              | 1 (3.3)                                          | 1 / 3.66                                         | 0                         | 0 / 0                              |
| Renal and urinary disorders                 | 1 (0.8)                   | 1 / 0.87                           | 3 (10.0)                                         | 4 / 14.64                                        | 2 (1.9)                   | 4 / 4.42                           |
| Leukocyturia                                | 0                         | 0 / 0                              | 1 (3.3)                                          | 1 / 3.66                                         | 1 (1.0)                   | 1 / 1.11                           |
| Dysuria                                     | 0                         | 0 / 0                              | 1 (3.3)                                          | 1 / 3.66                                         | 0                         | 0 / 0                              |
| Haematuria                                  | 0                         | 0 / 0                              | 1 (3.3)                                          | 1 / 3.66                                         | 0                         | 0 / 0                              |
| Urinary retention                           | 0                         | 0 / 0                              | 1 (3.3)                                          | 1 / 3.66                                         | 0                         | 0 / 0                              |
| Reproductive system breast disorders        | and 3 (2.3)               | 3 / 2.61                           | 0                                                | 0 / 0                                            | 1 (1.0)                   | 1 / 1.11                           |
| Respiratory, thoracic mediastinal disorders | and 10 (7.6)              | 11 / 9.57                          | 1 (3.3)                                          | 1 / 3.66                                         | 4 (3.9)                   | 5 / 5.53                           |
| Oropharyngeal pain                          | 5 (3.8)                   | 5 / 4.35                           | 0                                                | 0 / 0                                            | 3 (2.9)                   | 3 / 3.32                           |
| Rhinorrhoea                                 | 1 (0.8)                   | 1 / 0.87                           | 1 (3.3)                                          | 1 / 3.66                                         | 0                         | 0 / 0                              |
| Skin and subcutaneous tissue disorders      | 8 (6.1)                   | 10 / 8.70                          | 2 (6.7)                                          | 2 / 7.32                                         | 3 (2.9)                   | 4 / 4.42                           |
| Urticaria                                   | 2 (1.5)                   | 2 / 1.74                           | 0                                                | 0 / 0                                            | 1 (1.0)                   | 1 / 1.11                           |
| Erythema                                    | 1 (0.8)                   | 1 / 0.87                           | 1 (3.3)                                          | 1 / 3.66                                         | 0                         | 0 / 0                              |
| Hyperhidrosis                               | 1 (0.8)                   | 1 / 0.87                           | 1 (3.3)                                          | 1 / 3.66                                         | 0                         | 0 / 0                              |
| Pruritus                                    | 2 (1.5)                   | 2 / 1.74                           | 0                                                | 0 / 0                                            | 0                         | 0 / 0                              |
| Vascular disorders                          | 4 (3.1)                   | 4 / 3.48                           | 1 (3.3)                                          | 1 / 3.66                                         | 0                         | 0 / 0                              |
| Hypotension                                 | 2 (1.5)                   | 2 / 1.74                           | 0                                                | 0 / 0                                            | 0                         | 0 / 0                              |
| Hypertension                                | 0                         | 0 / 0                              | 1 (3.3)                                          | 1 / 3.66                                         | 0                         | 0 / 0                              |

N=number of patients in group, PT=preferred term, PY=patient year, SAF=safety population, SOC=system organ class, TEAE=treatment-emergent adverse event.

Note: *Patient years calculated as the sum of (last day of follow-up - first day of exposure + 1)/365.25 for all patients in group. Adverse events were summarized according to the randomized study drug sequence.

With regard to AE data by treatment sequence, the percentage of patients with TEAEs was similar in the PB006, switch and the EU-Tysabri groups (64.9, 73.3 and 68.9%), with event rates per 100 PY of 192.34, 219.62 and 194.65, respectively.

Most frequently reported in all groups were TEAEs in the SOCs infections and infestations (29.8, 50.0 and 33.0% in PB006, switch and EU-Tysabri groups, respectively) and nervous system disorders (25.2, 26.7 and 23.3% in PB006, switch and EU-Tysabri groups, respectively). On the PT level, most frequently reported was headache (19.1, 13.3 and 18.4% in PB006, switch and EU-Tysabri groups, respectively), followed by nasopharyngitis (8.4, 16.7 and 7.8% in PB006, switch and EU-Tysabri groups, respectively) and COVID-19 (8.4, 13.3 and 5.8% in PB006, switch and EU-Tysabri groups, respectively). While on the level  of  individual  PTs  the  frequencies  slightly  differed  between  the  PB006  and  EU-Tysabri  groups, sometimes favoring Tysabri and sometimes favoring PB006, the AE profile was overall considered to be similar between the 2 groups. In the switch group, the AE frequencies tended to be higher compared to the other 2 groups. However, when interpreting the data, the limited group size needs to be considered.

A summary of TEAEs after the switch of a subset of patients from EU-Tysabri to PB006 (i.e., time period from Week 24 to 48) is provided for the SSW population. The frequencies of TEAEs were similar in the PB006  continuing,  switch,  and  EU-Tysabri  continuing  groups  (45.1,  50.0  and  44.2%,  respectively). Comparing the AE data for patients switching from EU-Tysabri to PB006 versus patients continuing on EU-Tysabri no clinically meaningful differences were observed.

<div style=\"page-break-after: always\"></div>

## Adverse events related to study drug

Table 51: Study drug-related TEAEs by SOC and PT, by treatment sequence in study PB006-03-01 (SAF population)

|                                                            | PB006 300 mg N=131               | PB006 300 mg N=131               | PB006 after switch from EU-Tysabri 300 mg   | PB006 after switch from EU-Tysabri 300 mg   | EU-Tysabri 300 mg                | EU-Tysabri 300 mg                  |
|------------------------------------------------------------|----------------------------------|----------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|------------------------------------|
| System organ class Preferred term                          | Patients with event n (%)        | Number of events /rate per       | Patients with event n (%)                   | Number events /rate per                     | of Patients with event n (%)     | Number of events /rate per 100 PY* |
|                                                            |                                  | 100 PY*                          |                                             | 100 PY*                                     |                                  |                                    |
| Any event                                                  |                                  | 53 / 46.13                       | 8 (26.7)                                    | 15 / 54.90                                  | 22 (21.4)                        | 51 / 56.40                         |
|                                                            | 31 (23.7)                        |                                  |                                             |                                             |                                  |                                    |
| Blood and lymphatic system                                 | 1 (0.8)                          | 1 / 0.87                         | 0                                           | 0 / 0                                       | 2 (1.9)                          | 2 / 2.21                           |
| disorders Lymphadenitis                                    | 0                                | 0 / 0                            | 0                                           | 0 / 0                                       | 1 (1.0)                          | 1 / 1.11                           |
| Lymphopenia                                                | 1 (0.8)                          | 1 / 0.87                         | 0                                           | 0 / 0                                       | 0                                | 0 / 0                              |
| Neutropenia                                                | 0                                | 0 / 0                            | 0                                           | 0 / 0                                       | 1 (1.0)                          | 1 / 1.11                           |
| Eye disorders                                              | 0                                | 0 / 0                            | 0                                           | 0 / 0                                       | 1 (1.0)                          | 1 / 1.11                           |
| Ocular discomfort                                          | 0                                | 0 / 0                            | 0                                           | 0 / 0                                       | 1 (1.0)                          | 1 / 1.11                           |
| Gastrointestinal disorders                                 | 1 (0.8)                          | 1 / 0.87                         | 0                                           | 0 / 0                                       | 4 (3.9)                          | 5 / 5.53                           |
| Nausea                                                     | 1 (0.8)                          | 1 / 0.87                         | 0                                           | 0 / 0                                       | 2 (1.9)                          | 2 / 2.21                           |
| Constipation                                               | 0                                | 0 / 0                            | 0                                           | 0 / 0                                       | 1 (1.0)                          | 2 / 2.21                           |
| Vomiting                                                   | 0                                | 0 / 0                            | 0                                           | 0 / 0                                       | 1 (1.0)                          | 1 / 1.11                           |
| General disorders and                                      | 6 (4.6)                          | 6 / 5.22                         | 4 (13.3)                                    | 4 / 14.64                                   | 3 (2.9)                          | 3 / 3.32                           |
| administration site conditions 2                           | administration site conditions 2 | administration site conditions 2 | administration site conditions 2            | administration site conditions 2            | administration site conditions 2 | administration site conditions 2   |
| Hyperthermia                                               | (1.5)                            | 2 / 1.74                         | 1 (3.3)                                     | 1 / 3.66                                    | 0                                | 0 / 0                              |
| Pyrexia                                                    | 1 (0.8)                          | 1 / 0.87                         | 0                                           | 0 / 0                                       | 2 (1.9)                          | 2 / 2.21                           |
| Asthenia                                                   | 2 (1.5)                          | 2 / 1.74                         | 0                                           | 0 / 0                                       | 0                                | 0 / 0                              |
| Fatigue                                                    | 1 (0.8)                          | 0.87                             |                                             | 0 / 0                                       | 1 (1.0)                          | 1 / 1.11                           |
| Discomfort                                                 | 0                                | 1 /                              | 0 1 (3.3)                                   | 1 / 3.66                                    | 0                                | 0 / 0                              |
| Feeling hot                                                | 0                                | 0 / 0 0 / 0                      | 1 (3.3)                                     | 1 / 3.66                                    | 0                                | 0 / 0                              |
| Infusion site pain                                         | 0                                | 0 / 0                            | 1 (3.3)                                     | 1 / 3.66                                    | 0                                | 0 / 0                              |
| Hepatobiliary disorders                                    | 1 (0.8)                          | 1 / 0.87                         | 1 (3.3)                                     | 1 / 3.66                                    | 0                                | 0 / 0                              |
| Hyperbilirubinaemia                                        | 1 (0.8)                          | 1 / 0.87                         | 1 (3.3)                                     | 1 / 3.66                                    | 0                                | 0 / 0                              |
| Immune system disorders                                    | 0                                | 0 / 0                            | 1 (3.3)                                     | 1 / 3.66                                    | 0                                | 0 / 0                              |
| Hypersensitivity                                           | 0                                | 0 / 0                            | 1 (3.3)                                     | 1 / 3.66                                    | 0                                | 0 / 0                              |
| Infections and infestations                                | 6 (4.6)                          | 7 / 6.09                         | 3 (10.0)                                    | 3 / 10.98                                   | 9 (8.7)                          | 10 / 11.06                         |
| Cystitis                                                   | 2 (1.5)                          | 2 / 1.74                         | 0                                           | 0 / 0                                       | 1 (1.0)                          | 1 / 1.11                           |
| Oral herpes                                                | 1 (0.8)                          | 1 / 0.87                         | 1 (3.3)                                     | 1 / 3.66                                    | 1 (1.0)                          | 1 / 1.11                           |
| Pharyngitis                                                | 1 (0.8)                          | 1 / 0.87                         | 0                                           | 0 / 0                                       | 2 (1.9)                          | 2 / 2.21                           |
| Herpes simplex                                             | 1 (0.8)                          | 1 / 0.87                         | 0                                           | 0 / 0                                       | 1 (1.0)                          | 1 / 1.11                           |
| Bronchitis                                                 | 0                                | 0 / 0                            | 1 (3.3)                                     | 1 / 3.66                                    | 0                                | 0 / 0                              |
| Ear infection                                              | 1 (0.8)                          | 1 / 0.87                         | 0                                           | 0 / 0                                       | 0                                | 0 / 0                              |
| Furuncle                                                   | 0                                | 0 / 0                            | 0                                           | 0 / 0                                       | 1 (1.0)                          | 1 / 1.11                           |
| Laryngitis                                                 | 0                                | 0 / 0                            | (3.3)                                       | 1 / 3.66                                    | 0                                | 0 / 0                              |
| Sinusitis                                                  | 0                                | 0 / 0                            | 1 0                                         | 0 / 0                                       | 1 (1.0)                          | 1 / 1.11                           |
| Tinea versicolour                                          | 1 (0.8)                          | 1 / 0.87                         | 0                                           | 0 / 0                                       | 0                                | 0 / 0                              |
| Urinary tract infection                                    | 0                                | 0 / 0                            | 0                                           | 0 / 0                                       | 1 (1.0)                          | 1 / 1.11                           |
| Urinary tract infection enterococcal                       | 0                                | 0 / 0                            | 0                                           | 0 / 0                                       | 1 (1.0)                          | 1 / 1.11                           |
| Vulvovaginal candidiasis                                   | 0                                | 0 / 0                            | 0                                           | 0 / 0 1 / 3.66                              | 1 (1.0)                          | 1 / 1.11                           |
| Injury, poisoning and procedural complications             | 0                                | 0 / 0                            | 1 (3.3)                                     |                                             | 0                                | 0 / 0                              |
| Contusion                                                  | 0                                | 0 / 0                            | 1 (3.3)                                     | 1 / 3.66                                    | 0                                | 0 / 0                              |
| Investigations                                             | 4 (3.1)                          | 7 / 6.09                         | 1 (3.3)                                     | 2 / 7.32                                    | 3 (2.9)                          | 4 / 4.42                           |
| Gamma-glutamyltransferase                                  | 1 (0.8)                          | 1 / 0.87                         | 1 (3.3)                                     | 2 / 7.32                                    | 0                                | 0 / 0                              |
| increased Weight decreased                                 | 1 (0.8)                          | 1 / 0.87                         | 0                                           | 0 / 0                                       | 1 (1.0)                          | 1 / 1.11                           |
| Alanine aminotransferase increased                         | 1 (0.8)                          | 1 / 0.87                         | 0                                           | 0 / 0                                       | 0                                | 0 / 0                              |
| Aspartate aminotransferase increased                       | 0                                | 0 / 0                            | 0                                           | 0 / 0                                       | 1 (1.0)                          | 1 / 1.11                           |
| Bilirubin conjugated increased                             | (0.8)                            | 1 / 0.87                         | 0                                           | 0 / 0                                       | 0                                | 0 / 0                              |
|                                                            | 1                                |                                  |                                             |                                             |                                  |                                    |
| Blood triglycerides increased C-reactive protein increased | 1 (0.8) 1 (0.8)                  | 2 / 1.74                         | 0                                           | 0 / 0                                       | 0                                | 0 / 0 0 / 0                        |
| Lymphocyte count increased                                 | 0                                | 1 / 0.87 0 / 0                   | 0 0                                         | 0 / 0 0 / 0                                 | 0 1 (1.0)                        | 1 / 1.11                           |
| White blood cell count increased                           | 0                                | 0 / 0                            | 0                                           | 0 / 0                                       | 1 (1.0)                          | 1 / 1.11                           |

<div style=\"page-break-after: always\"></div>

|                                                 | PB006 300 mg N=131        |                                    | PB006 after switch from EU-Tysabri 300 mg N=30   | PB006 after switch from EU-Tysabri 300 mg N=30   | EU-Tysabri 300 mg N=103   | EU-Tysabri 300 mg N=103            |
|-------------------------------------------------|---------------------------|------------------------------------|--------------------------------------------------|--------------------------------------------------|---------------------------|------------------------------------|
| System organ class Preferred term               | Patients with event n (%) | Number of events /rate per 100 PY* | Patients with event n (%)                        | Number of events /rate per 100 PY*               | Patients with event n (%) | Number of events /rate per 100 PY* |
| Musculoskeletal and connective tissue disorders | 4 (3.1)                   | 4 / 3.48                           | 0                                                | 0 / 0                                            | 2 (1.9)                   | 3 / 3.32                           |
| Muscle spasms                                   | 2 (1.5)                   | 2 / 1.74                           | 0                                                | 0 / 0                                            | 1 (1.0)                   | 1 / 1.11                           |
| Myalgia                                         | 1 (0.8)                   | 1 / 0.87                           | 0                                                | 0 / 0                                            | 1 (1.0)                   | 1 / 1.11                           |
| Arthralgia                                      | 1 (0.8)                   | 1 / 0.87                           | 0                                                | 0 / 0                                            | 0                         | 0 / 0                              |
| Back pain                                       | 0                         | 0 / 0                              | 0                                                | 0 / 0                                            | 1 (1.0)                   | 1 / 1.11                           |
| Nervous system disorders                        | 10 (7.6)                  | 13 / 11.31                         | 1 (3.3)                                          | 1 / 3.66                                         | 2 (1.9)                   | 18 / 19.91                         |
| Headache                                        | 7 (5.3)                   | 9 / 7.83                           | 0                                                | 0 / 0                                            | 2 (1.9)                   | 16 / 17.70                         |
| Dizziness                                       | 2 (1.5)                   | 2 / 1.74                           | 1 (3.3)                                          | 1 / 3.66                                         | 1 (1.0)                   | 2 / 2.21                           |
| Dysgeusia                                       | 1 (0.8)                   | 1 / 0.87                           | 0                                                | 0 / 0                                            | 0                         | 0 / 0                              |
| Trigeminal neuralgia                            | 1 (0.8)                   | 1 / 0.87                           | 0                                                | 0 / 0                                            | 0                         | 0 / 0                              |
| Psychiatric disorders                           | 2 (1.5)                   | 2 / 1.74                           | 0                                                | 0 / 0                                            | 1 (1.0)                   | 1 / 1.11                           |
| Insomnia                                        | 2 (1.5)                   | 2 / 1.74                           | 0                                                | 0 / 0                                            | 1 (1.0)                   | 1 / 1.11                           |
| Renal and urinary disorders                     | 0                         | 0 / 0                              | 0                                                | 0 / 0                                            | 1 (1.0)                   | 1 / 1.11                           |
| Leukocyturia                                    | 0                         | 0 / 0                              | 0                                                | 0 / 0                                            | 1 (1.0)                   | 1 / 1.11                           |
| Reproductive system and breast disorders        | 1 (0.8)                   | 1 / 0.87                           | 0                                                | 0 / 0                                            | 0                         | 0 / 0                              |
| Menorrhagia                                     | 1 (0.8)                   | 1 / 0.87                           | 0                                                | 0 / 0                                            | 0                         | 0 / 0                              |
| Skin and subcutaneous tissue disorders          | 6 (4.6)                   | 7 / 6.09                           | 2 (6.7)                                          | 2 / 7.32                                         | 2 (1.9)                   | 3 / 3.32                           |
| Urticaria                                       | 2 (1.5)                   | 2 / 1.74                           | 0                                                | 0 / 0                                            | 1 (1.0)                   | 1 / 1.11                           |
| Erythema                                        | 1 (0.8)                   | 1 / 0.87                           | 1 (3.3)                                          | 1 / 3.66                                         | 0                         | 0 / 0                              |
| Hyperhidrosis                                   | 1 (0.8)                   | 1 / 0.87                           | 1 (3.3)                                          | 1 / 3.66                                         | 0                         | 0 / 0                              |
| Pruritus                                        | 2 (1.5)                   | 2 / 1.74                           | 0                                                | 0 / 0                                            | 0                         | 0 / 0                              |
| Alopecia                                        | 1 (0.8)                   | 1 / 0.87                           | 0                                                | 0 / 0                                            | 0                         | 0 / 0                              |
| Angioedema                                      | 0                         | 0 / 0                              | 0                                                | 0 / 0                                            | 1 (1.0)                   | 1 / 1.11                           |
| Rash                                            | 0                         | 0 / 0                              | 0                                                | 0 / 0                                            | 1 (1.0)                   | 1 / 1.11                           |
| Vascular disorders                              | 3 (2.3)                   | 3 / 2.61                           | 0                                                | 0 / 0                                            | 0                         | 0 / 0                              |
| Hypotension                                     | 2 (1.5)                   | 2 / 1.74                           | 0                                                | 0 / 0                                            | 0                         | 0 / 0                              |
| Blood pressure fluctuation                      | 1 (0.8)                   | 1 / 0.87                           | 0                                                | 0 / 0                                            | 0                         | 0 / 0                              |

N=number of patients in group, PT=preferred term, PY=patient year, SAF=safety population, SOC=system organ class, TEAE=treatment-emergent adverse event.

Note: *Patient years calculated as the sum of (last day of follow-up - first day of exposure + 1)/365.25 for all patients in group. Adverse events were summarized according to the randomized study drug sequence.

With regard to AE data by treatment sequence, the percentage of patients with study drug-related TEAEs was similar in the PB006, switch and the EU-Tysabri group (23.7, 26.7 and 21.4%), with event rates per 100 PY of 46.13, 54.90 and 56.40, respectively.

Most  frequently  reported  in  both  groups  were  study  drug-related  TEAEs  in  the  SOCs  infections  and infestations (4.6, 10.0 and 8.7% in PB006, switch and EU-Tysabri groups, respectively), nervous system disorders  (7.6,  3.3  and  1.9%  in  PB006,  switch  and  EU-Tysabri  groups,  respectively)  and  general disorders  and  administration  site  conditions  (4.6,  13.3  and  2.9%  in  PB006,  switch  and  EU-Tysabri groups, respectively). On the PT level, most frequently reported was headache (5.3, 0 and 1.9% in PB006, switch and EU-Tysabri groups, respectively), followed by dizziness (1.5, 3.3 and 1.0% in PB006, switch and EU-Tysabri groups, respectively). While on the level of individual PTs the frequencies slightly differed between groups, the AE profile was overall considered to be similar between the 3 groups.

With regard to data after the switch (week 24 to 48), the frequencies of study drug-related TEAEs were similar in the PB006 continuing, switch group and EU-Tysabri continuing groups (4.9, 10.0 and 7.4%, respectively). The total number of events in the 3 groups was 6, 3 and 7, respectively. Comparing the AE profile for patients switching from EU-Tysabri to PB006 versus patients continuing on EU-Tysabri no clinically meaningful differences were observed.

## Treatment-emergent adverse events by severity

<div style=\"page-break-after: always\"></div>

No TEAEs of CTCAE grade 4 or 5 were reported. The majority of TEAEs was of CTCAE grade 1 or 2. TEAEs of Grade 3 are summarized by SOC and PT, by treatment sequence in table below.

Table 52: TEAEs of CTCAE grade 3, by treatment sequence in study PB006-03-01 (SAF population)

|                                                 | PB006 N=131               |                                 | PB006 after switch from EU-Tysabri N=30   | PB006 after switch from EU-Tysabri N=30   | EU-Tysabri N=103             |                                 |
|-------------------------------------------------|---------------------------|---------------------------------|-------------------------------------------|-------------------------------------------|------------------------------|---------------------------------|
| System organ class Preferred term               | Patients with event n (%) | Number events /rate per 100 PY* | of Patients with event n (%)              | Number events /rate per 100 PY*           | of Patients with event n (%) | Number events /rate per 100 PY* |
| Any event                                       | 4 (3.1)                   | 4 / 3.48                        | 0                                         | 0 / 0                                     | 1 (1.0)                      | 1 / 1.11                        |
| Investigations                                  | 2 (1.5)                   | 2 / 1.74                        | 0                                         | 0 / 0                                     | 0                            | 0 / 0                           |
| Alanine aminotransferase increased              | 1 (0.8)                   | 1 / 0.87                        | 0                                         | 0 / 0                                     | 0                            | 0 / 0                           |
| Blood triglycerides increased                   | 1 (0.8)                   | 1 / 0.87                        | 0                                         | 0 / 0                                     | 0                            | 0 / 0                           |
| Musculoskeletal and connective tissue disorders | 0                         | 0 / 0                           | 0                                         | 0 / 0                                     | 1 (1.0)                      | 1 / 1.11                        |
| Pain in extremity                               | 0                         | 0 / 0                           | 0                                         | 0 / 0                                     | 1 (1.0)                      | 1 / 1.11                        |
| Respiratory, thoracic and mediastinal disorders | 1 (0.8)                   | 1 / 0.87                        | 0                                         | 0 / 0                                     | 0                            | 0 / 0                           |
| Nasal septum deviation                          | 1 (0.8)                   | 1 / 0.87                        | 0                                         | 0 / 0                                     | 0                            | 0 / 0                           |
| Skin and subcutaneous tissue disorders          | 1 (0.8)                   | 1 / 0.87                        | 0                                         | 0 / 0                                     | 0                            | 0 / 0                           |
| Urticaria                                       | 1 (0.8)                   | 1 / 0.87                        | 0                                         | 0 / 0                                     | 0                            | 0 / 0                           |

N=number of patients in group, PT=preferred term, PY=patient year, SAF=safety population, SOC=system organ class, TEAE=treatment-emergent adverse event. Note: *Patient years calculated as the sum of (last day of follow-up - first day of exposure + 1)/365.25 for all patients in group. Adverse events were summarized according to the randomized study drug sequence.

Treatment-emergent adverse events of CTCAE Grade 3 occurred in few patients (4 patients treated with PB006, 1 patient treated with EU-Tysabri, and no patients in the switch group).

With regard to events in PB006 group, the events alanine aminotransferase (ALT) increased and a nasal septum deviation were both assessed as not related and recovered or recovering. Nasal septum deviation was  serious.  The  event  of  blood  triglycerides  increased  was  assessed  as  probably  related,  with  the outcome being recovered. The event of urticaria was assessed as probably related, with the outcome being recovered. Study drug was discontinued due to this AE.

## 2.6.8.3. Serious adverse event/deaths/other significant events

## Study PB006-01-03

There were no fatal AEs in this study. SAEs were reported for 2 subjects and were unlikely related to study drug (based on investigator assessment) and were resolved within 1 or 2 days.

## Study PB006-03-01

There were no fatal AEs in this study. SAEs were reported for 5 subjects.

All  SAEs  except  for  an  event  of  hypotension  were  not  or  unlikely  related  to  study  drug,  based  on investigator assessment. Hypotension, experienced by one patient in the PB006 group, was assessed as possibly related to study drug, and the patient discontinued due to this SAE. A female (30-50 years of age)  patient  had  an  ongoing  medical  history  of  essential  hypertension.  She  received  a  total  of  12 infusions  of  PB006.  D uring  the  Week 44  infusion,  the  patient  experienced  the  SAE  of  moderate hypotension. (blood pressure decreased to below 70/50 mmHg). After medication, the patient's blood pressure normalized within few minutes, and the event was considered resolved on the same day. The investigator could not rule out infusion-related reaction and considered this event to be an important medical  event.  The  study  drug  was  permanently  discontinued  the  same  day,  and  the  patient  was

<div style=\"page-break-after: always\"></div>

withdrawn from the study on one month later. A causal relationship of the SAE of hypotension to the study drug (PB006) was recorded as possibly related.

## Other significant adverse events

Treatment-emergent adverse events leading to discontinuation occurred in 8 patients in the PB006 group and 4 patients in the EU-Tysabri group, and are presented for the entire treatment period in the following table.

Table 53: TEAEs leading to discontinuation in PB006-03-01

| Treatment group: PB006               | Treatment group: PB006      | Treatment group: PB006      |
|--------------------------------------|-----------------------------|-----------------------------|
| Preferred term                       | Relationship to study drug  | Outcome                     |
| Asthenia                             | Probably related            | Recovered/ resolved         |
| Hyperhidrosis                        | Probably related            | Recovered/ resolved         |
| Blood pressure fluctuation           | Probably related            | Recovered/ resolved         |
| Dizziness                            | Probably related            | Recovered/ resolved         |
| Ear infection                        | Possibly related            | Recovered/ resolved         |
| Herpes simplex                       | Possibly related            | Recovered/ resolved         |
| Trigeminal neuralgia                 | Possibly related            | Recovered/ resolved         |
| COVID-19                             | Not related                 | Recovered/ resolved         |
| Pruritus                             | Possibly related            | Recovered/ resolved         |
| Pruritus#                            | Possibly related            | Recovered/ resolved         |
| Urticaria#                           | Probably related            | Recovered/ resolved         |
| Hypotension                          | Possibly related            | Recovered/ resolved         |
| Urticaria#                           | Possibly related            | Recovered/ resolved         |
| Treatment group: EU-Tysabri          | Treatment group: EU-Tysabri | Treatment group: EU-Tysabri |
| Urinary tract infection enterococcal | Probably related            | Recovered/ resolved         |
| Hypersensitivity#                    | Related                     | Recovered/ resolved         |
| Pharyngitis                          | Possibly related            | Recovered/ resolved         |
| Urticaria#                           | Possibly related            | Recovered/ resolved         |
| Angioedema                           | Possibly related            | Recovered/ resolved         |

#Events occurred on the day of study drug administration.

Except for 1 patient in  the  PB006  group  (who  discontinued  due  to  COVID-19),  all  TEAEs  leading  to discontinuation  were  at  least  possibly  related  to  study  drug.  Most  common  TEAEs  leading  to discontinuation were pruritus and urticaria, which are known and common adverse drug reactions of natalizumab.

## Adverse events of special interest

AESIs were defined in the study protocol based information from the Tysabri label, and included PML, JCV  granule  cell  neuronopathy,  opportunistic  infections,  liver  injury,  hypersensitivity,  encephalitis, meningitis, and ARN. AESIs are provided by treatment sequence in the following table.

<div style=\"page-break-after: always\"></div>

Table 54: Treatment-emergent AESIs by SOC and PT, by treatment sequence in study PB006-03-01 (SAF population)

|                                        | PB006 300 mg N=131        | PB006 300 mg N=131              | PB006 after switch from EU-Tysabri 300 mg N=30   | PB006 after switch from EU-Tysabri 300 mg N=30   | EU-Tysabri 300 mg N=103      | EU-Tysabri 300 mg N=103            |
|----------------------------------------|---------------------------|---------------------------------|--------------------------------------------------|--------------------------------------------------|------------------------------|------------------------------------|
| System organ class Preferred term      | Patients with event n (%) | Number events /rate per 100 PY* | of Patients with event n (%)                     | Number events /rate per 100 PY*                  | of Patients with event n (%) | Number of events /rate per 100 PY* |
| Any event                              | 6 (4.6)                   | 6 / 5.22                        | 2 (6.7)                                          | 2 / 7.32                                         | 6 (5.8)                      | 8 / 8.85                           |
| Immune system disorders                | 0                         | 0 / 0                           | 1 (3.3)                                          | 1 / 3.66                                         | 0                            | 0 / 0                              |
| Hypersensitivity                       | 0                         | 0 / 0                           | 1 (3.3)                                          | 1 / 3.66                                         | 0                            | 0 / 0                              |
| Infections and infestations            | 2 (1.5)                   | 2 / 1.74                        | 1 (3.3)                                          | 1 / 3.66                                         | 5 (4.9)                      | 6 / 6.64                           |
| Oral herpes                            | 1 (0.8)                   | 1 / 0.87                        | 1 (3.3)                                          | 1 / 3.66                                         | 1 (1.0)                      | 1 / 1.11                           |
| Herpes simplex                         | 1 (0.8)                   | 1 / 0.87                        | 0                                                | 0 / 0                                            | 1 (1.0)                      | 1 / 1.11                           |
| Herpes zoster                          | 0                         | 0 / 0                           | 0                                                | 0 / 0                                            | 1 (1.0)                      | 1 / 1.11                           |
| Pharyngitis                            | 0                         | 0 / 0                           | 0                                                | 0 / 0                                            | 1 (1.0)                      | 1 / 1.11                           |
| Urinary tract infection                | 0                         | 0 / 0                           | 0                                                | 0 / 0                                            | 1 (1.0)                      | 1 / 1.11                           |
| Urinary tract infection enterococcal   | 0                         | 0 / 0                           | 0                                                | 0 / 0                                            | 1 (1.0)                      | 1 / 1.11                           |
| Investigations                         | 1 (0.8)                   | 1 / 0.87                        | 0                                                | 0 / 0                                            | 0                            | 0 / 0                              |
| Alanine aminotransferase increased     | 1 (0.8)                   | 1 / 0.87                        | 0                                                | 0 / 0                                            | 0                            | 0 / 0                              |
| Skin and subcutaneous tissue disorders | 3 (2.3)                   | 3 / 2.61                        | 0                                                | 0 / 0                                            | 1 (1.0)                      | 2 / 2.21                           |
| Urticaria                              | 2 (1.5)                   | 2 / 1.74                        | 0                                                | 0 / 0                                            | 1 (1.0)                      | 1 / 1.11                           |
| Angioedema                             | 0                         | 0 / 0                           | 0                                                | 0 / 0                                            | 1 (1.0)                      | 1 / 1.11                           |
| Pruritus                               | 1 (0.8)                   | 1 / 0.87                        | 0                                                | 0 / 0                                            | 0                            | 0 / 0                              |

AESI=adverse  event  of  special  interest,  N=number  of  patients  in  group,  PT=preferred  term,  PY=patient  year,  SAF=safety  population,  SOC=system  organ  class, TEAE=treatment-emergent adverse event.

Note: *Patient years calculated as the sum of (last day of follow-up - first day of exposure + 1)/365.25 for all patients in group. Adverse events were summarized according to the randomized study drug sequence.

Most commonly reported were events of herpes (with PTs oral herpes, herpes simplex, herpes zoster) and urticaria. The profile of AESIs was considered to be similar for PB006 and EU-Tysabri.

## Anti-JCV antibody status and PML risk evaluation

Throughout clinical development of PB006, the STRATIFY JCV DxSelect assay was used by Polpharma Biologics for screening of study subjects and as risk minimisation measures during the biosimilar clinical studies. In parallel, a new anti-JCV IgG assay was developed (ImmunoWELL JCV IgG assay) for use in clinical practice. Analytical performance of the ImmunoWELL JCV IgG test was validated for its precision, selectivity (interference and cross-reactivity), a potential hook-effect, and robustness (including sample and  kit  stability).  Effects  of  plasma  or  serum  sample  matrix  were  also  evaluated.  Provided  results confirmed the suitability of the assay for its intended use and the test has CE marking for the qualitative detection of antibodies to JC Virus in human serum or plasma.

Samples collected during the PB006 biosimilar clinical studies PB006-03-01 and PB006-01-03 were used for clinical validation of the ImmunoWELL JCV IgG assay against the STRATIFY JCV DxSelect assay by comparison of the STRATIFY JCV DxSelect test results with ImmunoWELL JCV IgG test results from matching samples (taken at the same time during the clinical studies).

A detailed clinical validation report has been provided. Further information on the design and validation of the ImmunoWELL JCV IgG assay is included in the instructions for use provided with the test kits.

Similar to the STRATIFY JCV DxSelect assay, upper and lower cut-offs were defined for the equivocal zone in a separate screening assay to balance sensitivity and specificity of the ImmunoWELL JCV IgG Test. This resulted in an equivocal zone ranging from 0.25 to 0.50 for the screening assay, similar to the cut-off values for the STRATIFY JCV DXSelect assay (0.20 to 0.40).

<div style=\"page-break-after: always\"></div>

Consecutively, a total of 397 unique samples were included in the final clinical performance evaluation. There were 200 healthy subjects evaluated with both the STRATIFY JCV DxSelect and the ImmunoWELL JCV IgG Test. In addition, 197 (RR)MS patients were evaluated with both the current standard assay and the ImmunoWELL JCV IgG Test.

Samples from healthy subjects covered the entire range of index values of the STRATIFY JCV DXSelect test (0 to &gt;4). However, due to the PML risk in MS patients, the index range for patient samples taken during clinical study PB006-03-01 only extended up to 1.5. This condition had previously been agreed with national scientific advice procedures. Despite the restricted index range for patient samples, the previously defined cut-off (0.5) falls well within the range of samples.

The correlation of index values from both assays is shown in the following figure, separately for healthy subjects (A) and MS patients (B).

Figure 7: Correlation of index values from both assays for healthy volunteers (A) and R(R)MS patients

<!-- image -->

|                       | two-sided95%oconfidenceintervalsfrom regression analysis   | two-sided95%oconfidenceintervalsfrom regression analysis   | two-sided95%oconfidenceintervalsfrom regression analysis   | two-sided95%oconfidenceintervalsfrom regression analysis   | two-sided95%oconfidenceintervalsfrom regression analysis   | two-sided95%oconfidenceintervalsfrom regression analysis   |
|-----------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
| parameter             | A: healthy subjects (full index range)                     | A: healthy subjects (full index range)                     | A: healthy subjects (full index range)                     | B: MS patients (index 0 - 1.5)                             | B: MS patients (index 0 - 1.5)                             | B: MS patients (index 0 - 1.5)                             |
|                       | value                                                      | lower                                                      | upper                                                      | value                                                      | lower                                                      | upper                                                      |
| intercept (target: 0) | 0.02                                                       | -0.00                                                      | 0.05                                                       | 0.01                                                       | -0.03                                                      | 0.04                                                       |
| slope (target: 1)     | 0.93                                                       | 0.90                                                       | 0.96                                                       | 1.07                                                       | 0.96                                                       | 1.26                                                       |

Note: samples from healthy subjects (panel A) were obtained from study PB006-01-03, samples from patients with relapsing remitting multiple sclerosis (RRMS, panel B) from study PB006-03-01

Further, clinical performance of the ImmunoWELL JCV IgG Test was compared to the STRATIFY JCV DxSelect  test  in  terms  of  assay  sensitivity,  specificity,  positive  predictive  value  (PPV)  and  negative predictive value (NPV). The results are summarised in the following table.

<div style=\"page-break-after: always\"></div>

Table 55: Assay sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV)

| Population         | Sensitivity   | Specificity   | PPV          | NPV          |
|--------------------|---------------|---------------|--------------|--------------|
| Multiple Sclerosis | 92% (83-97%)  | 74% (65-81%)  | 67% (57-76%) | 94% (87-98%) |
| Healthy Subjects   | 97% (92-99%)  | 73% (61-83%)  | 88% (81-98%) | 92% (82-98%) |

High concordance was found for assay sensitivity and NPV, whereas PPV had only 67% performance in MS patients. As the assay is supposed to reliably detect anti-JVC antibodies in patients, the values for sensitivity and NPV are the most critical ones, whereas a low PPV does not raise a concern for missing JVC  infections  in  patients.  However,  in  clinical  practice  the  above-described  cut-off  values  for determination of positive/negative results are of relatively minor importance. Rather, risk stratification is  currently  based on index values between 0.9 and 1.5 in clinical practice. Therefore, the applicant presented further comparative test data from the healthy subject population across the whole index range, and based on a regression analysis it was implied that the ImmunoWELL JCV IgG test might slightly underestimate the index estimated from the STRATIFY JCV DxSelect test (see also Discussion on clinical safety).

Moreover, the applicant provided an analysis with the focus on values in and around the range of 0.91.5 using additional data from the analysis of MS patient samples with higher JCV index values.

Data from the combined MS patient data set was used for correlation analysis and a high degree of correlation between the test results was observed at low (&lt;0.9), intermediate (0.9 - 1.5) and high index values  (1.5  -  2.5).  Similar  to  previous  observations  from  healthy  subject  samples,  the  correlation decreases at very high index values above approx. 2.5 (due to saturation effects/non-linearity of the qualitative ELISA test). This difference is regarded clinically not meaningful as all patients with high index values  are  in  the  'high  PML  risk'  category,  without  further  sub-stratification  by  index  value.  For regression analysis, the range &lt;2.5 was therefore selected, showing a high degree of correlation in terms of slope and intercept in the clinically relevant index range.

Figure 8: Correlation of index values from ImmunoWELL JCV IgG vs. STRATIFY JCV DxSelect using combined dataset from MS patient samples (PB006-03-01)

<!-- image -->

parameter two-sided 95% confidence intervals from regression analysis

<div style=\"page-break-after: always\"></div>

|                       |   value |   lower |   upper |
|-----------------------|---------|---------|---------|
| intercept (target: 0) |    0.03 |    0    |    0.06 |
| slope (target: 1)     |    0.95 |    0.89 |    1    |

At the relevant threshold values of 0.9 and 1.5, the estimated ImmunoWELL JCV IgG test values for MS patients are 0.882 (90% confidence interval: 0.849 - 0.921) and 1.451 (90% confidence interval: 1.388 - 1.517). The relative differences are 2.0% and 3.3.%, respectively. If a minor offset exists between the two assays, it is expected to be below 0.1 index values.

Table 56: Performance characteristics of ImmunoWELL JCV IgG (combined data set)

| MS patient population       | MS patient population   | MS patient population   | MS patient population   | MS patient population   |
|-----------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| STRATIFY JCV DxSelect value | ImmunoWELL JVC IgG      | ImmunoWELL JVC IgG      | ImmunoWELL JVC IgG      | ImmunoWELL JVC IgG      |
|                             | estimate                | 90% CI                  | abs. difference         | rel. difference         |
| 0.9                         | 0.882                   | 0.849 - 0.921           | -0.01775                | -2.0%                   |
| 1.5                         | 1.451                   | 1.388 - 1.517           | -0.04916                | -3.3%                   |
| 2                           | 1.925                   | 1.839 - 2.015           | -0.07534                | -3.8%                   |
| 2.5                         | 2.398                   | 2.287 - 2.510           | -0.10152                | -4.1%                   |

Sub-range analyses with the focus on values in and around the range of 0.9-1.5 were performed to determine sensitivity, specificity, NPV and PPV for the qualitative test results (positive/negative). The combined total data set from MS patient samples described above is shown as an example in the following figure  covering  the  entire  index  value  range  with  'true'  positives  (TP),  'false'  positives  (FP),  'true' negatives (TN) and 'false' negatives (FN) highlighted by colour.

Figure 9: True and false positives/negatives in combined total MS patient data set

<!-- image -->

The  applicant  also  assessed  the  binary  agreement  between  the  STRATIFY  JCV  DxSelect  and  the ImmunoWELL JCV IgG results at the threshold values of 0.9 and 1.5. Sensitivity in this analysis describes the percent of ImmunoWELL JCV IgG test index values above the threshold within those where STRATIFY JCV  DxSelect  index  values  are  above  the  threshold,  whereas  specificity  describes  the  percent  of ImmunoWELL JCV IgG test index values below the threshold within those where STRATFIY index values are below the threshold. For the combined MS patient data set at threshold index values, the results are visualized in the following figure, using the same color coding for 'true' positives, 'true' negatives, 'false' positives and 'false' negatives as above.

<div style=\"page-break-after: always\"></div>

Figure 10: Binary agreement at the threshold values of 0.9 (A) and 1.5 (B) in combined MS patient data set

<!-- image -->

TN/TP = True negative/positive FN/FP = False negative/positive

Furthermore,  the  binary  agreements  are  presented  using  threshold  values  of  0.8  and  1.4  for  the ImmunoWELL JCV IgG test and threshold values of 0.9 and 1.5 for the STRATFIY JCV DxSelect test. Separate  tables  are  shown  for  the  healthy  subject  population  from  study  PB006-01-03  and  for  the combined MS patient data set from study PB006-03-01 covering the index range above 1.5 as previously described.

Table 57: Binary agreement at the threshold values of 0.8/0.9 and 1.4/1.5*

| MS patient population (combined dataset)   | MS patient population (combined dataset)   | MS patient population (combined dataset)   | MS patient population (combined dataset)   | MS patient population (combined dataset)   | MS patient population (combined dataset)   | MS patient population (combined dataset)   | MS patient population (combined dataset)   | MS patient population (combined dataset)   |
|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
|                                            | threshold 0.8/0.9* STRATIFY JCV Dx Select  | threshold 0.8/0.9* STRATIFY JCV Dx Select  | threshold 0.8/0.9* STRATIFY JCV Dx Select  | threshold 0.8/0.9* STRATIFY JCV Dx Select  | threshold 1.4/1.5* STRATIFY JCV Dx Select  | threshold 1.4/1.5* STRATIFY JCV Dx Select  | threshold 1.4/1.5* STRATIFY JCV Dx Select  | threshold 1.4/1.5* STRATIFY JCV Dx Select  |
| ImmunoWELL                                 | Positive                                   | Positive                                   | Negative                                   | Negative                                   | Positive                                   | Positive                                   | Negative                                   | Negative                                   |
| JCV IgG                                    | N                                          | %                                          | N                                          | %                                          | N                                          | %                                          | N                                          | %                                          |
| Positive                                   | 130                                        | 92.86                                      | 17                                         | 9.83                                       | 106                                        | 91.38                                      | 8                                          | 4.06                                       |
| Negative                                   | 10                                         | 7.14                                       | 156                                        | 90.17                                      | 10                                         | 8.62                                       | 189                                        | 95.94                                      |
| Sensitivity                                | 92.9%                                      | 92.9%                                      | 92.9%                                      | 92.9%                                      | 91.4%                                      | 91.4%                                      | 91.4%                                      | 91.4%                                      |
| Specificity                                | 90.2%                                      | 90.2%                                      | 90.2%                                      | 90.2%                                      | 95.9%                                      | 95.9%                                      | 95.9%                                      | 95.9%                                      |
| PPV                                        | 88.4%                                      | 88.4%                                      | 88.4%                                      | 88.4%                                      | 93.0%                                      | 93.0%                                      | 93.0%                                      | 93.0%                                      |
| NPV                                        | 94.0%                                      | 94.0%                                      | 94.0%                                      | 94.0%                                      | 95.0%                                      | 95.0%                                      | 95.0%                                      | 95.0%                                      |

| Healthy subject population   | Healthy subject population                | Healthy subject population                | Healthy subject population                | Healthy subject population                | Healthy subject population                | Healthy subject population                | Healthy subject population                | Healthy subject population                |
|------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
|                              | threshold 0.8/0.9* STRATIFY JCV Dx Select | threshold 0.8/0.9* STRATIFY JCV Dx Select | threshold 0.8/0.9* STRATIFY JCV Dx Select | threshold 0.8/0.9* STRATIFY JCV Dx Select | threshold 1.4/1.5* STRATIFY JCV Dx Select | threshold 1.4/1.5* STRATIFY JCV Dx Select | threshold 1.4/1.5* STRATIFY JCV Dx Select | threshold 1.4/1.5* STRATIFY JCV Dx Select |
| ImmunoWELL                   | Positive                                  | Positive                                  | Negative                                  | Negative                                  | Positive                                  | Positive                                  | Negative                                  | Negative                                  |
| JCV IgG                      | N                                         | %                                         | N                                         | %                                         | N                                         | %                                         | N                                         | %                                         |
| Positive                     | 102                                       | 96.23                                     | 5                                         | 5.62                                      | 85                                        | 92.39                                     | 3                                         | 2.91                                      |
| Negative                     | 4                                         | 3.77                                      | 84                                        | 94.38                                     | 7                                         | 7.61                                      | 100                                       | 97.09                                     |

| Sensitivity   | 96.2%   | 92.4%       |
|---------------|---------|-------------|
| 94.4%         | 97.1%   | Specificity |
| 95.3%         | 96.6%   | PPV         |

<div style=\"page-break-after: always\"></div>

| NPV   | 95.5%   | 93.5%   |
|-------|---------|---------|

* 0.8 and 1.4 threshold values correspond to ImmunoWELL JCV IgG; 0.9 and 1.5 threshold values refer to STRATIFY JCV DxSelect PPV / NPV = positive / negative predictive values

For both, the combined MS patient populations and the healthy subject population, high sensitivities were  observed  at  the  threshold  values  of  0.9  (92.1%  and  94.3%)  and  1.5  (89.7%  and  91.3%), corresponding to the low numbers of false negatives. Also, the specificity values in this analysis indicate strong agreement with results of 91.9% and above. The revised threshold values of 0.8 and 1.4 generally lead to a minor improvement in sensitivity for the ImmunoWELL JCV IgG test (e.g. from 92.1% to 92.9% at  the  lower  threshold  and  from  89.7%  to  91.4%  at  the  upper  threshold  for  MS  patients)  and  a concomitant minor reduction in specificity (see Discussion on Clinical Safety).

All clinical studies included for safety reasons a PML follow-up visit 6 months after (last) dosing with study drug, to assess new neurological symptoms which could be suggestive of PML. Of note, for the healthy subject studies this visit was not mandatory, and in the time period between the end of study visit and the PML follow-up visit the subjects were not considered as study subjects.

## Study PB006-01-02

Screening for anti-JCV antibodies was only performed at screening, and subjects who were JCV-positive were not enrolled in the study. Of the 68 subjects who were screened, 39 were JCV-positive and therefore not eligible for inclusion in the study.

No PML cases were reported in the study and no new neurological symptoms, which could be suggestive for PML were observed on the additional follow-up visit on Day 169 (±1 week) after administration of the study drug.

## Study PB006-01-03

Subjects who were JCV-positive were not enrolled in the study. All subjects who were randomized were tested negative for anti-JCV antibodies at Screening 1. On Day 85, 19 subjects tested positive for antiJCV antibodies, 9 subjects after PB006, 4 subjects after EU-Tysabri, and 6 subjects after US-Tysabri.

No PML cases were reported in the study and no new neurological symptoms that could be suggestive for PML were observed for the subjects who returned for the additional follow-up visit on Day 169.

## Study PB006-03-01

While at baseline, no patients presented with a JCV index &gt;1.5, the percentage of patients who were JCV-positive with index &gt;1.5 increased during the treatment period in both groups. An index &gt;1.5 was reported for 4.9 and 4.5% of patients in the PB006 and EU-Tysabri groups, respectively, at Week 24 and for 6.0 and 5.9% of patients in the PB006 and EU-Tysabri groups, respectively, at Week 48.

No cases of PML occurred in this study. For 5 patients, PML was suspected based on MRI findings. PML was not confirmed in subsequent clinical evaluations in any of these patients.

Additionally, investigators were to monitor all patients who had received at least one dose of study drug (including  prematurely  withdrawn  patients)  for  PML  for  approximately  6  months  after  discontinuing natalizumab.  Of  the  265  patients  randomized,  253  subjects  completed  the  PML  follow-up  visit.  No subjects had any signs suggestive of PML at the follow-up visit.

## 2.6.8.4. Laboratory findings

Natalizumab binds to the α4 subunit of the α4β1 -integrin that is highly expressed on the surface of all leukocytes, with the exception of neutrophils.

<div style=\"page-break-after: always\"></div>

## Study PB006-01-03

In study PB006-01-03, increases from baseline in mean numbers of circulating leukocytes, lymphocytes, eosinophils and monocytes were reported, which were similar in all 3 treatment groups. These increases are consistent with expression of α4β1 on these white-cell subgroups and are a known PD effect of natalizumab [Polman et al. 2006].

Mean numbers of leukocytes, lymphocytes, eosinophils and monocytes at Day 36 and Day 85 (end of study) are summarized in the following table.

Table 58: Mean numbers of leukocytes, lymphocytes, eosinophils and monocytes in study PB006-01-03 (SAF population)

|                         | PB006 N=149   | EU-Tysabri N=151   | US-Tysabri N=150   |
|-------------------------|---------------|--------------------|--------------------|
| Leukocytes (x 10 9 /L)  |               |                    |                    |
| Baseline                | 6.13          | 6.01               | 6.16               |
| Day 36                  | 6.97          | 6.99               | 7.10               |
| Day 85                  | 5.50          | 5.60               | 5.68               |
| Lymphocytes (x 10 9 /L) |               |                    |                    |
| Baseline                | 1.89          | 1.92               | 1.91               |
| Day 36                  | 2.89          | 2.85               | 2.97               |
| Day 85                  | 1.77          | 1.79               | 1.83               |
| Eosinophils (x 10 9 /L) |               |                    |                    |
| Baseline                | 0.16          | 0.15               | 0.16               |
| Day 36                  | 0.24          | 0.23               | 0.24               |
| Day 85                  | 0.14          | 0.16               | 0.16               |
| Monocytes (x 10 9 /L)   |               |                    |                    |
| Baseline                | 0.44          | 0.43               | 0.45               |
| Day 36                  | 0.53          | 0.52               | 0.54               |
| Day 85                  | 0.42          | 0.41               | 0.42               |

For all these parameters the increases were transient, with values returning to or below baseline levels at Day 85. Changes from baseline in neutrophils were small.

In  addition,  small  mean  decreases  from  baseline  were  observed  for  haematocrit,  erythrocytes, hemoglobin and platelets.

The majority of subjects had at least 1 out-of-range clinical laboratory value. Most of these were minor and considered by the investigator to have no clinical implication.

Out-of-range values were considered to be clinically significant by the investigator for 4 subjects. For these subjects laboratory TEAEs were reported:

- One subject (EU-Tysabri): ALT increased and aspartate aminotransferase (AST) increased, both unlikely related to study drug, outcome recovered.
- One subject (PB006): leukocytosis, unlikely related to study drug, outcome recovered.
- One subject (EU-Tysabri): leukocyturia, unlikely related to study drug, outcome recovered.
- One subject (US-Tysabri): anaemia, unlikely related to study drug, outcome recovering/resolving.

In addition, the laboratory AE haematuria was reported in 1 subject (11031) in the PB006 group.

One subject had a positive pregnancy test on Day 85. On Day 109 the pregnancy was terminated by an induced abortion.

Overall, results for laboratory parameters were similar for PB006, EU-Tysabri and US-Tysabri.

## Study PB006-03-01

<div style=\"page-break-after: always\"></div>

## Hematology results

Notable findings with regard to mean changes from baseline included:

- Increases in eosinophils, with a mean change of 0.15 and 0.17 x 10 9 /L from baseline to end of study in PB006 and EU-Tysabri, respectively.
- Increases in leukocytes, with a mean change of 1.73 and 2.06 x 10 9 /L from baseline to end of study in PB006 and EU-Tysabri, respectively.
- Increases in lymphocytes, with a mean change of 1.57 and 1.76 x 10 9 /L from baseline to end of study in PB006 and EU-Tysabri, respectively.
- Increases in monocytes, with a mean change of 0.11 and 0.12 x 10 9 /L from baseline to end of study in PB006 and EU-Tysabri, respectively.
- Small decreases in hemoglobin, with a mean change of -5.3 and -1.5 g/L from baseline to end of study in PB006 and EU-Tysabri, respectively. Larger decreases were reported at other timepoints during the treatment period.

Generally, the changes from baseline were of a similar extent in both treatment groups. Increases in leukocytes, lymphocytes, eosinophils and monocytes and known PD effects of natalizumab; decreases in hemoglobin are known adverse reactions and described in the Tysabri SmPC. No clinically relevant changes from baseline were observed for the other parameters.

At baseline, most patients in both treatment groups had normal hematology values for all parameters. The majority of the changes from baseline for most abnormal hematology parameters were small, not clinically  relevant,  and  similar  between  the  treatment  groups.  Notable  findings  were  observed  for hemoglobin, leukocytes and lymphocytes.

Hemoglobin was reported as low at baseline for 8.4% and 10.5% of patients in the PB006 and EU-Tysabri groups, respectively. At all subsequent timepoints up to Week 40, a larger percentage of patients in both groups presented with low hemoglobin values. In both groups, the largest percentage of patients with low hemoglobin values was reported at Week 32 (with 19.5% in PB006 and 16.1% with EU-Tysabri).

At  the  end  of  study,  15.0  and  8.0%  of  patients  in  the  PB006  and  EU-Tysabri  groups,  respectively, reported low hemoglobin. However, in absolute values decreases in hemoglobin were rather small, with a mean change of -5.3 and -1.5 g/L from baseline to end of study in PB006 and EU-approved Tysabri, respectively (values at baseline were 141.6 g/L in both groups).

The percentage of patients with high leukocyte counts increased for both groups (14.4 and 14.8% in the PB006 and EU-approved Tysabri groups, respectively) at the end of study compared to baseline (3.8 and 5.3% patients in the PB006 and EU-Tysabri groups, respectively). Similarly, the percentage of patients with high lymphocyte counts increased for both groups (25.5 and 23.3% in the PB006 and EU-Tysabri groups, respectively) at the end of study compared to baseline (1.5 and 0% in the PB006 and EU-Tysabri groups, respectively). The largest percentage was reported at Week 40, when 33.0 and 31.5% of patients in the PB006 and EU-Tysabri group, respectively, presented with high lymphocytes.

Hematology values were categorized as within reference range (normal) or outside the reference range (low or high), and shifts in the categories between baseline were analyzed. Parameters showing a shift to  levels  outside  the  reference  range  (normal  to  low)  in ≥ 10% of patients in both treatment groups included  erythrocytes,  hemoglobin,  and  neutrophils/leukocytes.  Parameters  showing  a  shift  to  levels outside the reference range (normal to high) in ≥ 10% of patients in both treatment groups included leukocytes, lymphocytes, lymphocytes/leukocytes, and neutrophils. Parameters showing a shift to levels outside the reference range (normal to high) in ≥ 10% of patients in the PB006 group only included

<div style=\"page-break-after: always\"></div>

basophils/leukocytes and haematocrit. Parameters showing a shift to levels outside the reference range (normal to high) in ≥ 10% of patients in the EU-Tysabri group only included eosinophils/leukocytes.

## Hematology TEAEs

AEs  of  anaemia  were  reported  for  4  patients  in  the  PB006  group,  and  iron  deficiency  anaemia  and normocytic  anaemia  were  reported  for  1  patient  each  in  the  EU-Tysabri  group.  Lymphocyte  count increased and white blood cell count increased were reported as AE in 1 patient each in the EU-Tysabri group.  In  addition,  neutropenia  was  reported  in  1  patient  in  the  EU-approved  Tysabri  group,  and lymphopenia was reported in 1 patient in the PB006 group.

## Serum chemistry results

In general, mean serum chemistry values at baseline were similar for the PB006 and EU-Tysabri groups. The  mean  changes  from  baseline  were  generally  small,  not  clinically  relevant,  similar  between  the treatment groups, and did not indicate any clinically meaningful trend in serum chemistry values over the course of the study overall or within either treatment group.

At  baseline,  most  patients  in  both  treatment  groups  had  normal  serum  chemistry  values  for  most parameters. The majority of the changes from baseline for abnormal serum chemistry parameters were small, not clinically relevant, and similar between the treatment groups. At baseline, both treatment groups had patients with abnormal high cholesterol (40.5% in the PB006 group and 32.3% in the EUTysabri group) and abnormal high low density lipoprotein (LDL) cholesterol (35.1% in the PB006 group and 28.6% in the EU-Tysabri group) but no notable changes in either treatment group occurred for those parameters by the end of study (31.6 and 34.4% for cholesterol in the PB006 and EU-Tysabri groups, respectively, and 29.1 and 28.0% for LDL cholesterol in the PB006 and EU-Tysabri groups, respectively).

Chemistry values were categorized as within reference range (normal) or outside the reference range (low or high), and shifts in the categories between baseline were analyzed. Parameters showing a shift to levels outside the reference range (normal to high) in ≥ 10% of patients in both treatment groups included C-reactive protein, cholesterol, LDL cholesterol, and triglycerides. Parameters showing a shift to levels outside the reference range (normal to high) in ≥ 10% of patients in the PB006 group only included bilirubin and direct bilirubin. A shift in phosphate to levels outside the reference range (normal to low) in ≥ 10% of patients was reported in both treatment groups and a shift in high density lipoprotein cholesterol to levels outside the reference range (normal to low) in ≥ 10% of patients was reported for the Tysabri group only.

## Serum chemistry TEAEs

AEs of hyperbilirubinaemia were reported for 1 patient each in the PB006 and the switch groups, and bilirubin conjugated increased was reported for 1 patient in the PB006 group. With regard to liver enzyme elevations, ALT increased was reported for 2 patients in the PB006 group and for 1 patient in the EUTysabri group; AST increased was reported for 1 patient in the EU-Tysabri group, and gamma-glutamyl transferase increased was reported for 1 patient each in the PB006 and the switch group. Hyperlipidaemia was reported for 1 patient in the switch group, blood triglycerides increased was reported for 1 patient for the PB006 group and hypertriglyceridemia was reported for 1 patient in the EU-Tysabri group. Creactive protein increased was reported for 2 patients in the PB006 group and 1 patient in the EU-Tysabri group.

Overall, with regard to clinical laboratory, the results were similar for PB006 and EU-Tysabri. The safety profile of laboratory AEs was similar for PB006 and EU-Tysabri and in line with the published data for Tysabri.

<div style=\"page-break-after: always\"></div>

## 2.6.8.5. Immunological events

## Immunogenicity Assays

In  the  development  of  the  reference  product  Tysabri,  persistent  antibodies  were  associated  with  a substantial decrease in the effectiveness of natalizumab and an increased incidence of hypersensitivity reactions.  Additional  infusion-related  reactions  associated  with  persistent  antibodies  included  rigors, nausea,  vomiting  and  flushing.  At  that  time,  antibodies  against  natalizumab  were  detected  in approximately 10% of patients in 2-year controlled clinical trials in MS patients and persistent antinatalizumab antibodies developed in approximately 6% of patients.

The applicant has adopted an electrochemiluminescence immunoassay (ECLIA) bridging assay to screen, confirm and quantify in terms of titer of quantify natalizumab specific antibodies in human serum matrix. The adopted three-tiered approach for determination of ADAs was well described and developed. It is considered state of the art and valid for its intended use.

Further, the applicant presented a qualitative assay for the detection of neutralising ADA's in human serum.  The  presented  assay  was  well  described  and  established.  It  was  setup  correctly  and  fully validated. Thus it is considered valid for its intended use.

## Study PB006-01-02

The ADA test results of study PB006-01-02 indicated that a single IV infusion of 300 mg PB006 induced a treatment-emergent ADA response in 3 out of 10 subjects (30%) of subjects. While this was higher than the ADA incidence reported in the Tysabri studies that were conducted by the originator, this result is  consistent  with  a  higher  drug  tolerance  level  of  the  PB006  ADA  assay  compared  to  that  of  the originator's assay. The detected ADA response was not associated with any treatment-related adverse events.

## Study PB006-01-03

The  immunogenicity  of  PB006  (N=149  subjects)  was  evaluated  in  direct  comparison  to  EU-Tysabri (N=151) and US-Tysabri (N=150) following a single intravenous infusion of 3 mg PB006/kg to healthy volunteers.

There  was  no  detectable  difference  in  ADA  or  NAb  response  dynamics  in  subjects  receiving  PB006 compared to EU-Tysabri or US-Tysabri:

- The incidence of treatment-emergent ADA following a single intravenous infusion of 3 mg natalizumab/kg to healthy volunteers was similar across all three treatment groups: 87% for PB006 compared to 87% for EU-Tysabri and 92% for US-Tysabri.
- NAb was detected in the majority of ADA positive subjects, again at a similar incidence across the three treatment groups: 84% for PB006 compared to 77% for EU-Tysabri and 87% for US-Tysabri in terms of the total number of treated subjects.
- ADA and NAb titer profiles were indistinguishable across treatment groups

There was no treatment-related difference in the impact of ADA or NAb positive status on PK (AUC0-inf and  Cmax)  or  PD  (Blood  CD19+, α4 -integrin  receptor  saturation,  blood  CD34+,  soluble  VCAM-1  and soluble MAdCAM-1).

By all parameters evaluated, the immunogenicity profile of PB006 was indistinguishable from that of EUTysabri and US-Tysabri.

## Study PB006-03-01

<div style=\"page-break-after: always\"></div>

## Treatment-emergent ADA

Through Week 24, 79% of subjects in the PB006 treatment group were confirmed positive for treatmentemergent ADA compared to 74% for EU-Tysabri. For PB006, 23% of subjects were classified as transient ADA positive compared to 56% persistent ADA positive; for EU-Tysabri, 19% of subjects were classified as transient ADA positive compared to 55% persistent ADA positive.

Geometric mean maximal (Week 0 to 24) ADA titer for total treatment-emergent ADA positive was 223.6 for PB006 compared to 150.7 for EU-Tysabri. Median ADA titer in both treatment groups was 160.

The peak frequency of ADA positive subjects was at week 8 for PB006 (65% ADA positive) and EUTysabri  (61%  ADA  positive),  declining  progressively  thereafter  to  11%  for  PB006  and  10%  for  EUTysabri at week 48. Geometric mean ADA titer increased from the 24- to 48-week timepoints in the diminishing proportion of ADA positive subjects in both treatment groups.

Overall time-course of the ADA response to PB006 mirrored that of the ADA response to EU-Tysabri throughout  the  48-week  treatment  period  in  terms  of  ADA  frequency,  but  with  a  modestly  higher geometric mean ADA titer for PB006. As discussed in ISI sections 3.2.5 and 3.2.6, there was no difference in either the drug trough concentrations or efficacy parameters; and results from the comparative singledose PK study (PB006-01-03) indicated a modestly lower geometric mean ADA titer for PB006 compared to EU-Tysabri or US-Tysabri. While it is unclear if the observed difference in geometric ADA titer observed in the PB006-03-01 study represents a real difference, there was no impact on drug exposure or on efficacy.

## NAb

A relatively high proportion (approx. 87%) of ADA positive subjects were also NAb positive, indicating suitable  sensitivity  /  drug  tolerance  of  the  NAb  assay.  NAb  titers  were  also  measured  to  optimize  a comparison  of  the  relative  magnitude  of  the  humoral  immune  response  to  PB006  compared  to  EUTysabri.

At Week 24, in terms of the total number of treated subjects, 69% of subjects in the PB006 treatment group were positive for NAb compared to 66% for EU-Tysabri. Geometric mean maximal (Week 0 to 24) NAb titer was 39.2 for PB006 compared to 32.6 for EU-Tysabri. Median NAb titer for week 0 to 24 was 23.0 for PB006 compared to 26.0 for EU-Tysabri.

## Persistent ADA and NAb combined

In the confirmatory efficacy and safety study, PB006-03-01, there was a strong concordance between the ADA and NAb response dynamics in the PB006 treatment group compared to those for subjects treated  with  EU-Tysabri:  at  the  24-week  treatment  timepoint  corresponding  to  the  primary  efficacy endpoint, the incidence of persistent treatment-emergent ADA was 79% for PB006 compared with 74% for EU-Tysabri, allied to a NAb positive incidence of 69% for PB006 compared with 67% for EU- Tysabri in terms of the total number of treated subjects.

## Impact of ADA / NAb on systemic drug concentration

## PB006 vs. EU-Tysabri

Because serum drug levels represent the most sensitive indicator of ADA formation at levels that could influence clinical responses, serum total natalizumab trough concentration was compared for the ADA positive  vs.  ADA  negative  subpopulations  in  each  treatment  group  at  Week  24  and  Week  48.  A corresponding analysis for the NAb positive vs. NAb negative subpopulations was also performed.

At week 24, the geometric mean total serum natalizumab trough concentration was similar for ADA positive subjects treated with PB006 (11375.8 ng/mL) or EU-Tysabri (10405.1 ng/mL). For NAb positive

<div style=\"page-break-after: always\"></div>

subjects at Week 24, the geometric mean total serum natalizumab trough concentration was slightly higher for the PB006 treatment group (8350.6 ng/mL) compared to the EU- Tysabri treatment group (6957.4 ng/mL).

Serum natalizumab trough concentration was clearly lower in ADA positive subjects compared to ADA negative subjects in the same treatment group: at week 24, the geometric mean total serum natalizumab concentration  for  ADA  positive  subjects  treated  with  PB006  was  31%  of  that  for  the  ADA  negative subjects; for EU-Tysabri, the geometric mean total serum natalizumab trough concentration for ADA positive subjects treated with PB006 was 30% of that for the ADA negative subjects. The high overlap of the 95% CIs for serum total natalizumab trough concentration by ADA/NAb category supports the conclusion  that  there  was  no  difference  in  the  scale  of  impact  of  ADA  or  NAb  formation  on  serum natalizumab concentration following treatment with PB006 or EU-Tysabri for 24 weeks.

At week 48, the lower number of ADA positive (n=13 for PB006; n=9 for EU-Tysabri) or NAb positive (n=8 for PB006; n=4 for EU-Tysabri) subjects hampers the comparison across treatment groups. The geometric mean total serum natalizumab concentration for the ADA positive and NAb positive subjects in all treatment groups were lower than those at week 24, most likely reflecting the higher ADA and NAb titers measured at week 48 compared to week 24.

## Impact of ADA / NAb on efficacy endpoints

Overall, there was no treatment-related difference in the impact of ADA or NAb positive status on either the primary (week 24) or secondary (week 48) efficacy endpoints in study PB006-03-01. Although ADA titers increased during the 48-week treatment period, ADA and NAb frequency progressively declined, which could reduce the scale of any negative impact of increasing ADA / NAb titer on clinical efficacy at the treatment group level during continuing treatment. This may explain why the ADA / NAb positive subpopulations showed similar efficacy at week 48 compared to week 24 despite the higher ADA and NAb titers at week 48.

## Impact of ADA on clinical safety

Because infusion-related reactions associated with persistent antibody-positivity are a recognized risk for  Tysabri,  line  listings  are  presented  to  describe  the  relationship  of  hypersensitivity  reactions  and symptoms  corresponding  to  the  SMQ  term  'anaphylaxis'  reported  in  study  PB006-03-01  to  ADA positive/negative status and coincident ADA titer.

In  subjects  treated  with  PB006,  10  events  were  reported  from  9  subjects;  7  of  the  events  were considered  as  being  possibly  or  probably  related  to  drug  administration.  Five  of  the  7  events  were detected in subjects with a coincident classification of 'ADA positive'. One event of hypotension was coincident with an ADA titer value of 40960 and study discontinuation.

In  subjects  treated  with  EU-Tysabri,  5  events  were  reported  from  4  subjects;  3  of  the  events  were considered as being possibly-related to drug administration.

## Summary of immunogenicity  results  from  confirmatory  efficacy  and  safety  study  in  RRMS  patients, PB006-03-01

The following two tables summarize the relationship of the treatment-emergent ADA and NAb responses to relevant clinical parameters at Treatment Week 24 and Week 48 respectively.

<div style=\"page-break-after: always\"></div>

Table 59: Summary of ADA &amp; NAb response parameters vs. clinical impact in Week 0 to Week 24 of study PB006-03-01 (Safety Analysis Population)

| Parameter                                                                                 | PB006 (N=131)                     | EU-Tysabri (N=133)               |
|-------------------------------------------------------------------------------------------|-----------------------------------|----------------------------------|
| %ADA positive (Week 0 to 24):                                                             |                                   |                                  |
| • Total treatment-emergent • Transient • Persistent                                       | 79% (n=104) 23% (n=30) 56% (n=74) | 74% (n=98) 19% (n=25) 55% (n=73) |
| Geometric mean maximal (Week 0 to 24) ADA titer for total treatment-emergent ADA positive | 223.5 (n=104)                     | 150.7 (n=98)                     |
| %NAb positive (Week 0 to 24)                                                              | 69% (n=90)                        | 66% (n=88)                       |
| Geometric mean maximal (Week 0 to 24) NAb titer                                           | 39.2 (n=90)                       | 32.6 (n=88)                      |
| Geometric mean drug trough concentration at Week 24:                                      |                                   |                                  |
| • ADA negative                                                                            | 36155.8 (n=85) 11375.8 (n=37)     | 36200.9 (n=88) 10405.1 (n=37)    |
| • ADA positive                                                                            |                                   |                                  |
| • NAb negative                                                                            | 21662.0 (n=12)                    | 24419.8 (n=12)                   |
| • NAb positive                                                                            | 8350.6 (n=25)                     | 6908.9 (n=25)                    |
| Cumulative number of new active lesions at Week 24:                                       |                                   |                                  |
| • ADA negative                                                                            | 1.8 (n=27)                        | 1.9 (n=33)                       |
| • ADA positive                                                                            | 1.3 (n=99)                        | 1.9 (n=94)                       |
| • NAb negative                                                                            | 1.1 (n=13)                        | 2.8 (n=10)                       |
| • NAb positive                                                                            | 1.3 (n=86)                        | 1.8 (n=84)                       |
| Annualized Relapse Rate at Week 24:                                                       |                                   |                                  |
| • ADA negative                                                                            | 0.24 (n=27)                       | 0.06 (n=35)                      |
| • ADA positive                                                                            | 0.20 (n=104)                      | 0.18 (n=98)                      |
| • NAb negative                                                                            | 0.17 (n=14)                       | 0.00 (n=10)                      |
| • NAb positive                                                                            | 0.20 (n=90)                       | 0.21 (n=88)                      |

Includes n=30 subjects who switched to PB006 at week 24

Table 60: Summary of ADA &amp; NAb response parameters vs. clinical impact in Week 0 to Week 48 of study PB006-03-01 (Safety Analysis Population)

| Parameter                                                                                                        | PB006 (N=131)                                            | EU-Tysabri (N=103)                                      |
|------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------------|
| %ADA positive (Week 0 to 48): • Total treatment-emergent • Transient • Persistent                                | 79% (n=104) 22% (n=29) 57% (n=75)                        | 74% (n=76) 22% (n=23) 51% (n=53)                        |
| Geometric mean maximal (Week 0 to 48) ADA titer for total treatment-emergent ADA positive                        | 229.1 (n=104)                                            | 131.5 (n=76)                                            |
| %NAb positive (Week 0 to 48)                                                                                     | 69% (n=90)                                               | 67% (n=69)                                              |
| Geometric mean maximal (Week 0 to 48) NAb titer for NAb positive                                                 | 39.8 (n=90)                                              | 26.5 (n=69)                                             |
| Geometric mean drug trough concentration at Week 48: • ADA negative • ADA positive • NAb negative • NAb positive | 30005.2 (n=102) 7373.3 (n=13) 32246.3 (n=5) 2931.9 (n=8) | 34273.1 (n=84) 9493.9 (n=39) 21462.5 (n=5) 3424.9 (n=4) |
| Cumulative number of new active lesions at Week 48:                                                              | 1.9 (n=26)                                               | 1.4                                                     |
| • ADA negative                                                                                                   |                                                          | (n=25)                                                  |
| • ADA positive                                                                                                   | 1.4 (n=96) 1.1 (n=13)                                    | 2.7 (n=71) 6.4 (n=7)                                    |
| • NAb negative                                                                                                   |                                                          |                                                         |

<div style=\"page-break-after: always\"></div>

| • NAb positive                      | 1.4 (n=83)   | 2.3 (n=64)   |
|-------------------------------------|--------------|--------------|
| Annualized Relapse Rate at Week 48: |              |              |
| • ADA negative                      | 0.28 (n=27)  | 0.12 (n=27)  |
| • ADA positive                      | 0.14 (n=104) | 0.14 (n=76)  |
| • NAb negative                      | 0.16 (n=14)  | 0.15 (n=7)   |
| • NAb positive                      | 0.14 (n=90)  | 0.13 (n=69)  |

Excludes n=30 subjects who switched to PB006 at week 24

Finally, switching of 30 subjects who were treated for 24 weeks with EU-Tysabri to treatment with PB006 for 24 weeks was not associated with any impact on either the treatment-related humoral immune response to natalizumab or its clinical impact.

## 2.6.8.6. Discontinuation due to adverse events

Discontinuation due to adverse events occurred only in study PB006-03-01.

Overall, 12 patients experienced TEAEs leading to study drug discontinuation (8 [5.0%] patients in the PB006  group  and  4  [3.0%]  patients  in  the  Tysabri  group).  The  most  common  TEAEs  leading  to discontinuation in the PB006 group were pruritus (2 [1.5%] patients) and urticaria (2 [1.5%] patients), which are known common adverse drug reactions of natalizumab. One (0.8%) patient discontinued due to a TEAE of COVID-19. One (0.8%) patient experienced multiple TEAEs of asthenia, hyperhidrosis, blood pressure fluctuation, and dizziness after study drug infusion at Week 0. No treatment was given and all TEAEs resolved,  but  the  patient  withdrew  from  the  study  following  the  events.  One  (0.8%)  patient experienced multiple TEAEs of ear infection and herpes simplex (an AESI) approximately 1 month after study drug infusion at Visit 5; both events resolved. The patient later experienced a TEAE of trigeminal neuralgia and was withdrawn from the study following these events.

In the Tysabri group, 1 (0.8%) patient experienced multiple TEAEs of urticaria and angioedema (both AESIs) approximately 20 minutes after the start of the patient's second Tysabri IV infusion. The infusion was  stopped  and  the  patient  was  treated  for  both  events.  The  events  of  angioedema  and  urticaria resolved and the patient withdrew from the study.

## 2.6.9. Discussion on clinical safety

The assessment of safety in the PB006 clinical program was focused on the comparison of PB006 to Tysabri. Safety data with PB006 were collected in studies PB006-01-02, PB006-01-03 and PB006-03-01. The principal safety data for PB006 and comparative safety data with Tysabri is derived from the pivotal, Phase 1, single-dose study in 450 healthy subjects (PB006-01-03) and the pivotal Phase 3, multipledose study in 264 adult male and female RRMS patients (PB006-03-01) treated for up to 48 weeks (131 patients in the PB006 group and 133 in the Tysabri group up to week 24; afterwards a subset of 30 patients (22.6%) from the Tysabri group switched to PB006). Comparability of safety, tolerability and immunogenicity between the biosimilar candidate PB006 and the reference product, Tysabri EU, were secondary objectives of these studies. In both studies, safety analyses were based on the SAF, defined as all subjects who received at least one dose of study drug. In the Phase 3 study PB006-03-01, AESIs were defined in line with the SmPC of the reference product. Additional safety analyses were performed for the SSW population, defined as patients who received at least one infusion of study drug after the time point of re-randomization.

The overall concept of the safety evaluation is considered adequate to conclude on similarity between PB006 and Tysabri EU and the safety database is considered sufficient for establishment of safety for

<div style=\"page-break-after: always\"></div>

PB006 taking into account the well-known safety profile of the active substance and the fact that it is a biosimilar candidate.

Non-conformity with GCP was described for one of the study centres participating in the safety and efficacy study PB006-03-01. However, it was confirmed that all patients received the correct study drug and dose at all attended visits and there was no relevant impact on the safety data.

The safety profile of the switch population is difficult to interpret, since it cannot always be determined, if events are due to treatment with the test or reference product. AEs are therefore not assessed in detail in this population.

Overall, PB006 was administered to 159 healthy subjects as single dose (for 149 of these subjects at 3 mg/kg, and for 10 of these subjects at 300 mg), and to 161patients with RRMS as multiple doses of 300 mg in 4-weekly intervals for up to 12 doses. Tysabri (US-Tysabri or EU-Tysabri) was administered to 337 healthy subjects as single dose (1 to 6 mg/kg), and EU-Tysabri was administered to 133 patients with RRMS as multiple doses of 300 mg in 4-weekly intervals.

The overall number of subjects (healthy volunteers and patients) exposed to the study drugs as well as the dose levels administered and the duration of exposure are considered adequate.

In  study  PB006-01-03,  approximately  two-thirds  of  subjects  in  each  group  reported  any  TEAE,  and approximately  one  third  of  subjects  across  groups  had  study  drug-related  TEAEs.  No  fatal  TEAEs occurred. SAEs were reported for two subjects (1.3%; 6 SAEs overall) treated with US-Tysabri, while no SAEs occurred in the other two groups. No subject reported TEAEs leading to study drug discontinuation.

Most frequently reported were TEAEs in the SOCs nervous system disorders (30-33% across groups) and general disorders and administration site conditions (29-34% across groups).

On the PT level, most frequently reported was headache (26-30% across groups), followed by AEs related to the injection/infusion, with PTs of injection site reaction (18-21% across groups), infusion site reaction (1-4% across groups), vessel puncture site reaction (1-5% across groups), and catheter site related reaction (2-3% across groups).

In the majority of subjects (65.5%), TEAEs were mild and were reported with similar frequencies across the three study groups. Slightly more moderate TEAEs were reported in PB006 group (15 TEAEs in 11 subjects (7.4%)) and in Tysabri US (19 TEAEs in 12 subjects (8.0%)) than in Tysabri EU (5 TEAEs in 4 subjects (2.6%)).

Slight differences were noted in the PTs Infusion site reaction and Pyrexia, which required follow-up as they could be indicative of immunogenic reactions to PB006. Of the 4 subjects with pyrexia events in study PB006-01-03, pyrexia did not occur in close temporal relationship to study drug infusion in the 3 subjects who received PB006 and  noneof these 3 subjects reported concomitant AEs indicative of a systemic immunogenic reaction. Thus, it is unlikely that pyrexia was indicative of an immunological event in these subjects. Further it was assessed that the PT 'infusion site reaction' was used only temporarily at one study site, and corresponds to PT 'injection site reaction'. Overall, the frequency of injection site reaction was comparable across the 3 groups in study PB006-01-03.

In study PB006-03-01, the overall percentages of patients with TEAEs and with TEAEs related to study drug were similar across groups. Approximately two-thirds of patients in each group reported any TEAE, while in approximately 25% of patients in each group, study drug-related TEAEs occurred. However, the frequencies of TEAEs of Grade 3 and of TEAEs leading to discontinuations were numerically higher in the PB006 group than in the other groups. Despite minor imbalances observed between treatments, the nature and frequency of these AEs reported in study PB006-03-01 correspond to the safety profile of the reference product Tysabri and thus do not give reason to concern.

<div style=\"page-break-after: always\"></div>

The percentage of patients with study drug-related TEAEs was similar in the PB006, switch and the EUTysabri  group  (23.7,  26.7  and  21.4%),  with  event  rates  per  100  PY  of  46.13,  54.90  and  56.40, respectively.

Most  frequently  reported  in  both  groups  were  study  drug-related  TEAEs  in  the  SOCs  infections  and infestations, nervous system disorders and general disorders and administration site conditions. On the PT level, most frequently reported was headache, followed by dizziness.

Though, on the level of individual PTs the frequencies slightly differed between groups. Most strikingly, distinctly more patients in the PB006 group (10 patients) had nervous system disorders compared to the Tysabri group (2 patients), mostly in the PT headache (7 versus 2 patients). However, these events were only graded as mild or moderate; they are known adverse drug reactions of natalizumab and do not give rise to concern.

There were no fatal AEs in any of the studies conducted for this MAA.

There were 6 SAEs reported for 2 subjects in the PK/PD study. All of these SAEs were unlikely related to study drug (based on investigator assessment) and were resolved within 1 or 2 days.

There were 5 SAEs reported for 5 patients in the phase 3 study, 3 and 2 in the PB006 and Tysabri group, respectively. Three SAEs were not considered study drug related, 1 event of hypotension in the PB006 group was considered possibly related and led to study drug discontinuation; one event of tremor in the control group was considered unlikely related. All events in the PB006 group resolved without sequelae, whereas the two SAEs in the Tysabri group resolved with sequelae.

Adverse events of special interest were defined in the study protocol based on the Tysabri SmPC and included  PML,  JCV  granule  cell  neuropathy,  opportunistic  infection,  liver  injury,  hypersensitivity, encephalitis, meningitis, and ARN. The overall number of treatment emergent AESI was low (approx. 6%) and similar  between  groups.  The  most  frequently  reported  AESIs  were  events  of  urticaria  and herpes.

Discontinuation due to adverse events accounted for 4.5% overall and was twice as abundant in the PB006  group  compared  to  the  Tysabri  group.  Most  common  TEAEs  leading  to  discontinuation  were pruritus and urticaria, which are known and common adverse drug reactions of natalizumab. All of the events resolved.

In both pivotal studies, increases from baseline in mean numbers of circulating leukocytes, lymphocytes, eosinophils and monocytes were reported, which were similar between treatment groups. The increases are  consistent  with  expression  of α4β1 on  these  white-cell  subpopulations  and  are  a  known pharmacodynamic  effect  of  natalizumab  (Tysabri  SmPC).  Results  from  study  PB006-01-03  (which assessed laboratory parameters up to and including 85 days post-dose) suggested that the increases were transient, with values returning to or below baseline levels at Day 85.

In study PB006-03-01, AEs of anaemia were reported for 4 patients in the PB006 group versus none in the  Tysabri  group,  whereas  one  event  each  of  iron  deficient  anaemia  and  normocytic  anaemia  was observed in the Tysabri group. All of the anaemia events were judged as not related or unlikely related to study drug and none of the events was serious. Of note, anaemia has been reported as common AE for Tysabri. In this context, the findings of AEs pertaining to anaemia in study PB006-03-01 are not considered to be unusual.

The use of natalizumab has been associated with an increased risk of PML, an opportunistic infection caused by JCV, which may be fatal or result in severe disability. This virus also causes JCV granule cell neuronopathy which has been reported in patients treated with natalizumab. Symptoms of JCV GCN are similar to symptoms of PML (i.e. cerebellar syndrome).

<div style=\"page-break-after: always\"></div>

The presence of anti-JCV antibodies is considered a risk factor for PML and it has been shown that the level of anti-JCV antibody response (index) is associated with the level of risk for PML in anti-JCV antibody positive natalizumab treated patients who have not used prior immunosuppressants (Tysabri SmPC).

Thus, patients with anti-JCV antibodies were excluded from the phase 1 studies with PB006. Due to the relatively high prevalence of anti-JCV antibodies, patients presenting such antibodies could be enrolled into study PB006-03-01 but the index had to be below 1.5. Further, JCV status was a stratification factor at randomization. Further, all studies included a PML follow-up visit 6 months after (last) dosing with study drug, to assess neurological symptoms which could be suggestive of PML.

Although an increase in JCV index was observed throughout the phase 3 study with approx. 6% of patients having an index &gt;1.5 at week 48, no cases of PML occurred in this study. No subjects had any signs suggestive of PML at the follow-up visit, either.

Throughout clinical development of PB006, STRATIFY JCV DxSelect assay was used for screening of study subjects  and  as  risk  minimisation  during  the  biosimilar  clinical  studies.  In  parallel,  a  new  anti-JCV antibody assay was developed (ImmunoWELL JCV IgG test) for use in clinical practice.

In  response  to  concerns  on  test  development  and  test  validation,  the  applicant  explained  that development and validation were performed on independent data sets and this approach is endorsed.

The applicant further informed that there is no international reference standard for antibodies directed against JCV available. For this reason, the applicant developed the ImmunoWELL JCV IgG test with the intention  to  provide  the  same  readout  as  the  widely  used  and  established  STRATIFY  JCV  DXSelect, providing estimated values for the ImmunoWELL assay based on a regression fit with values from the STRATIFY JCV DxSelect test, to prove their agreement for healthy individuals and MS patients.

In order to rely on the established PML risk estimate algorithm, it is essential that the ImmunoWELL assay produces comparable test results as the STRATIFY JCV DxSelect assay and reports index values on a comparable scale as the STRATIFY JCV DxSelect assay. The applicant provided further information on the ImmunoWELL JCV IgG test and its comparability with the current standard STRATIFY JCV DxSelect assay,  including  the  instructions  for  use,  the  analytical  and  the  clinical  validation  report  of  the ImmunoWELL JCV IgG test and the EC declaration of conformity.

Although both tests (STRATIFY JCV DxSelect and ImmunoWell JCV IgG test) should reveal results on a comparable  scale,  the  difference  in  index  cut-off  values  between  the  two  tests  (0.2  -  0.4  for  the STRATIFY JCV DxSelect and 0.25 - 0.5 for the ImmunoWELL JCV IgG test) shows that the two tests are not fully identical. For justification of the cut-off values 0.25 and 0.5 for Ab negativity/positivity, the applicant referred to the conducted 'cut-off study' and stated that the selection of 0.25 and 0.5 was based on high sensitivity (&gt;99%) and specificity (&gt;90%), respectively. Details from the cut-off study were missing on the performance measures (sensitivity, specificity, NPV, PPV) for different cut-offs to understand the proceeding of cut-off selection. Although the actual question about justification of the cut-off of 0.25 and 0.5 was not answered in detail, it is acknowledged that CE-marking is available based on these.

However, the applicant was asked to elaborate on their proceeding for defining the chosen range for positivity/negativity (0.25-0.5). During the procedure, the applicant explained that the two JCV Ab tests are correlated and that decisions based on positivity cut-off are conservative based on the findings in the cohort of MS patients. While indeed, good correlation is observed in the cohort of MS patients, at first only subjects with a value &lt;1.5 based on the STRATIFY JCV DxSelect test were included, which could bias the regression fit. On request, the applicant presented further comparative test data from the healthy subject population across the whole index range, and based on a regression analysis it is implied that the ImmunoWELL JCV IgG test might slightly underestimate the index estimated from the STRATIFY JCV DxSelect test.

<div style=\"page-break-after: always\"></div>

To address this potential difference in PML risk stratification, the applicant proposed to subtract an offset of 0.1 index values from the PML risk threshold values (0.9, 1.5) defined for the STRATIFY JCV DxSelect assay. The proposed offset is based on an analysis that includes only data from the healthy subject population;  ideally,  data  across  the  entire  patient  population  should  have  served  as  the  basis  for determining the proposed offset. The scatter plot of index values from ImmunoWELL JCV IgG test vs. STRATIFY JCV DxSelect test using data from MS patients presented in Section Clinical Safety , shows that both tests agree quite well except in the upper range, where the ImmunoWELL JCV IgG test appears to underestimate the anti-JCV antibody index from the STRATIFY JCV DxSelect test. This trend was also observed  for  healthy  subjects,  which  the  offset  was  established  from.  It  is  questionable  if  a  linear regression actually delivers the best fit for such a dataset over the full range of values. However, in the index range up to 2.5, that clearly goes beyond the index range for clinical decision making, a linear regression appears appropriate, and estimated ImmunoWELL JCV IgG test values from this regression analysis at the cut-offs 0.9 and 1.5 appear similar to those in healthy subjects. Thus, the offset (for deduction from the PML risk threshold values) based on healthy subjects is also considered appropriate in the cohort of MS patients and can be acceptable.

Importantly, lowering the index levels by deducting an offset value for PML risk stratification based on the  ImmunoWELL  JCV  IgG  test  as  compared  to  the  STRATIFY  JCV  DxSelect  test  results  in  a  more conservative  approach  (compared  to  using  the  same  thresholds)  that  reduces  the  number  of  false negatives tests, i.e. the number of patients that would be eligible for treatment despite being at increased PML risk.

The applicant reported the binary agreement between the two tests in terms of sensitivity, specificity, NPV, and PPV at the newly proposed threshold values of 0.8 and 1.4 for the ImmunoWELL JCV IgG test and at the threshold values of 0.9 and 1.5 for the STRATFIY JCV DxSelect test, for healthy individuals and MS patients, respectively.  Both analyses revealed performance measures (sensitivity, specificity, PPV and NPV) around 90% in healthy individuals as well as MS patients, which indicate that treatment decisions would be similar for most patients regardless of the applied JCV test.

Eventually relevant specific information on risk stratification testing including applicable tests is provided as part of the educational material for healthcare professionals.

In order to account for potential differences between the results of different anti-JCV antibody assays, the applicant provided a general wording for SmPC section 4.4 without the use of specific antibody index values.

The applicant provided a comprehensive Integrated Summary of Immunogenicity presenting data from all three clinical studies where PB006 was administered. The analytical portfolio included a screening, confirmation  and  neutralisation  assay,  and  respective  methods  were  considered  suitable  for  their intended use.

The overall data showed up to 79% ADA positive patients in the phase 3 study. The peak value was observed  at  week  8  for  PB006  (65%  ADA  positive)  and  EU-Tysabri  (61%  ADA  positive),  declining progressively thereafter to 11% for PB006 and 10% for EU-Tysabri at week 48. Through to Week 24, in total, 79% of subjects in the PB006 treatment group were confirmed positive for treatment-emergent ADA  compared  to  74%  for  EU-Tysabri.  A  relatively  high  proportion  (approx.  87%)  of  ADA  positive subjects were also NAb positive.

The relative numbers of ADA and NAb positive subjects are much higher than described in the Tysabri SmPC. The higher detected ADA and NAb incidence compared to the originator's studies is most plausibly explained by superior drug tolerance of the methods applied in the PB006 program.

Although ADA and NAb frequency declined progressively after reaching a peak at week 8, subjects with persistent ADA and NAb showed increasing titer levels up to and including week 48.

<div style=\"page-break-after: always\"></div>

The applicant conducted a comprehensive evaluation of the impact of ADA or NAb on PK, efficacy and safety parameters in the two pivotal clinical studies.

Overall, no apparent differences in the treatment-emergent ADA or NAb profiles for PB006 compared to EU-Tysabri (or US-Tysabri), or in impact of ADA on PK or PD parameters were revealed in the single dose comparative PK/PD study PB006-01-03 in healthy volunteers.

Further, despite slightly higher ADA and NAb levels in the PB006 compared to the Tysabri group, the immunogenicity  profile  of  PB006,  including  ADA/NAb  responses  and  the  impact  on  relevant  clinical parameters,  was  similar  to  that  of  EU-Tysabri  during  chronic  administration  for  48  weeks  to  RRMS patients in the pivotal safety and efficacy study, PB006-03-01.

Overall, no clinically relevant differences in immunogenicity were detected between PB006 and Tysabri.

## 2.6.10. Conclusions on the clinical safety

Considering the provided safety data from the clinical development programme, PB006 and Tysabri can be concluded to be biosimilar in terms of safety and immunogenicity.

## 2.7. Risk Management Plan

2.7.1.

Safety concerns

Table 61: Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                               |
|------------------------------|------------------------------------------------------------------------------------------|
| Important identified risks   | Progressive multifocal leukoencephalopathy (PML)                                         |
| Important identified risks   | Serious herpes infections                                                                |
| Important potential risks    | Malignancies                                                                             |
| Missing information          | PML risk following switch from disease modifying therapies with immunosuppressant effect |

## 2.7.2. Pharmacovigilance plan

No additional pharmacovigilance activities.

## 2.7.3. Risk minimisation measures

<div style=\"page-break-after: always\"></div>

Table 62: Summary of pharmacovigilance activities and risk minimization activities by safety concerns

| Safety concern                                                           | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                            | Pharmacovigilance activities                                                                                                                                                                  |
|--------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Progressive multifocal leukoencephalopathy (PML)                         | Routine risk communication: Information in SmPC Sections 4.2, 4.3, 4.4, 4.8, and 5.1; and PL Sections 2 and 4 Legal status: Restricted medical prescription Additional risk minimization measures: Educational tools for HCPs (Physician Information and Management Guideline) Educational tools for patients/carers (patient alert card, treatment initiation form, treatment continuation form, and | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Specific adverse reaction follow-up questionnaire Additional pharmacovigilance activities: None |
| Serious herpes infections                                                | Routine risk communication: Information in SmPC Sections 4.3, 4.4, 4.8; and PL Sections 2 and 4 Legal status: Restricted medical prescription Additional risk minimization measures:                                                                                                                                                                                                                  | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Specific adverse reaction follow-up questionnaire Additional pharmacovigilance activities:      |
| Malignancies                                                             | Routine risk communication: Information in SmPC Sections 4.3 and 4.8; and PL Section 2 Legal status: Restricted medical prescription Additional risk minimization measures: None Routine risk communication:                                                                                                                                                                                          | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Specific adverse reaction follow-up questionnaire Additional pharmacovigilance activities: None |
| PML risk in patients switching from DMTs with immuno- suppressant effect | Information in SmPC Section 4.4 and PL Section 2. Legal status: Restricted medical prescription Additional risk minimization measures:                                                                                                                                                                                                                                                                | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                                              |

## 2.7.4. Conclusion

The CHMP considers that the risk management plan version 1.2 is acceptable.

## 2.8. Pharmacovigilance

## 2.8.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

<div style=\"page-break-after: always\"></div>

## 2.8.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.9. Product information

## 2.9.1. User consultation

No full user consultation with target patient groups on the package leaflet has been performed on the basis of a bridging report making reference to Tysabri (text) and Ziextenzo (layout/design). The bridging report submitted by the applicant has been found acceptable.

## 2.9.2. Additional monitoring

Pursuant  to  Article  23(1)  of  Regulation  No  (EU)  726/2004,  Tyruko  (natalizumab)  is  included  in  the additional monitoring list as it is a biological product that is not covered by the previous category and authorised after 1 January 2011

Therefore the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Biosimilarity assessment

## 3.1. Comparability exercise and indications claimed

Natalizumab, a monoclonal IgG4 antibody, is developed to have the same intravenous dosage form, route  of  administration,  dosing  regimen  and  presentation  as  the  reference  product  EU-Tysabri.  The concentration of natalizumab is the same as for Tysabri (20 mg/mL in 15 mL) but the formulation of PB006 differs from the formulation of the reference medicinal product.

The  marketing  authorization  is  claimed  for  treatment  of  multiple  sclerosis  for  the  following  patient groups:

· Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT).

· Patients with rapidly evolving severe RRMS defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing (GdE) lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load as compared to a previous recent MRI.

## Quality

The  applicant  presented  detailed  information  about  its  comprehensive  analytical  assessment  to demonstrate  similarity  between  PB006  and  the  reference  medicinal  product  EU-Tysabri  (INN: natalizumab).  The  analytical  similarity  study  includes  PB006  (natalizumab)  data  from  batches manufactured at full commercial scale. Biosimilarity was evaluated against an appropriate number of batches of the reference medicinal product, EU-approved Tysabri.

<div style=\"page-break-after: always\"></div>

The  relevant  quality  attributes  of  the  natalizumab  molecule  were  assessed  using  a  broad  panel  of orthogonal standard methods that are state-of-the-art and are suitable to characterise and compare relevant structural and functional features of the natalizumab PB006 in comparison to the RMP. Analytical methods cover primary and higher order structure, potency/binding and Fab arm exchange kinetics as well as purity and product related variants. For each parameter under investigation, the methodology and performance of the analyses was well described, batches used and experimental data derived were well presented including raw data or chromatograms/spectra where applicable. Based on the provided information  it  is  concluded  that  the  analytical  methods  are  suitable  and  sensitive  to  detect  minor differences.

The quality attributes were either evaluated against a min-max range (primary criterion) or assessed qualitatively. Generally, the critical quality attributes assessment was well described and the criticality ranking  can  be  followed.  Assigning  a  different  overall  risk  for  each  QA  considering  abundance, methodology and type of QA, is acceptable.

## Summary of clinical data

Two  pivotal  clinical  studies  were  conducted  to  establish  clinical  similarity  between  PB006  and  the reference product, Tysabri.

A clinical phase 1 study was conducted to demonstrate comparability in PK and PD of the biosimilar candidate PB006 and the reference medicinal product EU-Tysabri and US-Tysabri. Study PB006-01-03 was a randomized, double-blind study with 3 parallel arms in 453 healthy male and female subjects. Subjects received a single dose of 3 mg/kg PB006, EU-approved Tysabri, or US-licensed Tysabri as an IV infusion over a 60-minute period. Dosing was followed by PK and PD sampling for 85 days and a final follow-up visit 6 months (24 weeks) after dosing to assess new neurological symptoms that could be suggestive  for  PML.  Safety  was  monitored  throughout  the  study  by  repeated  clinical  and  laboratory evaluations. Samples were collected for immunogenicity assessments for 85 days.

The primary objective of the study was to demonstrate PK and PD similarity of PB006 to both US-licensed Tysabri and EU-approved Tysabri.

The primary PK endpoint was AUC0-inf of total natalizumab, as secondary PK endpoints, AUC0-t, Cmax, and tmax of total natalizumab were selected to support the PK comparability of PB006 to EU-Tysabri and USTysabri.  Further  secondary  PK  endpoints  were  AUC0-inf,  AUC0-t,  Cmax,  and  tmax  of  unexchanged natalizumab. The primary and secondary PK endpoints are in line with guidance (' Guideline on similar biological  medicinal  products  containing  monoclonal  antibodies  -  non-clinical  and  clinical  issues ' (EMA/CHMP/BMWP/403543/2010)).

For PD, two co-primary endpoints were selected: AUEC0-12w of baseline-adjusted CD19+, and AUEC0-12w of alpha-integrin % receptor saturation. As an additional analysis, AUEC4-12w for α4 -integrin %RS was specified. As secondary PD endpoints, Emax and tmax of baseline-adjusted CD19+, AUECbase\\_neg, Emin, tmin of sVCAM and sMAdCAM, and AUEC0-t, Emax, tmax of CD34+ were used.

The pivotal efficacy and safety study PB006-03-01 was conducted to compare PB006 to the EU reference product Tysabri in terms of efficacy, safety and immunogenicity.

This was a randomized, double-blind, active-controlled, parallel-group study to compare the efficacy, safety and immunogenicity of PB006 versus EU-Tysabri, and to demonstrate similarity between PB006 and EU-Tysabri in patients with RRMS.

A total of 265 patients were randomized and 264 patients overall were treated with study drug (131 and 133 patients in the PB006 and Tysabri groups, respectively).

<div style=\"page-break-after: always\"></div>

The dose of 300 mg, dosing frequency (once every 4 weeks), route and method of administration are in line with the SmPC of the reference product. The study was conducted over 44 weeks and 12 doses were administered to the PP population.

The primary endpoint, cumulative number of new active lesions over 24 weeks, and secondary endpoints, i.e.,  cumulative  number  of  new  active  lesions  over  48  weeks,  cumulative  number  of  new  GdE  T1weighted lesions over 24 and 48 weeks, number of patients without new GdE T1-weighted lesions over 24 and 48 weeks, cumulative number of new/enlarging T2-weighted lesions over 24 and 48 weeks, number  of  patients  without  new/enlarging  T2-weighted  lesions  over  24  and  48  weeks,  number  of persistent lesions after 24 and 48 weeks, annualized relapse rate after 24 and 48 weeks and change from baseline in EDSS after 24 and 48 weeks are considered adequate to assess the clinical similarity between the biosimilar candidate and the reference product because they examine the effect on brain lesion activity and measure the delay of the disability, respectively. Moreover, the efficacy endpoints are in line with the 'Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis' (EMA/CHMP/771815/2011, Rev. 2), the efficacy endpoints studied in the clinical trials which supported the MA of the reference product, Tysabri EU and the 'Guideline on similar biological medicinal products containing interferon beta' (EMA/CHMP/BMWP/652000/2010).

## 3.2. Results supporting biosimilarity

## Quality

Analytical similarity assessment was based on the analysis of PB006 batches and an appropriate number of EU-approved Tysabri batches, based on a broad panel of orthogonal, sensitive and state of the art analytical  methods,  including  supportive  data  from  US-licensed  Tysabri  batches.  The  comparison included the assessment of strength, composition, physicochemical, biophysical and in vitro functional properties, as well as structural characterisation and in-depth assessment of isolated product-related variants. Stability and degradation pathways were compared by a degradation study and by long-term, accelerated  and  stress  stability  studies.  Acceptance  ranges  were  pre-defined  as  min-max  ranges (primary criteria) and quality ranges (secondary criteria) for the EU-approved RMP, depending on their criticality, which was elaborated based on a comprehensive criticality assessment covering all relevant quality attributes. For all quality attributes including multiple attributes covering the mechanism of action high degree of analytical similarity of PB006 to the reference product EU-Tysabri has been demonstrated: Primary  structure  was  demonstrated  to  be  similar  by  100%  confirmation  of  the  sequence  (peptide mapping), molecular mass  analyses (intact and deglycosylated), and the same  locations of posttranslational modifications (N-terminal pyroglutamic acid, oxidation, deamidation, N-glycosylation). Highly similar higher order structure was shown. The main mechanism of action, binding to the α4 -subunit  of α4β1 and α4β7 integrins  expressed  on  the  surface  of  all  leukocytes  except  neutrophils inhibiting the α4 -mediated adhesion of leukocytes to their counter-receptor(s) VCAM-1, and MAdCAM-1, was evaluated by ELISA method and SPR. Potency values of analysed PB006 batches were comparable to EU-Tysabri and US batches. It was also shown that PB006 lacks for immunogenic Galili-motifs present in EU-licensed Tysabri. Minor differences with regard to charge and size heterogeneity are not considered impactful.  Differences  were  observed  for  oxidation,  free  thiols,  open  disulfide  bonds,  C-terminal amidation, N-glycan profiles, and basic variants. The stability and degradation profiles of PB006 and its RMP were comparable.  The  observed  analytical  differences  have  been  adequately  justified  and  it  is agreed that their impact on safety and efficacy seems minor. In addition, analytical comparability of USTysabri to EU-Tysabri has been sufficiently demonstrated as presented in a separate bridging report.

## Clinical

Pharmacology/PK

<div style=\"page-break-after: always\"></div>

The primary PK endpoint AUC0-inf of total natalizumab was met. The ratio of the pairwise comparison PB006 vs EU-Tysabri was 0.9864, 90% CI: 0.9410, 1.0340.

The secondary PK endpoints were supportive of similarity between PB006 and EU-Tysabri.

## Pharmacology/PD

Both co-primary PD endpoints were met.

AUEC0-12wk α4 -integrin %RS: The ratio of the pairwise comparison PB006 vs EU-Tysabri was 1.0142, 95% CI:  0.9667,  1.0641.  The  ratio  of  the  comparison  of  PB006  vs  pooled  Tysabri  was  0.9933,  95%  CI: 0.9523, 1.0362.

AUEC0-12wk of baseline-adjusted CD19+: The ratio of the pairwise comparison PB006 vs EU-Tysabri was 1.0163, 95% CI: 0.8787, 1.1754. The ratio of the comparison of PB006 vs pooled Tysabri was 1.0159, 95% CI: 0.8955, 1.1525.

The secondary PD endpoints were supportive of similarity between PB006 and EU-Tysabri.

## Efficacy

The primary efficacy endpoint cumulative number of new active lesions over 24 weeks was met. The point estimate for the exponentiated difference between Tysabri and PB006 was 0.17 and the 95% CI (0.613; 0.944) for the difference Tysabri minus PB006 was narrow and well within the specified margins (-2.1; 2.1).

The secondary efficacy endpoints were supportive of similarity between PB006 and EU-Tysabri.

## Safety and immunogenicity

A comprehensive safety and immunogenicity evaluation was conducted in the two pivotal clinical trials. Overall, no clinically relevant differences in safety or immunogenicity were detected between PB006 and Tysabri.

## 3.3. Uncertainties and limitations about biosimilarity

## Clinical

## Pharmacology

The study protocol was amended at several time points, with extensive changes to its design, including the primary endpoints, sample size, study population, conduct of the study (introduction of a pooling criterion to allow pooling of results of EU- and US-Tysabri for PD evaluation), and evaluation of study results. However, no severe impact on study integrity was identified.

## Pharmacology/PD

The relevance of the increase in CD19 positivity used as a co-primary PD endpoint is difficult to interpret.

The  used  equivalence  margins  for  assessment  of  PD  endpoints  were  already  criticised  during  EMA scientific advice provided prior to study initiation as being too wide. Also, no sound scientific justification for the acceptance ranges was provided.

No PD parameter was evaluated in the multiple-dose safety and efficacy study in patients.

## Efficacy

The equivalence margin for the primary efficacy evaluation was based on a single reference study with small sample size and the predefined acceptance range was considered too large to rule out a clinically

<div style=\"page-break-after: always\"></div>

relevant difference. However, the actual results accounted for a difference of less than one lesion and the 95% CI for the difference between the treatments displayed a narrow range of [-0.613; 0.944]. These results are considered sufficient to demonstrate similarity in clinical efficacy.

## Safety and immunogenicity

The switch of 30 patients from Tysabri EU to PB006 at week 24 is considered a study limitation as a comparative safety and immunogenicity assessment up to 48 weeks of the initial treatment groups PB006 and Tysabri EU are considered more useful for the biosimilarity assessment.

## 3.4. Discussion on biosimilarity

Overall, at the quality level similarity between PB006 and EU-sourced Tysabri, which was used as clinical comparator, could be demonstrated in a comprehensive analytical similarity exercise. In the PK/PD study EU-and  US-sourced  Tysabri  were  applied,  and  comparability  between  both  products  could  be demonstrated in the analytical similarity exercise.

Overall, the clinical comparison between PB006 and EU-sourced Tysabri demonstrated biosimilarity in terms of the pre-defined primary parameters for PK, PD and efficacy. Additionally, the secondary PK and efficacy  parameters  support  the  conclusion  of  biosimilarity,  as  does  the  assessment  of  safety  and immunogenicity.

## 3.5. Extrapolation of safety and efficacy

Not applicable

## 3.6. Additional considerations

Not applicable

## 3.7. Conclusions on biosimilarity and benefit risk balance

Based on the review of the submitted data, Tyruko is considered biosimilar to Tysabri. Therefore, a benefit/risk balance comparable to the reference product can be concluded.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Tyruko is favourable in the following indication(s):

Tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (RRMS) for the following patient groups:

- Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) (for exceptions and information about washout periods see sections 4.4 and 5.1)

or

<div style=\"page-break-after: always\"></div>

- Patients with rapidly evolving severe RRMS defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain Magnetic Resonance Imaging (MRI) or a significant increase in T2 lesion load as compared to a previous recent MRI.

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal  product  subject  to  restricted  medical  prescription  (see  Annex  I:  Summary  of  Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## · Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

- Risk Management Plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
- Additional risk minimisation measures

Based on how patients treated with Tyruko are currently monitored at national level, the MAH shall discuss and agree with the National Competent Authorities measures to enhance further this monitoring (e.g. registries, post-marketing surveillance studies) as appropriate. The MAH shall implement agreed measures for monitoring within a time frame agreed with the National Competent Authorities.

The educational programme is aimed at educating healthcare professionals and patients/carers of the potential and risk factors for the development of PML, its diagnosis and treatment, and the identification and management of possible sequelae.

The MAH shall ensure that in each Member State where Tyruko is marketed, all healthcare professionals and patients/carers who are expected to prescribe/use Tyruko have access to/are provided with the following educational materials:

- Physician educational materials:
- ˗ Summary of Product Characteristics
- ˗ Physician Information and Management Guidelines
- Patient information pack:

<div style=\"page-break-after: always\"></div>

- ˗ Package leaflet
- ˗ Patient alert card
- ˗ Treatment initiation and treatment continuation forms
- ˗ Treatment discontinuation form

These educational materials shall contain the following key elements:

## Physician Information and Management Guidelines:

- Background information on the increased risk of atypical/opportunistic infections, in particular    PML, which  may  occur  with  Tyruko  therapy,  including  a  detailed  discussion  of  data  (including epidemiology, aetiology, and pathology )  pertaining  to  the  development  of  PML  in  Tyrukotreated patients.
- Information relating to the identification of risk factors for Tyruko-associated PML, including details  of  the  PML  risk  estimates  algorithm  summarising  PML  risk  by  risk  factor  (anti-John Cunningham virus [JCV] antibody status,  prior  IS  use,  and  duration  of  treatment  [by  year  of treatment]), and stratification of this risk by index value when applicable.
- Information on extending the dosing interval for PML risk mitigation , including a reminder of the approved dosing schedule.
- Inclusion of monitoring guidance for MRI and anti-JCV antibody based on PML risk,  including recommended timing, protocols, and interpretation of results.
- Detail regarding the diagnosis of PML , including principals, clinical assessment (including MRI and laboratory testing), and differentiation between PML and MS.
- Management recommendations in the event of cases of suspected PML, including considerations on  the  effectiveness  of  PLEX  treatment  and  the  management  of  associated  IRIS  (immune reconstitution inflammatory syndrome).
- Detail  on  the prognosis on  PML,  including  information  on  improved  outcomes  observed  in asymptomatic PML cases.
- A reminder that irrespective of the presence or absence of PML risk factors, heightened clinical vigilance  for  PML  should  be  maintained  in  all  patients  treated  with  Tyruko  and  for  6  months following discontinuation of therapy .
- A reminder on the need to discuss the benefit/risk profile of Tyruko treatment with the patient, and the requirement to provide the patient information pack.

## Patient alert card:

- Reminder  to  patients  to  show  the  card  to  any  doctor  and/or  caregiver  involved  with  their treatment, and to keep the card with them for 6 months after the last dose of Tyruko treatment.
- Reminder to patients to read the package leaflet carefully before starting Tyruko, and not to start Tyruko if there is a serious problem with their immune system.
- Reminder to patients no to take any other long-term medicines for MS while receiving Tyruko.
- A description of PML, potential symptoms and management of PML.
- A reminder of where to report side effects.

<div style=\"page-break-after: always\"></div>

- Details of the patient, treating doctor and date Tyruko was started.

## Treatment initiation and treatment continuation forms:

- Information  on  PML  and  IRIS,  including  the  risk  of  developing  PML  during  Tyruko  treatment stratified by prior treatment with immunosuppressants and JCV infection.
- Confirmation that the doctor has discussed the risks of PML and the risk of IRIS if treatment is discontinued following suspicion of PML, and confirmation of patient understanding of the risks of PML and that they have received a copy of the treatment initiation form and a patient alert card.
- Patient details and prescriber name.

The treatment continuation form should contain the elements of the treatment initiation form and, in addition, a statement that the risks of PML increase with duration of treatment and that treatment beyond 24 months carries additional risk.

## Treatment discontinuation form

- Information for the patient that PML has been reported up to 6 months after stopping Tyruko,  and to therefore keep the patient alert card with them after treatment discontinuation.
- Reminder of PML symptoms, and when MRI imaging may be warranted.
- Reporting of side effects.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.